

# **Third National Report on Human Exposure to Environmental Chemicals**

**July 2005**

**Department of Health and Human Services  
Centers for Disease Control and Prevention**

**National Center for Environmental Health  
Division of Laboratory Sciences  
Atlanta, Georgia 30341-3724**

**NCEH Pub. No. 05-0570**

*Selected text revisions appear on pages 201-2 (February 2006) and pages 253, 269, and 281 (January 2007).*

---

*The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.*

## About CDC's Environmental Health Laboratory

---



Using advanced laboratory science and innovative techniques, scientists in CDC's Environmental Health Laboratory at the National Center of Environmental Health (NCEH) have helped change the face of environmental public health in this country. By recognizing chemicals that enter the body from environmental exposure, by responding to terrorism and public health emergencies involving chemicals, and by improving laboratory methods to measure chemical exposure, the laboratory has greatly enhanced the understanding of chemical exposure and related health effects for the nation and around the world.

For more than three decades, laboratory scientists at NCEH have been determining which environmental chemicals enter people's bodies, how much of those chemicals are actually present, and how the amounts of those chemicals may be related to health effects. The highly trained scientists measure levels of chemicals directly in people's blood or urine. Rather than predicting how much of a substance gets into people from estimates based on measurements in food, water, air, and other media, NCEH's laboratory scientists have taken out the guesswork by measuring low levels of chemicals that are actually in people's bodies. And they do so with precision, speed, and accuracy, measuring many chemicals in a very small amount—often a teaspoon or less—of blood or urine.



# Contents

<b>Introduction</b> .....	<b>1</b>
<b>Data Sources and Data Analysis</b> .....	<b>7</b>
<b>Toxicology and Health-Risk Information</b> .....	<b>11</b>
<b>Results by Chemical Group</b> .....	<b>13</b>
<b>Metals</b> .....	<b>13</b>
Antimony.....	15
Barium.....	19
Beryllium.....	23
Cadmium.....	26
Cesium.....	31
Cobalt.....	34
Lead.....	38
Mercury.....	45
Molybdenum.....	52
Platinum.....	56
Thallium.....	59
Tungsten.....	63
Uranium.....	67
<b>Tobacco Smoke</b> .....	<b>71</b>
Cotinine.....	73
<b>Polycyclic Aromatic Hydrocarbons</b> .....	<b>79</b>
1-Hydroxybenz[a]anthracene and 3- and 9-Hydroxybenz[a]anthracene.....	81
1-Hydroxybenzo[c]phenanthrene, 2-Hydroxybenzo[c]phenanthrene, and 3-Hydroxybenzo[c]phenanthrene.....	85
1-Hydroxychrysene, 2-Hydroxychrysene 3-Hydroxychrysene, 4-Hydroxychrysene, and 6-Hydroxychrysene....	91
3-Hydroxyfluoranthene.....	101
2-Hydroxyfluorene, 3-Hydroxyfluorene, and 9-Hydroxyfluorene.....	103
1-Hydroxyphenanthrene, 2-Hydroxyphenanthrene, 3-Hydroxyphenanthrene, 4-Hydroxyphenanthrene, and 9-Hydroxyphenanthrene.....	111
1-Hydroxypyrene.....	124
3-Hydroxybenzo[a]pyrene.....	127
1-Hydroxynaphthalene and 2-Hydroxynaphthalene.....	129
<b>Polychlorinated Dibenzo-<i>p</i>-dioxins, Polychlorinated Dibenzofurans, and Coplanar and Mono-ortho-     substituted Polychlorinated Biphenyls</b> .....	<b>135</b>
1,2,3,4,6,7,8,9-Octachlorodibenzo- <i>p</i> -dioxin (OCDD).....	140
1,2,3,4,6,7,8-Heptachlorodibenzo- <i>p</i> -dioxin (HpCDD).....	142
1,2,3,4,7,8-Hexachlorodibenzo- <i>p</i> -dioxin (HxCDD).....	144
1,2,3,6,7,8-Hexachlorodibenzo- <i>p</i> -dioxin (HxCDD).....	146
1,2,3,7,8,9-Hexachlorodibenzo- <i>p</i> -dioxin (HxCDD).....	148
1,2,3,7,8-Pentachlorodibenzo- <i>p</i> -dioxin (PeCDD).....	150
2,3,7,8-Tetrachlorodibenzo- <i>p</i> -dioxin (TCDD).....	152
1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF).....	154
1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF).....	156
1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF).....	158
1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF).....	160
1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF).....	162
1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF).....	164
1,2,3,7,8-Pentachlorodibenzofuran (PeCDF).....	166
2,3,4,6,7,8-Hexachlorodibenzofuran (HxCDF).....	168

2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) .....	170
2,3,7,8-Tetrachlorodibenzofuran (TCDF) .....	172
2,4,4'-Trichlorobiphenyl (PCB 28).....	174
2,3',4,4'-Tetrachlorobiphenyl (PCB 66) .....	176
2,4,4',5-Tetrachlorobiphenyl (PCB 74) .....	178
3,4,4',5-Tetrachlorobiphenyl (PCB 81) .....	180
2,3,3',4,4'-Pentachlorobiphenyl (PCB 105) .....	182
2,3',4,4',5-Pentachlorobiphenyl (PCB 118) .....	184
3,3',4,4',5-Pentachlorobiphenyl (PCB 126) .....	186
2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156) .....	188
2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157).....	190
2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167).....	192
3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169).....	194
2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189).....	196
<b>Non-dioxin-like Polychlorinated Biphenyls .....</b>	<b>201</b>
2,2',5,5'-Tetrachlorobiphenyl (PCB 52) .....	204
2,2',3,4,5'-Pentachlorobiphenyl (PCB 87) .....	206
2,2',4,4',5-Pentachlorobiphenyl (PCB 99) .....	208
2,2',4,5,5'-Pentachlorobiphenyl (PCB 101) .....	210
2,3,3',4',6-Pentachlorobiphenyl (PCB 110) .....	212
2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128).....	214
2,2',3,4,4',5' and 2,3,3',4,4',6-Hexachlorobiphenyl (PCB 138 & 158).....	216
2,2',3,4,5,5'-Hexachlorobiphenyl (PCB 146).....	218
2,2',3,4,5',6-Hexachlorobiphenyl (PCB 149).....	220
2,2',3,5,5',6-Hexachlorobiphenyl (PCB 151) .....	222
2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153).....	224
2,2',3,3',4,4',5-Heptachlorobiphenyl (PCB 170).....	226
2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172).....	228
2,2',3,3',4,5',6-Heptachlorobiphenyl (PCB 177).....	230
2,2',3,3',5,5',6-Heptachlorobiphenyl (PCB 178).....	232
2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180).....	234
2,2',3,4,4',5',6-Heptachlorobiphenyl (PCB 183).....	236
2,2',3,4,5,5',6-Heptachlorobiphenyl (PCB 187).....	238
2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194).....	240
2,2',3,3',4,4',5,6-Octachlorobiphenyl (PCB 195).....	242
2,2',3,3',4,4',5,6' and 2,2',3,4,4',5,5',6-Octachlorobiphenyl (PCB 196 & 203) .....	244
2,2',3,3',4,5,5',6'-Octachlorobiphenyl (PCB 199).....	246
2,2',3,3',4,4',5,5',6-Nonachlorobiphenyl (PCB 206).....	248
<b>Phthalates .....</b>	<b>253</b>
Mono-methyl Phthalate .....	255
Mono-ethyl Phthalate .....	257
Mono-n-butyl Phthalate.....	260
Mono-isobutyl Phthalate .....	260
Mono-benzyl Phthalate.....	264
Mono-cyclohexyl Phthalate.....	267
Mono-2-ethylhexyl Phthalate .....	269
Mono-(2-ethyl-5-hydroxyhexyl) Phthalate .....	269
Mono-(2-ethyl-5-oxohexyl) Phthalate.....	269
Mono-3-carboxypropyl Phthalate.....	277
Mono-n-octyl Phthalate .....	277
Mono-isononyl Phthalate .....	281

<b>Phytoestrogens</b> .....	<b>285</b>
Daidzein .....	288
Enterodiol .....	291
Enterolactone .....	294
Equol .....	297
Genistein .....	300
O-Desmethylangolensin .....	303
<b>Organochlorine Pesticides</b> .....	<b>309</b>
Hexachlorobenzene .....	310
Hexachlorocyclohexane .....	313
beta Hexachlorocyclohexane .....	313
gamma Hexachlorocyclohexane .....	315
Pentachlorophenol .....	317
2,4,5-Trichlorophenol .....	319
2,4,6-Trichlorophenol .....	319
Dichlorodiphenyltrichloroethane .....	324
<i>p,p'</i> -DDT .....	324
<i>p,p'</i> -DDE .....	326
<i>o,p'</i> -DDT .....	329
Chlordane .....	331
Oxychlordane .....	331
<i>trans</i> -Nonachlor .....	331
Heptachlor .....	331
Heptachlor Epoxide .....	336
Mirex .....	338
Aldrin .....	340
Dieldrin .....	340
Endrin .....	344
<b>Organophosphate Pesticides: Dialkyl Phosphate Metabolites</b> .....	<b>349</b>
Dimethylphosphate .....	351
Dimethylthiophosphate .....	354
Dimethyldithiophosphate .....	357
Diethylphosphate .....	359
Diethylthiophosphate .....	362
Diethyldithiophosphate .....	365
<b>Organophosphate Pesticides: Specific Metabolites</b> .....	<b>369</b>
Malathion Dicarboxylic Acid .....	370
<i>para</i> -Nitrophenol .....	372
3,5,6-Trichloro-2-pyridinol .....	375
2-Isopropyl-4-methyl-6-hydroxypyrimidine .....	379
2-(Diethylamino)-6-methylpyrimidin-4-ol/one .....	381
3-Chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol .....	383
<b>Herbicides</b> .....	<b>387</b>
2,4,5-Trichlorophenoxyacetic Acid .....	388
2,4-Dichlorophenoxyacetic Acid .....	390
2,4-Dichlorophenol .....	392
Atrazine Mercapturate .....	395
Alachlor Mercapturate .....	397
Acetochlor Mercapturate .....	399
Metolachlor Mercapturate .....	401

<b>Pyrethroids Pesticides .....</b>	<b>405</b>
4-Fluoro-3-phenoxybenzoic Acid .....	406
<i>cis</i> -3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane Carboxylic Acid.....	408
<i>trans</i> -3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane Carboxylic Acid.....	410
<i>cis</i> -3-(2,2-Dibromovinyl)-2,2-dimethylcyclopropane Carboxylic Acid.....	412
3-Phenoxybenzoic Acid .....	414
<b>Other Pesticides .....</b>	<b>417</b>
N,N-Diethyl-3-methylbenzamide .....	419
<i>ortho</i> -Phenylphenol .....	421
2,5-Dichlorophenol.....	423
<b>Carbamate Insecticides .....</b>	<b>429</b>
2-Isopropoxyphenol.....	430
Carbofuranphenol.....	432
<b>References .....</b>	<b>435</b>
<b>Appendix A. Limit of Detection Table.....</b>	<b>459</b>
<b>Appendix B. References for Biomonitoring Analytical Methods.....</b>	<b>463</b>
<b>Appendix C. Confidence Interval Estimation for Percentiles .....</b>	<b>465</b>
<b>Appendix D. Abbreviations and Acronyms .....</b>	<b>467</b>

## Introduction

The *National Report on Human Exposure to Environmental Chemicals* provides an ongoing assessment of the exposure of the U.S. population to environmental chemicals using biomonitoring. The *Second National Report on Human Exposure to Environmental Chemicals (Second Report)* was released in 2003 and presented biomonitoring exposure data for 116 environmental chemicals for the civilian, noninstitutionalized U.S. population over the 2-year period 1999-2000. This *Third Report* presents similar exposure data for the U.S. population for 148 environmental chemicals over the period 2001-2002. The *Third Report* also includes the data from the *Second Report*.

Chemicals or their metabolites were measured in blood and urine samples from a random sample of participants from the National Health and Nutrition Examination Survey (NHANES) conducted by CDC's National Center for Health Statistics. NHANES is a series of surveys designed to collect data on the health and nutritional status of the U.S. population.

For this *Report*, an environmental chemical means a chemical compound or chemical element present in air, water, food, soil, dust or other environmental media (e.g., consumer products). Biomonitoring is the assessment of

human exposure to chemicals by measuring the chemicals or their metabolites in human specimens such as blood or urine. A metabolite is chemical alteration of the original compound produced by body tissues. Blood and urine levels reflect the amount of the chemical that actually gets into the body from the environment.

Table 1 lists the chemicals measured in the *Second* and *Third Reports* and the years these chemicals were measured.

The new chemicals for the *Third Report* are—

- Pyrethroid insecticides.
- Additional polycyclic aromatic hydrocarbons (including benzo-[a]-pyrene).
- Aldrin, endrin, dieldrin.
- Additional phthalate metabolites.
- Additional pesticides and herbicides.
- Additional dioxins, furans, and polychlorinated biphenyls (PCBs).

We have not performed any analyses for differences in results between the 1999-2000 and 2001-2002 survey periods. As additional *Reports* are released every 2 years, it will become possible to analyze trends. Details on data analysis are presented in the section titled "Data Sources and Analysis."

**Table 1. Chemicals Measured in the *Second* and *Third Reports***

Chemical	1999-2000	2001-2002
<b>Metals</b>		
Antimony	•	•
Barium	•	•
Beryllium	•	•
Cadmium	•	•
Cesium	•	•
Cobalt	•	•
Lead	•	•
Mercury	•	•
Molybdenum	•	•
Platinum	•	•
Tungsten	•	•
Thallium	•	•
Uranium	•	•
<b>Tobacco Smoke</b>		
Cotinine	•	•
<b>Phytoestrogens</b>		
Daidzein	•	•
Enterodiol	•	•
Enterolactone	•	•
Equol	•	•
Genistein	•	•
O-Desmethylangolensin	•	•

Chemical	1999-2000	2001-2002
<b>Polycyclic Aromatic Hydrocarbons</b>		
1-Hydroxybenz[a]anthracene	•	•
3-Hydroxybenz[a]anthracene and 9-Hydroxybenz[a]anthracene	•	•
1-Hydroxybenzo[c]phenanthrene	•	•
2-Hydroxybenzo[c]phenanthrene	•	•
3-Hydroxybenzo[c]phenanthrene	•	•
1-Hydroxychrysene		•
2-Hydroxychrysene		•
3-Hydroxychrysene	•	•
4-Hydroxychrysene		•
6-Hydroxychrysene	•	•
3-Hydroxyfluoranthene	•	
2-Hydroxyfluorene	•	•
3-Hydroxyfluorene	•	•
9-Hydroxyfluorene		•
1-Hydroxyphenanthrene	•	•
2-Hydroxyphenanthrene	•	•
3-Hydroxyphenanthrene	•	•
4-Hydroxyphenanthrene		•
9-Hydroxyphenanthrene		•
1-Hydroxypyrene	•	•
3-Hydroxybenzo[a]pyrene		•
1-Hydroxynaphthalene		•
2-Hydroxynaphthalene		•

Chemical	1999-2000	2001-2002
<b>Polychlorinated Dibenzo-p-dioxins, Dibenzofurans, Coplanar and Mono-Ortho-Substituted Biphenyls</b>		
1,2,3,4,6,7,8,9-Octachlorodibenzo-p-dioxin (OCDD)	•	•
1,2,3,4,6,7,8-Heptachlorodibenzo-p-dioxin (HpCDD)	•	•
1,2,3,4,7,8-Hexachlorodibenzo-p-dioxin (HxCDD)	•	•
1,2,3,6,7,8-Hexachlorodibenzo-p-dioxin (HxCDD)	•	•
1,2,3,7,8,9-Hexachlorodibenzo-p-dioxin (HxCDD)	•	•
1,2,3,7,8-Pentachlorodibenzo-p-dioxin (PeCDD)	•	•
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	•	•
1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF)	•	•
1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF)	•	•
1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF)	•	•
1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF)	•	•
1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF)	•	•
1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF)	•	•
1,2,3,7,8-Pentachlorodibenzofuran (PeCDF)	•	•
2,3,4,6,7,8-Hexachlorodibenzofuran (HxCDF)	•	•
2,3,4,7,8-Pentachlorodibenzofuran (PeCDF)	•	•
2,3,7,8-Tetrachlorodibenzofuran (TCDF)	•	•
2,4,4'-Trichlorobiphenyl (PCB 28)	•	•
2,3',4,4'-Tetrachlorobiphenyl (PCB 66)	•	•
2,4,4',5-Tetrachlorobiphenyl (PCB 74)	•	•
3,4,4',5-Tetrachlorobiphenyl (PCB 81)	•	•
2,3,3',4,4'-Pentachlorobiphenyl (PCB 105)	•	•
2,3',4,4',5-Pentachlorobiphenyl (PCB 118)	•	•
3,3',4,4',5-Pentachlorobiphenyl (PCB 126)	•	•
2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156)	•	•
2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157)	•	•
2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167)	•	•
3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169)	•	•
2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189)	•	•
<b>Non-dioxin-like Polychlorinated Biphenyls</b>		
2,2',5,5'-Tetrachlorobiphenyl (PCB 52)	•	•
2,2',3,4,5'-Pentachlorobiphenyl (PCB 87)	•	•
2,2',4,4',5-Pentachlorobiphenyl (PCB 99)	•	•
2,2',4,5,5'-Pentachlorobiphenyl (PCB 101)	•	•
2,3,3',4',6-Pentachlorobiphenyl (PCB 110)	•	•
2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128)	•	•
2,2',3,4,4',5' and 2,3,3',4,4',6-Hexachlorobiphenyl (PCB 138&158)	•	•
2,2',3,4',5,5'-Hexachlorobiphenyl (PCB 146)	•	•
2,2',3,4',5,6'-Hexachlorobiphenyl (PCB 149)	•	•
2,2',3,5,5',6-Hexachlorobiphenyl (PCB 151)	•	•
2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153)	•	•
2,2',3,3',4,4',5-Heptachlorobiphenyl (PCB 170)	•	•
2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172)	•	•
2,2',3,3',4,5,6'-Heptachlorobiphenyl (PCB 177)	•	•
2,2',3,3',5,5',6-Heptachlorobiphenyl (PCB 178)	•	•
2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180)	•	•
2,2',3,4,4',5,6-Heptachlorobiphenyl (PCB 183)	•	•
2,2',3,4',5,5',6-Heptachlorobiphenyl (PCB 187)	•	•
2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194)	•	•
2,2',3,3',4,4',5,5',6-Octachlorobiphenyl (PCB 195)	•	•
2,2',3,3',4,4',5,6' and 2,2',3,4,4',5,5',6-Octachlorobiphenyl (PCB196&203)	•	•
2,2',3,3',4,5,5',6-Octachlorobiphenyl (PCB 199)	•	•
2,2',3,3',4,4',5,5',6'-Nonachlorobiphenyl (PCB 206)	•	•
<b>Other Pesticides</b>		
N,N-Diethyl-3-methylbenzamide	•	•
ortho-Phenylphenol	•	•
2,5-Dichlorophenol	•	•
<b>Carbamate Pesticides</b>		
2-Isopropoxyphenol	•	•
Carbofuranphenol	•	•

Chemical	1999-2000	2001-2002
<b>Phthalates</b>		
Mono-methyl phthalate		•
Mono-ethyl phthalate	•	•
Mono-n-butyl phthalate	•	•
Mono-isobutyl phthalate		•
Mono-benzyl phthalate	•	•
Mono-cyclohexyl phthalate	•	•
Mono-2-ethylhexyl phthalate	•	•
Mono-(2-ethyl-5-oxohexyl) phthalate		•
Mono-(2-ethyl-5-hydroxyhexyl) phthalate		•
Mono-n-octyl phthalate	•	•
Mono-(3-carboxypropyl) phthalate		•
Mono-isononyl phthalate	•	•
<b>Organochlorine Pesticides</b>		
Hexachlorobenzene	•	•
Beta-hexachlorocyclohexane	•	•
Gamma-hexachlorocyclohexane	•	•
Pentachlorophenol	•	•
2,4,5-Trichlorophenol	•	•
2,4,6-Trichlorophenol	•	•
p,p'-DDT	•	•
p,p'-DDE	•	•
o,p'-DDT	•	•
Oxychlorane	•	•
trans-Nonachlor	•	•
Heptachlor epoxide	•	•
Mirex	•	•
Aldrin		•
Dieldrin		•
Endrin		•
<b>Organophosphate Insecticides: Dialkyl Phosphate Metabolites</b>		
Dimethylphosphate	•	•
Dimethylthiophosphate	•	•
Dimethyldithiophosphate	•	•
Diethylphosphate	•	•
Diethylthiophosphate	•	•
Diethyldithiophosphate	•	•
<b>Organophosphate Insecticides: Specific Metabolites</b>		
Malathion dicarboxylic acid	•	•
para-Nitrophenol	•	•
3,5,6-Trichloro-2-pyridinol	•	•
2-Isopropyl-4-methyl-6-hydroxypyrimidine	•	•
2-(Diethylamino)-6-methylpyrimidin-4-ol/one		•
3-Chloro-7-hydroxy-4-methyl-2H-chromen-2-one/ol		•
<b>Herbicides</b>		
2,4,5-Trichlorophenoxyacetic acid	•	•
2,4-Dichlorophenoxyacetic acid	•	•
2,4-Dichlorophenol	•	•
Alachlor mercapturate	•	•
Atrazine mercapturate	•	•
Acetochlor mercapturate		•
Metolachlor mercapturate		•
<b>Pyrethroid Pesticides</b>		
4-Fluoro-3-phenoxybenzoic acid		•
cis-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid		•
trans-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropane carboxylic acid		•
cis-3-(2,2-Dibromovinyl)-2,2-dimethylcyclopropane carboxylic acid		•
3-Phenoxybenzoic acid		•

## Public Health Uses of the Report

The overall purpose of the *Report* is to provide unique exposure information to scientists, physicians, and health officials to help prevent disease that results from exposure to environmental chemicals. Specific public health uses of the exposure information in the *Third Report* are—

- To determine which chemicals get into Americans and at what concentrations.
- For chemicals with a known toxicity level, to determine the prevalence of people with levels above those toxicity levels.
- To establish reference ranges that can be used by physicians and scientists to determine whether a person or group has an unusually high exposure.
- To assess the effectiveness of public health efforts to reduce exposure of Americans to specific chemicals.
- To determine whether exposure levels are higher among minorities, children, women of childbearing age, or other potentially vulnerable groups.
- To track, over time, trends in levels of exposure of the population.
- To set priorities for research on human health effects.

## Data Presented for Each Environmental Chemical

*The Report presents tables of descriptive statistics on the distribution of blood or urine levels for each environmental chemical. Statistics include unadjusted geometric means and percentiles with confidence intervals.*

Geometric means are calculated by taking the log of each concentration, then calculating the mean of those log values, and finally, taking the antilog of that mean (the calculation can be done using any log base, such as 10 or e). A geometric mean provides a better estimate of central tendency for data that are distributed with a long tail at the upper end of the distribution. This type of distribution is common when measuring environmental chemicals in blood or urine. The geometric mean is influenced less by high values than is the arithmetic mean.

Percentiles (50<sup>th</sup>, 75<sup>th</sup>, 90<sup>th</sup>, and 95<sup>th</sup>) are given to provide additional information about the shape of the distribution. In the *Third Report*, 10<sup>th</sup> and 25<sup>th</sup> percentiles are no longer included in order to provide adequate space in the tables to cover multiple years of data. Many of the tables in the *Report* are heavily filled with data. For tables with data entered for the 50<sup>th</sup>, 90<sup>th</sup>, and 95<sup>th</sup>

percentiles, figures showing these percentiles have also been included to help readers visualize the analytical results. Vertical lines above and below the point estimate of the percentile in these graphs represent the 95% confidence interval, which gives an estimate of uncertainty for that percentile. Percentile estimates for both survey periods are plotted.

For urine measurements, data are shown for the both the concentration in urine and the concentration corrected for urine-creatinine level. Serum measurements for chemicals that concentrate in lipid (e.g., dioxins, furans, PCBs, organochlorine pesticides) are presented per gram of total lipid in the serum and also per whole weight of serum.

*General information is provided for each chemical that also aids the interpretation of levels.*

A brief overview of information about each chemical is provided in the text to address common uses, sources of human exposure, disposition in the body, and known human health effects or major consistent effects in animals. Additionally, studies from other populations where blood and urine levels are available are presented for comparison.

The text also discusses briefly differences among demographic groups obtained by comparing the geometric means adjusted for the demographic covariates of age, gender, race/ethnicity, and when applicable, urinary creatinine, serum cotinine, or a lipid level. These adjusted geometric means are not shown in the tables. See the section titled “Data Sources and Data Analysis” for more details.

## Interpreting Report Exposure Data: Important Factors

### The survey design provides estimates for the U.S. population.

NHANES is designed to provide estimates for the civilian, noninstitutionalized U.S. population. The NHANES design does not select or exclude participants on the basis of their potential for low or high exposure to a chemical. The current design does not permit examination of exposure levels by locality, state, or region; seasons of the year; proximity to sources of exposure; or use of particular products. For example, it is not possible to extract a subset of the data and examine levels of blood lead that represent levels in a particular state’s population.

**Data from earlier Reports are included in the Third Report.**

The *Third Report* includes data from the *First* and *Second Reports* in the tables and charts. One exception is that 10<sup>th</sup> and 25<sup>th</sup> percentiles are no longer included in the *Report* because of space limitations in the tables. Each chemical has 50<sup>th</sup>, 75<sup>th</sup>, 90<sup>th</sup>, and 95<sup>th</sup> percentiles included in the tables along with the unadjusted geometric means and sample sizes for the survey periods (i.e., 1999-2000 and 2001-2002) for which that chemical was analyzed. Current plans are to release future *Reports* of the exposure of the U.S. population to cover 2-year periods (e.g., 2003-2004, 2005-2006, 2007-2008).

**Statistical tests for significance of trends over time should await additional data from future Reports. More detailed research analyses of the data in the Report is encouraged.**

We have not performed statistical tests for trends over time given that data are available only for the 1999-2000 and 2001-2002 survey periods. New data will be released for the U.S. population every 2 years, with the next release covering the survey period 2003-2004. With additional data points it will be possible to describe patterns over time and in some cases test for trends. We plan to investigate trends in future *Reports* for chemicals that have at least 3 survey periods

More in-depth statistical analysis, including additional covariates, interactions and predictive variables, are beyond the scope of this document. We hope that scientists will be stimulated to examine the data further through analysis of the raw data available at <http://www.cdc.gov/nchs/nhanes.htm>.

**Research studies, separate from the Report, are required to determine which blood or urine levels are safe and which are associated with disease.**

The measurement of an environmental chemical in a person's blood or urine does not by itself mean that the chemical causes disease. Advances in analytical methods allow us to measure low levels of environmental chemicals in people, but separate studies of varying exposure levels and health effects are needed to determine which blood or urine levels result in disease. These studies must also consider other factors such as duration of exposure. The *Third Report* does not present new data on health risks from different exposures.

For some environmental chemicals, such as lead, research studies have given us a good understanding of the health risks associated with different blood lead levels. However, for many environmental chemicals, we need more research to assess health risks from different blood or urine levels. The results shown in the *Third Report* should help prioritize and foster research on human health risks that result from exposure to environmental chemicals.

Not all the chemicals in the *Report* are measured in the same individuals. Therefore, it is not possible to determine how many of the 148 chemicals were found at detectable levels in a given person. As noted above, the presence of a chemical does not imply disease. The levels or concentrations of the chemical are more important determinants of the relation to disease, when established in appropriate research studies, than the detection or presence of a chemical.

For more information about exposure to environmental chemicals, see the section titled "Toxicology and Health-Risk Information," which includes Internet reference sites. Each environmental chemical can be searched in databases at these Web sites using its chemical name or the Chemical Abstract Service (CAS) number, which is provided in the *Third Report*. The Agency for Toxic Substances and Disease Registry's (ATSDR) Toxicological Profiles and ToxFAQs provide good summaries of toxicology information as well as answers to common questions about exposure and health effects.

**Blood and urine levels of a chemical should not be confused with levels of the chemical in air, water, food, soil, or dust.**

Concentrations of environmental chemicals in blood or urine are not the same as those in air, water, food, soil, or dust. For example, a chemical concentration of 10 µg/L in water does not produce a level of 10 µg/L in blood or urine. Blood or urine levels may reflect exposure from one or more sources, including air, water, food, soil, and dust.

Levels of a chemical in blood and urine are determined by how much of the chemical has entered the body through all routes of exposure, including ingestion, inhalation, or dermal absorption, and how the chemical is distributed in body tissues, transformed into metabolites, and eliminated from the body. Although the levels in the blood and urine are measures of the amount of a chemical that has entered the body by all routes of exposure, the blood or urine level alone does not determine which exposure source or which route of

exposure has occurred. Except for metals, most measurements in urine quantify chemical metabolites.

## Biomonitoring Exposure Measurements

The blood and urine exposure measurements presented in the *Third Report* were made at CDC's Environmental Health Laboratory (Division of Laboratory Sciences, National Center for Environmental Health). The analytical methods used for measuring the environmental chemicals or their metabolites in blood and urine were based on isotope dilution mass spectrometry, inductively coupled plasma mass spectrometry, or graphite furnace atomic absorption spectrometry. References for the analytical methods used to measure the different chemicals are provided in Appendix B. Laboratory measurements undergo extensive quality control and quality assurance review, including tolerance limits for operational parameters, the measurement of quality control samples in each analytical run to detect unacceptable performance in accuracy or precision, and verification of traceable calibration materials.

For chemicals measured in urine, levels are presented two ways: per volume of urine and per gram of creatinine. Levels per gram of creatinine (i.e., creatinine-corrected) adjust for urine dilution. For example, if one person has consumed more fluids than another person, his or her urine output is likely higher and the urine more dilute than that of the latter person. Creatinine is excreted from the body at a relatively constant rate over time, so expressing the result per gram of creatinine helps adjust for the effects of urinary dilution. The range and mean of

creatinine levels were 2-650 mg/dL and 136.4 mg/dL in NHANES 1999-2000, and 5-774 mg/dL and 130.6 mg/dL in NHANES 2001-2002, respectively, results that are typical for the general U.S. population (see Barr et al., 2005). Creatinine corrects for urinary dilution in individual specimens, although this dilution variability has little effect on point estimates (e.g., means, percentiles). Interpretation of creatinine corrected results should also recognize that creatinine correction can also partially adjust for differences in lean body mass or renal function among persons.

For dioxins, furans, PCBs, and organochlorine pesticides, serum levels are presented per gram of total lipid and per whole weight of serum. These compounds are lipophilic and concentrate in the body's lipid stores, including the lipid in serum. Serum levels reported per gram of total lipid reflect the amount of these compounds that are stored in body fat. Serum levels per whole weight of serum are also included to facilitate comparison with studies investigating exposure to these chemicals that have published results in these units.

Units of measurement are important. Results are reported here using standard units, generally conforming to those most commonly used in biomonitoring measurements. Useful unit conversions are presented in Table 2.

## Selection of Chemicals Included in the Report

Chemicals in the *Report* were selected on the basis of scientific data that suggested exposure in the U.S. population; the seriousness of health effects known or suspected to result from some levels of exposure; the need to assess the efficacy of public health actions to reduce exposure to a chemical; the availability of a biomonitoring analytical method with adequate accuracy, precision, sensitivity, specificity, and throughput; the availability of adequate blood or urine samples; and the incremental analytical cost to perform the biomonitoring analysis for the chemical. The availability of biomonitoring methods with adequate performance and acceptable cost was a major consideration.

In October 2002, CDC solicited nominations for candidate chemicals or categories of chemical to include in future *Reports* (*Federal Register*, Vol. 67, No. 194, October 7, 2002) and received nominations for hundreds of chemicals. Details on the prioritization process for scoring the nominated chemicals and the resulting scores are available at [www.cdc.gov/exposurereport/chemical\\_nominations.htm](http://www.cdc.gov/exposurereport/chemical_nominations.htm).

**Table 2. Units of Measurements and Conversions**

Unit	Abbreviation	Value
liter	L	
deciliter	dL	10 <sup>-1</sup> liters
milliliter	mL	10 <sup>-3</sup> liters
gram	g	
milligram	mg	10 <sup>-3</sup> grams
microgram	µg	10 <sup>-6</sup> grams
nanogram	ng	10 <sup>-9</sup> grams
picogram	pg	10 <sup>-12</sup> grams
femtogram	fg	10 <sup>-15</sup> grams
parts-per-million	ppm	1 µg/g, or approximately 1 µg/mL or 1 mg/L
parts-per-billion	ppb	1 ng/g, or approximately 1 ng/mL or 1 µg/L
parts-per-trillion	ppt	1 pg/g, or approximately 1 pg/mL or 1 ng/L
parts-per-quadrillion	ppq	1 fg/g, or approximately 1 fg/mL or 1 pg/L



## Data Sources and Data Analysis

### The National Health and Nutrition Examination Survey (NHANES)

Biomonitoring measurements for the *Report* were made in samples from participants in NHANES. NHANES is a series of surveys conducted by CDC's National Center for Health Statistics (NCHS) that is designed to collect data on the health and nutritional status of the U.S. population. NHANES collects information about a wide range of health-related behaviors, performs a physical examination and collects samples for laboratory tests. NHANES is unique in its ability to examine public health issues in the U.S. population, such as risk factors for cardiovascular disease. Beginning in 1999, NHANES became a continuous survey, sampling the U.S. population annually and releasing the data in 2-year cycles. The sampling plan follows a complex, stratified, multistage, probability-cluster design to select a representative sample of the civilian, noninstitutionalized population in the United States.

The NHANES protocol includes a home interview followed by a standardized physical examination in a mobile examination center. As part of the examination component, blood is obtained by venipuncture for participants aged 1 year and older, and urine specimens are collected from people aged 6 years and older. Additional detailed information on the design and conduct of the NHANES survey is available at <http://www.cdc.gov/nchs/nhanes.htm>.

Environmental chemicals were measured in either blood or urine specimens collected as part of the examination component of NHANES. The age range for which a chemical was measured varied by chemical group. Most of the environmental chemicals were measured in randomly selected subsamples within specific age groups. Randomization of subsample selection is built into the NHANES design before sample collection begins. This subsampling was needed to ensure an adequate quantity of sample for analysis and to accommodate the throughput of the mass spectrometry analytical methods.

Age groups and sample sizes for each exposure measurement are provided in each of the tables of results. Blood lead and cadmium levels were measured in all people aged 1 year and older. Serum cotinine was measured in the entire NHANES sample for ages 3 years and older. Total blood mercury was measured in children aged 1-5 years and in women aged 16-49 years. Urine mercury was measured in women aged 16-49 years.

Metals, phthalates, polycyclic aromatic hydrocarbons (PAHs), and phytoestrogens were measured in urine from a random one-third subsample of people aged 6 years and older.

Urinary levels of herbicides, selected pesticides, and metabolites of organophosphate pesticides were measured in a random one-half subsample of children aged 6-11 years in 1999 and 2000, a random one-quarter subsample of people aged 12-59 years in 1999, and a random one-third subsample of people aged 12 years and older in 2000. These chemicals also were measured in a random one-third subsample of people aged 6 years and older in 2001 and 2002. Dioxins, furans, polychlorinated biphenyls (PCBs), and organochlorine pesticides were measured in serum from a random one-third subsample of people aged 12 years and older in 1999 and 2000. In 2001 and 2002, dioxins, furans, and coplanar PCBs were measured in a random one-third subsample of people aged 20 years and older and organochlorine pesticides and other PCBs were measured in a random one-third subsample of people aged 12 years and older.

### Data Analysis

Because the NHANES sample design is complex, sample weights must be used to adjust for the unequal probability of selection into the survey. Sample weights also are used to adjust for possible bias resulting from nonresponse and are post-stratified to U.S. Census Bureau estimates of the U.S. population. Data were analyzed using the statistical software package Statistical Analysis System (SAS) (SAS Institute Inc., 2002) and the statistical software package SUDAAN (SUDAAN Release 8.0, 2001). SUDAAN uses sample weights and calculates variance estimates that account for the complex survey design.

Guidelines for the analysis of NHANES data are provided by NCHS at [http://www.cdc.gov/nchs/data/nhanes/nhanes\\_general\\_guidelines\\_june\\_04.pdf](http://www.cdc.gov/nchs/data/nhanes/nhanes_general_guidelines_june_04.pdf). These guidelines note that the previous analysis of 1999-2000 data used a jackknife method (available within SUDAAN) for variance estimation that was based on replicate weights. To better address multiple 2-year data sets and combining 2-year data sets into 4-year data sets, NCHS developed a new approach based on masked variance units that uses a Taylor series (linearization) method that is also available in SUDAAN. More details on this approach are provided in the analytical guidelines.

In the *Third Report*, all variance estimates (both 1999-2000 and 2001-2002 data) were calculated using the Taylor series (linearization) method within SUDAAN. In the *Second Report*, 1999-2000 variance estimates were calculated using the jackknife method (See Appendix C for details). The two methods produce very similar, but not identical, variance estimates. Consequently, some confidence intervals for 1999-2000 presented in the *Second Report* will differ slightly from confidence intervals for the same time period presented in the *Third Report*.

Selected percentiles and unadjusted geometric means of analyte concentrations are presented in tables and charts. Percentile estimates were calculated using SAS Proc Univariate using weighted data. Results are shown for the total population and also by age group, gender, and race/ethnicity as defined in NHANES. For these analyses, race/ethnicity is categorized as Mexican American, non-Hispanic black, and non-Hispanic white. Other racial/ethnic groups are sampled, but the proportion of the total population represented by other racial/ethnic groups is not large enough to produce valid estimates. Other racial/ethnic groups are included in estimates that are based on the entire population sample. Age groups are shown for each chemical in the results table. Gender is coded as male or female.

In the text (not in the tables), results are presented of comparisons of geometric mean levels for different demographic groups using analysis of covariance (ANCOVA), which included as covariates age, gender, race/ethnicity, urine creatinine and serum cotinine, as appropriate. ANCOVA allows for comparison of geometric means of two demographic groups after adjusting for these covariates. For example, when comparing geometric mean blood lead levels for adolescents to those for adults, the ANCOVA would first adjust the geometric mean blood lead level for adolescents for gender, race/ethnicity, and serum cotinine and also the geometric mean blood lead level for adults for gender, race/ethnicity, and serum cotinine. The ANCOVA was performed using SUDAAN with a significance level for statistical testing of  $\alpha = 0.025$ . These analyses were conducted separately for each two year survey period and differences for each survey period were not statistically compared.

Urine creatinine is included as a continuous variable in the ANCOVA for chemicals measured in urine to adjust for urinary dilution. Cotinine is a major metabolite of nicotine and a good indicator of smoking status. Therefore, log cotinine is also included as a continuous variable in ANCOVA analyses of dioxins; furans; PCBs;

organochlorine pesticides; PAHs; and the metals (lead, cadmium, mercury, antimony, barium, molybdenum, thallium) to adjust for known or probable effects of smoking on the levels of these chemicals in blood or urine, including the contribution of chemicals contained in smoke and the effect of chemicals in smoke on the metabolism of other measured chemicals. The decision to adjust for log cotinine was determined by whether log cotinine was a significant predictor of the chemical's concentration and results of research that examined cotinine as a predictive variable.

Concentrations less than the limit of detection (LOD) were assigned a value equal to the LOD divided by the square root of 2 for calculation of geometric means. The LOD is the level at which the measurement has a 95% probability of being greater than zero (Taylor, 1987). Assigning a value of the LOD divided by 2 made little difference in geometric mean estimates. Percentile estimates that are less than the LOD for the chemical analysis are reported as "< LOD." If the proportion of results below the LOD was greater than 40%, geometric means were not calculated. Appendix A contains a table of LOD values for each chemical. For the same chemical, LOD values may change over time as a result of improvements to analytical methods. One possible consequence is that results may be reported as "< LOD" in the 1999-2000 data but be reported as a concentration value above the LOD in 2001-2002 because the analytical method had improved. Thus, for proper interpretation, the LOD values in the tables of descriptive statistics tables should be referenced to the LOD table in Appendix A.

For most chemicals, the LOD is constant for each sample analyzed. For dioxins, furans, PCBs, organochlorine pesticides, and a few other pesticides, each individual sample has its own LOD. These analyses have an individual LOD for each sample, mostly because the sample volume used for analysis differed for each sample. A higher sample volume results in a lower LOD (i.e., a better ability to detect low levels). For these chemicals, the maximum LOD value is provided in the LOD table in Appendix A. The maximum LOD was the highest LOD among all the individual samples analyzed. In general, the mean LOD was about 40-50% of the maximum LOD.

The same procedure for imputing values below the LOD in calculations of geometric means was used for chemicals with individual LODs for each sample. That is, concentrations less than the individual LOD were assigned a value equal to the individual LOD divided by the square root of 2. For chemicals that had individual

sample LODs, a conservative rule was used for reporting percentiles: if any individual sample LOD in the demographic group was above the percentile estimate, the percentile estimate was not reported.

For chemicals measured in urine, separate tables are presented for the chemical concentration expressed per volume of urine (uncorrected table) and the chemical concentration expressed per gram of creatinine (creatinine corrected table). Geometric mean and percentile calculations were performed separately for each of these concentrations. LOD calculations were performed using the chemical concentration expressed per volume of urine, because this concentration determines the analytical sensitivity. For this reason, LOD results for urine measurements in Appendix A are in weight per volume of urine. In the creatinine corrected tables, a result for a geometric mean or percentile was reported as < LOD if the corresponding geometric mean or percentile was < LOD in the uncorrected table. So for example, if the 50th percentile for males was < LOD in the uncorrected table, it would also be < LOD in the creatinine corrected table.

For chemicals measured in serum lipid, separate tables are presented for the chemical concentration expressed per volume of serum (lipid unadjusted table) and the chemical concentration expressed per amount of lipid (lipid adjusted table). Geometric mean and percentile calculations were performed separately for each of these concentrations. LOD calculations were performed using the chemical concentration expressed per amount of lipid, because this concentration determines the analytical sensitivity. For this reason, LOD results for chemicals measured in serum lipid in Appendix A are in weight per amount of lipid. In the lipid unadjusted tables, a result for a geometric mean or percentile was reported as < LOD if the corresponding geometric mean or percentile was < LOD in the lipid adjusted table.



## Toxicology and Health-Risk Information

The *Third Report* presents new data on the exposure of the U.S. population to environmental chemicals. The measurement of an environmental chemical in a person's blood or urine does not by itself mean that the chemical causes disease. Advances in analytical methods allow us to measure lower and lower levels of environmental chemicals in people. Separate studies of varying exposure levels and health effects are required to determine which blood and urine levels are safe and which result in disease.

If available, generally recognized guidelines for blood or urine levels for each chemical are presented in the *Third Report* in the text discussion provided for each chemical or chemical group. These guidelines are usually from federal agencies. One exception is the American Conference of Governmental Industrial Hygienists (ACGIH), a private organization that publishes biological exposure indices (BEIs) which "generally indicate a concentration below which nearly all workers should not experience adverse health effects" (ACGIH, 2001). BEIs are blood or urine levels of a chemical that correspond to air-exposure limits for workers set by ACGIH. This organization notes that these values are for workers and that it is not appropriate to apply them to the general population. Information about the BEI level is provided here for comparison, not to imply that the BEI is a safety level for general population exposure. For most chemicals reported here, such guidelines are not available.

The *Report* also provides written information about each chemical or chemical group regarding uses, sources of human exposure, disposition in the body, and major effects, if known. In addition, selected studies have been provided, where possible, to permit comparison of blood and urine levels of a chemical in other population groups. Although the information in the text is provided as a brief overview for each chemical, it is not intended as a comprehensive review of each chemical. Generally, information was retrieved from major texts, consensus documents, and federal agency reviews, and then supplemented with published scientific investigations obtained by electronic searches in national and international databases.

### Information Available on the Internet

Links to nonfederal organizations are provided solely as a service to our readers. These links do not constitute an endorsement of these organizations or their programs by CDC or the federal government. CDC is not responsible for the content of an individual organization's Web pages found at these links. For information about toxicology and health risks, see the following sites:

#### U.S. Government-Related Internet Links

*Centers for Disease Control and Prevention (CDC) and Agency for Toxic Substances and Disease Registry (ATSDR)*

- NIOSH Pocket Guide to Chemical Hazards: <http://www.cdc.gov/niosh/npg/npgd0000.html>
- Registry of Toxic Effects of Chemical Substances (RTECS): <http://www.cdc.gov/niosh/rtecs>
- Tobacco Information and Prevention Source: <http://www.cdc.gov/tobacco>
- National Center for Health Statistics: <http://www.cdc.gov/nchs>
- National Health and Nutrition Examination Survey: <http://www.cdc.gov/nchs/nhanes.htm>
- Childhood Lead Poisoning Prevention Program: <http://www.cdc.gov/nceh/lead/lead.htm>
- Pesticides and Public Health: Integrated Methods of Mosquito Management: <http://www.cdc.gov/ncidod/eid/vol7no1/rose.htm>
- National Institute for Occupational Safety and Health (NIOSH), Occupational Health and Safety Guidelines for Chemical Hazards: <http://www.cdc.gov/niosh/81-123.html>
- Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles and ToxFAQs: <http://www.atsdr.cdc.gov/toxprofiles> or <http://www.atsdr.cdc.gov/toxfaq.html>

*U.S. Department of Health and Human Services (U.S. DHHS)*

- Environmental Health Policy Committee: <http://web.health.gov/environment>

*U.S. Food and Drug Administration (U.S. FDA)*

- Center for Devices and Radiological Health: <http://www.fda.gov/cdrh>
- Center for Food Safety and Applied Nutrition: <http://www.cfsan.fda.gov>
- National Center for Toxicological Research: <http://www.fda.gov/nctr>

*National Institutes of Health (NIH)*

- National Cancer Institute (NCI): <http://www.nci.nih.gov>
- National Institute of Child Health and Human Development (NICHD): <http://www.nichd.nih.gov>
- National Institute for Environmental Health Sciences (NIEHS): <http://www.niehs.nih.gov>
- National Toxicology Program (NTP) Chemical Health and Safety Data: <http://ntp.niehs.nih.gov/index.cfm?objectid=03610FA5-C828-304B-FE31F1182E8F764C>
- National Toxicology Program (NTP) Report on Carcinogens: <http://ntp.niehs.nih.gov/ntpweb/index.cfm?objectid=72016262-BDB7-CEBA-FA60E922B18C2540>
- Chemical Carcinogenesis Research Information System: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CCRIS>
- Hazardous Substances Data Bank (HSDB®): <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB>

*U.S. Environmental Protection Agency (U.S. EPA)*

- Office of Air and Radiation (OAR): <http://www.epa.gov/oar>
- Office of Environmental Information (OEI): <http://www.epa.gov/oei>
- Office of Prevention, Pesticides, and Toxic Substances (OPPTS): <http://www.epa.gov/opptsmt/index.htm>
- Office of Research and Development (ORD): <http://www.epa.gov/ORD>
- Office of Water (OW): <http://www.epa.gov/OW>
- Office of Pesticide Programs: <http://www.epa.gov/pesticides>
- EPA Integrated Risk-Information System (IRIS): <http://www.epa.gov/iris>
- EPA Envirofacts: [http://www.epa.gov/enviro/index\\_java.html](http://www.epa.gov/enviro/index_java.html)
- Lead: <http://www.epa.gov/OGWDW/dwh/c-ioc/lead.html>

*U.S. Department of Agriculture (USDA)*

- Food Safety and Inspection Service: <http://www.fsis.usda.gov>
- USDA, Forest Service Pesticide Fact Sheets: <http://www.fs.fed.us/foresthealth/pesticide>

*U.S. Department of Energy (DOE)*

- Office of Environment, Safety and Health: <http://tis.eh.doe.gov/portal/home.htm>

*U.S. Department of Housing and Urban Development (HUD)*

- Office of Healthy Homes and Lead-Hazard Control: <http://www.hud.gov/offices/lead>

*U.S. Consumer Product Safety Commission (CPSC)*

- <http://www.cpsc.gov>

*U.S. Department of Transportation (DOT)*

- Hazardous Materials Emergency-Response Guidebook: <http://hazmat.dot.gov/pubs/erg/gydebook.htm>

*U.S. Department of Labor, Occupational Safety and Health Administration (OSHA)*

- <http://www.osha.gov/index.html>

**Other Related Internet Sites**

- American College of Occupational and Environmental Medicine: <http://www.acoem.org>
- Association of Occupational and Environmental Clinics: <http://www.aoec.org>
- Association of Public Health Laboratories: <http://www.aphl.org>
- Chemfinder: <http://www.chemfinder.com>
- International Chemical Safety Cards: <http://www.ilo.org/public/english/protection/safework/cis/products/icsc/dtasht/index.htm>
- International Programme on Chemical Safety (IPCS): <http://www.who.int/pcs>
- Material Safety Data Sheets (MSDS): [www.hazard.com/msds](http://www.hazard.com/msds)
- National Research Council (NRC) Toxicological Effects of Methylmercury: <http://books.nap.edu/books/0309071402/html/index.html>

## Results by Chemical Group

---

### Metals



# Antimony

CAS No. 7440-36-0

## General Information

In nature, antimony can be found in ores or other minerals, often combined with oxygen to form antimony trioxide. Elemental antimony can exist in one of four valences in its various chemical and physical forms: -3, 0, +3 and +5. Antimony is used in metal alloys, storage batteries, solder, sheet and pipe metal, ammunition, metal bearings, castings, and pewter. Antimony is used as a fire-retardant in textiles and plastics. It is also used in paints, ceramics, fireworks, enamels, and glass. Stibine is a metal hydride form of antimony used in the semiconductor industry. Two antimony compounds (sodium stibogluconate and antimony potassium tartrate) are used as antiparasitic medications.

Antimony enters the environment from natural sources and from its use in industry. People are exposed to

antimony primarily from food and to a lesser extent from air and drinking water. Workplace exposures occur as a result of breathing the air near industries such as smelters, coal-fired plants, and refuse incinerators that process or release antimony. Dermal contact with soil, water, or other substances containing antimony is another means of exposure.

The absorption, distribution, and excretion of antimony vary depending on its oxidation state. Urinary excretion appears to be greater for pentavalent antimony than for trivalent compounds (Elinder and Friberg, 1986). An elimination half-life of about 95 hours has been estimated after occupational exposures (Kentner et al., 1995).

Inorganic antimony salts irritate the mucous membranes, skin, and eyes. Acute inhalational exposure to antimony has been associated with irritation of the respiratory tract

### Table 3. Antimony

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.132</b> (.120-.145)	<b>.130</b> (.120-.140)	<b>.210</b> (.200-.230)	<b>.330</b> (.300-.350)	<b>.420</b> (.390-.460)	2276
	01-02	<b>.134</b> (.126-.142)	<b>.130</b> (.120-.130)	<b>.180</b> (.180-.190)	<b>.260</b> (.240-.300)	<b>.340</b> (.320-.390)	2690
<b>Age group</b>							
6-11 years	99-00	<b>.176</b> (.154-.200)	<b>.190</b> (.160-.200)	<b>.260</b> (.230-.280)	<b>.350</b> (.300-.390)	<b>.400</b> (.320-.600)	316
	01-02	<b>.146</b> (.134-.160)	<b>.150</b> (.130-.160)	<b>.200</b> (.180-.210)	<b>.260</b> (.230-.310)	<b>.330</b> (.280-.380)	368
12-19 years	99-00	<b>.158</b> (.141-.178)	<b>.170</b> (.150-.180)	<b>.230</b> (.210-.270)	<b>.340</b> (.290-.420)	<b>.460</b> (.350-.510)	663
	01-02	<b>.169</b> (.156-.184)	<b>.150</b> (.140-.180)	<b>.230</b> (.220-.250)	<b>.350</b> (.320-.400)	<b>.460</b> (.360-.480)	762
20 years and older	99-00	<b>.123</b> (.112-.137)	<b>.110</b> (.100-.120)	<b>.190</b> (.180-.220)	<b>.310</b> (.280-.330)	<b>.420</b> (.390-.470)	1297
	01-02	<b>.128</b> (.119-.136)	<b>.120</b> (.120-.130)	<b>.170</b> (.160-.190)	<b>.240</b> (.220-.280)	<b>.330</b> (.280-.380)	1560
<b>Gender</b>							
Males	99-00	<b>.143</b> (.131-.157)	<b>.140</b> (.130-.150)	<b>.240</b> (.220-.250)	<b>.350</b> (.320-.370)	<b>.470</b> (.390-.570)	1132
	01-02	<b>.145</b> (.136-.154)	<b>.130</b> (.130-.150)	<b>.200</b> (.180-.200)	<b>.310</b> (.280-.330)	<b>.390</b> (.350-.430)	1335
Females	99-00	<b>.122</b> (.109-.137)	<b>.120</b> (.100-.130)	<b>.190</b> (.180-.220)	<b>.300</b> (.270-.330)	<b>.390</b> (.350-.460)	1144
	01-02	<b>.125</b> (.117-.133)	<b>.110</b> (.110-.120)	<b>.180</b> (.160-.190)	<b>.240</b> (.210-.260)	<b>.310</b> (.260-.350)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.132</b> (.108-.161)	<b>.130</b> (.110-.160)	<b>.200</b> (.180-.240)	<b>.300</b> (.250-.370)	<b>.410</b> (.330-.560)	787
	01-02	<b>.142</b> (.130-.154)	<b>.120</b> (.110-.130)	<b>.200</b> (.160-.220)	<b>.250</b> (.230-.300)	<b>.360</b> (.300-.390)	683
Non-Hispanic blacks	99-00	<b>.175</b> (.148-.207)	<b>.180</b> (.150-.200)	<b>.260</b> (.220-.290)	<b>.390</b> (.310-.470)	<b>.490</b> (.400-.620)	554
	01-02	<b>.180</b> (.164-.197)	<b>.160</b> (.150-.180)	<b>.250</b> (.210-.280)	<b>.350</b> (.320-.410)	<b>.450</b> (.370-.530)	667
Non-Hispanic whites	99-00	<b>.128</b> (.115-.144)	<b>.120</b> (.110-.140)	<b>.210</b> (.180-.220)	<b>.320</b> (.280-.350)	<b>.400</b> (.350-.500)	768
	01-02	<b>.126</b> (.117-.135)	<b>.120</b> (.120-.130)	<b>.180</b> (.170-.180)	<b>.240</b> (.220-.270)	<b>.340</b> (.310-.390)	1132

and impaired pulmonary function (Renes, 1953). Pulmonary edema may occur in severe cases (Cordasco et al., 1973). Dysrhythmias and T-wave changes on electrocardiogram have also been noted in people after both therapeutic (Berman, 1988; Ming-Hsin et al., 1958) and occupational exposures (Briegner et al., 1954). Ingestion of antimony may cause people to experience a metallic taste, and gastrointestinal symptoms such as vomiting, diarrhea, abdominal pain, and ulcers (Werrin, 1962). The toxicity of stibine after acute inhalational exposure has been reported to be similar to that of arsine, resulting in hemolysis with abdominal and back pain (Dernehl et al., 1944).

Workplace standards for air exposure to antimony have been established by OSHA and ACGIH. Antimony trioxide is rated as being possibly carcinogenic to humans by IARC. Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at <http://www.epa.gov/iris> and from ATSDR's Toxicological Profiles at

<http://www.atsdr.cdc.gov/toxprofiles>.

### Interpreting Levels of Urinary Antimony Reported in the Tables

Urinary antimony levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Previous studies reporting measurements in general populations (Minoia et al., 1990; Paschal et al., 1998) or compiled reference ranges (Hamilton et al., 1994) have found values slightly higher than those reported here, which may be due to methodologic, population, or exposure differences. Several investigations of airborne exposures to antimony in workers show urinary levels that are many times higher than those seen in this *Report*, even when exposure levels were below workplace air standards (Iavicoli et al., 2002; Kentner et al., 1995; Ludersdorf et al., 1987; Bailly et al., 1991).

**Table 4. Antimony (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.124</b> (.108-.143)	<b>.119</b> (.102-.143)	<b>.185</b> (.163-.213)	<b>.274</b> (.233-.333)	<b>.382</b> (.333-.430)	2276
	01-02	<b>.126</b> (.119-.134)	<b>.120</b> (.115-.126)	<b>.173</b> (.162-.188)	<b>.265</b> (.242-.296)	<b>.364</b> (.320-.414)	2689
<b>Age group</b>							
6-11 years	99-00	<b>.191</b> (.147-.248)	<b>.183</b> (.156-.220)	<b>.250</b> (.196-.414)	<b>.439</b> (.271-.741)	<b>.537</b> (.333-1.30)	316
	01-02	<b>.178</b> (.159-.200)	<b>.173</b> (.150-.193)	<b>.228</b> (.200-.272)	<b>.338</b> (.265-.480)	<b>.469</b> (.313-.727)	368
12-19 years	99-00	<b>.121</b> (.104-.140)	<b>.119</b> (.095-.146)	<b>.176</b> (.146-.206)	<b>.259</b> (.206-.310)	<b>.310</b> (.228-.421)	663
	01-02	<b>.121</b> (.112-.131)	<b>.115</b> (.106-.127)	<b>.159</b> (.138-.186)	<b>.224</b> (.199-.245)	<b>.266</b> (.244-.310)	762
20 years and older	99-00	<b>.118</b> (.104-.135)	<b>.111</b> (.096-.136)	<b>.174</b> (.149-.209)	<b>.263</b> (.227-.320)	<b>.352</b> (.320-.391)	1297
	01-02	<b>.122</b> (.115-.129)	<b>.115</b> (.108-.121)	<b>.167</b> (.153-.179)	<b>.265</b> (.241-.296)	<b>.364</b> (.318-.405)	1559
<b>Gender</b>							
Males	99-00	<b>.112</b> (.099-.127)	<b>.108</b> (.095-.127)	<b>.164</b> (.146-.181)	<b>.226</b> (.204-.268)	<b>.319</b> (.235-.391)	1132
	01-02	<b>.114</b> (.107-.123)	<b>.108</b> (.103-.115)	<b>.153</b> (.138-.171)	<b>.228</b> (.205-.250)	<b>.333</b> (.272-.421)	1334
Females	99-00	<b>.137</b> (.117-.161)	<b>.131</b> (.108-.164)	<b>.212</b> (.176-.247)	<b>.318</b> (.257-.400)	<b>.425</b> (.357-.485)	1144
	01-02	<b>.139</b> (.131-.148)	<b>.132</b> (.124-.140)	<b>.196</b> (.178-.211)	<b>.295</b> (.267-.317)	<b>.371</b> (.333-.444)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.120</b> (.107-.135)	<b>.114</b> (.105-.129)	<b>.167</b> (.148-.203)	<b>.249</b> (.207-.313)	<b>.333</b> (.280-.357)	787
	01-02	<b>.138</b> (.128-.149)	<b>.129</b> (.117-.143)	<b>.182</b> (.159-.203)	<b>.269</b> (.229-.308)	<b>.338</b> (.308-.429)	682
Non-Hispanic blacks	99-00	<b>.114</b> (.099-.133)	<b>.112</b> (.098-.130)	<b>.163</b> (.144-.183)	<b>.236</b> (.195-.338)	<b>.339</b> (.255-.425)	554
	01-02	<b>.123</b> (.113-.134)	<b>.115</b> (.106-.126)	<b>.163</b> (.150-.181)	<b>.232</b> (.208-.267)	<b>.300</b> (.248-.373)	667
Non-Hispanic whites	99-00	<b>.129</b> (.109-.152)	<b>.124</b> (.102-.152)	<b>.195</b> (.167-.225)	<b>.298</b> (.239-.352)	<b>.400</b> (.333-.444)	768
	01-02	<b>.127</b> (.117-.138)	<b>.120</b> (.113-.130)	<b>.176</b> (.159-.198)	<b>.280</b> (.241-.317)	<b>.380</b> (.318-.471)	1132


## Comparing Adjusted Geometric Means

Geometric mean levels of urinary antimony for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary antimony were slightly higher for the group aged 6-11 years than for either groups aged 12-19 years or 20 years and older. The group aged 12-19 years had higher levels than the group aged 20 years and older. Mexican Americans had slightly higher levels than non-Hispanic whites. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of antimony in urine does not mean that the level of antimony causes an adverse health effect. Whether antimony at the levels reported here is a cause for health concern is not yet known; more research is needed. These urine antimony data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of antimony than are found in the general population. These data will also help scientists plan and conduct research about exposure to antimony and health effects.

**Figure 1. Antimony (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



## Barium

CAS No. 7440-39-3

### General Information

Elemental barium is a silver-white metal. Barium's abundance in the earth's crust is approximately 0.05%. In nature, it combines with other chemicals such as sulfur or carbon and oxygen to form numerous barium salts. Of the various salts, approximately half are freely soluble in water, whereas the others are practically insoluble (notably barium sulfate and barium carbonate). Barium compounds are used by the oil and gas industries to make drilling muds. These compounds are also produced commercially for use in paint, bricks, tiles, glass, rubber, depilatories, fireworks, and ceramics. Medically, barium sulfate is used as a contrast medium for taking radiographs of the gastrointestinal tract. Barium salts are available for sale as rodenticides.

People can be exposed to barium in air, water, and food.

Small amounts of barium can be released into the air during mining and other industrial processes. Workers employed by industries that make or use barium compounds are exposed to barium dust. Certain foods, such as brazil nuts, are exceptionally high in barium (Genter, 2001).

The health effects of exposure to barium compounds depend on the dose, chemical form, water solubility, and route of exposure. Toxicity from soluble barium salts is rare but occurs after intentional or accidental ingestion of barium carbonate in rodenticides (Genter, 2001). Barium blocks cellular efflux of potassium resulting in extracellular profound hypokalemia. Symptoms include perioral paresthesias, vomiting, diarrhea, weakness, paralysis, hypertension, and cardiac dysrhythmias. The lethal dose of barium by ingestion is reported to be between 0.8-0.9 grams (Jourdan et al., 2001).

**Table 5. Barium**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>1.50</b> (1.35-1.66)	<b>1.50</b> (1.30-1.70)	<b>3.00</b> (2.70-3.40)	<b>5.40</b> (4.60-6.10)	<b>6.80</b> (6.20-8.40)	2180
	01-02	<b>1.52</b> (1.41-1.65)	<b>1.63</b> (1.50-1.75)	<b>3.12</b> (2.76-3.51)	<b>5.22</b> (4.73-5.74)	<b>7.48</b> (6.54-8.12)	2690
<b>Age group</b>							
6-11 years	99-00	<b>2.15</b> (1.70-2.72)	<b>2.20</b> (1.80-2.30)	<b>3.90</b> (2.60-6.10)	<b>6.40</b> (5.20-8.30)	<b>8.30</b> (5.00-76.2)	297
	01-02	<b>1.80</b> (1.44-2.26)	<b>2.08</b> (1.74-2.49)	<b>3.62</b> (2.86-4.39)	<b>5.37</b> (4.26-7.38)	<b>6.88</b> (5.37-8.49)	368
12-19 years	99-00	<b>1.97</b> (1.78-2.19)	<b>2.00</b> (1.60-2.30)	<b>3.50</b> (3.10-4.00)	<b>5.90</b> (4.80-7.00)	<b>9.70</b> (5.90-13.1)	621
	01-02	<b>2.03</b> (1.76-2.34)	<b>2.27</b> (1.96-2.53)	<b>4.09</b> (3.48-4.72)	<b>6.69</b> (5.55-7.87)	<b>9.00</b> (7.25-11.4)	762
20 years and older	99-00	<b>1.36</b> (1.24-1.51)	<b>1.40</b> (1.30-1.70)	<b>2.70</b> (2.50-3.00)	<b>5.00</b> (4.20-5.50)	<b>6.40</b> (5.70-8.30)	1262
	01-02	<b>1.43</b> (1.32-1.54)	<b>1.50</b> (1.39-1.65)	<b>2.85</b> (2.55-3.26)	<b>4.86</b> (4.53-5.47)	<b>7.14</b> (6.08-8.12)	1560
<b>Gender</b>							
Males	99-00	<b>1.70</b> (1.54-1.88)	<b>1.80</b> (1.70-2.00)	<b>3.10</b> (2.80-3.40)	<b>5.50</b> (4.20-6.30)	<b>7.50</b> (5.90-9.40)	1083
	01-02	<b>1.64</b> (1.47-1.82)	<b>1.80</b> (1.63-1.98)	<b>3.15</b> (2.76-3.73)	<b>5.52</b> (4.82-6.35)	<b>7.87</b> (6.49-9.32)	1335
Females	99-00	<b>1.33</b> (1.15-1.53)	<b>1.50</b> (1.20-1.60)	<b>2.80</b> (2.30-3.10)	<b>5.10</b> (4.20-5.90)	<b>6.80</b> (5.60-10.4)	1097
	01-02	<b>1.43</b> (1.30-1.56)	<b>1.43</b> (1.28-1.63)	<b>3.10</b> (2.73-3.43)	<b>4.86</b> (4.44-5.88)	<b>7.15</b> (6.32-7.86)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>1.35</b> (1.25-1.46)	<b>1.30</b> (1.20-1.50)	<b>2.60</b> (2.30-2.90)	<b>4.50</b> (4.00-5.10)	<b>6.30</b> (5.50-6.80)	692
	01-02	<b>1.21</b> (1.06-1.37)	<b>1.24</b> (1.08-1.45)	<b>2.55</b> (2.04-2.90)	<b>4.31</b> (3.65-5.49)	<b>6.08</b> (5.21-8.22)	683
Non-Hispanic blacks	99-00	<b>1.34</b> (1.12-1.62)	<b>1.30</b> (1.20-1.50)	<b>2.50</b> (2.20-2.80)	<b>5.10</b> (3.70-6.40)	<b>7.40</b> (5.40-13.9)	540
	01-02	<b>1.30</b> (1.14-1.48)	<b>1.41</b> (1.22-1.62)	<b>2.61</b> (2.31-2.82)	<b>4.28</b> (3.70-5.18)	<b>5.99</b> (4.87-7.26)	667
Non-Hispanic whites	99-00	<b>1.56</b> (1.36-1.80)	<b>1.70</b> (1.60-2.00)	<b>3.30</b> (2.80-3.70)	<b>5.40</b> (4.50-6.20)	<b>7.20</b> (6.20-8.80)	765
	01-02	<b>1.61</b> (1.46-1.77)	<b>1.67</b> (1.53-1.82)	<b>3.30</b> (2.86-3.73)	<b>5.66</b> (4.94-6.30)	<b>7.70</b> (6.61-8.49)	1132

Chronic accumulation of inhaled barium dust in the lung tissue may cause baritosis, a benign condition that may occur among barite ore miners. Chronic exposures to natural levels of barium in drinking water have not produced general health effects or evidence of cardiovascular risk (Brenniman and Levy, 1984; Wones et al., 1990). Workplace standards for external air exposure to various barium salts have been established by OSHA and a drinking water standard has been established by U.S. EPA. Barium is not rated for carcinogenicity. Information about external exposure and health effects is available from the U.S. EPA's IRIS Web site at <http://www.epa.gov/iris> and from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### Interpreting Levels of Urinary Barium Reported in the Tables

Urinary barium levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range

to be a representative sample of the U.S. population. Previous studies reporting urinary levels of barium in general populations have found values generally similar to those documented in this *Report* (Minoia et al., 1990; Paschal et al., 1998). In addition, levels determined in clinically submitted specimens are broadly comparable (Komaromy-Hiller et al., 2000). Median urinary levels of barium found in welders of barium-containing electrodes were 60 times higher than the median levels in this *Report* (Zschesche et al., 1992) without obvious adverse effects. Urinary concentrations in acute poisonings are often hundreds to thousands times higher.

### Comparing Adjusted Geometric Means

Geometric mean levels of urinary barium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary barium were higher for the group aged 6-11 years than either groups aged 12-19 years or aged 20 years and

**Table 6. Barium (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.


	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>1.40</b> (1.26-1.56)	<b>1.41</b> (1.28-1.54)	<b>2.54</b> (2.18-2.89)	<b>4.68</b> (3.85-5.47)	<b>6.27</b> (5.47-8.09)	2180
	01-02	<b>1.44</b> (1.31-1.58)	<b>1.48</b> (1.35-1.63)	<b>2.76</b> (2.51-3.03)	<b>4.58</b> (4.14-4.95)	<b>6.24</b> (5.28-7.27)	2689
<b>Age group</b>							
6-11 years	99-00	<b>2.37</b> (1.68-3.32)	<b>2.35</b> (1.83-2.92)	<b>4.46</b> (2.55-6.46)	<b>8.77</b> (3.75-22.0)	<b>11.4</b> (5.45-22.0)	297
	01-02	<b>2.20</b> (1.91-2.52)	<b>2.41</b> (2.19-2.83)	<b>3.91</b> (3.29-4.51)	<b>4.96</b> (4.58-6.00)	<b>6.71</b> (5.20-8.47)	368
12-19 years	99-00	<b>1.51</b> (1.34-1.70)	<b>1.39</b> (1.26-1.59)	<b>2.48</b> (1.97-3.06)	<b>4.36</b> (3.23-5.39)	<b>6.95</b> (4.24-11.4)	621
	01-02	<b>1.45</b> (1.33-1.59)	<b>1.56</b> (1.31-1.77)	<b>2.88</b> (2.68-3.12)	<b>4.50</b> (3.84-5.20)	<b>5.55</b> (4.81-6.10)	762
20 years and older	99-00	<b>1.30</b> (1.19-1.42)	<b>1.33</b> (1.20-1.45)	<b>2.32</b> (2.08-2.62)	<b>4.29</b> (3.62-4.91)	<b>5.65</b> (5.28-6.33)	1262
	01-02	<b>1.37</b> (1.24-1.50)	<b>1.40</b> (1.24-1.52)	<b>2.53</b> (2.23-2.84)	<b>4.38</b> (4.02-5.00)	<b>6.55</b> (5.00-7.64)	1559
<b>Gender</b>							
Males	99-00	<b>1.32</b> (1.22-1.42)	<b>1.36</b> (1.23-1.47)	<b>2.39</b> (2.11-2.57)	<b>4.24</b> (3.48-5.00)	<b>5.61</b> (4.39-10.2)	1083
	01-02	<b>1.30</b> (1.16-1.45)	<b>1.34</b> (1.19-1.50)	<b>2.46</b> (2.14-2.83)	<b>4.50</b> (3.73-4.95)	<b>5.42</b> (4.81-7.51)	1334
Females	99-00	<b>1.49</b> (1.27-1.74)	<b>1.46</b> (1.29-1.68)	<b>2.65</b> (2.13-3.46)	<b>4.86</b> (3.96-6.38)	<b>7.36</b> (5.25-11.3)	1097
	01-02	<b>1.59</b> (1.45-1.75)	<b>1.63</b> (1.48-1.79)	<b>2.98</b> (2.75-3.30)	<b>4.76</b> (4.38-5.31)	<b>6.97</b> (5.86-7.52)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>1.21</b> (1.10-1.33)	<b>1.17</b> (1.03-1.37)	<b>2.39</b> (2.10-2.59)	<b>4.00</b> (3.33-4.80)	<b>5.31</b> (4.80-6.51)	692
	01-02	<b>1.18</b> (1.03-1.34)	<b>1.16</b> (1.00-1.38)	<b>2.33</b> (1.90-2.61)	<b>3.68</b> (3.29-4.10)	<b>4.95</b> (4.24-6.80)	682
Non-Hispanic blacks	99-00	<b>.881</b> (.703-1.11)	<b>.904</b> (.710-1.06)	<b>1.64</b> (1.36-2.00)	<b>3.27</b> (2.26-4.76)	<b>4.84</b> (3.57-10.8)	540
	01-02	<b>.891</b> (.777-1.02)	<b>.920</b> (.754-1.11)	<b>1.64</b> (1.44-2.03)	<b>2.86</b> (2.48-3.37)	<b>3.96</b> (3.52-4.68)	667
Non-Hispanic whites	99-00	<b>1.56</b> (1.38-1.77)	<b>1.55</b> (1.36-1.74)	<b>2.72</b> (2.27-3.24)	<b>5.00</b> (3.81-6.02)	<b>6.60</b> (5.52-10.2)	765
	01-02	<b>1.62</b> (1.49-1.76)	<b>1.66</b> (1.49-1.82)	<b>3.04</b> (2.76-3.32)	<b>4.95</b> (4.55-5.41)	<b>6.71</b> (5.57-7.64)	1132

older. Levels in the group aged 12-19 years were higher than the group aged 20 years and older. Levels in non-Hispanic whites were higher than in non-Hispanic blacks and Mexican Americans. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of barium in urine does not mean that the level of barium causes an adverse health effect. Whether barium at the levels reported here is a cause for health concern is not yet known; more research is needed. These urine barium data provide physicians with a reference range so that they can determine whether people have been exposed to higher levels of barium than are found in the general population. These data will also help scientists plan and conduct research about exposure to barium and health effects.

**Figure 2. Barium (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



# Beryllium

CAS No. 7440-41-7

## General Information

Pure beryllium is a hard gray metal. The lightest of all metals, beryllium can be found in mineral rocks, coal, soil, and volcanic dust. Beryllium compounds are commercially mined, and the beryllium is refined for use in mirrors and in special metal alloys used in the automobile, computer, nuclear, electrical, aircraft, and machine-parts industries. Beryllium is also used in the production of sports equipment such as golf clubs and bike frames. In medicine, beryllium is used in instruments, x-ray machines, and dental bridges.

Exposure to beryllium occurs mostly in the workplace, near some hazardous waste sites, and from breathing tobacco smoke. Two types of minerals, bertrandite and beryl, are mined for commercial recovery of beryllium. In the workplace, beryllium dust enters the body

primarily through the lungs, where it remains for years, but there are little data available on how the metal accumulates in the lungs. Low-level beryllium exposure occurs through breathing air, eating food, or drinking water containing the metal. Small amounts of beryllium dust can enter air from burning coal and oil.

Beryllium may be harmful if inhaled. The effects depend on the concentration of beryllium in the inhaled air and the duration of air exposure. Air levels greater than 100  $\mu\text{g}/\text{m}^3$  can result in erythema and edema of the lung mucosa, producing pneumonitis. Chronic beryllium disease, or berylliosis, is a granulomatous interstitial lung disease that results from chronic beryllium inhalation and immunologic response. Skin contact with beryllium may also produce dermatitis, and some people demonstrate a hypersensitivity reaction to beryllium. Contact dermatitis and subcutaneous nodules have been reported with skin

**Table 7. Beryllium**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g}/\text{L}$ ) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2465
	01-02	*	< LOD	< LOD	< LOD	< LOD	2690
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	340
	01-02	*	< LOD	< LOD	< LOD	< LOD	368
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	719
	01-02	*	< LOD	< LOD	< LOD	.140 (<LOD-.160)	762
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1406
	01-02	*	< LOD	< LOD	< LOD	< LOD	1560
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1227
	01-02	*	< LOD	< LOD	< LOD	.130 (<LOD-.150)	1335
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1238
	01-02	*	< LOD	< LOD	< LOD	< LOD	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	884
	01-02	*	< LOD	< LOD	< LOD	< LOD	683
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	667
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	822
	01-02	*	< LOD	< LOD	< LOD	< LOD	1132

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

exposure to beryllium.

Workplace air standards for external exposure have been established by OSHA and ACGIH. NTP considers beryllium to be a known carcinogen. IARC states that beryllium is an animal carcinogen, and sufficient evidence exists to consider beryllium and beryllium compounds as carcinogenic in people, causing lung and central nervous system cancers. More information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at <http://www.epa.gov/iris> and from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### Interpreting Levels of Urinary Beryllium Reported in the Tables

Urinary beryllium levels were measured in a subsample of NHANES participants aged 6 years old and older. Participants were selected within the specified age range

to be a representative sample of the U.S. population. Comparable to the 1999-2000 subsample analysis, levels of beryllium were mostly undetectable. Previous studies have reported urinary levels for general populations as either undetectable concentrations or have not had comparable detection limits (Komaromy-Hiller et al., 2000; Minoia et al., 1990; Paschal et al., 1998). A summary of reference ranges taken from previous studies suggested that a true reference range for urinary beryllium is below the detection limits in past applications (less than 1 µg/L) (Hamilton et al., 1994). Apostoli and Schaller (2001) suggest that previous detection limits are inadequate to quantitate normal human exposure. In that study, urinary beryllium in workers correlated with air exposure measures, and when air levels were below the recommended threshold limit value, urinary beryllium concentrations ranged from 0.12 to 0.15 µg/L. The 95<sup>th</sup> percentiles in this *Report* for people aged 12-19 years and for males (0.14 µg/L and 0.13 µg/L, respectively) are similar to those values reported by Apostoli and Schaller (2001). Because the

**Table 8. Beryllium (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2465
	01-02	*	< LOD	< LOD	< LOD	< LOD	2689
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	340
	01-02	*	< LOD	< LOD	< LOD	< LOD	368
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	719
	01-02	*	< LOD	< LOD	< LOD	.231 (.173-.273)	762
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1406
	01-02	*	< LOD	< LOD	< LOD	< LOD	1559
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1227
	01-02	*	< LOD	< LOD	< LOD	.281 (.237-.333)	1334
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1238
	01-02	*	< LOD	< LOD	< LOD	< LOD	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	884
	01-02	*	< LOD	< LOD	< LOD	< LOD	682
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	667
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	822
	01-02	*	< LOD	< LOD	< LOD	< LOD	1132

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

detection limit documented in this *Report* was 0.13 µg/L and because most of the samples were undetectable, these NHANES 1999-2002 levels are likely to be lower than levels considered safe for workers.

Finding a measurable amount of beryllium in urine does not mean that the level of beryllium causes an adverse health effect. Whether beryllium at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary beryllium data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of beryllium than are found in the general population. These data will also help scientists plan and conduct research about exposure to beryllium and health effects.

## Cadmium

CAS No. 7440-43-9

### General Information

Cadmium is a soft, malleable, bluish-white metal that is obtained chiefly as a by-product during the processing of zinc-containing ores (principally sphalerite, as zinc sulfide) and to a lesser extent during the refining of lead and copper from sulfide ore. The predominant commercial use of cadmium is in the manufacture of batteries (78% of uses). The use of cadmium in pigments accounts for 12% of consumption; in coatings and plating another 8% is used, and the remainder is used in stabilizers for plastic (1.5%), and nonferrous alloys and other uses (0.5%). From 2001 through 2004, the commercial use of cadmium declined approximately 70% in response to environmental concerns (U.S. Geological

Survey, 2004). Emissions of cadmium into the environment occur mainly via anthropogenic activities, such as secondary lead smelting, primary copper smelting, primary lead production, hazardous and municipal waste incineration, and petroleum refining (U.S. EPA, 1992).

Cadmium is absorbed via inhalation and ingestion. Inhalation of cigarette smoke is a predominant source in smokers. For nonsmokers who are not exposed to cadmium in the workplace, food is the largest source of cadmium intake and absorption. An analysis of food-intake rates and food-cadmium concentrations for the U.S. population recently estimated a geometric mean daily cadmium intake of 18.9 µg/day, or 0.4 µg/kg/day

**Table 9. Cadmium in blood**

Geometric mean and selected percentiles of blood concentrations (in µg/L) for the U.S. population aged 1 year and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 1 and older</b>	99-00	<b>.412</b> (.378-.449)	<b>.300</b> (.300-.400)	<b>.600</b> (.500-.600)	<b>1.00</b> (.900-1.00)	<b>1.30</b> (1.20-1.40)	7970
	01-02	*	<b>.300</b> (<LOD-.300)	<b>.400</b> (.400-.500)	<b>.900</b> (.900-1.10)	<b>1.30</b> (1.20-1.60)	8945
<b>Age group</b>							
1-5 years	99-00	*	< LOD	<b>.300</b> (<LOD-.300)	<b>.400</b> (.300-.400)	<b>.400</b> (.300-.400)	723
	01-02	*	< LOD	< LOD	< LOD	<b>.300</b> (<LOD-.300)	898
6-11 years	99-00	*	< LOD	<b>.300</b> (<LOD-.300)	<b>.400</b> (.300-.400)	<b>.400</b> (.400-.500)	905
	01-02	*	< LOD	< LOD	< LOD	<b>.400</b> (.300-.400)	1044
12-19 years	99-00	<b>.333</b> (.304-.366)	<b>.300</b> (<LOD-.300)	<b>.300</b> (.300-.400)	<b>.800</b> (.600-.900)	<b>1.10</b> (.900-1.10)	2135
	01-02	*	< LOD	<b>.300</b> (<LOD-.300)	<b>.400</b> (.400-.500)	<b>.800</b> (.600-1.10)	2231
20 years and older	99-00	<b>.468</b> (.426-.513)	<b>.400</b> (.300-.400)	<b>.600</b> (.600-.700)	<b>1.00</b> (1.00-1.10)	<b>1.50</b> (1.40-1.60)	4207
	01-02	*	<b>.300</b> (.300-.400)	<b>.600</b> (.500-.600)	<b>1.10</b> (.900-1.20)	<b>1.60</b> (1.30-1.80)	4772
<b>Gender</b>							
Males	99-00	<b>.403</b> (.368-.441)	<b>.400</b> (.300-.400)	<b>.600</b> (.500-.600)	<b>1.00</b> (.900-1.10)	<b>1.30</b> (1.20-1.50)	3913
	01-02	*	<b>.300</b> (<LOD-.300)	<b>.400</b> (.400-.500)	<b>.900</b> (.900-1.10)	<b>1.40</b> (1.20-1.80)	4339
Females	99-00	<b>.421</b> (.386-.460)	<b>.300</b> (.300-.400)	<b>.600</b> (.500-.600)	<b>1.00</b> (.800-1.00)	<b>1.30</b> (1.10-1.40)	4057
	01-02	*	<b>.300</b> (.300-.400)	<b>.500</b> (.500-.600)	<b>1.00</b> (.900-1.10)	<b>1.40</b> (1.20-1.60)	4606
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.395</b> (.367-.424)	<b>.400</b> (.300-.400)	<b>.400</b> (.400-.500)	<b>.700</b> (.700-.900)	<b>1.10</b> (.900-1.30)	2742
	01-02	*	< LOD	<b>.300</b> (.300-.400)	<b>.600</b> (.500-.700)	<b>1.00</b> (.700-1.30)	2268
Non-Hispanic blacks	99-00	<b>.393</b> (.361-.427)	<b>.300</b> (.300-.400)	<b>.600</b> (.500-.600)	<b>1.00</b> (.800-1.10)	<b>1.40</b> (1.10-1.50)	1842
	01-02	*	< LOD	<b>.400</b> (.400-.500)	<b>1.00</b> (.900-1.00)	<b>1.40</b> (1.20-1.50)	2219
Non-Hispanic whites	99-00	<b>.420</b> (.376-.470)	<b>.400</b> (.300-.400)	<b>.500</b> (.500-.600)	<b>1.00</b> (.900-1.10)	<b>1.30</b> (1.20-1.40)	2716
	01-02	*	< LOD	<b>.500</b> (.500-.600)	<b>.900</b> (.900-1.10)	<b>1.40</b> (1.20-1.80)	3806

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

(Choudhury et al., 2001). Although several studies have found that the average gastrointestinal absorption of dietary cadmium is on the order of 5% (Diamond et al., 2003), two balance studies have suggested that this value may be five- to ten-fold greater in young women than in the general population (Kikuchi et al., 2003; Horiguchi et al., 2004a). With chronic exposure, cadmium accumulates in the liver and the kidney, with one-third to one half of the total amount accumulating in the kidney (Nordberg and Nordberg, 2001). In both organs, cadmium tightly binds to metallothionein, an inducible metal-binding protein that provides protection against many of cadmium's toxic effects (Klaasen et al., 1999). The estimated half-life of cadmium in the kidney is one to four decades (ATSDR, 1999; Diamond et al., 2003).

The kidney is a critical target for cadmium. Renal tubular damage and glomerular damage can be caused by high-dose chronic exposure, which may occur in people who are occupationally exposed, and is manifested by irreversible proteinuria and progressive reductions in

glomerular filtration rate (Roels et al., 1999). Increased urinary excretion of calcium and phosphorus and decreased hydroxylation of vitamin D metabolites that accompany advanced tubular damage may result in overt, and often painful, osteomalacia or osteoporosis, typified by a condition known as "Itai-Itai disease" that afflicted women living in a cadmium-polluted region of Japan. Several recent epidemiological investigations in Belgium (Staessen et al., 1996; Hotz et al., 1999; Staessen et al., 1999), Sweden (Jarup et al., 2000; Alfvén et al., 2002; Olsson et al., 2002), Japan (Suwazono et al., 2000; Ezaki et al., 2003; Horiguchi et al., 2004b) China (Jin et al., 2004), and the United States (Noonan et al., 2002) have detected an association between relatively low-level environmental cadmium exposure and biomarkers of renal dysfunction or diminished bone mineral density. Environmental exposure from cadmium pollution has been linked to an increased rate of end-stage renal disease in a Swedish population residing in the vicinity of two battery manufacturing plants (Hellstrom et al., 2001). Although all the mechanisms of cadmium toxicity

**Table 10. Cadmium in urine**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.193</b> (.169-.220)	<b>.232</b> (.214-.249)	<b>.475</b> (.436-.519)	<b>.858</b> (.763-.980)	<b>1.20</b> (1.06-1.33)	2257
	01-02	<b>.210</b> (.189-.235)	<b>.229</b> (.207-.255)	<b>.458</b> (.423-.482)	<b>.839</b> (.753-.919)	<b>1.20</b> (1.07-1.28)	2690
<b>Age group</b>							
6-11 years	99-00	*	<b>.078</b> (.061-.101)	<b>.141</b> (.115-.173)	<b>.219</b> (.178-.233)	<b>.279</b> (.211-.507)	310
	01-02	<b>.061</b> (<LOD-.081)	<b>.077</b> (.067-.092)	<b>.140</b> (.112-.160)	<b>.219</b> (.184-.262)	<b>.282</b> (.260-.326)	368
12-19 years	99-00	<b>.092</b> (.067-.126)	<b>.128</b> (.107-.148)	<b>.202</b> (.183-.232)	<b>.329</b> (.272-.372)	<b>.424</b> (.366-.596)	648
	01-02	<b>.109</b> (.087-.136)	<b>.135</b> (.114-.157)	<b>.210</b> (.189-.247)	<b>.327</b> (.289-.366)	<b>.442</b> (.366-.480)	762
20 years and older	99-00	<b>.281</b> (.253-.313)	<b>.306</b> (.261-.339)	<b>.551</b> (.510-.621)	<b>.979</b> (.836-1.13)	<b>1.31</b> (1.13-1.57)	1299
	01-02	<b>.273</b> (.249-.299)	<b>.280</b> (.261-.308)	<b>.545</b> (.493-.607)	<b>.955</b> (.855-1.06)	<b>1.28</b> (1.20-1.43)	1560
<b>Gender</b>							
Males	99-00	<b>.199</b> (.165-.241)	<b>.227</b> (.193-.263)	<b>.462</b> (.381-.539)	<b>.892</b> (.748-1.15)	<b>1.41</b> (.980-1.83)	1121
	01-02	<b>.201</b> (.177-.229)	<b>.223</b> (.191-.257)	<b>.445</b> (.393-.481)	<b>.870</b> (.741-1.03)	<b>1.22</b> (1.12-1.38)	1335
Females	99-00	<b>.187</b> (.153-.229)	<b>.239</b> (.220-.255)	<b>.492</b> (.456-.540)	<b>.806</b> (.705-.980)	<b>1.10</b> (1.01-1.19)	1136
	01-02	<b>.219</b> (.192-.251)	<b>.234</b> (.202-.265)	<b>.466</b> (.433-.519)	<b>.817</b> (.733-.886)	<b>1.17</b> (.918-1.36)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.191</b> (.157-.233)	<b>.202</b> (.167-.221)	<b>.438</b> (.351-.551)	<b>.813</b> (.686-.977)	<b>1.12</b> (.886-1.38)	780
	01-02	<b>.160</b> (.135-.189)	<b>.181</b> (.171-.198)	<b>.321</b> (.285-.362)	<b>.559</b> (.430-.733)	<b>.766</b> (.633-1.15)	683
Non-Hispanic blacks	99-00	<b>.283</b> (.208-.387)	<b>.312</b> (.243-.412)	<b>.633</b> (.498-.806)	<b>1.22</b> (.892-1.38)	<b>1.48</b> (1.30-1.72)	546
	01-02	<b>.277</b> (.229-.336)	<b>.302</b> (.257-.354)	<b>.580</b> (.476-.713)	<b>1.04</b> (.843-1.38)	<b>1.51</b> (1.28-1.74)	667
Non-Hispanic whites	99-00	<b>.175</b> (.148-.206)	<b>.220</b> (.194-.246)	<b>.455</b> (.388-.510)	<b>.797</b> (.714-1.01)	<b>1.17</b> (.963-1.47)	760
	01-02	<b>.204</b> (.179-.231)	<b>.221</b> (.191-.255)	<b>.445</b> (.394-.479)	<b>.813</b> (.717-.875)	<b>1.17</b> (.989-1.24)	1132

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

are uncertain, key factors may involve perturbation of zinc-dependent biochemical processes, induction of oxidative stress, aberrant gene expression, estrogenic effects (Johnson et al., 2003), or altered cell signaling and steroidogenesis (Misra et al., 2003; Waalkes, 2003; Henson and Chedrese, 2004).

Acute and heavy airborne exposure to dusts and fumes, as may occur from welding on cadmium-alloyed metals, may result in severe, potentially fatal pneumonitis (Fernandez et al., 1996). Chronic inhalation exposure to cadmium particulate has been associated with changes in pulmonary function and chest radiography consistent with emphysema (Davison et al., 1988). Among U.S. adult smokers and former smokers studied in NHANES III, increases in urinary cadmium were associated with obstructive changes in pulmonary function (Mannino et al., 2004). Workplace exposure to airborne cadmium particulate has been associated with decrements in olfactory function (Mascagni et al., 2003). Animal studies have demonstrated reproductive and teratogenic

effects. Two recent small epidemiologic studies have noted a positive association of environmental cadmium levels in maternal urine or blood with gestational age (Nishijo et al., 2002) and birth height (Zhang et al., 2004). NTP has determined that cadmium is a known human carcinogen. Potential modes of action have recently been reviewed (Waalkes, 2003). Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at <http://www.epa.gov/iris> and from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### Interpreting Levels of Cadmium in Blood and Urine Reported in the Tables

In the NHANES 2001-2002 sample, blood cadmium levels were measured in all participants aged 1 year and older, and urine cadmium levels were measured in a sample of people aged 6 years and older. Participants were selected to be a representative sample of the U.S.

**Table 11. Cadmium in urine (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.181</b> (.157-.209)	<b>.219</b> (.199-.238)	<b>.423</b> (.391-.446)	<b>.712</b> (.645-.757)	<b>.933</b> (.826-1.07)	2257
	01-02	<b>.199</b> (.181-.218)	<b>.212</b> (.194-.232)	<b>.404</b> (.377-.440)	<b>.690</b> (.630-.754)	<b>.917</b> (.813-.998)	2689
<b>Age group</b>							
6-11 years	99-00	*	<b>.085</b> (.063-.107)	<b>.147</b> (.123-.182)	<b>.210</b> (.171-.316)	<b>.300</b> (.184-.607)	310
	01-02	<b>.075</b> (.059-.094)	<b>.100</b> (.083-.112)	<b>.166</b> (.136-.192)	<b>.233</b> (.206-.281)	<b>.291</b> (.221-.440)	368
12-19 years	99-00	<b>.071</b> (.051-.098)	<b>.093</b> (.084-.106)	<b>.147</b> (.130-.163)	<b>.215</b> (.204-.240)	<b>.283</b> (.222-.404)	648
	01-02	<b>.078</b> (.067-.091)	<b>.091</b> (.085-.101)	<b>.136</b> (.123-.143)	<b>.191</b> (.175-.234)	<b>.280</b> (.234-.321)	762
20 years and older	99-00	<b>.267</b> (.247-.289)	<b>.288</b> (.261-.304)	<b>.484</b> (.433-.545)	<b>.769</b> (.727-.818)	<b>1.07</b> (.927-1.17)	1299
	01-02	<b>.261</b> (.236-.289)	<b>.273</b> (.247-.303)	<b>.481</b> (.426-.518)	<b>.776</b> (.691-.850)	<b>.979</b> (.874-1.12)	1559
<b>Gender</b>							
Males	99-00	<b>.154</b> (.131-.182)	<b>.174</b> (.158-.191)	<b>.329</b> (.293-.382)	<b>.617</b> (.537-.700)	<b>.788</b> (.696-.929)	1121
	01-02	<b>.159</b> (.143-.177)	<b>.168</b> (.157-.182)	<b>.334</b> (.304-.364)	<b>.532</b> (.491-.653)	<b>.757</b> (.690-.856)	1334
Females	99-00	<b>.211</b> (.170-.261)	<b>.267</b> (.239-.308)	<b>.473</b> (.423-.551)	<b>.783</b> (.690-.917)	<b>1.09</b> (.813-1.38)	1136
	01-02	<b>.245</b> (.216-.278)	<b>.263</b> (.228-.297)	<b>.479</b> (.414-.541)	<b>.792</b> (.687-.884)	<b>.985</b> (.876-1.16)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.175</b> (.137-.223)	<b>.181</b> (.144-.225)	<b>.331</b> (.266-.418)	<b>.612</b> (.441-.828)	<b>.843</b> (.674-1.13)	780
	01-02	<b>.156</b> (.136-.178)	<b>.170</b> (.150-.184)	<b>.282</b> (.263-.340)	<b>.501</b> (.388-.614)	<b>.693</b> (.507-.839)	682
Non-Hispanic blacks	99-00	<b>.183</b> (.140-.240)	<b>.201</b> (.168-.241)	<b>.414</b> (.343-.472)	<b>.658</b> (.516-.827)	<b>.873</b> (.722-.962)	546
	01-02	<b>.190</b> (.156-.232)	<b>.195</b> (.174-.225)	<b>.385</b> (.336-.449)	<b>.676</b> (.559-.850)	<b>.917</b> (.725-1.08)	667
Non-Hispanic whites	99-00	<b>.175</b> (.146-.209)	<b>.219</b> (.191-.250)	<b>.432</b> (.387-.470)	<b>.729</b> (.666-.783)	<b>1.00</b> (.826-1.16)	760
	01-02	<b>.205</b> (.184-.229)	<b>.224</b> (.208-.242)	<b>.421</b> (.382-.470)	<b>.719</b> (.668-.784)	<b>.931</b> (.806-1.05)	1132

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

population. Blood cadmium reflects both recent and cumulative exposures. During typical environmental exposure, urinary cadmium predominantly reflects cumulative exposure and the concentration of cadmium in the kidney (Nordberg and Nordberg, 2001; Lauwerys and Hoet, 2001; Satarug et al., 2002).

A general population survey of approximately 4,700 adults in Germany in 1998 found levels of cadmium in blood and urine that were also similar or slightly higher than the adult values reported in the 1999-2000 and 2001-2002 samples (Becker et al., 2002; Becker et al., 2003). Creatinine-corrected urine cadmium values obtained in a study of 361 subjects from a U.S. community, where smelting activity had occurred in the past, and an unexposed comparison community were also similar to the corresponding values in this *Report* (Noonan et al., 2002). A general population survey of 10,753 adult Japanese women found geometric mean urinary cadmium levels that were approximately four-to five-fold higher than the levels found for U.S. adults in this *Report*. (Ezaki et al., 2003). People who are occupationally exposed may have blood and urine levels that are higher than levels in the general population. The 95<sup>th</sup> percentiles for blood cadmium levels in this *Report* are less than the OSHA criterion (OSHA, 29 CFR 1910.1027) for blood cadmium (5 µg/L), and the 95<sup>th</sup> percentile for urine cadmium is less than the OSHA criterion for urine cadmium (3 µg/gram of creatinine). Occupational criteria are provided here for comparison only, not to imply a safety level for general population exposure.

In recent studies, levels of urinary cadmium greater than or equal to 1 µg/gram of creatinine have been associated with increases in urinary protein markers of renal tubular function (Jarup et al., 2000; Moriguchi et al., 2004; Noonan et al., 2002). In addition, a decrease in bone density has been correlated with urinary cadmium excretion among middle-aged women with a mean urinary cadmium concentration of approximately 1 µg/gram creatinine (Staessen et al., 1999), and among women older than 60 years, the odds of low bone-mineral density increased by nearly three-fold when the blood cadmium level exceeded 1.1 µg/L (Alfven et al., 2002). In this *Report*, the urinary and blood cadmium levels at the 95<sup>th</sup> and 90<sup>th</sup> percentiles, respectively, approach these cited values associated with subclinical changes in renal function and bone mineral density. Further research is needed to address the public health consequences of such exposure in the United States.

### Comparing Adjusted Geometric Means

Geometric mean levels of blood cadmium in the NHANES 2001-2002 sample could not be calculated for


this *Report* due to an insufficient number of samples with detectable levels of cadmium. The adjusted geometric mean levels of blood cadmium for the demographic groups were compared previously in the NHANES 1999-2000 sample after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). Adjusted geometric mean levels of blood cadmium were slightly higher in the group aged 20 years and older than either of the groups aged 6-11 or the 12-19 years; and the group aged 12-19 years was higher than the group aged 6-11 years. Females had slightly higher blood cadmium levels than males. Mexican Americans had higher adjusted geometric mean levels of blood cadmium than non-Hispanic whites or non-Hispanic blacks; and non-Hispanic blacks had higher blood cadmium levels than non-Hispanic whites. Similar relationships for age and gender were found in a study of NHANES III participants (Paschal et al., 2000).

Due to a recently demonstrated interference from molybdenum oxide when measuring low-level urinary cadmium using the ICP-MS method, both the 1999-2000 and 2001-2002 data were corrected for this interference based on the molybdenum measurement and expected proportion of molybdenum oxide. Geometric mean levels of urinary cadmium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine. In the NHANES 2001-2002 sample, the group aged 20 years and older had higher adjusted geometric mean levels of urinary cadmium than in either of the groups aged 6-11 or 12-19 years. Females had higher urinary cadmium levels than males. Higher urinary cadmium values in females than in males have been observed in other general population studies (Olsson et al., 2002) and, as noted previously, may be a possible consequence of increased gastrointestinal absorption of cadmium in females. It is unknown whether these differences associated with age, gender or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of cadmium in blood or urine does not mean that the level of cadmium will result in an adverse health effect. These data provide physicians with a reference range so they can determine whether or not people have been exposed to higher levels of cadmium than are found in the general population. These data also will help scientists plan and conduct research about the relation between exposure to cadmium and health effects.

**Figure 3. Cadmium in urine (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



# Cesium

CAS No. 7440-46-2

## General Information

Cesium is a silver-white metal that is found naturally in rock, soil, and clay. Inorganic cesium compounds are commonly used in photomultiplier tubes, vacuum tubes, scintillation counters, infrared lamps, semiconductors, high-power gas-ion devices, and as polymerization catalysts and photographic emulsions. Radioactive  $^{137}\text{Cs}$  has been used medically to treat cancer.

Most human exposure to cesium occurs through the diet. For absorbed cesium salts, the body half-life is estimated to be 70-109 days based on  $^{137}\text{Cs}$  exposures. Little is known about the health effects of this metal although cesium is generally of low toxicity when given to animals. However, cesium hydroxide is corrosive and irritating when concentrations are high. Workplace air standards for external exposure for certain cesium salts

are recommended by NIOSH on the basis of these irritant effects. It is not known whether cesium compounds are carcinogenic.

## Interpreting Levels of Urinary Cesium Reported in the Tables

Urinary cesium levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. In one study of clinically submitted specimens (Komaromy-Hiller et al., 2000), mean urinary cesium concentrations were slightly lower than those reported here. In a small population study of Europeans, Minoia et al. (1990) found average urinary cesium levels to be comparable to levels in this *Report*. Median values in the NHANES 1999-2000 and 2001-2002 subsamples are more than

**Table 12. Cesium**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/L}$ ) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>4.35</b> (4.00-4.74)	<b>4.80</b> (4.40-5.30)	<b>7.10</b> (6.50-7.70)	<b>9.60</b> (8.80-10.3)	<b>11.4</b> (10.2-12.9)	2464
	01-02	<b>4.81</b> (4.40-5.26)	<b>5.49</b> (5.09-5.89)	<b>7.91</b> (7.47-8.39)	<b>10.4</b> (9.56-11.4)	<b>12.6</b> (11.1-13.8)	2690
<b>Age group</b>							
6-11 years	99-00	<b>4.87</b> (4.08-5.81)	<b>5.60</b> (4.60-6.70)	<b>7.30</b> (6.70-8.00)	<b>9.00</b> (7.90-10.1)	<b>9.70</b> (8.90-10.4)	340
	01-02	<b>4.87</b> (4.08-5.82)	<b>5.61</b> (4.69-6.52)	<b>7.96</b> (6.77-8.84)	<b>9.79</b> (8.64-10.6)	<b>11.1</b> (10.2-12.4)	368
12-19 years	99-00	<b>4.55</b> (4.09-5.05)	<b>5.10</b> (4.30-5.60)	<b>6.80</b> (6.10-7.70)	<b>8.80</b> (8.00-9.40)	<b>10.4</b> (8.90-12.3)	718
	01-02	<b>5.22</b> (4.57-5.95)	<b>5.62</b> (5.13-6.12)	<b>7.55</b> (7.13-8.04)	<b>9.71</b> (9.12-11.1)	<b>12.0</b> (10.0-15.0)	762
20 years and older	99-00	<b>4.26</b> (3.94-4.62)	<b>4.80</b> (4.40-5.30)	<b>7.10</b> (6.50-7.60)	<b>9.80</b> (8.80-10.5)	<b>11.6</b> (10.2-13.2)	1406
	01-02	<b>4.74</b> (4.32-5.20)	<b>5.43</b> (5.05-5.87)	<b>7.96</b> (7.43-8.52)	<b>10.6</b> (9.73-11.5)	<b>12.8</b> (11.2-14.2)	1560
<b>Gender</b>							
Males	99-00	<b>4.84</b> (4.35-5.38)	<b>5.50</b> (4.60-5.90)	<b>7.50</b> (6.90-8.20)	<b>9.70</b> (8.60-10.7)	<b>11.6</b> (10.3-13.0)	1226
	01-02	<b>5.34</b> (4.89-5.84)	<b>6.11</b> (5.61-6.64)	<b>8.26</b> (7.84-9.08)	<b>10.8</b> (10.1-12.1)	<b>12.8</b> (11.3-15.0)	1335
Females	99-00	<b>3.95</b> (3.63-4.29)	<b>4.50</b> (4.10-4.80)	<b>6.60</b> (6.20-7.30)	<b>9.10</b> (8.30-9.90)	<b>11.1</b> (9.90-12.9)	1238
	01-02	<b>4.36</b> (3.95-4.81)	<b>4.87</b> (4.45-5.25)	<b>7.29</b> (6.71-8.01)	<b>9.77</b> (9.07-11.0)	<b>12.4</b> (10.4-13.8)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>4.32</b> (3.82-4.89)	<b>4.70</b> (4.20-5.10)	<b>6.60</b> (6.20-7.10)	<b>9.10</b> (8.00-9.80)	<b>10.9</b> (9.50-12.6)	884
	01-02	<b>4.63</b> (4.10-5.24)	<b>5.29</b> (4.59-5.89)	<b>7.08</b> (6.42-7.99)	<b>9.13</b> (7.86-11.3)	<b>11.3</b> (8.81-14.9)	683
Non-Hispanic blacks	99-00	<b>4.94</b> (4.33-5.64)	<b>5.40</b> (4.80-6.30)	<b>7.40</b> (6.80-8.20)	<b>9.80</b> (8.80-10.8)	<b>11.5</b> (9.80-13.1)	568
	01-02	<b>4.93</b> (4.70-5.17)	<b>5.31</b> (5.05-5.63)	<b>7.36</b> (6.97-7.59)	<b>9.44</b> (8.71-9.68)	<b>10.7</b> (10.1-12.3)	667
Non-Hispanic whites	99-00	<b>4.25</b> (3.83-4.72)	<b>4.70</b> (4.20-5.50)	<b>7.10</b> (6.50-7.80)	<b>9.60</b> (8.80-10.4)	<b>11.7</b> (10.3-13.3)	821
	01-02	<b>4.77</b> (4.27-5.32)	<b>5.46</b> (4.97-6.03)	<b>7.97</b> (7.43-8.55)	<b>10.4</b> (9.54-11.4)	<b>12.6</b> (11.0-13.8)	1132

twice the median values reported in a nonrandom subsample from NHANES III (1988-1994) (Paschal et al., 1998), which may be due to methodologic, population, or exposure differences.

### Comparing Adjusted Geometric Means

Geometric mean levels of urinary cesium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary cesium were slightly higher for children aged 6-11 years than for either of the groups aged 12-19 years or 20 years and older. The group aged 12-19 years had lower levels than the 20 year and older group. Mexican Americans had higher levels than non-Hispanic blacks. Non-Hispanic whites had higher levels than non-Hispanic blacks. It is unknown whether these differences associated with age or race/ethnicity represent

differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of cesium in urine does not mean that the level of cesium causes an adverse health effect. Whether cesium at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary cesium data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of cesium than levels found in the general population. These data will also help scientists plan and conduct research about exposure to cesium and health effects.


**Table 13. Cesium (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>4.10</b> (3.96-4.25)	<b>4.12</b> (3.97-4.27)	<b>5.41</b> (5.21-5.70)	<b>7.14</b> (6.83-7.50)	<b>8.64</b> (8.00-9.30)	2464
	01-02	<b>4.54</b> (4.30-4.79)	<b>4.44</b> (4.20-4.64)	<b>6.06</b> (5.66-6.47)	<b>8.18</b> (7.62-8.95)	<b>10.2</b> (8.84-11.7)	2689
<b>Age group</b>							
6-11 years	99-00	<b>5.34</b> (5.03-5.67)	<b>5.42</b> (5.03-6.04)	<b>6.63</b> (6.18-7.13)	<b>8.23</b> (7.13-9.41)	<b>9.89</b> (7.88-10.1)	340
	01-02	<b>5.95</b> (5.48-6.46)	<b>5.91</b> (5.43-6.53)	<b>7.77</b> (7.00-8.28)	<b>9.19</b> (8.35-11.9)	<b>11.9</b> (9.38-12.3)	368
12-19 years	99-00	<b>3.43</b> (3.29-3.58)	<b>3.52</b> (3.29-3.68)	<b>4.35</b> (4.17-4.56)	<b>5.31</b> (4.97-5.79)	<b>6.56</b> (5.33-8.09)	718
	01-02	<b>3.73</b> (3.41-4.08)	<b>3.55</b> (3.36-3.74)	<b>4.74</b> (4.40-5.13)	<b>6.10</b> (5.35-7.63)	<b>8.05</b> (6.44-9.82)	762
20 years and older	99-00	<b>4.08</b> (3.88-4.29)	<b>4.06</b> (3.85-4.29)	<b>5.38</b> (5.04-5.85)	<b>7.17</b> (6.84-7.58)	<b>8.60</b> (7.91-9.30)	1406
	01-02	<b>4.54</b> (4.30-4.78)	<b>4.42</b> (4.20-4.59)	<b>5.94</b> (5.64-6.40)	<b>8.15</b> (7.46-8.97)	<b>10.2</b> (8.74-11.7)	1559
<b>Gender</b>							
Males	99-00	<b>3.78</b> (3.65-3.91)	<b>3.78</b> (3.60-3.96)	<b>4.96</b> (4.72-5.20)	<b>6.45</b> (6.18-6.70)	<b>7.71</b> (7.01-8.64)	1226
	01-02	<b>4.22</b> (3.96-4.51)	<b>4.10</b> (3.87-4.41)	<b>5.60</b> (5.27-6.03)	<b>7.67</b> (6.90-8.48)	<b>9.46</b> (8.22-11.5)	1334
Females	99-00	<b>4.43</b> (4.20-4.68)	<b>4.44</b> (4.14-4.77)	<b>5.92</b> (5.36-6.47)	<b>7.70</b> (7.16-8.06)	<b>9.38</b> (8.00-10.4)	1238
	01-02	<b>4.86</b> (4.58-5.16)	<b>4.72</b> (4.50-5.06)	<b>6.54</b> (5.93-7.00)	<b>8.47</b> (7.84-9.79)	<b>10.3</b> (8.95-12.2)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>3.99</b> (3.73-4.25)	<b>3.95</b> (3.64-4.13)	<b>5.09</b> (4.79-5.38)	<b>6.64</b> (6.08-7.10)	<b>7.96</b> (7.20-8.95)	884
	01-02	<b>4.51</b> (4.00-5.08)	<b>4.51</b> (3.82-4.95)	<b>5.91</b> (5.31-6.64)	<b>7.77</b> (6.60-10.0)	<b>10.0</b> (7.60-20.5)	682
Non-Hispanic blacks	99-00	<b>3.21</b> (2.90-3.56)	<b>3.26</b> (3.05-3.44)	<b>4.30</b> (4.00-4.55)	<b>5.49</b> (5.00-5.98)	<b>6.33</b> (5.91-7.04)	568
	01-02	<b>3.38</b> (3.19-3.57)	<b>3.34</b> (3.05-3.60)	<b>4.41</b> (4.15-4.78)	<b>5.87</b> (5.63-6.29)	<b>6.75</b> (6.41-7.03)	667
Non-Hispanic whites	99-00	<b>4.26</b> (4.07-4.47)	<b>4.28</b> (4.05-4.50)	<b>5.63</b> (5.26-6.05)	<b>7.27</b> (6.84-7.83)	<b>8.68</b> (7.93-9.38)	821
	01-02	<b>4.81</b> (4.55-5.08)	<b>4.62</b> (4.42-4.96)	<b>6.33</b> (5.91-6.68)	<b>8.46</b> (7.84-9.39)	<b>10.3</b> (9.04-11.8)	1132

**Figure 4. Cesium in urine (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



## Cobalt

CAS No. 7440-48-4

### General Information

Cobalt is a magnetic element that occurs in nature either as a steel-gray, shiny, hard metal or in combination with other elements. The cobalt used in U.S. industry is imported or obtained by recycling scrap metal that contains cobalt. Among its many uses are the manufacture of superalloys used in gas turbines in aircraft engines, hard-metal alloys (in combination with tungsten carbide), blue-colored pigments, and fertilizers. Cobalt is used as a drying agent in paints, varnishes, and inks. It is also a component of porcelain enamel applied to steel bathroom fixtures, large appliances, and kitchenware. Cobalt compounds are used as catalysts in the production of oil and gas and in the synthesis of polyester and other materials. Cobalt compounds are also used in the manufacture of battery electrodes, steel-belted radial tires, automobile airbags, diamond-polishing

wheels, and magnetic recording media.

Cobalt occurs naturally in airborne dust, seawater, and many types of soil. It is also emitted into the environment from burning coal and oil and from car and truck exhaust. Usual human exposure is from food sources. Cobalt may be released into the systemic circulation of patients who receive joint prostheses that are fabricated from cobalt alloys (Lhotka et al., 2003). Exposure in the workplace may come from electroplating, the refining or processing of alloys, the grinding of tungsten carbide-type, hard-metal cutting tools, and the use of diamond-polishing wheels containing cobalt metal. Workplace standards for external air exposure to cobalt and several of its compounds have been established by OSHA and ACGIH.

**Table 14. Cobalt**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.375</b> (.336-.419)	<b>.400</b> (.360-.440)	<b>.630</b> (.570-.670)	<b>.940</b> (.890-1.03)	<b>1.32</b> (1.16-1.48)	2465
	01-02	<b>.379</b> (.355-.404)	<b>.410</b> (.380-.430)	<b>.610</b> (.570-.660)	<b>.930</b> (.860-1.00)	<b>1.27</b> (1.15-1.44)	2690
<b>Age group</b>							
6-11 years	99-00	<b>.499</b> (.427-.583)	<b>.520</b> (.430-.600)	<b>.740</b> (.610-.900)	<b>1.03</b> (.860-1.12)	<b>1.22</b> (1.03-1.50)	340
	01-02	<b>.452</b> (.377-.543)	<b>.510</b> (.430-.610)	<b>.710</b> (.660-.810)	<b>1.07</b> (.940-1.21)	<b>1.28</b> (1.17-1.53)	368
12-19 years	99-00	<b>.519</b> (.463-.581)	<b>.520</b> (.480-.550)	<b>.810</b> (.670-.890)	<b>1.16</b> (1.01-1.47)	<b>1.52</b> (1.26-2.56)	719
	01-02	<b>.515</b> (.469-.564)	<b>.520</b> (.470-.570)	<b>.750</b> (.690-.840)	<b>1.23</b> (1.07-1.32)	<b>1.59</b> (1.37-1.99)	762
20 years and older	99-00	<b>.343</b> (.305-.386)	<b>.360</b> (.320-.410)	<b>.560</b> (.510-.640)	<b>.880</b> (.800-.950)	<b>1.28</b> (1.07-1.39)	1406
	01-02	<b>.352</b> (.333-.373)	<b>.370</b> (.350-.400)	<b>.550</b> (.520-.590)	<b>.860</b> (.790-.930)	<b>1.15</b> (1.04-1.42)	1560
<b>Gender</b>							
Males	99-00	<b>.371</b> (.331-.416)	<b>.400</b> (.360-.440)	<b>.580</b> (.530-.630)	<b>.810</b> (.730-.890)	<b>1.01</b> (.900-1.12)	1227
	01-02	<b>.367</b> (.338-.399)	<b>.390</b> (.360-.410)	<b>.540</b> (.510-.590)	<b>.780</b> (.740-.840)	<b>1.05</b> (.960-1.14)	1335
Females	99-00	<b>.379</b> (.333-.431)	<b>.410</b> (.340-.460)	<b>.670</b> (.590-.790)	<b>1.17</b> (.930-1.36)	<b>1.49</b> (1.28-1.98)	1238
	01-02	<b>.390</b> (.364-.417)	<b>.430</b> (.390-.440)	<b>.660</b> (.620-.700)	<b>1.05</b> (.980-1.16)	<b>1.44</b> (1.22-1.81)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.418</b> (.348-.502)	<b>.470</b> (.370-.530)	<b>.660</b> (.620-.760)	<b>1.05</b> (.950-1.19)	<b>1.47</b> (1.25-1.67)	884
	01-02	<b>.398</b> (.373-.424)	<b>.420</b> (.400-.450)	<b>.640</b> (.600-.710)	<b>.950</b> (.850-1.03)	<b>1.20</b> (1.06-1.48)	683
Non-Hispanic blacks	99-00	<b>.434</b> (.405-.465)	<b>.420</b> (.390-.470)	<b>.680</b> (.620-.750)	<b>1.15</b> (1.02-1.25)	<b>1.45</b> (1.23-2.04)	568
	01-02	<b>.435</b> (.388-.487)	<b>.410</b> (.380-.440)	<b>.650</b> (.540-.810)	<b>1.15</b> (.840-1.63)	<b>1.75</b> (1.32-2.22)	667
Non-Hispanic whites	99-00	<b>.369</b> (.316-.431)	<b>.400</b> (.340-.450)	<b>.620</b> (.550-.700)	<b>.930</b> (.820-1.07)	<b>1.29</b> (1.02-1.65)	822
	01-02	<b>.359</b> (.327-.394)	<b>.380</b> (.350-.430)	<b>.580</b> (.520-.650)	<b>.870</b> (.800-.930)	<b>1.16</b> (1.04-1.32)	1132

Cobalt constitutes 4% by weight of vitamin B-12 (cobalamin), an essential human nutrient. A nutritional requirement for cobalt not contained in dietary cobalamin has not been established. Cobalt is absorbed by oral and pulmonary routes. Human studies with <sup>60</sup>Co administered as soluble cobalt chloride have measured oral absorption ranging from approximately 1% to 25% (Smith et al., 1972). Once absorbed and distributed in the body, cobalt is excreted predominantly in the urine and to a lesser extent in the feces. Elimination reflects a multi-compartmental model dominated by compartments with half-lives on the order of several hours to a week, but with a minor fraction (10% to 15%) exhibiting a half-life of several years (Smith et al., 1972; Mosconi et al., 1994). A portion of cobalt retained for long periods is concentrated in the liver. Lung retention of cobalt compounds of low solubility, such as cobalt oxide, may be prolonged, with some fractions exhibiting pulmonary clearance half-lives of 1-2 years (Hedge et al., 1979). Recent inhalation exposure to soluble cobalt compounds may be monitored effectively by measuring cobalt in

urine or blood (Lison et al., 1994).

Most toxic effects of cobalt have been encountered in workplace situations. Cobalt compounds are a recognized cause of allergic contact dermatitis (Dickel et al., 2001; Lisi et al., 2003; Thomssen et al., 2001). Occupational exposure to cobalt-containing dusts has caused occupational asthma (Shirakawa et al., 1989; Pisati and Zedda, 1994). "Hard metal disease," an interstitial lung disorder with findings that range from alveolitis to pulmonary fibrosis, has been associated with exposure to dusts that contain cobalt, usually in combination with tungsten carbide (Cugell et al., 1990). The extent to which cobalt exposure alone causes interstitial lung disease is unresolved (Swennen et al., 1993; Linna et al., 2003)

Cobalt was once added as a foaming agent to beer and caused outbreaks of cardiomyopathy among heavy drinkers in the mid-1960s (Alexander et al., 1972). Other case reports have suggested a link between occupational cobalt exposure and cardiomyopathy (Jarvis et al., 1992).

**Table 15. Cobalt (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.353</b> (.319-.391)	<b>.328</b> (.302-.365)	<b>.515</b> (.457-.581)	<b>.810</b> (.679-.963)	<b>1.16</b> (.938-1.50)	2465
	01-02	<b>.358</b> (.333-.384)	<b>.335</b> (.313-.360)	<b>.523</b> (.487-.562)	<b>.844</b> (.750-.955)	<b>1.15</b> (1.00-1.28)	2689
<b>Age group</b>							
6-11 years	99-00	<b>.547</b> (.467-.640)	<b>.554</b> (.449-.647)	<b>.774</b> (.626-.938)	<b>1.00</b> (.830-1.48)	<b>1.23</b> (.895-1.50)	340
	01-02	<b>.552</b> (.508-.599)	<b>.548</b> (.503-.609)	<b>.756</b> (.660-.829)	<b>1.00</b> (.900-1.25)	<b>1.30</b> (1.03-1.73)	368
12-19 years	99-00	<b>.391</b> (.353-.433)	<b>.378</b> (.329-.407)	<b>.535</b> (.469-.595)	<b>.824</b> (.632-1.16)	<b>1.44</b> (.821-3.54)	719
	01-02	<b>.368</b> (.343-.396)	<b>.352</b> (.327-.372)	<b>.534</b> (.471-.611)	<b>.851</b> (.673-.949)	<b>1.06</b> (.932-1.24)	762
20 years and older	99-00	<b>.328</b> (.297-.362)	<b>.306</b> (.280-.328)	<b>.471</b> (.428-.522)	<b>.727</b> (.632-.905)	<b>1.12</b> (.861-1.36)	1406
	01-02	<b>.337</b> (.313-.363)	<b>.312</b> (.293-.336)	<b>.474</b> (.435-.513)	<b>.792</b> (.704-.955)	<b>1.15</b> (.963-1.33)	1559
<b>Gender</b>							
Males	99-00	<b>.290</b> (.259-.324)	<b>.279</b> (.248-.301)	<b>.400</b> (.365-.449)	<b>.608</b> (.534-.728)	<b>.833</b> (.667-1.10)	1227
	01-02	<b>.290</b> (.272-.310)	<b>.277</b> (.256-.297)	<b>.392</b> (.361-.425)	<b>.642</b> (.574-.707)	<b>.848</b> (.786-.929)	1334
Females	99-00	<b>.426</b> (.378-.479)	<b>.407</b> (.362-.457)	<b>.605</b> (.550-.694)	<b>.955</b> (.781-1.29)	<b>1.50</b> (1.11-1.83)	1238
	01-02	<b>.435</b> (.404-.468)	<b>.408</b> (.382-.438)	<b>.635</b> (.560-.708)	<b>.993</b> (.867-1.16)	<b>1.29</b> (1.12-1.60)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.386</b> (.339-.439)	<b>.376</b> (.333-.419)	<b>.598</b> (.500-.669)	<b>.895</b> (.826-1.00)	<b>1.23</b> (1.11-1.35)	884
	01-02	<b>.388</b> (.361-.417)	<b>.361</b> (.333-.394)	<b>.591</b> (.500-.662)	<b>.872</b> (.777-.990)	<b>1.10</b> (.990-1.27)	682
Non-Hispanic blacks	99-00	<b>.282</b> (.275-.289)	<b>.257</b> (.243-.278)	<b>.417</b> (.378-.462)	<b>.707</b> (.600-.785)	<b>.975</b> (.757-1.60)	568
	01-02	<b>.298</b> (.275-.323)	<b>.268</b> (.251-.294)	<b>.444</b> (.392-.511)	<b>.728</b> (.582-.917)	<b>1.03</b> (.740-1.55)	667
Non-Hispanic whites	99-00	<b>.369</b> (.324-.421)	<b>.351</b> (.313-.387)	<b>.533</b> (.452-.611)	<b>.861</b> (.667-1.16)	<b>1.25</b> (.895-1.57)	822
	01-02	<b>.362</b> (.331-.396)	<b>.343</b> (.313-.368)	<b>.523</b> (.479-.562)	<b>.830</b> (.736-.983)	<b>1.16</b> (.983-1.33)	1132

Cobalt compounds were formerly used in the treatment of anemia, a probable consequence of their capacity to stimulate erythropoietin production (Goldberg et al., 1988). A recent study observed elevated serum cobalt levels in association with excessive erythrocytosis among residents of a high-altitude mining community (Jefferson et al., 2002). Pharmaceutical preparations of cobalt used in the past as hematinics have been associated with the development of overt hypothyroidism (Kriss et al., 1955), and a subclinical decrement in thyroid production was observed in a study of cobalt-production workers (Swennen et al., 1993).

Cobalt compounds have elicited numerous genotoxic effects in both *in vitro* and *in vivo* assays (De Boeck et al., 2003) and have produced lung cancer in rats and mice following chronic inhalation (Bucher et al., 1999). An industry-wide study of hard-metal workers in France observed an increased mortality from lung cancer (Moulin et al., 1998). IARC considers cobalt and its compounds as possibly carcinogenic to humans. Information about external exposure (i.e., environmental levels) and health effects is available from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### Interpreting Levels of Urinary Cobalt Reported in the Tables

Urinary cobalt levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. The levels of cobalt measured in the adults in the NHANES 2001-2002 also are similar to those found in recent smaller general population surveys of European adults (Kristiansen et al., 1997; White and Sabbioni, 1998). Because concentrations of cobalt in the urine decline rapidly within 24 hours after an exposure ceases (Alexandersson et al., 1988), urinary measurements mainly reflect recent exposure, although substantial occupational exposure can produce elevated urinary levels for many weeks.

Individuals with occupational exposure to cobalt often have urinary cobalt levels that are many times higher than those of the general population (ATSDR, 2004). The ACGIH biological exposure index (BEI) for inorganic forms of cobalt (except insoluble cobalt oxides) is 15 µg/L (ACGIH, 2001). Information about the BEI is provided here for comparison, not to imply that the BEI is a safety level for general population exposure. For workers exposed to cobalt in the air, a distinction should be made between soluble cobalt and

insoluble (oxides and metallic) cobalt (Christensen and Poulsen, 1994; Lison et al., 1994). Exposure to soluble cobalt salts will produce proportionately higher urinary levels because of better absorption. Correlations between air-exposure levels and urinary cobalt levels in hard-metal fabricators are well documented (Ichikawa et al., 1985; Linnainmaa and Kiilunen, 1997; ACGIH 2001; Kraus et al., 2001; Lauwers and Hoet, 2001).


### Comparing Adjusted Geometric Means

Geometric mean levels of urinary cobalt for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary cobalt were slightly higher for children aged 6-11 years than for people aged 12-19 years, with both age groups having higher levels than people aged 20 years and older. Urinary cobalt levels in females were higher than in males, and levels in non-Hispanic blacks were slightly lower than in either Mexican Americans or non-Hispanic whites. Relative higher urinary cobalt levels in females than in males have been noted in other investigations and may reflect increased cobalt uptake by premenopausal women (Kristiansen et al., 1997). It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of cobalt in urine does not mean that the level of cobalt causes an adverse health effect. Whether cobalt at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary cobalt data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of cobalt than are found in the general population. These data will also help scientists plan and conduct research about exposure to cobalt and health effects.

**Figure 5. Cobalt (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



**Lead**

CAS No. 7439-92-1

**General Information**

Elemental lead, a malleable, dense, blue-gray metal, is a naturally occurring element found in soils and rocks. It can be combined to form inorganic and organic molecules, such as lead phosphate and tetraethyl lead. Lead has a variety of uses in the manufacture of storage batteries; solders (particularly for electrical components and automobile radiators); metal alloys (including brass, bronze, and certain types of steel); plastics; leaded glass; ceramic glazes; ammunition; antique-molded or cast ornaments; and shielding used as protection from radiation sources. In the past, lead was added to residential paints and gasoline, and it has been used in plumbing for centuries. Small amounts of lead also may

be emitted from the burning of fossil fuels.

Since the elimination of leaded gasoline in the United States and the removal of lead from solder in canned food containers, adult lead exposures tend to be limited to certain occupational and recreational sources. For children, the major sources of exposure are from deteriorated lead-based paint and the resulting dust and soil contamination. However, less common sources of exposure still exist, including lead-glazed ceramic pottery; pewter utensils and drinking vessels; plumbing systems with lead-soldered joints or lead pipes; lead-based painted surfaces undergoing renovation or demolition; lead-containing folk remedies; bullet fragments retained in human tissue; lead-contaminated

**Table 16. Lead in blood**

Geometric mean and selected percentiles of blood concentrations (in µg/dL) for the U.S. population aged 1 year and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 1 and older</b>	99-00	<b>1.66</b> (1.60-1.72)	<b>1.60</b> (1.50-1.60)	<b>2.40</b> (2.30-2.60)	<b>3.80</b> (3.60-3.90)	<b>4.90</b> (4.60-5.30)	7970
	01-02	<b>1.45</b> (1.39-1.51)	<b>1.40</b> (1.30-1.40)	<b>2.20</b> (2.10-2.20)	<b>3.40</b> (3.10-3.50)	<b>4.40</b> (4.20-4.70)	8945
<b>Age group</b>							
1-5 years	99-00	<b>2.23</b> (1.96-2.53)	<b>2.20</b> (1.90-2.50)	<b>3.30</b> (2.80-3.80)	<b>4.80</b> (4.00-6.60)	<b>7.00</b> (6.10-8.30)	723
	01-02	<b>1.70</b> (1.55-1.87)	<b>1.50</b> (1.40-1.70)	<b>2.50</b> (2.20-2.80)	<b>4.10</b> (3.40-5.00)	<b>5.80</b> (4.70-6.90)	898
6-11 years	99-00	<b>1.51</b> (1.36-1.66)	<b>1.30</b> (1.20-1.50)	<b>2.00</b> (1.70-2.40)	<b>3.30</b> (2.70-3.60)	<b>4.50</b> (3.40-6.20)	905
	01-02	<b>1.25</b> (1.14-1.36)	<b>1.10</b> (1.00-1.30)	<b>1.60</b> (1.50-1.80)	<b>2.70</b> (2.40-3.00)	<b>3.70</b> (3.00-4.70)	1044
12-19 years	99-00	<b>1.10</b> (1.04-1.17)	<b>1.00</b> (.900-1.10)	<b>1.40</b> (1.30-1.60)	<b>2.30</b> (2.10-2.30)	<b>2.80</b> (2.60-3.00)	2135
	01-02	<b>.942</b> (.899-.986)	<b>.800</b> (.800-.900)	<b>1.20</b> (1.20-1.30)	<b>1.90</b> (1.80-2.00)	<b>2.70</b> (2.30-2.90)	2231
20 years and older	99-00	<b>1.75</b> (1.68-1.81)	<b>1.70</b> (1.60-1.70)	<b>2.50</b> (2.50-2.60)	<b>3.90</b> (3.70-4.00)	<b>5.20</b> (4.80-5.50)	4207
	01-02	<b>1.56</b> (1.49-1.62)	<b>1.60</b> (1.50-1.60)	<b>2.20</b> (2.20-2.30)	<b>3.60</b> (3.30-3.70)	<b>4.60</b> (4.20-4.90)	4772
<b>Gender</b>							
Males	99-00	<b>2.01</b> (1.93-2.09)	<b>1.80</b> (1.80-1.90)	<b>2.90</b> (2.80-3.00)	<b>4.40</b> (4.10-4.80)	<b>6.00</b> (5.40-6.40)	3913
	01-02	<b>1.78</b> (1.71-1.86)	<b>1.70</b> (1.70-1.80)	<b>2.70</b> (2.50-2.80)	<b>3.90</b> (3.70-4.10)	<b>5.30</b> (5.00-5.50)	4339
Females	99-00	<b>1.37</b> (1.32-1.43)	<b>1.30</b> (1.20-1.30)	<b>1.90</b> (1.90-2.10)	<b>3.00</b> (2.90-3.20)	<b>4.00</b> (3.70-4.20)	4057
	01-02	<b>1.19</b> (1.14-1.25)	<b>1.10</b> (1.10-1.20)	<b>1.80</b> (1.70-1.80)	<b>2.60</b> (2.40-2.70)	<b>3.60</b> (3.00-3.80)	4606
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>1.83</b> (1.75-1.91)	<b>1.80</b> (1.60-1.80)	<b>2.70</b> (2.60-2.90)	<b>4.20</b> (3.90-4.50)	<b>5.80</b> (5.10-6.60)	2742
	01-02	<b>1.46</b> (1.34-1.60)	<b>1.50</b> (1.30-1.60)	<b>2.20</b> (2.00-2.60)	<b>3.60</b> (3.30-4.00)	<b>5.40</b> (4.40-6.60)	2268
Non-Hispanic blacks	99-00	<b>1.87</b> (1.75-2.00)	<b>1.70</b> (1.60-1.90)	<b>2.80</b> (2.50-2.90)	<b>4.20</b> (4.00-4.60)	<b>5.70</b> (5.20-6.10)	1842
	01-02	<b>1.65</b> (1.52-1.80)	<b>1.60</b> (1.40-1.70)	<b>2.50</b> (2.30-2.80)	<b>4.20</b> (3.80-4.60)	<b>5.70</b> (5.30-6.50)	2219
Non-Hispanic whites	99-00	<b>1.62</b> (1.55-1.69)	<b>1.60</b> (1.50-1.60)	<b>2.40</b> (2.30-2.40)	<b>3.60</b> (3.40-3.70)	<b>5.00</b> (4.40-5.70)	2716
	01-02	<b>1.43</b> (1.37-1.48)	<b>1.40</b> (1.30-1.40)	<b>2.10</b> (2.10-2.20)	<b>3.10</b> (3.00-3.40)	<b>4.10</b> (3.90-4.50)	3806

dust in indoor firing ranges; and contact with soil, dust, or water contaminated by active or inactive mining or smelting operations. Children may also be exposed to lead brought into the home on the work clothes of adults whose work involves lead.

Following inhalation of fine lead particulate or fume or ingestion of soluble lead compounds, absorbed lead is bound to erythrocytes and is distributed initially to multiple soft tissues, including the brain, kidneys, bone marrow, and gonads, and to a slower extent to the subperiosteal surface and matrix of bone. Lead also undergoes transplacental transport and poses a potential hazard to the fetus. The kinetics of lead clearance from the body are characterized by a multi-compartmental model, predominantly composed of the blood and soft tissues, with a half-life of 1 to 2 months, and the skeleton, with a half-life of years to decades.

Approximately 70% of lead excretion occurs via the urine, with lesser amounts eliminated via the feces, and scant amounts through sweat, hair, and nails (Leggett,

1993; O'Flaherty, 1993). The fraction of absorbed lead not undergoing prompt excretion, which is approximately half of the absorbed lead, may be incorporated into bone, the site of about 90% of the body lead burden in most adults.

Lead exerts multisystemic toxic effects through a variety of mechanisms, including interference in the function of essential cations such as calcium, zinc, and iron; inhibition of certain enzymes; binding to ion channels and regulatory proteins; generation of reactive oxygen species; and alteration in gene expression. Large amounts of lead in the body can cause clinical anemia, kidney injury, abdominal pain, seizures, encephalopathy, and paralysis. An increased prevalence of anemia has been observed with blood lead levels (BLLs) in excess of 25 µg/dL in children (Schwartz et al., 1990), or higher than 50 µg/dL in adults (Lilis et al., 1977). Kidney toxicity associated with chronic high-dose lead exposure includes interstitial and peritubular fibrosis, but low-level environmental lead exposure also can be associated with

**Table 17. Lead in urine**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.766</b> (.708-.828)	<b>.800</b> (.700-.800)	<b>1.30</b> (1.30-1.40)	<b>2.10</b> (2.00-2.30)	<b>2.90</b> (2.60-3.20)	2465
	01-02	<b>.677</b> (.637-.718)	<b>.600</b> (.600-.700)	<b>1.20</b> (1.10-1.20)	<b>2.00</b> (1.80-2.00)	<b>2.60</b> (2.50-2.80)	2690
<b>Age group</b>							
6-11 years	99-00	<b>1.07</b> (.955-1.20)	<b>1.00</b> (.900-1.20)	<b>1.50</b> (1.40-1.60)	<b>2.40</b> (1.80-3.00)	<b>3.40</b> (2.40-5.00)	340
	01-02	<b>.753</b> (.661-.857)	<b>.800</b> (.600-.800)	<b>1.20</b> (1.00-1.30)	<b>2.00</b> (1.60-2.40)	<b>2.60</b> (2.10-3.60)	368
12-19 years	99-00	<b>.659</b> (.579-.749)	<b>.600</b> (.500-.800)	<b>1.10</b> (.900-1.20)	<b>1.70</b> (1.40-2.10)	<b>2.20</b> (1.90-2.50)	719
	01-02	<b>.564</b> (.526-.605)	<b>.600</b> (.500-.600)	<b>.900</b> (.800-1.10)	<b>1.50</b> (1.40-1.70)	<b>1.90</b> (1.70-2.10)	762
20 years and older	99-00	<b>.752</b> (.691-.818)	<b>.700</b> (.700-.800)	<b>1.40</b> (1.20-1.50)	<b>2.10</b> (1.90-2.30)	<b>2.90</b> (2.50-3.20)	1406
	01-02	<b>.688</b> (.641-.738)	<b>.700</b> (.600-.700)	<b>1.20</b> (1.10-1.20)	<b>1.90</b> (1.80-2.10)	<b>2.80</b> (2.50-2.90)	1560
<b>Gender</b>							
Males	99-00	<b>.923</b> (.822-1.04)	<b>.900</b> (.800-.900)	<b>1.60</b> (1.40-1.80)	<b>2.40</b> (2.20-2.90)	<b>3.40</b> (2.90-3.70)	1227
	01-02	<b>.808</b> (.757-.862)	<b>.700</b> (.700-.800)	<b>1.30</b> (1.30-1.50)	<b>2.40</b> (2.20-2.70)	<b>3.20</b> (2.90-3.50)	1335
Females	99-00	<b>.642</b> (.589-.701)	<b>.600</b> (.600-.700)	<b>1.20</b> (1.10-1.30)	<b>1.90</b> (1.60-2.10)	<b>2.40</b> (2.00-2.90)	1238
	01-02	<b>.573</b> (.535-.613)	<b>.500</b> (.500-.600)	<b>1.00</b> (1.00-1.10)	<b>1.50</b> (1.40-1.70)	<b>2.20</b> (1.90-2.40)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>1.02</b> (.915-1.13)	<b>1.00</b> (.900-1.20)	<b>1.70</b> (1.60-1.90)	<b>2.80</b> (2.50-3.40)	<b>4.10</b> (3.10-5.40)	884
	01-02	<b>.833</b> (.745-.931)	<b>.900</b> (.700-1.00)	<b>1.50</b> (1.20-1.70)	<b>2.40</b> (2.00-2.90)	<b>3.20</b> (2.70-3.70)	683
Non-Hispanic blacks	99-00	<b>1.11</b> (1.00-1.23)	<b>1.10</b> (1.00-1.20)	<b>1.90</b> (1.50-2.00)	<b>2.90</b> (2.40-3.50)	<b>4.20</b> (3.30-5.70)	568
	01-02	<b>.940</b> (.833-1.06)	<b>.900</b> (.800-.900)	<b>1.50</b> (1.30-1.80)	<b>2.60</b> (2.00-3.20)	<b>3.70</b> (2.90-4.80)	667
Non-Hispanic whites	99-00	<b>.695</b> (.625-.773)	<b>.700</b> (.600-.700)	<b>1.30</b> (1.10-1.40)	<b>1.90</b> (1.70-2.20)	<b>2.60</b> (2.30-3.00)	822
	01-02	<b>.610</b> (.572-.651)	<b>.600</b> (.600-.700)	<b>1.00</b> (1.00-1.10)	<b>1.80</b> (1.70-2.00)	<b>2.40</b> (2.10-2.50)	1132

small decrements in renal function (Payton et al., 1994; Kim et al., 1996; Muntner et al., 2003).

Low-level environmental lead exposure has been associated with subclinical decrements in neurocognitive function in young children and elevated blood pressure in adults. Although in 1991 the Centers for Disease Control and Prevention (CDC) established 10 µg/dL as a blood lead concentration of concern in children, no threshold for lead's effects has yet been identified (National Research Council, 1993). Recent studies have suggested possible neurodevelopmental effects at blood lead concentrations of less than 10 µg/dL (Lanphear et al., 2000; Canfield et al., 2003); further assessment is ongoing. In adults, subtle, nonspecific neurocognitive effects may occur at BLLs as low as 20-60 µg/dL (Mantere et al., 1984; Schwartz et al., 2001), with overt encephalopathy, seizures, and peripheral neuropathy at higher levels (e.g., levels greater than 100 µg/dL). Results of studies of adults with occupational or environmental lead exposure have shown consistent

associations between increased BLLs and increased blood pressure (Schwartz, 1995; Staessen et al., 1995; Nash et al., 2003) and associations between increased bone lead concentrations and blood pressure (Hu et al., 1996; Korrick et al., 1999).

The potential adverse effects of lead on reproduction are an area of ongoing research and may include increased spontaneous abortion in women (Borja-Aburto et al., 1999) and problems with sperm formation in men (Alexander et al., 1996; Telisman et al., 2000). The International Agency for Research on Cancer (IARC) considers lead as a possible human carcinogen, and the National Toxicology Program (NTP) considers lead and its compounds as reasonably anticipated to be human carcinogens (NTP, 2005), but further study is needed on the relation between lead exposure and cancer in people (Jemal et al., 2002).

**Table 18. Lead in urine (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.721</b> (.700-.742)	<b>.700</b> (.677-.725)	<b>1.11</b> (1.06-1.15)	<b>1.70</b> (1.62-1.85)	<b>2.37</b> (2.21-2.76)	2465
	01-02	<b>.639</b> (.603-.677)	<b>.634</b> (.586-.676)	<b>1.03</b> (.962-1.08)	<b>1.52</b> (1.42-1.60)	<b>2.03</b> (1.89-2.22)	2689
<b>Age group</b>							
6-11 years	99-00	<b>1.17</b> (.975-1.41)	<b>1.06</b> (.918-1.22)	<b>1.55</b> (1.22-1.97)	<b>2.71</b> (1.67-4.66)	<b>4.66</b> (1.97-18.0)	340
	01-02	<b>.918</b> (.841-1.00)	<b>.870</b> (.798-.933)	<b>1.26</b> (1.12-1.43)	<b>2.33</b> (1.59-3.64)	<b>3.64</b> (1.83-5.56)	368
12-19 years	99-00	<b>.496</b> (.460-.535)	<b>.469</b> (.408-.508)	<b>.702</b> (.655-.828)	<b>1.10</b> (.981-1.28)	<b>1.65</b> (1.15-2.78)	719
	01-02	<b>.404</b> (.380-.428)	<b>.373</b> (.342-.400)	<b>.602</b> (.541-.702)	<b>.990</b> (.882-1.18)	<b>1.41</b> (1.07-1.63)	762
20 years and older	99-00	<b>.720</b> (.683-.758)	<b>.712</b> (.667-.739)	<b>1.10</b> (1.02-1.18)	<b>1.69</b> (1.53-1.87)	<b>2.31</b> (2.11-2.62)	1406
	01-02	<b>.658</b> (.617-.703)	<b>.649</b> (.608-.702)	<b>1.04</b> (.992-1.11)	<b>1.51</b> (1.40-1.61)	<b>2.00</b> (1.85-2.19)	1559
<b>Gender</b>							
Males	99-00	<b>.720</b> (.679-.763)	<b>.693</b> (.645-.734)	<b>1.10</b> (.991-1.22)	<b>1.68</b> (1.50-2.09)	<b>2.43</b> (2.15-3.03)	1227
	01-02	<b>.639</b> (.607-.673)	<b>.638</b> (.586-.684)	<b>1.01</b> (.957-1.08)	<b>1.55</b> (1.41-1.61)	<b>2.06</b> (1.88-2.43)	1334
Females	99-00	<b>.722</b> (.681-.765)	<b>.706</b> (.667-.746)	<b>1.11</b> (1.05-1.16)	<b>1.74</b> (1.50-2.02)	<b>2.38</b> (2.03-2.88)	1238
	01-02	<b>.639</b> (.594-.688)	<b>.625</b> (.571-.670)	<b>1.03</b> (.938-1.11)	<b>1.50</b> (1.39-1.61)	<b>1.98</b> (1.85-2.15)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.940</b> (.876-1.01)	<b>.882</b> (.796-1.02)	<b>1.43</b> (1.36-1.56)	<b>2.38</b> (2.08-2.77)	<b>3.31</b> (2.78-4.18)	884
	01-02	<b>.810</b> (.731-.898)	<b>.769</b> (.702-.893)	<b>1.28</b> (1.09-1.44)	<b>2.05</b> (1.75-2.50)	<b>2.78</b> (2.55-3.33)	682
Non-Hispanic blacks	99-00	<b>.722</b> (.659-.790)	<b>.667</b> (.583-.753)	<b>1.11</b> (.988-1.20)	<b>1.98</b> (1.56-2.51)	<b>2.83</b> (2.20-3.88)	568
	01-02	<b>.644</b> (.559-.742)	<b>.606</b> (.510-.710)	<b>.962</b> (.853-1.19)	<b>1.79</b> (1.36-2.33)	<b>2.75</b> (2.04-3.98)	667
Non-Hispanic whites	99-00	<b>.696</b> (.668-.725)	<b>.677</b> (.645-.718)	<b>1.07</b> (.997-1.14)	<b>1.66</b> (1.50-1.83)	<b>2.31</b> (1.94-2.82)	822
	01-02	<b>.615</b> (.579-.654)	<b>.621</b> (.571-.667)	<b>1.00</b> (.930-1.06)	<b>1.46</b> (1.37-1.52)	<b>1.88</b> (1.61-2.00)	1132

## Interpreting Levels of Lead in Blood and Urine Reported in the Tables

Levels of lead in blood were measured in all participants aged 1 year and older and urine lead levels were measured in a sample of people aged 6 years and older. Participants were selected to be a representative sample of the U.S. population. Blood lead measurement is the preferred method of evaluating lead exposure and its health effects in people. BLLs are contributed to by both recent intake and an equilibration with stored lead in other tissues, particularly in the skeleton. Urinary lead measurements are more variable than blood lead levels for a given individual.

The U.S. adult population has similar or slightly lower BLLs than adults in other developed nations. A general population survey of 4,646 adults in Germany in 1998 reported a geometric mean blood lead concentration of 3.07  $\mu\text{g/dL}$  (Becker et al., 2002), a value nearly twice that found for U.S. adults in the 2001-2002 NHANES sample. A general population survey of 1,164 adults in Italy in 2000 found blood lead values slightly more than double those reported for U.S. adults in the 2001-2002 NHANES sample (Apostoli et al., 2002a).

In 1991, CDC designated 10  $\mu\text{g/dL}$  as the blood lead level of concern in children, a level associated with the risk for subtle neurodevelopmental impairments. For children 1- 5 years old sampled over the four year period 1999-2002, the geometric mean BLL was 1.9  $\mu\text{g/dL}$  (1.8-2.1), with 1.6% (1.1-2.3) of the children having BLLs greater than or equal to 10  $\mu\text{g/dL}$ . Data from NHANES III, (phase 2, 1991-1994) showed that 4.4% of children aged 1-5 years had BLLs greater than or equal to 10  $\mu\text{g/dL}$ , and the geometric mean BLL for children aged 1-5 years was 2.7  $\mu\text{g/dL}$  (Pirkle et al., 1998). State childhood blood lead surveillance systems reported blood lead results for 2.4 million children to CDC in 2001. Of these children, 3.09% had a confirmed BLL of greater than or equal to 10  $\mu\text{g/dL}$  (CDC, 2003a). Among a predominantly non-white population of U.S. children aged 0 to 17 years who were screened at an urban medical center in Washington, D.C. in 2001 and 2002, the geometric mean BLL in males was 3.2  $\mu\text{g/dL}$  ( $n = 5,584$ ) and 3.0  $\mu\text{g/dL}$  in females ( $n = 5,562$ ) (Soldin et al., 2003). These levels are higher than levels in similar age groups in the 2001-2002 NHANES sample and may reflect a higher prevalence of elevated BLLs that occur among children who 1) are non-Hispanic black and Mexican American; 2) live in urban settings; 3) are from lower socioeconomic groups; 4) are immigrants, refugees, or 5) reside in housing built before 1950 (CDC, 2003a; CDC, 2002; Geltman et al., 2001). In places where leaded gasoline is still used, such as in

Bangladesh, BLLs among school children are similar to BLLs measured in the United States before lead was removed from gasoline (i.e., a mean BLL of 15.0  $\mu\text{g/dL}$  and 87.4% of children with levels in excess of 10  $\mu\text{g/dL}$  [Kaiser et al., 2001]).

The U.S. Department of Labor, Occupational Safety and Health Administration (OSHA) requires monitoring of blood lead levels when occupational exposure to airborne levels of lead exceeds the established action level of greater than 30 micrograms per cubic meter of air (OSHA, 29 CFR 1910.1025). First established in the late 1970s, OSHA regulations have required medical removal of workers from workplace lead exposure when blood lead concentrations exceed 50  $\mu\text{g/dL}$  or at lower levels per a physician's discretion. The American Conference of Governmental Industrial Hygienists (ACGIH, 2001) established a Biological Exposure Index (BEI) for inorganic lead in 1995 which recommended that BLL in workers remain less than 30  $\mu\text{g/dL}$ . Levels for adults in the NHANES 1999-2000 and 2001-2002 samples are generally below these worker thresholds (four adult NHANES participants were above 30  $\mu\text{g/dL}$ ).

## Comparing Adjusted Geometric Means

Geometric mean BLLs for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and log serum cotinine (data not shown). In NHANES 2001-2002, adjusted geometric mean BLLs were higher in children aged 1-5 years than in children aged 6-11 years, and both these age groups had higher levels than did those aged 12-19 years. BLLs in adults aged 20 years and older were higher than BLLs in the group aged 12-19 years. BLLs for males were higher than those for females. Non-Hispanic whites had lower BLLs than non-Hispanic blacks.

For urinary lead in NHANES 2001-2002, adjusted geometric mean levels of urinary lead in the group aged 6-11 years were higher than either the group aged 12-19 years or the group aged 20 years and older. The group aged 20 years and older had higher levels than the group aged 12-19 years. Mexican Americans had higher urinary levels than either non-Hispanic blacks or whites. Non-Hispanic blacks had higher levels than non-Hispanic whites. Males had slightly higher levels than females.


It is unknown whether these differences associated with age, gender or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight. For instance, to account for the decreasing BLLs observed with increasing ages during childhood, several explanations are possible, including

decreasing exposure, dilution of lead by growth of body mass, or changing equilibria with bone turnover.

These blood and urine levels of lead provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of lead than are found in the general population. These data will also help scientists plan and conduct research about exposure to lead and health effects.


**Figure 6. Lead in blood**

Selected percentiles with 95% confidence intervals of blood concentrations (in  $\mu\text{g}/\text{dL}$ ) for the U.S. population aged 1 year and older, National Health and Nutrition Examination Survey, 1999-2002.



**Figure 7. Lead in urine (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



# Mercury

CAS No. 7439-97-6

## General Information

Mercury is a naturally occurring metal that has elemental (metallic), inorganic, and organic forms. Elemental mercury is a shiny, silver-white liquid (quicksilver) obtained predominantly from the refining of mercuric sulfide in cinnabar ore. Elemental mercury is used to produce chlorine gas and caustic soda for industrial applications. Other major uses include electrical equipment (e.g., thermostats and switches), electrical lamps, thermometers, sphygmomanometers and barometers, and dental amalgam. Inorganic mercury exists in two oxidative states (mercurous and mercuric) that combine with other elements, such as chlorine (e.g., mercuric chloride), sulfur, or oxygen, to form inorganic mercury compounds or salts. Inorganic mercury compounds such as mercuric oxide are used in the production of batteries and pigments. Pharmaceutical applications of mercury have been declining, although certain organomercury compounds are still used as preservatives (e.g., thimerosal, phenylmercuric acetate) or topical antiseptics (e.g.,

merbromin). Some cosmetic skin creams from countries other than the U.S. may contain mercury. Folk medicines may contain mercury compounds, and elemental mercury is used ritually in some Latin American and Caribbean communities.

Elemental mercury is released into the air from the combustion of fossil fuels (primarily coal), solid-waste incineration, and mining and smelting. Through biogeochemical cycling, some atmospheric elemental mercury is deposited on land and water. In addition, water can be contaminated by the direct release of elemental and inorganic mercury from industrial processes. Metabolism of mercury by microorganisms in sediments creates methyl mercury, an organomercurial compound, which can bioaccumulate in terrestrial and especially aquatic food chains. The ingestion of methyl mercury, predominantly from fish and other seafood, constitutes the main source of dietary mercury exposure in the general population. Using the 1999-2000 NHANES data, it was estimated that women 16 to 49 years of age ingest a geometric

**Table 19. Mercury in blood**

Geometric mean and selected percentiles of blood concentrations (in µg/L) for males and females aged 1 to 5 years and females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Age Group</b>							
1-5 years (females and males)	99-00	<b>.343</b> (.297-.395)	<b>.300</b> (.200-.300)	<b>.500</b> (.500-.600)	<b>1.40</b> (1.00-2.30)	<b>2.30</b> (1.20-3.50)	705
	01-02	<b>.318</b> (.268-.377)	<b>.300</b> (.200-.300)	<b>.700</b> (.500-.800)	<b>1.20</b> (.900-1.60)	<b>1.90</b> (1.40-2.90)	872
Females	99-00	<b>.377</b> (.299-.475)	<b>.200</b> (.200-.300)	<b>.800</b> (.500-1.10)	<b>1.60</b> (1.00-2.80)	<b>2.70</b> (1.30-5.50)	318
	01-02	<b>.329</b> (.265-.407)	<b>.300</b> (.200-.300)	<b>.700</b> (.500-.800)	<b>1.30</b> (1.00-2.10)	<b>2.60</b> (1.30-4.90)	432
Males	99-00	<b>.317</b> (.269-.374)	<b>.200</b> (.200-.300)	<b>.500</b> (.500-.600)	<b>1.10</b> (.800-1.60)	<b>2.10</b> (1.10-3.50)	387
	01-02	<b>.307</b> (.256-.369)	<b>.300</b> (.200-.300)	<b>.600</b> (.400-.700)	<b>1.30</b> (.900-1.70)	<b>1.70</b> (1.40-2.00)	440
16-49 years (females only)	99-00	<b>1.02</b> (.825-1.27)	<b>.900</b> (.800-1.20)	<b>2.00</b> (1.50-3.00)	<b>4.90</b> (3.70-6.30)	<b>7.10</b> (5.30-11.3)	1709
	01-02	<b>.833</b> (.738-.940)	<b>.700</b> (.700-.800)	<b>1.70</b> (1.40-1.90)	<b>3.00</b> (2.70-3.50)	<b>4.60</b> (3.70-5.90)	1928
<b>Race/ethnicity</b> (females, 16-49 years)							
Mexican Americans	99-00	<b>.820</b> (.664-1.01)	<b>.900</b> (.700-1.00)	<b>1.40</b> (1.20-2.00)	<b>2.60</b> (2.00-3.60)	<b>4.00</b> (2.70-5.50)	579
	01-02	<b>.667</b> (.541-.824)	<b>.700</b> (.500-.800)	<b>1.10</b> (1.00-1.40)	<b>2.10</b> (1.70-3.00)	<b>3.50</b> (2.30-4.40)	527
Non-hispanic blacks	99-00	<b>1.35</b> (1.06-1.73)	<b>1.30</b> (1.10-1.70)	<b>2.60</b> (1.80-3.40)	<b>4.80</b> (3.30-6.60)	<b>5.90</b> (4.20-11.7)	370
	01-02	<b>1.06</b> (.871-1.29)	<b>1.10</b> (.800-1.20)	<b>1.80</b> (1.50-2.20)	<b>3.20</b> (2.20-3.90)	<b>4.10</b> (3.30-6.00)	436
Non-hispanic whites	99-00	<b>.944</b> (.726-1.23)	<b>.900</b> (.700-1.10)	<b>1.90</b> (1.30-3.30)	<b>5.00</b> (3.00-6.90)	<b>6.90</b> (4.50-12.0)	588
	01-02	<b>.800</b> (.697-.919)	<b>.800</b> (.700-.800)	<b>1.50</b> (1.30-2.00)	<b>3.00</b> (2.20-3.70)	<b>4.60</b> (3.30-6.80)	806

**Table 20. Mercury in urine**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Age group (females)</b>							
16-49 years	99-00	<b>.719</b> (.622-.831)	<b>.760</b> (.610-.910)	<b>1.62</b> (1.43-1.94)	<b>3.15</b> (2.55-3.92)	<b>5.00</b> (3.59-5.79)	1748
	01-02	<b>.606</b> (.553-.665)	<b>.580</b> (.500-.670)	<b>1.37</b> (1.23-1.55)	<b>2.91</b> (2.53-3.17)	<b>3.99</b> (3.50-4.63)	1960
<b>Race/ethnicity (females, 16-49 years)</b>							
Mexican Americans	99-00	<b>.724</b> (.656-.799)	<b>.650</b> (.560-.810)	<b>1.69</b> (1.45-2.07)	<b>3.68</b> (3.10-4.45)	<b>5.62</b> (4.91-7.38)	595
	01-02	<b>.592</b> (.502-.699)	<b>.560</b> (.420-.710)	<b>1.35</b> (1.09-1.76)	<b>2.84</b> (2.32-3.85)	<b>4.13</b> (2.81-6.24)	531
Non-Hispanic blacks	99-00	<b>1.06</b> (.832-1.35)	<b>1.03</b> (.850-1.51)	<b>2.30</b> (1.83-3.03)	<b>4.81</b> (3.41-6.18)	<b>6.98</b> (5.04-10.3)	381
	01-02	<b>.772</b> (.616-.966)	<b>.740</b> (.540-.930)	<b>1.76</b> (1.30-2.37)	<b>3.50</b> (2.57-4.97)	<b>5.18</b> (3.61-6.92)	442
Non-Hispanic whites	99-00	<b>.657</b> (.557-.774)	<b>.710</b> (.520-.870)	<b>1.50</b> (1.31-1.77)	<b>2.84</b> (2.39-3.32)	<b>4.05</b> (3.16-5.52)	594
	01-02	<b>.565</b> (.501-.637)	<b>.540</b> (.450-.650)	<b>1.31</b> (1.09-1.56)	<b>2.70</b> (2.22-3.16)	<b>3.62</b> (3.13-4.54)	826

mean of 1.22 micrograms of mercury per day from fish/seafood (approximately 85% as methyl mercury) (Mahaffey et al., 2004). Inhalation of mercury volatilized from dental amalgam is another major source of mercury exposure in the general population and is estimated to result in a daily intake of 1-5 µg per day (U.S. DHHS, 1993). Accidental spills of elemental mercury, which create the potential for subsequent volatilization and inhalation of mercury vapor, have often required public health intervention (Zeitz et al., 2002).

The kinetics of the different forms of mercury vary considerably. Elemental mercury, absorbed mainly through inhalation of volatilized vapor, undergoes distribution to most tissues, with the highest concentrations occurring in the kidney (Hursh et al., 1980; Barregard et al., 1999). After absorption of elemental mercury, blood concentrations decline initially with a rapid half-life of approximately 1-3 days followed by a slower half-life of approximately 1 week to 3 weeks (Barregard et al., 1992; Sandborgh-Englund et al., 1998). The slow-phase half-life may be several weeks longer in people with chronic occupational exposure (Sallsten et al., 1993). After exposure to elemental mercury, excretion of mercury occurs predominantly through the kidney (Sandborgh-Englund et al., 1998), and peak urine mercury levels can lag behind peak blood levels by days to a few weeks (Barregard et al., 1992); thereafter, for both acute and chronic exposures, urinary mercury levels

decline with a half-life of approximately 1-3 months (Roels et al., 1991; Jonsson et al., 1999).

About 15% of inorganic mercury is absorbed from the human gastrointestinal tract (Rahola et al., 1973). Lesser penetration of inorganic mercury occurs through the blood-brain barrier than occurs with either elemental or methyl mercury (Hattula and Rahola, 1975; Vahter et al., 1994). The half-life of inorganic mercury in blood is similar to the slow-phase half-life of mercury after inhalation of elemental mercury. Excretion occurs by renal and fecal routes.

The fraction of methyl mercury absorbed from the gastrointestinal tract is about 95% (Aberg et al., 1969; Miettinen et al., 1971). Methyl mercury enters the brain and other tissues (Vahter et al., 1994) and then undergoes slow dealkylation to inorganic mercury. Human pharmacokinetic studies indicate that methyl mercury declines in blood and the whole body with a half-life of approximately 50 days (Sherlock et al., 1984; Smith et al., 1994; Smith and Farris, 1996). After exposure to methyl mercury, greater than two-thirds of the mercury is excreted via the feces, with a relatively minor amount eliminated as inorganic mercury in the urine (Smith et al., 1994; Smith and Farris, 1996). Small fractions of inorganic mercury and methyl mercury are incorporated into hair (Suzuki et al., 1993), which has been used in epidemiologic studies as a biomarker of exposure to methyl mercury (McDowell et al., 2004).

**Table 21. Mercury in urine (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Age group (females)</b>							
16-49 years	99-00	<b>.710</b> (.624-.806)	<b>.723</b> (.636-.833)	<b>1.41</b> (1.24-1.65)	<b>2.48</b> (2.10-2.97)	<b>3.27</b> (2.85-3.92)	1748
	01-02	<b>.620</b> (.579-.664)	<b>.650</b> (.582-.709)	<b>1.27</b> (1.15-1.42)	<b>2.30</b> (2.07-2.45)	<b>3.00</b> (2.68-3.39)	1960
<b>Race/ethnicity (females, 16-49 years)</b>							
Mexican Americans	99-00	<b>.685</b> (.580-.809)	<b>.639</b> (.508-.790)	<b>1.45</b> (1.27-1.61)	<b>2.89</b> (2.21-3.42)	<b>4.51</b> (3.07-5.68)	595
	01-02	<b>.600</b> (.526-.686)	<b>.596</b> (.426-.709)	<b>1.32</b> (1.04-1.47)	<b>2.41</b> (2.14-2.77)	<b>3.21</b> (2.65-4.46)	531
Non-Hispanic blacks	99-00	<b>.658</b> (.520-.831)	<b>.615</b> (.475-.892)	<b>1.22</b> (.909-1.79)	<b>2.56</b> (1.69-3.99)	<b>3.99</b> (2.76-5.14)	381
	01-02	<b>.522</b> (.410-.665)	<b>.516</b> (.387-.664)	<b>1.03</b> (.742-1.47)	<b>1.97</b> (1.42-3.25)	<b>3.21</b> (1.87-4.44)	442
Non-Hispanic whites	99-00	<b>.706</b> (.605-.824)	<b>.721</b> (.631-.846)	<b>1.41</b> (1.23-1.72)	<b>2.46</b> (1.99-2.97)	<b>3.05</b> (2.46-4.00)	594
	01-02	<b>.632</b> (.578-.691)	<b>.655</b> (.569-.744)	<b>1.28</b> (1.14-1.45)	<b>2.30</b> (2.03-2.56)	<b>2.95</b> (2.45-3.53)	826

Inorganic mercury and methyl mercury are also distributed into human breast milk, although the process may be more efficient for inorganic mercury (Grandjean et al., 1995; Oskarsson et al., 1996). Transplacental transport of methyl mercury and elemental mercury has been demonstrated in animal models. In a recent human study, concentrations of mercury in umbilical cord blood were correlated with mercury concentrations in maternal hair, maternal fish/seafood consumption, and maternal dental amalgam (Bjornberg et al., 2003). A recent meta-analysis of human studies of the ratio of mercury in umbilical cord blood to maternal blood produced an estimate of 1.7 (Stern and Smith, 2003).

The health effects of mercury are diverse and can depend on the form of the mercury to which a person is exposed and the severity and length of exposure. Acute, high-dose exposure to elemental mercury vapor may cause severe pneumonitis. At levels below those that cause acute lung injury, overt signs and symptoms of chronic inhalation may include tremor; gingivitis; and neurocognitive and behavioral disturbances, particularly irritability, depression, short-term memory loss, fatigue, anorexia, and sleep disturbance (Bidstrup et al., 1951; Smith et al., 1970; Smith et al., 1983). Subclinical neurological effects of low-level occupational exposure to elemental mercury have been found in some investigations (Chapman et al., 1990; Bittner et al., 1998), but an impact of low-level environmental exposure, such as that resulting from

dental amalgam, has not been established (Factor-Litvak et al., 2003; Bates et al., 2004a).

Exposure to inorganic mercury usually occurs by ingestion. The most prominent effect is on the kidneys, where mercury accumulates, and leads to tubular necrosis. In addition, there may be an irritant or corrosive effect on the gastrointestinal tract (Sanchez-Sicilia et al., 1963). Occupational exposure to elemental mercury vapor has been associated with subclinical effects on biomarkers of renal dysfunction (Cardenas et al., 1993). Acrodynia, a sporadic and predominantly pediatric syndrome in which the constellation of findings may include anorexia, insomnia, irritability, hypertension, maculopapular rash, pain in the extremities and pinkish discoloration of the hands and feet, has been associated with a variety of exposures to elemental mercury and inorganic mercury compounds (Tunnessen et al., 1987).

Overt poisoning from methyl mercury primarily affects the central nervous system, causing paresthesias, ataxia, dysarthria, hearing impairment, and progressive constriction of the visual fields, typically after a latent period of weeks to months. Methyl mercury has well-characterized adverse reproductive effects. High-level prenatal exposure may result in a constellation of developmental deficits that include mental retardation, cerebellar ataxia, dysarthria, limb deformities, altered physical growth, sensory impairments, and cerebral

palsy (National Research Council, 2000). In recent epidemiologic studies, lower levels of prenatal exposure due to maternal seafood consumption have been associated with an increased risk for abnormal neurocognitive test results in children (National Research Council, 2000; Rice et al., 2003). Although recent investigations have suggested a possible link between chronic ingestion of methyl mercury and an increased risk for myocardial infarction (Guallar et al., 2002; National Research Council, 2000), the existence of a causal relation is unresolved. Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at <http://www.epa.gov/iris>, the U.S. EPA's mercury homepage at <http://www.epa.gov/mercury>, and from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### Interpreting Levels of Mercury in Blood and Urine Reported in the Tables

Blood mercury levels were measured in a subsample of NHANES participants aged 1-5 years and in females aged 16-49 years. Participants were selected within the specified age range to be a representative sample of the U.S. population. The measurement of total blood mercury includes both inorganic and organic forms. In the general population, the total blood mercury concentration is due mostly to the dietary intake of organic forms, particularly of methyl mercury. Little organic mercury is excreted in the urine. Urinary mercury consists mostly of inorganic mercury (Cianciola et al., 1997; Kingman et al., 1998). These distinctions can assist in interpreting mercury blood levels in people. Total blood mercury levels are known to increase with greater fish consumption (Grandjean et al., 1995; Mahaffey and Mergler, 1998; Sanzo et al., 2001; Dewailly et al., 2001), and urine levels will increase with the number of teeth filled with mercury-containing amalgams (Becker et al., 2003).

The data in this *Report* are similar or slightly lower than levels found in other population studies. In Germany, for example, the geometric mean for blood mercury was 0.58 µg/L for 4,645 adults aged 18 to 69 years participating in a 1998 representative population survey (Becker et al., 2002). During the years 1996 through 1998, Benes et al. (2000) studied 1,216 blood donors in the Czech Republic (896 men and 320 women; average age 33 years) and 758 children (average age 9.9 years). The median concentration of blood mercury for adults was 0.78 µg/L and 0.46 µg/L for the juvenile population. A cohort of 1,127 U.S. men

(mean age 52.8 years, range 40 years to 78 years) with no occupational exposure to mercury, but who received dental care at military facilities during the mid to late 1990s, had an average blood mercury concentration of 2.55 µg/L (Kingman et al., 1998).

Blood mercury levels in both the 1999-2000 and 2001-2002 subsamples are below levels considered associated with known health effects. When blood mercury levels rise to about 100 µg/L following recent inorganic or elemental mercury poisoning, abnormal renal function tests may occur with low frequency. Total blood mercury levels in this *Report* were also well below levels established as occupational exposure guidelines. ACGIH recommends that the blood levels of inorganic mercury in workers not exceed 15 µg/L (six participants in the survey had higher levels, although these levels were unlikely to be due to inorganic forms of mercury). Information about the biological exposure indices (BEIs) is provided here for comparison, not to imply that the BEI is a safety level for general population exposure.

Clinically observable signs of ataxia and paresthesias occur with low frequency when blood mercury levels rise to about 100 µg/L following recent methyl mercury poisoning. However, the developing fetus may be the most susceptible to the effects of ongoing methyl mercury exposure (National Research Council, 2000). A cord blood mercury level of 85 µg/L (lower 95% confidence bound = 58 µg/L) is associated with a 5% increase in the prevalence of an abnormal Boston Naming Test (NRC, 2000). *Report* data for the period 1999-2002 show that all women of childbearing age had levels below 58 µg/L, a concentration associated with neurologic effects in the fetus. These data show that 5.7% of women of childbearing age had levels between 5.8 and 58 µg/L; that is, levels within a factor of 10 of those associated with neurological effects. Better defining safe levels of mercury in maternal blood is a priority area for additional research. EPA has set an oral reference dose (RfD, a daily dose considered to be safe) for methyl mercury of 0.1 µg/kg/day, derived in part from this and other associated blood levels in outcome studies. A specific value for the blood mercury concentration that corresponds to the RfD has not been established (Rice, 2004).

Urinary mercury levels in recent German (Becker et al., 2003), Czech (Benes et al., 2002), and Italian (Apostoli et al., 2002b) adult population surveys were roughly similar to the values found for women in the 2001-2002 NHANES subsample. An expert-panel

report recently prepared for the U.S. Department of Health and Human Services (U.S. DHHS) noted that several studies have observed a modest, reversible increase in urinary N-acetyl-glucosaminidase, a biomarker of perturbation in renal tubular function, among workers with urinary mercury concentrations of greater than or equal to 25-35  $\mu\text{g/L}$  (Life Sciences Research Office, 2004). The ACGIH (2001) currently recommends that urinary inorganic mercury in workers not exceed 35  $\mu\text{g/gram}$  of creatinine.

### **Comparing Adjusted Geometric Means**


Geometric mean levels of blood mercury for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, creatinine, and log serum cotinine (data not shown). In NHANES 2001-2002, non-Hispanic black females aged 16-49 years had higher levels than non-Hispanic white and Mexican-American females aged 16-49 years. Non-Hispanic white females aged 16-49 years had higher levels than Mexican American females aged 16-49 years. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

For urinary mercury levels, there were no differences of the adjusted geometric means among the three race/ethnicity groups.

Finding a measurable amount of mercury in blood or urine does not mean that the level of mercury causes an adverse health effect. These data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of mercury than are found in the general population. These data will also help scientists plan and conduct research about mercury exposure and health effects.


**Figure 8. Mercury in blood**

Selected percentiles with 95% confidence intervals of blood concentrations (in  $\mu\text{g/L}$ ) for males and females aged 1 to 5 years and females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.



**Figure 9. Mercury in urine (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for females aged 16 to 49 years in the U.S. population, National Health and Nutrition Examination Survey, 1999-2002.



## Molybdenum

CAS No. 7439-98-7

### General Information

Elemental molybdenum is a silver-white, hard metal with many commercial uses, including the production of metal alloys. Compounds of molybdenum are used as corrosion inhibitors; hydrogenation catalysts; lubricants; alloys in steel; chemical reagents in hospital laboratories; and in pigments for ceramics, inks and paints.

Molybdenum is a nutritionally essential trace element and enters the body primarily from dietary sources. Molybdenum is a cofactor for a limited number of human enzymes, principally sulfite oxidase and xanthine oxidase (Kisker et al., 1997). The recommended dietary allowance for adult men and women is 45 µg/day (Institute of Medicine, 2001), and the average dietary daily intake of molybdenum is approximately 100 µg/day (WHO, 1996; Institute of Medicine, 2001). Molybdenum

occurs in natural waters and may be present in concentrations of several hundred micrograms per liter or higher in ground and surface water in the vicinity of mining operations or ore deposits. In industry, dust and other fine particles produced during the refining or shaping of molybdenum or molybdenum-containing alloys are sources of exposure.

Gastrointestinal absorption of molybdenum averages 88-93% for dietary intakes of 22 to 1490 µg/day. Excretion occurs predominantly via the kidney, which exerts homeostatic regulation over molybdenum balance. At a daily oral molybdenum dose of 24 µg, urinary excretion over a six day period was 18% of the ingested dose, but at daily oral doses of 95 µg and 428 µg, urinary excretion over a six day period rose to 50% and 67% of the ingested dose, respectively (Turnlund et al., 1995).

**Table 22. Molybdenum**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>45.9</b> (40.1-52.6)	<b>50.7</b> (44.6-58.4)	<b>84.9</b> (78.7-92.3)	<b>134</b> (125-146)	<b>178</b> (154-216)	2257
	01-02	<b>45.0</b> (42.1-48.0)	<b>52.4</b> (48.9-55.5)	<b>83.3</b> (79.1-88.5)	<b>124</b> (117-130)	<b>165</b> (145-176)	2690
<b>Age group</b>							
6-11 years	99-00	<b>78.2</b> (61.0-100)	<b>83.4</b> (67.7-105)	<b>126</b> (106-147)	<b>174</b> (147-242)	<b>267</b> (159-840)	310
	01-02	<b>63.3</b> (53.4-75.0)	<b>69.2</b> (63.0-77.6)	<b>109</b> (94.5-124)	<b>169</b> (138-197)	<b>197</b> (161-291)	368
12-19 years	99-00	<b>54.3</b> (47.6-62.0)	<b>60.6</b> (52.2-70.3)	<b>93.3</b> (79.9-109)	<b>146</b> (112-171)	<b>183</b> (146-216)	648
	01-02	<b>60.6</b> (55.5-66.2)	<b>65.7</b> (58.7-73.1)	<b>96.9</b> (91.8-108)	<b>145</b> (129-159)	<b>179</b> (155-227)	762
20 years and older	99-00	<b>41.7</b> (36.7-47.4)	<b>46.5</b> (40.5-52.3)	<b>76.7</b> (73.4-82.2)	<b>125</b> (114-134)	<b>167</b> (143-206)	1299
	01-02	<b>41.1</b> (38.3-44.1)	<b>47.4</b> (43.7-51.2)	<b>79.0</b> (71.9-83.6)	<b>114</b> (103-124)	<b>150</b> (130-166)	1560
<b>Gender</b>							
Males	99-00	<b>52.7</b> (45.7-60.7)	<b>57.4</b> (48.5-68.4)	<b>93.2</b> (83.8-106)	<b>150</b> (128-187)	<b>213</b> (161-278)	1121
	01-02	<b>51.0</b> (46.6-55.7)	<b>56.9</b> (51.8-62.6)	<b>88.5</b> (81.6-96.5)	<b>130</b> (120-141)	<b>169</b> (145-194)	1335
Females	99-00	<b>40.4</b> (34.8-46.8)	<b>45.5</b> (40.4-52.0)	<b>77.2</b> (71.0-85.7)	<b>118</b> (105-138)	<b>154</b> (132-180)	1136
	01-02	<b>39.9</b> (37.2-42.9)	<b>45.7</b> (42.7-49.0)	<b>78.4</b> (72.6-82.9)	<b>114</b> (104-128)	<b>158</b> (130-177)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>47.0</b> (42.1-52.4)	<b>53.2</b> (49.0-59.0)	<b>80.3</b> (73.7-91.7)	<b>120</b> (103-139)	<b>152</b> (120-217)	780
	01-02	<b>49.3</b> (46.5-52.3)	<b>55.7</b> (50.4-61.0)	<b>86.3</b> (80.8-94.1)	<b>133</b> (113-155)	<b>177</b> (142-207)	683
Non-Hispanic blacks	99-00	<b>57.7</b> (51.0-65.2)	<b>61.8</b> (55.0-71.5)	<b>97.7</b> (85.0-110)	<b>151</b> (126-188)	<b>202</b> (150-274)	546
	01-02	<b>53.2</b> (49.9-56.7)	<b>60.3</b> (54.2-63.1)	<b>89.9</b> (81.0-101)	<b>130</b> (121-147)	<b>166</b> (147-170)	667
Non-Hispanic whites	99-00	<b>44.5</b> (37.0-53.4)	<b>48.5</b> (41.1-59.8)	<b>85.0</b> (76.7-95.9)	<b>135</b> (119-154)	<b>178</b> (146-223)	760
	01-02	<b>42.2</b> (38.5-46.2)	<b>48.9</b> (44.2-53.2)	<b>80.7</b> (71.9-85.8)	<b>117</b> (108-129)	<b>152</b> (134-180)	1132

Molybdenum is generally considered to be of low toxicity to people, and clinical or epidemiological evidence of adverse effects is limited. Chronic exposure to high levels may possibly result in higher serum uric acid levels and gout-like illness (Koval'skiy et al., 1961; U.S. EPA, 1993). Based on studies finding adverse reproductive effects in rats and mice, the Panel on Micronutrients of the Institute of Medicine identified a no observed adverse effect level (NOAEL) of 0.9 mg/kg/day and established a tolerable upper intake level of 0.03 mg/kg/day in humans (Institute of Medicine, 2001). A long term inhalation bioassay of molybdenum trioxide in mice yielded “some evidence” of carcinogenicity (NTP, 1997). A recent case-control study suggested a possible link between occupational exposure to molybdenum and lung cancer (Droste et al., 1999) but the available epidemiological data are scant and molybdenum has not been systematically evaluated for carcinogenicity by U.S. EPA or IARC.

### Interpreting Levels of Urinary Molybdenum Reported in the Tables

Urinary molybdenum levels were measured in a subsample of NHANES participants aged 6 years and older. Subsamples were randomly selected within the specified age range to be a representative sample of the U.S. population. Because molybdenum is an essential element for good health, intake and loss in the urine is expected. The levels documented for adults in the NHANES 2001-2002 subsample are broadly comparable to levels reported for adults in recent smaller European population surveys (Minoia et al., 2002; White and Sabbioni, 1998; Iversen et al., 1998). Among infants, urinary molybdenum concentrations may be slightly lower than other age groups (Sievers et al., 2001).

**Table 23. Molybdenum (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>43.2</b> (40.0-46.6)	<b>41.5</b> (38.5-45.2)	<b>63.5</b> (59.3-68.8)	<b>108</b> (97.3-115)	<b>144</b> (125-171)	2257
	01-02	<b>42.5</b> (39.9-45.2)	<b>42.2</b> (40.1-45.2)	<b>62.0</b> (58.4-66.4)	<b>98.8</b> (90.1-109)	<b>130</b> (120-149)	2689
<b>Age group</b>							
6-11 years	99-00	<b>85.9</b> (73.7-100)	<b>78.9</b> (71.6-88.4)	<b>122</b> (107-133)	<b>173</b> (130-243)	<b>213</b> (154-1040)	310
	01-02	<b>77.2</b> (73.1-81.5)	<b>77.5</b> (71.8-84.5)	<b>109</b> (99.4-120)	<b>154</b> (129-170)	<b>185</b> (165-219)	368
12-19 years	99-00	<b>41.9</b> (39.3-44.6)	<b>40.5</b> (37.7-44.4)	<b>57.3</b> (51.5-62.5)	<b>85.0</b> (67.4-107)	<b>109</b> (78.4-185)	648
	01-02	<b>43.4</b> (40.8-46.1)	<b>44.1</b> (40.8-47.2)	<b>60.6</b> (57.6-63.7)	<b>85.5</b> (79.7-93.8)	<b>106</b> (94.8-118)	762
20 years and older	99-00	<b>39.6</b> (36.9-42.6)	<b>38.5</b> (36.1-41.0)	<b>56.4</b> (53.5-60.7)	<b>92.5</b> (83.1-100)	<b>120</b> (116-147)	1299
	01-02	<b>39.3</b> (36.8-42.0)	<b>39.6</b> (36.4-42.1)	<b>57.2</b> (52.9-61.0)	<b>86.7</b> (75.2-96.8)	<b>122</b> (109-139)	1559
<b>Gender</b>							
Males	99-00	<b>40.8</b> (37.5-44.3)	<b>38.5</b> (37.2-40.4)	<b>62.4</b> (55.9-68.4)	<b>101</b> (83.9-118)	<b>131</b> (112-179)	1121
	01-02	<b>40.3</b> (37.1-43.8)	<b>40.2</b> (36.3-43.3)	<b>60.4</b> (54.8-66.3)	<b>91.3</b> (83.4-106)	<b>123</b> (107-155)	1334
Females	99-00	<b>45.5</b> (41.5-50.0)	<b>43.7</b> (39.5-48.8)	<b>64.4</b> (59.5-70.5)	<b>111</b> (95.2-121)	<b>149</b> (122-181)	1136
	01-02	<b>44.6</b> (42.2-47.1)	<b>45.1</b> (42.2-46.9)	<b>63.6</b> (59.5-69.4)	<b>107</b> (92.5-119)	<b>136</b> (117-169)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>42.9</b> (40.6-45.4)	<b>43.2</b> (40.9-45.6)	<b>61.6</b> (57.2-65.5)	<b>89.0</b> (80.0-103)	<b>115</b> (93.7-137)	780
	01-02	<b>48.1</b> (44.3-52.2)	<b>48.4</b> (44.8-52.3)	<b>71.5</b> (66.4-76.0)	<b>103</b> (90.0-120)	<b>129</b> (109-155)	682
Non-Hispanic blacks	99-00	<b>37.2</b> (33.4-41.6)	<b>37.0</b> (33.0-41.2)	<b>55.9</b> (49.6-63.3)	<b>88.2</b> (69.1-112)	<b>117</b> (88.3-141)	546
	01-02	<b>36.5</b> (34.1-39.0)	<b>37.5</b> (35.1-38.9)	<b>57.1</b> (49.7-62.4)	<b>78.3</b> (71.5-92.0)	<b>109</b> (81.1-127)	667
Non-Hispanic whites	99-00	<b>44.5</b> (40.2-49.2)	<b>42.1</b> (38.8-47.3)	<b>65.3</b> (58.9-71.3)	<b>116</b> (101-126)	<b>172</b> (131-195)	760
	01-02	<b>42.5</b> (39.3-46.0)	<b>41.9</b> (39.3-45.6)	<b>61.2</b> (57.1-67.2)	<b>104</b> (88.7-120)	<b>138</b> (120-163)	1132


### **Comparing Adjusted Geometric Means**

Geometric mean levels of urinary molybdenum for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, creatinine, and log serum cotinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary molybdenum were higher for children aged 6-11 years than for people aged 12-19 years or aged 20 years and older. The group aged 12-19 years had higher levels than the group aged 20 years and older. Non-Hispanic blacks had slightly lower levels than non-Hispanic whites and Mexican Americans. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

These urinary molybdenum data provide physicians with a reference range so that they can determine whether people have been exposed to higher levels of molybdenum than are found in the general population. These data will also help scientists plan and conduct research about molybdenum exposure and health effects.

**Figure 10. Molybdenum (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



## Platinum

CAS No. 7440-06-4

### General Information

Platinum is a silver-gray, lustrous metal found naturally in extremely low amounts in the earth's crust and typically is associated with sulfide-ore bodies of nickel, copper, and iron. Important properties of platinum are its resistance to corrosion, strength at high temperatures, and high catalytic activity.

Platinum compounds are also used in electrodes and jewelry, as oxidation catalysts in chemical manufacturing, in thick-film circuits printed on ceramic substrates, and as drugs (e.g., cisplatin, carboplatin) in the treatment of cancer. Platinum-rhodium and platinum-palladium crystals are used as catalysts in petroleum refining and in the control of automobile-exhaust emissions. Platinum-rhodium compounds are also used in glass and glass-fiber manufacture and in high-

temperature thermocouples. Higher environmental soil concentrations of platinum have been associated with nearby roadways due to vehicular emissions (Farago et al., 1998), although the ambient air concentrations of platinum associated with its use in automotive engine catalytic converters are estimated to be 10,000 times lower than occupational exposure limits.

The acute and chronic toxic effects of exposure to platinum are highly dependent on the type of compound (e.g., metallic, inorganic salt, or organometallic), the route of exposure (e.g., intravenous (medicinal use), inhalational, cutaneous, oral), and duration of exposure. Platinum metal is considered biologically inert, whereas platinum compounds (e.g., salts) can cause acute and chronic irritant and immune-mediated hypersensitivity reactions, such as bronchitis and asthma following inhalational exposure. Also, contact dermatitis following

**Table 24. Platinum**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2465
	01-02	*	< LOD	< LOD	< LOD	< LOD	2690
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	340
	01-02	*	< LOD	< LOD	< LOD	< LOD	368
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	719
	01-02	*	< LOD	< LOD	< LOD	< LOD	762
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1406
	01-02	*	< LOD	< LOD	< LOD	< LOD	1560
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1227
	01-02	*	< LOD	< LOD	< LOD	< LOD	1335
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1238
	01-02	*	< LOD	< LOD	< LOD	< LOD	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	884
	01-02	*	< LOD	< LOD	< LOD	< LOD	683
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	667
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	822
	01-02	*	< LOD	< LOD	< LOD	< LOD	1132

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

topical exposure may occur in occupational exposure settings (e.g., platinum refining plants).

Workplace air standards for external exposure are generally established for soluble salts of platinum by OSHA and ACGIH, or recommended for the metal form by NIOSH (Czerczak & Gromiec, 2000). The pharmaceutical cisplatin is an animal carcinogen as determined by NTP and a possible human carcinogen. The carcinogenicity of other platinum compounds remains uncertain. Information about external exposure (i.e., environmental levels) and health effects is available on line (W.H.O. International Programme on Chemical Safety at <http://www.inchem.org>).

### Interpreting Levels of Urinary Platinum Reported in the Tables

Urinary platinum levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range

to be a representative sample of the U.S. population. In the NHANES 2001-2002 subsample, as in the previously tested 1999-2000 subsample, urinary platinum levels were detectable in only a few percent of the sample (detection limit was 0.04 µg/L). Older studies reporting measurements in general populations have found detectable and higher values than the value of the detection limit reported in this *Report* (Vaughan et al., 1992; Paschal et al., 1998), which may be due to methodologic, population, or exposure differences. Recently, several studies have shown that background concentrations in general populations are usually less than 0.005 µg/L (Iavicoli et al., 2004; Wilhelm et al., 2003) or less than 0.01 µg/L (Becker et al., 2003; Herr et al., 2003).

One study found that traffic-control police had no greater urinary platinum concentrations than office-based control subjects (Iavicoli et al., 2004). Gold-platinum alloys used for dental fillings also may contribute to urinary platinum concentrations (Schierl, 2001; Herr et al., 2003).

**Table 25. Platinum (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2465
	01-02	*	< LOD	< LOD	< LOD	< LOD	2689
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	340
	01-02	*	< LOD	< LOD	< LOD	< LOD	368
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	719
	01-02	*	< LOD	< LOD	< LOD	< LOD	762
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1406
	01-02	*	< LOD	< LOD	< LOD	< LOD	1559
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1227
	01-02	*	< LOD	< LOD	< LOD	< LOD	1334
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1238
	01-02	*	< LOD	< LOD	< LOD	< LOD	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	884
	01-02	*	< LOD	< LOD	< LOD	< LOD	682
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	667
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	822
	01-02	*	< LOD	< LOD	< LOD	< LOD	1132

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

Platinum-industry and precious-metal workers can have urinary concentrations 1,000 times higher than general populations (Schierl et al., 1998). The handling of cisplatin and carboplatin by pharmacy and other hospital personnel has been associated with modest (ten-fold or less) elevations in urinary platinum concentrations (Ensslin et al., 1997; Pethran et al., 2003).

Finding a measurable amount of platinum in urine does not mean that the level of platinum causes an adverse health effect. Whether platinum at the levels reported here is a cause for health concern is not yet known; more research is needed. These urine platinum data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of platinum than are found in the general population. These data will also help scientists plan and conduct research about exposure to platinum and health effects.

# Thallium

CAS No. 7440-28-0

## General Information

Elemental thallium is a blue-white metal found in small amounts in soil and in sulfide-based minerals. In the past, thallium was obtained as a by-product of the smelting of other metals; however, it has not been specifically mined or refined in the United States since 1984. It is still used in relatively small amounts in pharmaceutical and electronics manufacturing, the latter being the current major industrial consumer of thallium in this country. In the United States, thallium has been restricted from pesticidal (rodenticidal, insecticidal, and fungicidal) or cosmetic (depilatory) uses.

Thallium exposure occurs primarily from industrial processes such as coal-burning and smelting. From these and other sources, thallium is produced in a fine particulate form that can be absorbed through inhalation

or ingestion. Thallium disappears from the blood with a half-life of several days representing distribution into other tissues. In addition, thallium readily crosses the placenta and also distributes into breast milk. Elimination from the body tissues is slow, occurring via urine and feces.

Thallium produces toxicity by replacing intracellular potassium in the body, though additional mechanisms of action are possible. Since thallium salts are colorless, odorless, and tasteless, there is potential for undetected malevolent use. Severe accidental thallium poisoning has involved the ingestion of rat poisons that contain water-soluble thallium salts. Relatively high-dose intentional or accidental ingestion can result in gastrointestinal symptoms followed by multi-organ failure, neurologic injury, and death. Peripheral neuropathy and alopecia are well-documented effects of acute and chronic exposures.

**Table 26. Thallium**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.176</b> (.162-.192)	<b>.200</b> (.180-.210)	<b>.280</b> (.260-.310)	<b>.400</b> (.370-.420)	<b>.450</b> (.420-.470)	2413
	01-02	<b>.165</b> (.154-.177)	<b>.180</b> (.170-.200)	<b>.270</b> (.260-.290)	<b>.360</b> (.350-.380)	<b>.440</b> (.410-.470)	2653
<b>Age group</b>							
6-11 years	99-00	<b>.201</b> (.167-.243)	<b>.200</b> (.150-.260)	<b>.300</b> (.250-.350)	<b>.410</b> (.330-.450)	<b>.440</b> (.350-.590)	336
	01-02	<b>.172</b> (.147-.202)	<b>.200</b> (.160-.220)	<b>.290</b> (.230-.330)	<b>.340</b> (.330-.360)	<b>.380</b> (.360-.420)	362
12-19 years	99-00	<b>.202</b> (.181-.225)	<b>.210</b> (.200-.240)	<b>.290</b> (.270-.340)	<b>.410</b> (.390-.430)	<b>.460</b> (.430-.510)	697
	01-02	<b>.200</b> (.182-.220)	<b>.210</b> (.190-.240)	<b>.300</b> (.290-.320)	<b>.360</b> (.340-.390)	<b>.460</b> (.400-.500)	746
20 years and older	99-00	<b>.170</b> (.157-.183)	<b>.180</b> (.170-.200)	<b>.290</b> (.260-.310)	<b>.400</b> (.370-.420)	<b>.450</b> (.420-.470)	1380
	01-02	<b>.159</b> (.147-.173)	<b>.190</b> (.170-.200)	<b>.270</b> (.250-.290)	<b>.380</b> (.350-.400)	<b>.440</b> (.400-.490)	1545
<b>Gender</b>							
Males	99-00	<b>.197</b> (.179-.217)	<b>.220</b> (.190-.240)	<b>.310</b> (.280-.350)	<b>.390</b> (.360-.440)	<b>.440</b> (.420-.480)	1200
	01-02	<b>.184</b> (.173-.196)	<b>.200</b> (.190-.220)	<b>.290</b> (.270-.290)	<b>.380</b> (.350-.390)	<b>.420</b> (.390-.460)	1313
Females	99-00	<b>.159</b> (.145-.175)	<b>.180</b> (.150-.200)	<b>.270</b> (.240-.290)	<b>.380</b> (.340-.410)	<b>.450</b> (.410-.490)	1213
	01-02	<b>.149</b> (.137-.163)	<b>.150</b> (.150-.170)	<b>.250</b> (.230-.280)	<b>.370</b> (.330-.400)	<b>.430</b> (.400-.500)	1340
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.172</b> (.150-.196)	<b>.190</b> (.160-.220)	<b>.260</b> (.240-.290)	<b>.370</b> (.320-.420)	<b>.450</b> (.370-.520)	861
	01-02	<b>.160</b> (.148-.173)	<b>.180</b> (.150-.190)	<b>.250</b> (.240-.270)	<b>.330</b> (.310-.360)	<b>.400</b> (.350-.440)	675
Non-Hispanic blacks	99-00	<b>.217</b> (.197-.239)	<b>.220</b> (.200-.240)	<b>.340</b> (.300-.380)	<b>.440</b> (.390-.510)	<b>.550</b> (.460-.620)	561
	01-02	<b>.202</b> (.187-.218)	<b>.210</b> (.200-.230)	<b>.290</b> (.270-.330)	<b>.400</b> (.380-.440)	<b>.520</b> (.440-.590)	657
Non-Hispanic whites	99-00	<b>.170</b> (.153-.188)	<b>.200</b> (.160-.220)	<b>.280</b> (.250-.320)	<b>.400</b> (.360-.420)	<b>.440</b> (.420-.480)	801
	01-02	<b>.159</b> (.147-.172)	<b>.180</b> (.160-.190)	<b>.270</b> (.250-.290)	<b>.350</b> (.320-.380)	<b>.430</b> (.390-.460)	1114

Workplace air standards for external exposure are generally established by OSHA and ACGIH. Chronic high-level exposures have been associated with weight loss, arthralgias, and polyneuropathy. IARC and NTP consider the evidence for the carcinogenicity of thallium as inadequate or unclassifiable. Information about external exposure (i.e., environmental levels) and health effects is available from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### Interpreting Levels of Urinary Thallium Reported in the Tables

Urinary thallium levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Previous studies have suggested that normal background urinary thallium concentrations are less than 1 µg/L (Schaller et al., 1980; Brockhaus et al., 1981; Minoia et al., 1990), which are consistent with levels documented

in this NHANES 2001-2002 subsample and the previous 1999-2000 subsample. Other population surveys have demonstrated urinary levels of roughly similar magnitude (White and Sabbioni, 1998; Minoia et al., 1990; Paschal et al., 1998).

Urinary concentrations of 100 µg/L in asymptomatic workers (500 times higher than median levels observed in this *Report*) are thought to correspond to workplace exposures at the threshold limit value of 0.1 mg/m<sup>3</sup> (Marcus, 1985). Brockhaus et al. (1981) studied 1,265 people living near a thallium-emitting cement plant in Germany. Nearby residents were exposed by eating garden plants on which thallium had been deposited. Seventy-eight percent of the urine specimens in that study contained more than 1 µg/L, with concentrations ranging up to 76.5 µg/L. There was no increase in the prevalence of symptoms at levels less than 20 µg/L and only a slight increase in nonspecific symptoms above 20 µg/L.

**Table 27. Thallium (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in µg/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.166</b> (.159-.173)	<b>.168</b> (.162-.176)	<b>.224</b> (.217-.233)	<b>.297</b> (.273-.319)	<b>.366</b> (.338-.387)	2413
	01-02	<b>.156</b> (.151-.162)	<b>.156</b> (.148-.164)	<b>.215</b> (.208-.222)	<b>.287</b> (.278-.300)	<b>.348</b> (.337-.365)	2652
<b>Age group</b>							
6-11 years	99-00	<b>.221</b> (.197-.248)	<b>.221</b> (.196-.236)	<b>.292</b> (.229-.356)	<b>.375</b> (.318-.469)	<b>.424</b> (.356-.600)	336
	01-02	<b>.211</b> (.198-.226)	<b>.207</b> (.198-.221)	<b>.286</b> (.257-.321)	<b>.370</b> (.333-.402)	<b>.411</b> (.389-.456)	362
12-19 years	99-00	<b>.153</b> (.146-.160)	<b>.154</b> (.146-.162)	<b>.205</b> (.191-.219)	<b>.257</b> (.231-.278)	<b>.321</b> (.265-.364)	697
	01-02	<b>.143</b> (.137-.150)	<b>.145</b> (.135-.152)	<b>.196</b> (.184-.207)	<b>.269</b> (.250-.289)	<b>.307</b> (.299-.333)	746
20 years and older	99-00	<b>.162</b> (.153-.171)	<b>.167</b> (.154-.176)	<b>.217</b> (.207-.230)	<b>.285</b> (.271-.300)	<b>.364</b> (.325-.389)	1380
	01-02	<b>.153</b> (.147-.159)	<b>.152</b> (.144-.161)	<b>.210</b> (.200-.217)	<b>.277</b> (.263-.292)	<b>.342</b> (.313-.362)	1544
<b>Gender</b>							
Males	99-00	<b>.154</b> (.147-.161)	<b>.156</b> (.149-.164)	<b>.202</b> (.192-.214)	<b>.269</b> (.254-.297)	<b>.338</b> (.300-.364)	1200
	01-02	<b>.146</b> (.140-.153)	<b>.148</b> (.141-.156)	<b>.192</b> (.184-.204)	<b>.259</b> (.245-.278)	<b>.307</b> (.291-.342)	1312
Females	99-00	<b>.178</b> (.167-.189)	<b>.182</b> (.169-.196)	<b>.244</b> (.226-.259)	<b>.313</b> (.281-.366)	<b>.380</b> (.333-.462)	1213
	01-02	<b>.167</b> (.158-.176)	<b>.167</b> (.153-.179)	<b>.233</b> (.217-.250)	<b>.313</b> (.282-.348)	<b>.375</b> (.348-.402)	1340
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.158</b> (.147-.170)	<b>.159</b> (.148-.175)	<b>.212</b> (.200-.234)	<b>.282</b> (.266-.304)	<b>.338</b> (.306-.389)	861
	01-02	<b>.156</b> (.145-.169)	<b>.155</b> (.145-.167)	<b>.204</b> (.190-.221)	<b>.286</b> (.250-.315)	<b>.361</b> (.301-.424)	674
Non-Hispanic blacks	99-00	<b>.142</b> (.133-.152)	<b>.140</b> (.129-.151)	<b>.200</b> (.184-.214)	<b>.277</b> (.244-.307)	<b>.383</b> (.286-.462)	561
	01-02	<b>.138</b> (.128-.150)	<b>.136</b> (.125-.146)	<b>.194</b> (.170-.212)	<b>.256</b> (.238-.278)	<b>.321</b> (.271-.387)	657
Non-Hispanic whites	99-00	<b>.169</b> (.160-.179)	<b>.173</b> (.167-.181)	<b>.226</b> (.215-.240)	<b>.300</b> (.271-.325)	<b>.364</b> (.333-.377)	801
	01-02	<b>.161</b> (.155-.167)	<b>.161</b> (.153-.171)	<b>.220</b> (.214-.231)	<b>.291</b> (.278-.304)	<b>.347</b> (.327-.375)	1114


### Comparing Adjusted Geometric Means

Geometric mean levels of urinary thallium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary thallium were slightly higher for people aged 6-11 years than for the other two age groups. It is unknown whether these differences associated with age represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding low amounts of thallium in urine does not mean that the level of thallium causes adverse health effects. Whether thallium at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary thallium data provide physicians with a reference range so that they can determine whether individuals or groups have been exposed to higher levels of thallium than are found in the general population. These data will also help scientists plan and conduct research about thallium exposure and health effects.

**Figure 11. Thallium (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



# Tungsten

CAS No. 7440-33-7

## General Information

Tungsten is a steel-gray to tin-white metal naturally occurring in the earth's crust, mainly as scheelite (CaWO<sub>4</sub>). A major use of tungsten is in the production of hard metals, such as tungsten carbide, which is used in rock drills and metal-cutting tools, and ferrotungsten, which is used in the steel industry. Additionally, tungsten compounds are used as lubricating agents, filaments for incandescent lamps, bronzes in pigments, and as catalysts in the petroleum industry.

Most background environmental exposures to tungsten are from the soluble forms, such as tungstate salts, whereas occupational exposure is from tungsten metal dusts released during the grinding or drilling of metals. Drinking water also can be a source of exposure. Workplace air standards for external exposure have been

established by ACGIH or recommended by NIOSH. Evidence is lacking for the carcinogenicity of tungsten; it has not been classified with respect to its carcinogenicity by either IARC or NTP.

Only limited information is available on the toxicity of tungsten. Human illness from low-level environmental or occupational exposure has not been well established. Although workers occupationally exposed to tungsten carbide may develop serious lung disease ("hard metal" disease), their illness may stem from co-exposure to cobalt mixed with tungsten carbide rather than to tungsten itself.

**Table 28. Tungsten**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.093</b> (.087-.100)	<b>.090</b> (.080-.090)	<b>.180</b> (.160-.190)	<b>.320</b> (.280-.360)	<b>.500</b> (.420-.550)	2338
	01-02	<b>.082</b> (.073-.092)	<b>.060</b> (.060-.080)	<b>.150</b> (.130-.180)	<b>.300</b> (.260-.340)	<b>.450</b> (.370-.560)	2652
<b>Age group</b>							
6-11 years	99-00	<b>.158</b> (.123-.204)	<b>.160</b> (.100-.200)	<b>.260</b> (.210-.330)	<b>.490</b> (.380-.560)	<b>.590</b> (.510-.950)	320
	01-02	<b>.137</b> (.110-.170)	<b>.140</b> (.100-.160)	<b>.250</b> (.200-.340)	<b>.450</b> (.360-.690)	<b>.770</b> (.510-1.53)	363
12-19 years	99-00	<b>.113</b> (.097-.132)	<b>.110</b> (.090-.120)	<b>.200</b> (.170-.230)	<b>.360</b> (.300-.430)	<b>.530</b> (.380-.800)	679
	01-02	<b>.113</b> (.095-.135)	<b>.100</b> (.090-.130)	<b>.210</b> (.180-.240)	<b>.390</b> (.310-.520)	<b>.570</b> (.430-.710)	744
20 years and older	99-00	<b>.084</b> (.078-.091)	<b>.070</b> (.060-.080)	<b>.150</b> (.130-.180)	<b>.270</b> (.250-.320)	<b>.440</b> (.360-.520)	1339
	01-02	<b>.073</b> (.065-.082)	<b>.060</b> (.050-.060)	<b>.130</b> (.110-.160)	<b>.250</b> (.210-.300)	<b>.370</b> (.300-.490)	1545
<b>Gender</b>							
Males	99-00	<b>.107</b> (.096-.120)	<b>.100</b> (.080-.110)	<b>.210</b> (.180-.230)	<b>.380</b> (.310-.470)	<b>.530</b> (.470-.650)	1160
	01-02	<b>.088</b> (.074-.105)	<b>.080</b> (.060-.090)	<b>.160</b> (.130-.210)	<b>.330</b> (.260-.390)	<b>.490</b> (.380-.580)	1307
Females	99-00	<b>.082</b> (.077-.087)	<b>.070</b> (.060-.070)	<b>.140</b> (.130-.160)	<b>.270</b> (.240-.290)	<b>.390</b> (.320-.470)	1178
	01-02	<b>.076</b> (.069-.084)	<b>.060</b> (.050-.060)	<b>.140</b> (.120-.170)	<b>.280</b> (.230-.320)	<b>.430</b> (.330-.530)	1345
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.113</b> (.095-.133)	<b>.100</b> (.090-.120)	<b>.190</b> (.160-.240)	<b>.390</b> (.300-.520)	<b>.550</b> (.420-.830)	790
	01-02	<b>.101</b> (.093-.109)	<b>.090</b> (.080-.110)	<b>.180</b> (.170-.200)	<b>.370</b> (.310-.430)	<b>.560</b> (.450-.670)	680
Non-Hispanic blacks	99-00	<b>.113</b> (.101-.126)	<b>.090</b> (.080-.110)	<b>.200</b> (.170-.240)	<b>.360</b> (.290-.460)	<b>.550</b> (.420-.810)	562
	01-02	<b>.096</b> (.080-.116)	<b>.080</b> (.060-.110)	<b>.150</b> (.120-.230)	<b>.310</b> (.270-.400)	<b>.460</b> (.390-.580)	649
Non-Hispanic whites	99-00	<b>.092</b> (.084-.100)	<b>.070</b> (.060-.090)	<b>.170</b> (.150-.190)	<b>.310</b> (.270-.380)	<b>.460</b> (.380-.520)	802
	01-02	<b>.076</b> (.066-.088)	<b>.050</b> (.040-.070)	<b>.150</b> (.120-.170)	<b>.290</b> (.230-.350)	<b>.430</b> (.330-.560)	1117

## Interpreting Levels of Urinary Tungsten Reported in the Tables

Urinary tungsten levels were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. A nonrandom subsample from NHANES III demonstrated higher values than those in this *Report* (Paschal et al., 1998), possibly due to methodologic, population, or exposure differences. One small study of unexposed individuals (n = 14) yielded values similar to those reported here (Schramel et al., 1997). Median urinary tungsten levels may be increased as much as 15-fold over median levels in this *Report* due to natural increases in drinking water sources (CDC, 2003b). During grinding operations that release tungsten metal into the air, workers had elevated urinary tungsten levels that were more than 900 times higher than the overall geometric mean in the NHANES 1999-2000 subsample (Kraus et al., 2001). The application of the technique of neutron

activation analysis to a control group of non-metal workers showed mean urinary tungsten levels similar to levels at the 95<sup>th</sup> percentile of the NHANES 1999-2000 subsample, whereas the tungsten-worker group had mean urine levels 35 times higher (Nicolaou et al., 1987). Patients with medically-inserted tungsten embolization coils showed elevated tungsten levels in blood, urine, and hair (Bachthaler et al., 2004). Urinary tungsten levels in these patients were often hundreds-fold higher than demonstrated in this *Report*.

## Comparing Adjusted Geometric Means

Geometric mean levels of urinary tungsten for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2002-2002, the group aged 6-11 years had higher adjusted geometric mean levels of urinary tungsten than either of the groups aged 12-19 years or 20 years and older. The group aged 12-19 years had higher

**Table 29. Tungsten (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.


	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.087</b> (.080-.095)	<b>.080</b> (.075-.086)	<b>.146</b> (.136-.158)	<b>.270</b> (.206-.333)	<b>.381</b> (.302-.459)	2338
	01-02	<b>.078</b> (.069-.087)	<b>.074</b> (.064-.084)	<b>.138</b> (.122-.154)	<b>.255</b> (.216-.300)	<b>.359</b> (.315-.436)	2651
<b>Age group</b>							
6-11 years	99-00	<b>.174</b> (.150-.201)	<b>.169</b> (.136-.198)	<b>.293</b> (.216-.333)	<b>.438</b> (.331-.667)	<b>.614</b> (.452-.880)	320
	01-02	<b>.168</b> (.144-.197)	<b>.158</b> (.139-.188)	<b>.275</b> (.231-.326)	<b>.412</b> (.333-.554)	<b>.634</b> (.436-1.28)	363
12-19 years	99-00	<b>.084</b> (.078-.091)	<b>.079</b> (.074-.084)	<b>.138</b> (.124-.158)	<b>.231</b> (.180-.287)	<b>.339</b> (.237-.465)	679
	01-02	<b>.081</b> (.071-.092)	<b>.081</b> (.072-.091)	<b>.147</b> (.122-.167)	<b>.250</b> (.208-.301)	<b>.359</b> (.272-.431)	744
20 years and older	99-00	<b>.080</b> (.072-.089)	<b>.074</b> (.067-.082)	<b>.130</b> (.115-.143)	<b>.218</b> (.179-.301)	<b>.339</b> (.245-.426)	1339
	01-02	<b>.070</b> (.063-.079)	<b>.067</b> (.057-.075)	<b>.119</b> (.099-.139)	<b>.214</b> (.176-.267)	<b>.321</b> (.250-.429)	1544
<b>Gender</b>							
Males	99-00	<b>.083</b> (.074-.094)	<b>.073</b> (.063-.086)	<b>.146</b> (.126-.165)	<b>.279</b> (.198-.386)	<b>.439</b> (.329-.605)	1160
	01-02	<b>.071</b> (.060-.083)	<b>.064</b> (.056-.077)	<b>.125</b> (.098-.152)	<b>.255</b> (.203-.306)	<b>.364</b> (.300-.431)	1306
Females	99-00	<b>.091</b> (.085-.098)	<b>.084</b> (.080-.091)	<b>.145</b> (.136-.158)	<b>.265</b> (.200-.301)	<b>.339</b> (.300-.381)	1178
	01-02	<b>.085</b> (.077-.094)	<b>.083</b> (.075-.091)	<b>.143</b> (.128-.162)	<b>.258</b> (.216-.317)	<b>.353</b> (.317-.538)	1345
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.106</b> (.093-.120)	<b>.100</b> (.086-.115)	<b>.184</b> (.152-.214)	<b>.327</b> (.267-.392)	<b>.493</b> (.354-.727)	790
	01-02	<b>.098</b> (.090-.108)	<b>.089</b> (.081-.100)	<b>.163</b> (.143-.187)	<b>.294</b> (.256-.370)	<b>.554</b> (.410-.797)	679
Non-Hispanic blacks	99-00	<b>.073</b> (.064-.083)	<b>.071</b> (.061-.081)	<b>.124</b> (.109-.154)	<b>.201</b> (.188-.222)	<b>.360</b> (.217-.465)	562
	01-02	<b>.066</b> (.056-.077)	<b>.060</b> (.049-.079)	<b>.109</b> (.090-.125)	<b>.199</b> (.153-.285)	<b>.340</b> (.250-.414)	649
Non-Hispanic whites	99-00	<b>.091</b> (.083-.100)	<b>.081</b> (.077-.088)	<b>.149</b> (.135-.167)	<b>.278</b> (.200-.354)	<b>.383</b> (.302-.462)	802
	01-02	<b>.078</b> (.068-.088)	<b>.073</b> (.061-.085)	<b>.138</b> (.120-.156)	<b>.253</b> (.209-.308)	<b>.353</b> (.286-.453)	1117

levels than the group aged 20 years and older. Levels in Mexican Americans were higher than in non-Hispanic blacks and non-Hispanic whites. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of tungsten in urine does not mean that the level of tungsten causes an adverse health effect. Whether tungsten at the levels reported here is a cause for health concern is not yet known; more research is needed. These urinary tungsten data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of tungsten than are found in the general population. These data will also help scientists plan and conduct research about exposure to tungsten and health effects.

**Figure 12. Tungsten (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



# Uranium

CAS No. 7440-61-1

## General Information

Uranium is a silver-white, extremely dense, and weakly radioactive metal. It is typically extracted from ores containing less than 1% natural uranium. Natural uranium is a mixture of three isotopes:  $^{238}\text{U}$  (99.2739%),  $^{235}\text{U}$  (0.7204%), and  $^{234}\text{U}$  (0.0057%). It usually occurs as an inorganic compound with oxygen, chlorine, or other elements. Uranium has many commercial uses, including its use in nuclear weapons, nuclear fuel, in some ceramics, and as an aid in electron microscopy and photography. Depleted uranium (DU) refers to uranium in which the proportion of  $^{235}\text{U}$  and  $^{234}\text{U}$  isotopes have been reduced, compared with the proportion in natural uranium. DU is used in the production of armor-piercing projectiles.

Human exposure to uranium occurs primarily in the workplace by inhaling dust and other small particles. Exposure to insoluble uranium oxides and uranium metal via inhalation results in retention of these forms of uranium in the lungs and other tissues with little excretion in the urine. Soluble forms of uranium salts are poorly absorbed in the gastrointestinal tract, but these small amounts can be reflected in urinary measurements. Some uranium can be absorbed from food and water, especially in areas where large amounts of uranium occur naturally. Soluble uranium compounds may exhibit some dermal absorption. Exposure to DU can occur after internal contact with DU-containing shrapnel or dust.

After absorption, soluble uranium is predominantly distributed to the kidneys and the bones. Approximately 50% of uranium is eliminated in the urine within the first

**Table 30. Uranium**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/L}$ ) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.008</b> (.007-.009)	<b>.007</b> (.006-.007)	<b>.013</b> (.010-.016)	<b>.026</b> (.021-.038)	<b>.046</b> (.036-.054)	2464
	01-02	<b>.009</b> (.007-.010)	<b>.008</b> (.006-.009)	<b>.014</b> (.011-.016)	<b>.029</b> (.022-.037)	<b>.046</b> (.034-.062)	2690
<b>Age group</b>							
6-11 years	99-00	<b>.009</b> (.007-.011)	<b>.007</b> (.005-.007)	<b>.013</b> (.009-.019)	<b>.032</b> (.018-.048)	<b>.046</b> (.033-.066)	340
	01-02	<b>.008</b> (.007-.010)	<b>.008</b> (.006-.010)	<b>.014</b> (.010-.020)	<b>.025</b> (.020-.036)	<b>.037</b> (.025-.049)	368
12-19 years	99-00	<b>.009</b> (.008-.011)	<b>.009</b> (.008-.010)	<b>.014</b> (.012-.018)	<b>.025</b> (.020-.043)	<b>.043</b> (.028-.072)	719
	01-02	<b>.010</b> (.008-.012)	<b>.009</b> (.008-.012)	<b>.017</b> (.012-.023)	<b>.030</b> (.021-.042)	<b>.041</b> (.027-.088)	762
20 years and older	99-00	<b>.008</b> (.006-.009)	<b>.007</b> (.005-.008)	<b>.012</b> (.009-.016)	<b>.026</b> (.021-.038)	<b>.045</b> (.035-.054)	1405
	01-02	<b>.009</b> (.007-.010)	<b>.007</b> (.006-.009)	<b>.014</b> (.011-.016)	<b>.030</b> (.022-.039)	<b>.046</b> (.034-.059)	1560
<b>Gender</b>							
Males	99-00	<b>.009</b> (.008-.011)	<b>.007</b> (.007-.010)	<b>.015</b> (.012-.020)	<b>.036</b> (.024-.046)	<b>.053</b> (.040-.067)	1227
	01-02	<b>.009</b> (.008-.011)	<b>.008</b> (.007-.010)	<b>.014</b> (.012-.019)	<b>.033</b> (.023-.043)	<b>.046</b> (.035-.065)	1335
Females	99-00	<b>.007</b> (.006-.008)	<b>.006</b> (.005-.007)	<b>.011</b> (.009-.014)	<b>.023</b> (.016-.032)	<b>.035</b> (.026-.050)	1237
	01-02	<b>.008</b> (.007-.010)	<b>.008</b> (.006-.009)	<b>.013</b> (.011-.016)	<b>.027</b> (.018-.037)	<b>.040</b> (.029-.062)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.017</b> (.012-.023)	<b>.015</b> (.011-.021)	<b>.032</b> (.019-.053)	<b>.059</b> (.040-.127)	<b>.113</b> (.054-.279)	883
	01-02	<b>.013</b> (.010-.016)	<b>.011</b> (.009-.015)	<b>.022</b> (.016-.027)	<b>.039</b> (.031-.054)	<b>.054</b> (.045-.067)	683
Non-Hispanic blacks	99-00	<b>.009</b> (.007-.011)	<b>.007</b> (.006-.010)	<b>.013</b> (.010-.019)	<b>.028</b> (.018-.045)	<b>.049</b> (.030-.067)	568
	01-02	<b>.008</b> (.007-.009)	<b>.007</b> (.007-.009)	<b>.012</b> (.010-.013)	<b>.020</b> (.017-.027)	<b>.030</b> (.023-.037)	667
Non-Hispanic whites	99-00	<b>.007</b> (.006-.009)	<b>.007</b> (.005-.007)	<b>.012</b> (.008-.014)	<b>.023</b> (.016-.033)	<b>.041</b> (.027-.051)	822
	01-02	<b>.008</b> (.007-.009)	<b>.006</b> (.006-.008)	<b>.012</b> (.010-.014)	<b>.026</b> (.018-.034)	<b>.036</b> (.028-.049)	1132

24 hours after exposure. Following exposure to soluble uranium salts, the initial half-life of uranium is considered to be about 15 days (Bhattacharyya et al., 1992), representing distribution and excretion, with a much slower elimination from bone. After inhalation exposure of insoluble uranium, the half-life for disappearance from the lung is several years (Durakovic et al., 2003).

Health effects from uranium exposure occur from chemical toxicity. Radiation risks from exposure to natural uranium are very low. Nephrotoxicity, the primary toxic effect attributed to chronic uranium exposure in people, manifests as tubular damage and appears reversible with decreasing exposure. Workplace air standards for external exposure to soluble and insoluble uranium compounds have been established by OSHA and ACGIH. Although older evaluations suggested the carcinogenicity of uranium among smokers, the U.S. EPA has withdrawn its classification for carcinogenicity; IARC and NTP have no ratings.

Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA's IRIS Web site at <http://www.epa.gov/iris> and from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### Interpreting Levels of Urinary Uranium Reported in the Tables

Urine uranium levels were measured in a subsample of NHANES participants aged 6 years old and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. The analytical method measures only levels of the  $^{238}\text{U}$  isotope and not levels of the  $^{235}\text{U}$  isotope ( $^{235}\text{U}$  is higher in enriched uranium used as nuclear fuel). More than 99% of naturally occurring uranium is  $^{238}\text{U}$ .

A previous nonrandom subsample from NHANES III (n = 499) showed concentrations that are essentially similar to those in this *Report* (Ting et al., 1999). Dang et

**Table 31. Uranium (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>.007</b> (.006-.009)	<b>.007</b> (.006-.009)	<b>.013</b> (.010-.016)	<b>.024</b> (.019-.030)	<b>.034</b> (.027-.053)	2464
	01-02	<b>.008</b> (.007-.010)	<b>.007</b> (.006-.009)	<b>.014</b> (.011-.018)	<b>.026</b> (.020-.033)	<b>.040</b> (.028-.054)	2689
<b>Age group</b>							
6-11 years	99-00	<b>.009</b> (.007-.012)	<b>.008</b> (.006-.010)	<b>.015</b> (.010-.024)	<b>.030</b> (.016-.044)	<b>.037</b> (.030-.077)	340
	01-02	<b>.010</b> (.008-.011)	<b>.010</b> (.008-.012)	<b>.015</b> (.013-.019)	<b>.027</b> (.018-.032)	<b>.033</b> (.027-.048)	368
12-19 years	99-00	<b>.007</b> (.006-.008)	<b>.006</b> (.005-.008)	<b>.010</b> (.009-.014)	<b>.020</b> (.014-.030)	<b>.030</b> (.019-.074)	719
	01-02	<b>.007</b> (.006-.008)	<b>.007</b> (.006-.008)	<b>.012</b> (.009-.016)	<b>.020</b> (.014-.026)	<b>.026</b> (.020-.042)	762
20 years and older	99-00	<b>.007</b> (.006-.009)	<b>.007</b> (.005-.008)	<b>.013</b> (.010-.016)	<b>.024</b> (.019-.029)	<b>.034</b> (.025-.051)	1405
	01-02	<b>.008</b> (.007-.010)	<b>.007</b> (.006-.009)	<b>.014</b> (.011-.019)	<b>.027</b> (.020-.039)	<b>.043</b> (.030-.063)	1559
<b>Gender</b>							
Males	99-00	<b>.007</b> (.006-.009)	<b>.006</b> (.005-.008)	<b>.011</b> (.009-.015)	<b>.021</b> (.017-.028)	<b>.035</b> (.024-.056)	1227
	01-02	<b>.007</b> (.006-.008)	<b>.007</b> (.006-.008)	<b>.012</b> (.010-.015)	<b>.022</b> (.018-.028)	<b>.033</b> (.025-.047)	1334
Females	99-00	<b>.008</b> (.007-.010)	<b>.007</b> (.006-.009)	<b>.013</b> (.010-.017)	<b>.024</b> (.019-.033)	<b>.034</b> (.027-.054)	1237
	01-02	<b>.009</b> (.008-.011)	<b>.009</b> (.007-.011)	<b>.016</b> (.012-.021)	<b>.029</b> (.021-.042)	<b>.045</b> (.031-.067)	1355
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>.015</b> (.011-.022)	<b>.015</b> (.011-.020)	<b>.028</b> (.016-.058)	<b>.059</b> (.027-.146)	<b>.100</b> (.042-.270)	883
	01-02	<b>.012</b> (.010-.016)	<b>.012</b> (.009-.016)	<b>.021</b> (.015-.028)	<b>.033</b> (.024-.053)	<b>.049</b> (.033-.077)	682
Non-Hispanic blacks	99-00	<b>.006</b> (.004-.007)	<b>.005</b> (.004-.006)	<b>.008</b> (.006-.013)	<b>.017</b> (.011-.028)	<b>.028</b> (.018-.048)	568
	01-02	<b>.005</b> (.005-.006)	<b>.005</b> (.005-.006)	<b>.008</b> (.007-.010)	<b>.013</b> (.011-.014)	<b>.017</b> (.014-.029)	667
Non-Hispanic whites	99-00	<b>.007</b> (.006-.009)	<b>.007</b> (.006-.009)	<b>.012</b> (.010-.015)	<b>.021</b> (.017-.027)	<b>.030</b> (.024-.050)	822
	01-02	<b>.008</b> (.007-.009)	<b>.007</b> (.006-.009)	<b>.013</b> (.011-.016)	<b>.025</b> (.018-.032)	<b>.034</b> (.025-.051)	1132

al. (1992), Karpas et al. (1996), and Galletti (2003) reported urinary levels for small groups of normal individuals in a range similar to those values seen in both the 1999-2000 and 2001-2002 subsamples. In addition, other studies have demonstrated urinary uranium concentrations that are consistent with levels documented in this *Report*, in that the reported levels were below their respective detection limits (Hamilton et al., 1994; Komaromy-Hiller et al., 2000; Byrne et al., 1991).

In one study, 105 people exposed to well water containing natural uranium in the range of 1.8 to 7770  $\mu\text{g/L}$  (median 157  $\mu\text{g/L}$ ) had urinary levels of uranium as high as 9.55  $\mu\text{g/L}$  (median 0.162  $\mu\text{g/L}$ ) (Orloff et al., 2003). Eighty-five percent of the levels were above the 95<sup>th</sup> percentile of the NHANES 1999-2000 subsample. In another study of people drinking well water with high natural uranium concentrations, the median urinary concentration was 0.078  $\mu\text{g/L}$  (ranging up to 5.65  $\mu\text{g/L}$ ), and a subtle effect of uranium on calcium and phosphate fractional clearance was indicated (within the normal range of these measures), but without effects on other biochemical or traditional markers of renal function (Kurtio et al., 2002). The urinary uranium levels reported here for the NHANES 2001-2002 subsample are well below any of these aforementioned levels.

The U.S. Nuclear Regulatory Commission (U.S. NRC) has set an action level of 15  $\mu\text{g/L}$  for uranium in urine to protect people who are occupationally exposed to uranium (U.S. NRC, 1978). Six workers in a depleted uranium program had concentrations of 0.110 to 45  $\mu\text{g/L}$  (Ejnik et al., 2000). Several recent studies have investigated urinary uranium levels in veterans who served during the 1991 Gulf War. In one study, 17 soldiers with embedded shrapnel had a median urinary uranium concentration of 2.61  $\mu\text{g/g}$  creatinine and 28 soldiers who may have been exposed to DU by inhalation, ingestion, or wound contamination, but in whom no shrapnel was embedded, had a mean urinary uranium concentration of 0.066  $\mu\text{g/g}$  creatinine (Gwiazda et al., 2004). In a much larger study of a group of 446 Gulf War veterans who were concerned about past exposure to DU, the geometric mean urinary uranium concentration was 0.011  $\mu\text{g/L}$  (McDiarmid, et al., 2004).

### Comparing Adjusted Geometric Means


Geometric mean levels of urinary uranium for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary uranium in the group aged 6-11 years were

higher than the groups aged 12-19 years. Mexican Americans had higher levels than either non-Hispanic blacks or non-Hispanic whites, and non-Hispanic whites had higher levels than non-Hispanic blacks. Females had slightly higher adjusted geometric mean levels of urinary uranium than males. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of uranium in urine does not mean that the level of uranium causes an adverse health effect. Whether uranium at the levels reported here is cause for health concern is unknown; more research is needed. These urinary uranium data provide physicians with a reference range so that they can determine whether people have been exposed to higher levels of uranium than are found in the general population. These data will also help scientists plan and conduct research about uranium exposure and health effects.

**Figure 13. Uranium (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



## Results by Chemical Group

---

### Tobacco Smoke



## Cotinine

CAS No. 486-56-6

### General Information

Tobacco use is the most important preventable cause of premature morbidity and mortality in the United States. The consequences of smoking and of using smokeless tobacco products are well known and include an increased risk for cancer, emphysema, cardiovascular disease, and possibly other disorders.

Inhalation of tobacco smoke is the main source of nicotine exposure for the general population. Cigarettes contain about 1.5% nicotine by weight (Kozlowski et al., 1998), producing roughly 1-2 mg of bioavailable nicotine per cigarette (Institute of Medicine, 2001). Nicotine can also be absorbed from the gastrointestinal tract and skin as a result of chewing tobacco or chewing gum or using skin patches that contain nicotine. Workers who harvest

tobacco can be exposed to nicotine and intoxicated as a result of the transdermal absorption of nicotine contained in the plant. Some other plants also contain nicotine in smaller amounts. Nicotine has been used previously as an insecticide and is still available for that purpose in its sulfate and alkaloid forms.

Up to 92% of the nicotine delivered in smoke is absorbed from the lungs into the blood stream (Armitage et al., 1975; Iwase et al., 1991). Air concentrations of nicotine in public spaces where smoking is allowed are about 1-10  $\mu\text{g}/\text{m}^3$ . Once absorbed, nicotine has a half-life in blood plasma of several hours (Benowitz, 1996). Cotinine is a metabolite of nicotine and is currently regarded as the best biomarker in active smokers and in nonsmokers exposed to environmental tobacco smoke (ETS). Measuring cotinine is preferred over measuring

**Table 32. Cotinine**

Geometric mean and selected percentiles of serum concentrations (in ng/mL) for the non-smoking U.S. population aged 3 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 3 and older</b>	99-00	*	<b>.059</b> (<LOD-.070)	<b>.236</b> (.190-.300)	<b>1.02</b> (.750-1.25)	<b>1.96</b> (1.60-2.62)	5999
	01-02	<b>.062</b> (.050-.077)	†	<b>.163</b> (.123-.224)	<b>.932</b> (.737-1.17)	<b>2.19</b> (1.83-2.44)	6813
<b>Age group</b>							
3-11 years	99-00	*	<b>.109</b> (.063-.180)	<b>.500</b> (.259-1.09)	<b>1.88</b> (.997-3.44)	<b>3.37</b> (1.42-4.79)	1174
	01-02	<b>.110</b> (.076-.160)	<b>.071</b> (<LOD-.124)	<b>.570</b> (.306-1.01)	<b>2.23</b> (1.60-2.78)	<b>3.21</b> (2.53-4.01)	1414
12-19 years	99-00	*	<b>.107</b> (.080-.160)	<b>.540</b> (.428-.660)	<b>1.65</b> (1.48-1.92)	<b>2.56</b> (2.09-3.39)	1773
	01-02	<b>.086</b> (.059-.126)	<b>.051</b> (<LOD-.109)	<b>.352</b> (.189-.580)	<b>1.53</b> (1.09-2.12)	<b>3.12</b> (2.47-3.99)	1902
20 years and older	99-00	*	< LOD	<b>.167</b> (.140-.193)	<b>.630</b> (.530-.810)	<b>1.48</b> (1.28-1.66)	3052
	01-02	<b>.052</b> (<LOD-.063)	†	<b>.113</b> (.090-.150)	<b>.623</b> (.465-.770)	<b>1.38</b> (1.11-1.84)	3497
<b>Gender</b>							
Males	99-00	*	<b>.080</b> (.059-.109)	<b>.302</b> (.220-.394)	<b>1.20</b> (.950-1.49)	<b>2.39</b> (1.66-3.22)	2789
	01-02	<b>.075</b> (.059-.095)	†	<b>.230</b> (.165-.316)	<b>1.17</b> (.932-1.42)	<b>2.44</b> (2.23-2.97)	3149
Females	99-00	*	< LOD	<b>.179</b> (.148-.220)	<b>.850</b> (.597-1.14)	<b>1.85</b> (1.33-2.45)	3210
	01-02	<b>.053</b> (<LOD-.066)	†	<b>.123</b> (.092-.180)	<b>.711</b> (.537-.990)	<b>1.76</b> (1.32-2.16)	3664
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	<b>.138</b> (.110-.176)	<b>.506</b> (.370-.726)	<b>1.21</b> (.900-1.70)	2241
	01-02	<b>.060</b> (<LOD-.084)	†	<b>.157</b> (.080-.308)	<b>.727</b> (.452-1.19)	<b>2.11</b> (1.14-2.98)	1877
Non-Hispanic blacks	99-00	*	<b>.131</b> (.111-.150)	<b>.505</b> (.400-.625)	<b>1.43</b> (1.18-1.75)	<b>2.34</b> (1.84-3.50)	1333
	01-02	<b>.164</b> (.136-.197)	<b>.132</b> (.106-.161)	<b>.570</b> (.436-.760)	<b>1.77</b> (1.54-2.01)	<b>3.12</b> (2.47-4.25)	1599
Non-Hispanic whites	99-00	*	<b>.050</b> (<LOD-.070)	<b>.210</b> (.150-.310)	<b>.950</b> (.621-1.40)	<b>1.92</b> (1.48-3.02)	1950
	01-02	<b>.052</b> (<LOD-.068)	†	<b>.119</b> (.087-.180)	<b>.800</b> (.571-1.11)	<b>1.88</b> (1.49-2.30)	2845

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† 83% of measurements had a LOD of 0.015 ng/mL and 17% of measurements had a LOD of 0.050 ng/mL. See note in text.

nicotine because cotinine persists longer in the body (plasma half-life is about 16 hours) (Benowitz and Jacob, 1994). Cotinine can be measured in serum, urine, saliva, and hair. Nonsmokers exposed to typical levels of ETS have serum cotinine levels of less than 1 ng/mL, with heavy exposure to ETS producing levels in the 1-10 ng/mL range. Active smokers almost always have levels higher than 10 ng/mL and sometimes higher than 500 ng/mL.

Nicotine stimulates preganglionic cholinergic receptors within peripheral sympathetic autonomic ganglia and at cholinergic sites within the central nervous system. Nicotine indirectly causes a release of dopamine in the brain regions that control pleasure and motivation, a process leading to addiction. Acute tobacco or nicotine intoxication can produce dizziness, nausea, vomiting, diaphoresis, salivation, diarrhea, variable changes in blood pressure and heart rate, seizures, and death. Symptoms of nicotine withdrawal include irritability, craving, cognitive and sleep disturbances, and increased appetite.

Tobacco smoke is considered a human carcinogen by IARC and NTP. Lung cancer is the leading cancer-related killer of both men and women in the United States, and smoking is by far the leading cause of lung cancer. Persistent exposure to ETS is associated with an increased risk for lung cancer. More recently, coronary heart disease (Whincup et al., 2004) and prothrombotic risk factors (Bazzano et al., 2003) have been associated with ETS exposure. ETS may exacerbate asthma among susceptible children and increase the risk for lower respiratory-tract illnesses, such as bronchitis and pneumonia, among young children. Exposure to ETS has also been associated recently with decrements in pulmonary function in adults with asthma (Eisner, 2002). More information about the effects of smoking and nicotine can be found at: <http://www.nida.nih.gov/researchreports/nicotine/nicotine.html>.

### Interpreting Levels of Serum Cotinine Reported in the Table

Serum cotinine levels were measured in a subsample of nonsmoking NHANES participants aged 3 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. Nonsmoking is defined as a serum cotinine level of less than or equal to 10 ng/mL. Choosing a cutoff of 15 ng/mL makes little difference in the results. Serum cotinine has been measured in many studies of non-smoking populations, and such levels are similar or

slightly higher than those reported here, depending on the degree of ETS exposure.

From 1988 through 1991, as part of NHANES III, CDC determined that the median level (50<sup>th</sup> percentile) of cotinine among nonsmokers in the United States was 0.20 ng/mL (Pirkle et al., 1996). Since that 1988-1991 survey period, median levels of cotinine (as measured in NHANES 1999-2002) have decreased 68% in children, 69% in adolescents, and about 75% in adults. This reduction in cotinine levels suggests a major reduction in exposure of the general U.S. population to ETS since the period 1988-1991.

Note: Results are reported as less than the limit of detection (LOD) if they are less than the LOD of the individual sample, which could be either 0.015 ng/mL or 0.050 ng/mL for the 2001-2002 subsample (more sensitive instrumentation was introduced during 2001-2002 analyses). The reporting requirement for a geometric mean is that 60% of the serum cotinine levels must be greater than or equal to the respective specimen-specific LOD. To calculate geometric means and percentiles, measurements below their LOD are assigned values of LOD/square root of 2.

The reporting requirement for percentiles is that they must be greater than the maximum LOD (i.e., greater than 0.050 ng/mL). This requirement avoids confusion in interpretation that could result if a percentile estimate was lower than one of the two LODs. These two reporting requirements (one for geometric means and one for percentiles) occasionally result in a geometric mean being reported with no estimate being reported for the 50<sup>th</sup> percentile (as is the case for cotinine). For completeness, we list here, for 2001-2002, the computed 50<sup>th</sup> percentiles (with 95% confidence limits), recognizing that these estimates are in between the two LODs; that is, between 0.015 ng/mL-0.050 ng/mL.

Age 3 years and older	0.035	(0.032-0.052)
Age 20 years and older	0.034	(0.024-0.038)
Males	0.045	(0.035-0.063)
Females	0.034	(0.023-0.038)
Mexican Americans	0.036	(0.025-0.060)
Non-Hispanic whites	0.034	(0.022-0.043)

### Comparing Adjusted Geometric Means

Geometric mean levels of serum cotinine for the demographic groups in the NHANES 2001-2002 subsample were compared after adjusting for the covariates of age, race/ethnicity, and gender (data not

shown). Both groups aged 3-11 years and 12-19 years had higher adjusted geometric mean levels of cotinine than the group aged 20 years and older. Males had higher levels than females. Non-Hispanic whites and Mexican Americans both had lower levels than non-Hispanic blacks. Higher levels of cotinine have previously been reported for non-Hispanic blacks (Caraballo et al., 1998). It is unknown whether these age, gender, and race/ethnicity differences represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

These serum cotinine data will help public health officials determine whether or not people have been exposed to higher levels of ETS than are found in the general population. These data will also help scientists plan and conduct research about exposure to ETS and health effects.



## Results by Chemical Group

---

### Polycyclic Aromatic Hydrocarbons



## Polycyclic Aromatic Hydrocarbons

### General Information

Polycyclic aromatic hydrocarbons (PAHs) are a class of chemicals that result from the incomplete burning of coal, oil, gas, wood, garbage, or other organic substances, such as tobacco and charbroiled meat. Exposure to these chemicals usually occurs as exposure to mixtures and not to individual chemicals. Exposure can occur through air, water, soil, or food. PAHs enter the air from motor vehicle exhaust, residential and industrial furnaces, tobacco smoke, volcanoes, agricultural burning, residential wood burning, and wildfires. Seasonal variations in exposure to PAHs are known to occur. The soil and water near industrialized areas can contain elevated concentrations of PAHs. Foods that contain PAHs include smoked, charcoal-broiled, and roasted foods and plant foods that become contaminated by atmospheric deposition. Cereal products (e.g., wheat, corn, oats, and barley) may contain PAHs because of methods used to dry them.

Workers in certain occupational settings are exposed to PAHs from the burning or coking of petroleum products. Workplace situations include coke production, coal gasification and gas refinery, iron or steel production, roofing tar and asphalt application, chimney sweeping,

waste incineration, and aluminum smelting. Coal tar is composed of PAHs and can be used as a medical therapy for psoriasis. OSHA have developed criteria on the allowable levels of these chemicals in the workplace. The U.S. EPA and The U.S. Food and Drug Administration (U.S. FDA) have only limited or preliminary standards for a few PAHs in water or food.

PAHs can be absorbed through the skin, respiratory tract, and gastrointestinal tract (Ramesh et al., 2004). In cells, some PAHs can bind and stimulate the Ah receptor, which in turn induces a greater metabolism of the PAHs themselves to products that can interact with DNA and promote cancer (Nebert et al., 2004). Lung, genitourinary, and skin cancers have been reported in occupational settings, where the amount of exposure is greater than it is in the general population (Lloyd, 1971; Redmond et al., 1976; Boffetta et al., 1997; Bostrom et al., 2002; Armstrong et al., 2004). Additionally, PAH exposure may affect the immune system (Li et al., 2003) and reduce fetal growth (Dejmek et al., 2000; Perera et al., 2003). Early studies have been limited by the inability to evaluate the isolated effects of individual PAHs and other contributing carcinogens, such as those in tobacco smoke. IARC classifies benz[a]anthracene and benzo[a]pyrene as probable human carcinogens, and

**Table 33. Polycyclic Aromatic Hydrocarbons (PAHs) and their metabolites**

PAH (CAS number)	Urinary hydroxylated metabolite (CAS number)
Benz[a]anthracene (56-55-3)	1-Hydroxybenz[a]anthracene (69847-26-3) 3-Hydroxybenz[a]anthracene (4834-35-9) and 9-Hydroxybenz[a]anthracene
Benzo[c]phenanthrene (195-19-7)	1-Hydroxybenzo[c]phenanthrene 2-Hydroxybenzo[c]phenanthrene (22717-94-8) 3-Hydroxybenzo[c]phenanthrene
Chrysene (218-01-9)	1-Hydroxychrysene(63019-38-5) 2-Hydroxychrysene (65945-06-4) 3-Hydroxychrysene (63019-39-6) 4-Hydroxychrysene (63019-40-9) 6-Hydroxychrysene (37515-51-8)
Fluoranthene (206-44-0)	3-Hydroxyfluoranthrene
Fluorene (86-73-7)	2-Hydroxyfluorene (2443-58-5) 3-Hydroxyfluorene (6344-67-8) 9-Hydroxyfluorene (484-17-3)
Phenanthrene (85-01-8)	1-Hydroxyphenanthrene (2433-56-9) 2-Hydroxyphenanthrene 3-Hydroxyphenanthrene (605-87-8) 4-Hydroxyphenanthrene (7651-86-7) 9-Hydroxyphenanthrene (484-17-3)
Pyrene (129-00-0)	1-Hydroxypyrene (5315-79-7)
Benzo[a]pyrene (50-32-8)	3-Hydroxybenzo[a]pyrene (13345-21-6)
Naphthalene (91-20-3)	1-Hydroxynaphthalene (90-15-3) 2-Hydroxynaphthalene (135-19-3)

benzo[b]fluoranthene, benzo[j]fluoranthene, benzo[k]fluoranthene, and indeno[1,2,3,cd]pyrene as possible human carcinogens. The NTP lists the following chemicals as reasonably anticipated to be human carcinogens: benz[a]anthracene, benzo[b]fluoranthene, benzo[j]fluoranthene, benzo[k]fluoranthene, benzo[a]pyrene, dibenz[a,h]acridine, dibenz[a,j]acridine, dibenz[a,h]anthracene, 7H-dibenzo-[c,g]carbazole, dibenzo[a,e]pyrene, dibenzo[a,h]pyrene, dibenzo[a,i]pyrene, dibenzo[a,l]pyrene, indeno[1,2,3-cd]pyrene, and 5-methylchrysene (NTP, 2002). The U.S. EPA has classified as probable carcinogens the following: benz[a]anthracene, benzo[a]pyrene, benzo[b]fluoranthene, benzo[k]fluoranthene, chrysene, dibenz[a,h]anthracene, and indeno[1,2,3-cd]pyrene. Pyrene was reviewed by IARC and determined it not to be classifiable as to its human carcinogenicity. In 2005, NTP listed naphthalene as reasonably anticipated to be a human carcinogen (NTP, 2005). IARC, NTP, and U.S. EPA also list chemical mixtures (e.g., soot, coke-oven emissions, coal tars), which contain PAH chemicals, as known carcinogens.

Information about external exposure (i.e., environmental levels) and health effects is available in several reviews (Bostrom et al., 2002, Armstrong et al., 2004) as well as from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### **Interpreting Levels of Urinary PAH Metabolites Reported in the Tables**

Urinary levels of hydroxylated metabolites of PAHs were measured in a subsample of NHANES participants aged 6 years old and older. Participants were selected within the specified age range to be a representative sample of the U.S. population.

Measurement of these 22 metabolites reflects exposure to PAHs that has occurred within the previous few days. Some of the parent PAHs can produce more than one measureable urinary metabolite. Table 34 shows the relation between PAHs and their metabolites. The hydroxylated metabolites of the PAHs are excreted in human urine both as free hydroxylated metabolites and as hydroxylated metabolites conjugated to glucuronic acid and sulfate. Measurements provided in this *Report* include both free and conjugated forms of the hydroxylated metabolites.

Finding a measurable amount of one or more metabolites in the urine does not mean that the levels of the PAHs metabolites cause an adverse health effect. Whether levels of PAH metabolites at the levels reported here are

cause for health concern is not known; more research is needed. These data provide physicians with a reference range so that they can determine whether people have been exposed to higher levels of PAHs than are found in the general population. These data will help scientists plan and conduct research on exposure to PAHs and health effects.

# 1-Hydroxybenz[a]anthracene and 3- and 9-Hydroxybenz[a]anthracene

Metabolites of Benz[a]anthracene, CAS No. 56-55-3

## Interpreting Levels of Urinary Benz[a]anthracene Metabolites Reported in the Tables

Urinary levels of 1-hydroxybenz[a]anthracene and combined levels of 3-hydroxybenz[a]-anthracene and 9-hydroxybenz[a]anthracene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Similar levels of 1- and 3-hydroxybenz[a]anthracene have been reported in a small sample of pre-school children (Wilson et al., 2003). A sampling of 24 adults and 24 children from low income households in North Carolina found higher urinary levels of urinary 1-hydroxybenz[a]anthracene and 3-hydroxybenz[a]-anthracene, exceeding five- to ten-fold the concentrations measured in the NHANES 1999-2002 subsamples (Chuang et al., 1999). Workers manufacturing fireproof stone had 3-hydroxybenz[a]anthracene levels that were

10-100 times higher than the levels that were found in the NHANES 1999-2002 subsamples (Gundel et al., 2000).

**Table 34. 1-Hydroxybenz[a]anthracene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2084
	01-02	*	< LOD	< LOD	< LOD	30.0 (22.0-36.0)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	276
	01-02	*	< LOD	< LOD	13.0 (<LOD-30.0)	45.0 (19.0-56.0)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	626
	01-02	*	< LOD	< LOD	4.00 (<LOD-19.0)	38.0 (10.0-68.0)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1182
	01-02	*	< LOD	< LOD	< LOD	26.0 (21.0-34.0)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1004
	01-02	*	< LOD	< LOD	10.0 (<LOD-20.0)	30.0 (23.0-39.0)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1080
	01-02	*	< LOD	< LOD	< LOD	30.0 (15.0-40.0)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	6.80 (<LOD-10.9)	667
	01-02	*	< LOD	< LOD	< LOD	21.0 (<LOD-38.0)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	5.20 (<LOD-7.20)	465
	01-02	*	< LOD	< LOD	30.0 (13.0-42.0)	59.0 (30.0-89.0)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	779
	01-02	*	< LOD	< LOD	< LOD	27.0 (20.0-37.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 35. 1-Hydroxybenz[a]anthracene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2084
	01-02	*	< LOD	< LOD	< LOD	27.0 (19.6-32.4)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	276
	01-02	*	< LOD	< LOD	21.5 (10.0-28.0)	34.0 (27.0-50.5)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	626
	01-02	*	< LOD	< LOD	12.4 (6.83-24.8)	28.0 (14.8-38.0)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1182
	01-02	*	< LOD	< LOD	< LOD	24.5 (18.4-31.1)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1004
	01-02	*	< LOD	< LOD	12.7 (10.2-17.0)	24.8 (18.4-33.8)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1080
	01-02	*	< LOD	< LOD	< LOD	27.0 (17.5-33.9)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	15.7 (9.43-18.3)	667
	01-02	*	< LOD	< LOD	< LOD	21.5 (14.1-33.3)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	7.36 (5.41-11.0)	465
	01-02	*	< LOD	< LOD	17.5 (10.7-28.1)	33.9 (17.5-61.6)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	779
	01-02	*	< LOD	< LOD	< LOD	28.0 (18.7-32.7)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 36. 3- and 9-Hydroxybenz[a]anthracene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	<b>7.50</b> (6.00-9.90)	<b>11.6</b> (8.40-15.6)	2152
	01-02	*	< LOD	< LOD	<b>11.0</b> (<LOD-15.0)	<b>24.0</b> (19.0-31.0)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	<b>7.70</b> (<LOD-11.9)	<b>14.4</b> (7.70-49.8)	<b>32.0</b> (9.50-71.0)	285
	01-02	*	< LOD	< LOD	< LOD	<b>14.0</b> (11.0-21.0)	387
12-19 years	99-00	*	< LOD	<b>6.20</b> (<LOD-7.50)	<b>10.5</b> (8.80-13.8)	<b>14.9</b> (11.4-16.8)	652
	01-02	*	< LOD	< LOD	<b>14.0</b> (<LOD-18.0)	<b>28.0</b> (18.0-42.0)	735
20 years and older	99-00	*	< LOD	< LOD	<b>5.80</b> (<LOD-7.20)	<b>8.80</b> (6.50-11.8)	1215
	01-02	*	< LOD	< LOD	<b>11.0</b> (<LOD-16.0)	<b>23.0</b> (18.0-31.0)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>7.90</b> (5.70-12.6)	<b>13.5</b> (9.20-18.8)	1033
	01-02	*	< LOD	< LOD	<b>15.0</b> (12.0-18.0)	<b>25.0</b> (20.0-31.0)	1349
Females	99-00	*	< LOD	< LOD	<b>7.10</b> (6.00-9.10)	<b>10.3</b> (8.90-11.9)	1119
	01-02	*	< LOD	< LOD	< LOD	<b>21.0</b> (14.0-35.0)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>7.70</b> (6.80-8.90)	<b>11.1</b> (8.10-14.2)	688
	01-02	*	< LOD	< LOD	<b>11.0</b> (<LOD-16.0)	<b>23.0</b> (16.0-31.0)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>7.60</b> (5.80-11.5)	<b>11.6</b> (7.30-19.0)	488
	01-02	*	< LOD	< LOD	<b>18.0</b> (15.0-25.0)	<b>35.0</b> (22.0-46.0)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>7.60</b> (5.60-10.3)	<b>11.8</b> (7.70-18.0)	793
	01-02	*	< LOD	< LOD	<b>11.0</b> (<LOD-18.0)	<b>23.0</b> (18.0-36.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 37. 3- and 9-Hydroxybenz[a]anthracene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	<b>12.2</b> (10.1-14.6)	<b>17.6</b> (15.7-21.1)	2152
	01-02	*	< LOD	< LOD	<b>21.4</b> (19.2-23.7)	<b>31.8</b> (28.4-35.5)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	<b>9.61</b> (6.63-14.6)	<b>18.1</b> (10.3-29.6)	<b>23.6</b> (12.8-40.5)	285
	01-02	*	< LOD	< LOD	< LOD	<b>29.6</b> (23.7-39.8)	387
12-19 years	99-00	*	< LOD	<b>5.09</b> (4.42-5.94)	<b>7.69</b> (6.44-8.64)	<b>10.0</b> (8.50-11.9)	652
	01-02	*	< LOD	< LOD	<b>18.2</b> (15.2-24.8)	<b>29.1</b> (21.5-50.7)	735
20 years and older	99-00	*	< LOD	< LOD	<b>12.2</b> (10.2-14.3)	<b>17.4</b> (15.2-21.1)	1215
	01-02	*	< LOD	< LOD	<b>21.5</b> (20.3-24.5)	<b>32.3</b> (28.1-35.5)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>9.77</b> (8.09-12.7)	<b>14.7</b> (10.7-19.0)	1033
	01-02	*	< LOD	< LOD	<b>18.7</b> (15.6-21.9)	<b>26.3</b> (21.5-35.3)	1349
Females	99-00	*	< LOD	< LOD	<b>14.1</b> (12.3-16.5)	<b>21.1</b> (16.5-22.4)	1119
	01-02	*	< LOD	< LOD	< LOD	<b>33.8</b> (29.8-39.8)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>10.8</b> (8.84-15.5)	<b>18.1</b> (11.9-21.6)	688
	01-02	*	< LOD	< LOD	<b>21.5</b> (17.2-28.4)	<b>32.3</b> (27.3-36.3)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>6.77</b> (5.76-9.05)	<b>10.9</b> (7.45-14.1)	488
	01-02	*	< LOD	< LOD	<b>17.6</b> (14.5-22.2)	<b>28.4</b> (21.5-41.2)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>13.1</b> (10.3-16.5)	<b>19.0</b> (16.5-22.4)	793
	01-02	*	< LOD	< LOD	<b>23.7</b> (20.9-25.6)	<b>33.8</b> (29.6-37.4)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

# 1-Hydroxybenzo[c]phenanthrene, 2-Hydroxybenzo[c]phenanthrene, and 3-Hydroxybenzo[c]phenanthrene

*Metabolites of Benzo[c]phenanthrene, CAS No. 195-19-7*

Urinary levels of 1-hydroxybenzo[c]phenanthrene, 2-hydroxybenzo[c]phenanthrene, and 3-hydroxybenzo[c]phenanthrene were measured in a subsample of NHANES participants aged 6 years and older.

**Table 38. 1-Hydroxybenzo[c]phenanthrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	<b>8.20</b> (<LOD-13.1)	<b>17.2</b> (10.8-31.3)	<b>31.0</b> (19.0-47.2)	2200
	01-02	*	< LOD	< LOD	< LOD	<b>34.0</b> (16.0-54.0)	2732
<b>Age group</b>							
6-11 years	99-00	*	< LOD	<b>9.10</b> (<LOD-17.5)	<b>17.0</b> (9.20-40.1)	<b>32.1</b> (13.8-254)	297
	01-02	*	< LOD	< LOD	< LOD	<b>15.0</b> (<LOD-35.0)	385
12-19 years	99-00	*	< LOD	<b>9.50</b> (7.10-13.2)	<b>18.0</b> (12.4-31.2)	<b>31.2</b> (16.9-48.1)	665
	01-02	*	< LOD	< LOD	< LOD	<b>29.0</b> (11.0-64.0)	728
20 years and older	99-00	*	< LOD	<b>8.10</b> (<LOD-12.8)	<b>16.9</b> (10.5-31.0)	<b>30.3</b> (19.4-47.2)	1238
	01-02	*	< LOD	< LOD	<b>4.00</b> (<LOD-19.0)	<b>37.0</b> (16.0-79.0)	1619
<b>Gender</b>							
Males	99-00	*	< LOD	<b>8.40</b> (<LOD-13.8)	<b>18.0</b> (11.5-33.6)	<b>35.4</b> (25.2-47.2)	1054
	01-02	*	< LOD	< LOD	< LOD	<b>19.0</b> (5.00-33.0)	1340
Females	99-00	*	< LOD	<b>8.20</b> (<LOD-13.3)	<b>16.5</b> (9.80-25.8)	<b>24.7</b> (15.2-47.2)	1146
	01-02	*	< LOD	< LOD	<b>13.0</b> (<LOD-37.0)	<b>51.0</b> (26.0-94.0)	1392
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	<b>12.9</b> (7.40-20.2)	<b>21.9</b> (15.2-32.4)	<b>32.4</b> (23.3-47.5)	716
	01-02	*	< LOD	< LOD	<b>11.0</b> (<LOD-84.0)	<b>52.0</b> (9.00-105)	659
Non-Hispanic blacks	99-00	*	< LOD	<b>7.60</b> (<LOD-9.90)	<b>12.8</b> (8.20-32.4)	<b>30.3</b> (11.0-49.2)	497
	01-02	*	< LOD	< LOD	< LOD	<b>21.0</b> (<LOD-72.0)	687
Non-Hispanic whites	99-00	*	< LOD	<b>8.40</b> (<LOD-14.4)	<b>17.0</b> (10.0-32.9)	<b>29.4</b> (16.7-58.7)	806
	01-02	*	< LOD	< LOD	< LOD	<b>35.0</b> (15.0-83.0)	1205

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 39. 1-Hydroxybenzo[c]phenanthrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	<b>10.1</b> (7.69-13.3)	<b>22.8</b> (15.7-30.0)	<b>36.1</b> (23.5-62.3)	2200
	01-02	*	< LOD	< LOD	< LOD	<b>41.3</b> (21.0-70.8)	2732
<b>Age group</b>							
6-11 years	99-00	*	< LOD	<b>9.73</b> (7.29-17.7)	<b>22.7</b> (10.7-39.6)	<b>32.8</b> (20.5-80.5)	297
	01-02	*	< LOD	< LOD	< LOD	<b>28.3</b> (7.00-114)	385
12-19 years	99-00	*	< LOD	<b>7.69</b> (5.73-10.2)	<b>16.3</b> (11.5-22.0)	<b>24.3</b> (16.3-34.0)	665
	01-02	*	< LOD	< LOD	< LOD	<b>21.5</b> (15.0-46.7)	728
20 years and older	99-00	*	< LOD	<b>10.5</b> (7.88-13.8)	<b>23.5</b> (15.4-33.3)	<b>37.4</b> (23.5-80.7)	1238
	01-02	*	< LOD	< LOD	<b>12.4</b> (8.50-20.7)	<b>45.9</b> (20.7-76.5)	1619
<b>Gender</b>							
Males	99-00	*	< LOD	<b>8.61</b> (6.67-11.1)	<b>18.6</b> (12.7-26.7)	<b>28.8</b> (22.8-37.1)	1054
	01-02	*	< LOD	< LOD	< LOD	<b>18.7</b> (12.2-37.2)	1340
Females	99-00	*	< LOD	<b>11.8</b> (8.24-17.5)	<b>25.1</b> (15.4-41.1)	<b>40.4</b> (21.1-93.3)	1146
	01-02	*	< LOD	< LOD	<b>19.3</b> (9.55-45.5)	<b>69.6</b> (33.3-103)	1392
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	<b>12.3</b> (9.47-17.0)	<b>26.7</b> (19.0-36.3)	<b>37.1</b> (27.1-50.0)	716
	01-02	*	< LOD	< LOD	<b>16.2</b> (5.12-54.5)	<b>42.0</b> (12.4-106)	659
Non-Hispanic blacks	99-00	*	< LOD	<b>5.75</b> (4.32-7.86)	<b>11.8</b> (7.80-20.5)	<b>21.1</b> (11.4-40.5)	497
	01-02	*	< LOD	< LOD	< LOD	<b>14.0</b> (5.38-78.5)	687
Non-Hispanic whites	99-00	*	< LOD	<b>10.4</b> (7.84-14.3)	<b>23.9</b> (15.4-36.4)	<b>37.4</b> (22.8-86.9)	806
	01-02	*	< LOD	< LOD	< LOD	<b>45.7</b> (19.1-87.5)	1205

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 40. 2-Hydroxybenzo[c]phenanthrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	<b>14.3</b> (9.60-19.6)	<b>21.2</b> (16.5-28.1)	2175
	01-02	*	< LOD	< LOD	< LOD	<b>13.0</b> (6.00-20.0)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	<b>7.00</b> (<LOD-16.2)	<b>19.9</b> (11.6-34.9)	<b>30.2</b> (14.2-47.2)	285
	01-02	*	< LOD	< LOD	< LOD	< LOD	387
12-19 years	99-00	*	< LOD	< LOD	<b>14.0</b> (8.90-20.0)	<b>20.0</b> (14.6-32.3)	657
	01-02	*	< LOD	< LOD	< LOD	< LOD	735
20 years and older	99-00	*	< LOD	< LOD	<b>13.5</b> (8.50-21.2)	<b>20.1</b> (14.0-29.4)	1233
	01-02	*	< LOD	< LOD	< LOD	<b>16.0</b> (9.00-24.0)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	<b>7.00</b> (<LOD-10.9)	<b>16.9</b> (12.2-23.8)	<b>29.0</b> (22.2-34.9)	1046
	01-02	*	< LOD	< LOD	< LOD	<b>13.0</b> (6.00-20.0)	1349
Females	99-00	*	< LOD	< LOD	<b>11.9</b> (8.20-17.5)	<b>17.0</b> (12.8-22.0)	1129
	01-02	*	< LOD	< LOD	< LOD	<b>13.0</b> (<LOD-27.0)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>12.2</b> (8.10-17.1)	<b>17.0</b> (12.2-28.9)	686
	01-02	*	< LOD	< LOD	< LOD	<b>15.0</b> (<LOD-42.0)	665
Non-Hispanic blacks	99-00	*	< LOD	<b>10.0</b> (<LOD-16.6)	<b>20.0</b> (14.4-34.3)	<b>34.3</b> (19.0-51.6)	495
	01-02	*	< LOD	< LOD	< LOD	<b>18.0</b> (<LOD-23.0)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>13.5</b> (8.40-20.5)	<b>21.2</b> (15.0-29.4)	810
	01-02	*	< LOD	< LOD	< LOD	<b>15.0</b> (<LOD-22.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 41. 2-Hydroxybenzo[c]phenanthrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	<b>20.0</b> (16.0-23.7)	<b>28.2</b> (23.1-30.9)	2175
	01-02	*	< LOD	< LOD	< LOD	<b>20.3</b> (15.9-23.3)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	<b>11.4</b> (9.53-13.0)	<b>23.1</b> (12.3-32.0)	<b>34.3</b> (20.0-67.3)	285
	01-02	*	< LOD	< LOD	< LOD	< LOD	387
12-19 years	99-00	*	< LOD	< LOD	<b>11.7</b> (8.77-15.0)	<b>16.4</b> (11.7-26.1)	657
	01-02	*	< LOD	< LOD	< LOD	< LOD	735
20 years and older	99-00	*	< LOD	< LOD	<b>20.9</b> (16.0-26.7)	<b>28.6</b> (25.3-32.8)	1233
	01-02	*	< LOD	< LOD	< LOD	<b>21.4</b> (16.7-29.1)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	<b>8.42</b> (6.96-10.9)	<b>17.3</b> (13.3-23.1)	<b>25.3</b> (19.3-34.3)	1046
	01-02	*	< LOD	< LOD	< LOD	<b>17.5</b> (13.5-23.3)	1349
Females	99-00	*	< LOD	< LOD	<b>20.9</b> (16.6-26.7)	<b>30.0</b> (26.7-30.9)	1129
	01-02	*	< LOD	< LOD	< LOD	<b>21.9</b> (16.7-35.0)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>15.5</b> (11.7-20.8)	<b>22.9</b> (16.6-25.0)	686
	01-02	*	< LOD	< LOD	< LOD	<b>23.3</b> (14.0-53.7)	665
Non-Hispanic blacks	99-00	*	< LOD	<b>7.38</b> (5.57-11.7)	<b>16.7</b> (11.7-22.3)	<b>23.3</b> (18.0-33.0)	495
	01-02	*	< LOD	< LOD	< LOD	<b>13.2</b> (10.9-18.4)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>20.8</b> (16.1-25.3)	<b>28.6</b> (25.3-32.0)	810
	01-02	*	< LOD	< LOD	< LOD	<b>21.9</b> (16.7-28.2)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 42. 3-Hydroxybenzo[c]phenanthrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2172
	01-02	*	< LOD	< LOD	< LOD	11.0 (8.00-16.0)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	287
	01-02	*	< LOD	< LOD	8.00 (<LOD-13.0)	13.0 (8.00-24.0)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	657
	01-02	*	< LOD	< LOD	< LOD	12.0 (<LOD-21.0)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	< LOD	11.0 (8.00-16.0)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1045
	01-02	*	< LOD	< LOD	7.00 (<LOD-11.0)	11.0 (9.00-15.0)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1127
	01-02	*	< LOD	< LOD	< LOD	12.0 (6.00-18.0)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	689
	01-02	*	< LOD	< LOD	< LOD	14.0 (8.00-21.0)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	491
	01-02	*	< LOD	< LOD	< LOD	14.0 (<LOD-26.0)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	807
	01-02	*	< LOD	< LOD	< LOD	11.0 (8.00-15.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 43. 3-Hydroxybenzo[c]phenanthrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2172
	01-02	*	< LOD	< LOD	< LOD	15.9 (14.6-16.7)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	< LOD	287
	01-02	*	< LOD	< LOD	10.9 (8.75-14.0)	14.6 (12.5-15.9)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	657
	01-02	*	< LOD	< LOD	< LOD	13.1 (10.0-17.5)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	< LOD	15.9 (14.3-17.1)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	1045
	01-02	*	< LOD	< LOD	9.46 (8.54-10.5)	12.5 (11.3-15.9)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1127
	01-02	*	< LOD	< LOD	< LOD	16.7 (15.9-19.6)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	689
	01-02	*	< LOD	< LOD	< LOD	17.5 (14.0-23.3)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	491
	01-02	*	< LOD	< LOD	< LOD	13.4 (10.7-18.4)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	807
	01-02	*	< LOD	< LOD	< LOD	15.9 (14.3-16.7)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

# 1-Hydroxychrysene, 2-Hydroxychrysene 3-Hydroxychrysene, 4-Hydroxychrysene, and 6-Hydroxychrysene

*Metabolites of Chrysene, CAS No. 218-01-9*

## Interpreting Levels of Urinary Chrysene Metabolites Reported in the Tables

Urinary levels of 1-hydroxychrysene, 2-hydroxychrysene 3-hydroxychrysene, 4-hydroxychrysene, and 6-hydroxychrysene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Similar levels of 6-hydroxychrysene have been reported in pre-school children (Wilson et al., 2003). A sampling of 24 adults and 24 children from low income households in North Carolina found higher levels of urinary 6-hydroxychrysene, exceeding five- to ten-fold the concentrations measured in the NHANES 1999-2002 subsamples (Chuang et al., 1999).

**Table 44. 1-Hydroxychrysene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	*	< LOD	13.0 (<LOD-27.0)	64.0 (46.0-78.0)	105 (85.0-138)	2748
<b>Age group</b>							
6-11 years	01-02	*	< LOD	< LOD	35.0 (19.0-52.0)	69.0 (37.0-83.0)	387
12-19 years	01-02	*	< LOD	8.00 (<LOD-23.0)	46.0 (31.0-62.0)	71.0 (50.0-119)	735
20 years and older	01-02	*	< LOD	17.0 (<LOD-30.0)	71.0 (53.0-87.0)	116 (92.0-147)	1626
<b>Gender</b>							
Males	01-02	*	< LOD	23.0 (<LOD-38.0)	73.0 (55.0-89.0)	107 (87.0-152)	1349
Females	01-02	*	< LOD	5.00 (<LOD-20.0)	49.0 (31.0-71.0)	92.0 (74.0-134)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	62.0 (31.0-102)	104 (74.0-206)	665
Non-Hispanic blacks	01-02	*	< LOD	19.0 (<LOD-47.0)	78.0 (53.0-103)	135 (81.0-190)	692
Non-Hispanic whites	01-02	*	< LOD	12.0 (<LOD-28.0)	60.0 (42.0-79.0)	105 (75.0-143)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 45. 1-Hydroxychrysene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	*	< LOD	17.1 (11.3-25.0)	50.0 (41.2-59.7)	89.2 (71.4-104)	2748
<b>Age group</b>							
6-11 years	01-02	*	< LOD	< LOD	42.6 (22.2-54.7)	58.1 (47.0-74.2)	387
12-19 years	01-02	*	< LOD	13.3 (7.61-18.6)	35.0 (28.3-41.0)	49.3 (37.4-65.7)	735
20 years and older	01-02	*	< LOD	18.1 (11.7-28.5)	55.9 (42.8-70.2)	103 (78.9-120)	1626
<b>Gender</b>							
Males	01-02	*	< LOD	19.4 (11.7-28.8)	50.0 (41.1-57.7)	86.4 (59.7-109)	1349
Females	01-02	*	< LOD	15.9 (10.6-23.3)	50.0 (38.9-66.0)	91.5 (69.2-126)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	58.2 (36.3-92.5)	108 (61.8-147)	665
Non-Hispanic blacks	01-02	*	< LOD	18.3 (6.48-33.9)	56.6 (37.9-83.0)	106 (62.4-154)	692
Non-Hispanic whites	01-02	*	< LOD	16.5 (10.9-24.7)	47.3 (38.4-59.4)	91.5 (68.6-107)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 46. 2-Hydroxychrysene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	*	< LOD	< LOD	11.0 (<LOD-26.0)	31.0 (14.0-45.0)	2748
<b>Age group</b>							
6-11 years	01-02	*	< LOD	< LOD	22.0 (<LOD-43.0)	39.0 (13.0-49.0)	387
12-19 years	01-02	*	< LOD	< LOD	9.00 (<LOD-32.0)	32.0 (<LOD-49.0)	735
20 years and older	01-02	*	< LOD	< LOD	10.0 (<LOD-23.0)	32.0 (12.0-46.0)	1626
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	12.0 (<LOD-28.0)	34.0 (13.0-50.0)	1349
Females	01-02	*	< LOD	< LOD	9.00 (<LOD-22.0)	31.0 (12.0-43.0)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	15.0 (<LOD-39.0)	665
Non-Hispanic blacks	01-02	*	< LOD	< LOD	20.0 (<LOD-43.0)	43.0 (17.0-65.0)	692
Non-Hispanic whites	01-02	*	< LOD	< LOD	9.00 (<LOD-24.0)	27.0 (11.0-45.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 47. 2-Hydroxychrysene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	*	< LOD	< LOD	17.5 (12.1-24.5)	27.8 (20.9-35.0)	2748
<b>Age group</b>							
6-11 years	01-02	*	< LOD	< LOD	21.9 (17.2-29.0)	29.9 (22.0-34.2)	387
12-19 years	01-02	*	< LOD	< LOD	14.3 (8.14-18.5)	24.1 (15.2-35.0)	735
20 years and older	01-02	*	< LOD	< LOD	17.6 (11.7-25.2)	27.8 (20.6-38.9)	1626
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	17.3 (9.72-24.9)	26.3 (18.2-34.2)	1349
Females	01-02	*	< LOD	< LOD	18.2 (14.0-24.5)	30.2 (21.7-39.4)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	21.8 (15.9-31.3)	665
Non-Hispanic blacks	01-02	*	< LOD	< LOD	19.5 (7.50-32.4)	30.8 (18.4-45.5)	692
Non-Hispanic whites	01-02	*	< LOD	< LOD	17.3 (11.7-25.0)	27.1 (20.3-35.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 48. 3-Hydroxychrysene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2233
	01-02	*	< LOD	< LOD	27.0 (24.0-31.0)	42.0 (36.0-46.0)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	11.0 (<LOD-44.8)	300
	01-02	*	< LOD	< LOD	21.0 (15.0-38.0)	42.0 (22.0-62.0)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	11.3 (<LOD-17.2)	674
	01-02	*	< LOD	< LOD	23.0 (18.0-30.0)	37.0 (27.0-39.0)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	29.0 (25.0-31.0)	43.0 (37.0-47.0)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	10.1 (<LOD-17.7)	1067
	01-02	*	< LOD	< LOD	30.0 (25.0-37.0)	45.0 (37.0-54.0)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1166
	01-02	*	< LOD	< LOD	25.0 (20.0-30.0)	35.0 (30.0-44.0)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	10.8 (<LOD-14.5)	722
	01-02	*	< LOD	< LOD	24.0 (18.0-28.0)	30.0 (27.0-38.0)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	515
	01-02	*	< LOD	< LOD	25.0 (16.0-35.0)	43.0 (28.0-63.0)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	807
	01-02	*	< LOD	9.00 (<LOD-15.0)	30.0 (25.0-34.0)	44.0 (36.0-49.0)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 49. 3-Hydroxychrysene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	2233
	01-02	*	< LOD	< LOD	35.0 (27.1-41.5)	56.8 (47.4-62.5)	2748
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	26.9 (17.5-46.2)	300
	01-02	*	< LOD	< LOD	36.8 (23.8-62.5)	67.3 (36.7-89.9)	387
12-19 years	99-00	*	< LOD	< LOD	< LOD	17.3 (13.7-21.9)	674
	01-02	*	< LOD	< LOD	28.2 (20.0-40.7)	43.8 (33.8-57.0)	735
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	35.8 (26.7-44.6)	57.8 (50.0-63.6)	1626
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	20.6 (17.5-29.2)	1067
	01-02	*	< LOD	< LOD	28.2 (24.1-35.0)	47.6 (40.9-57.0)	1349
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1166
	01-02	*	< LOD	< LOD	40.9 (30.2-50.0)	65.0 (51.6-83.0)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	33.3 (21.9-37.1)	722
	01-02	*	< LOD	< LOD	28.4 (24.4-35.8)	42.0 (30.0-54.0)	665
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	515
	01-02	*	< LOD	< LOD	22.8 (15.1-30.5)	35.0 (23.0-62.5)	692
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	807
	01-02	*	< LOD	16.3 (13.9-18.4)	40.6 (31.8-47.4)	61.8 (51.5-70.2)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 50. 4-Hydroxychrysene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2748
<b>Age group</b>							
6-11 years	01-02	*	< LOD	< LOD	< LOD	5.00 (<LOD-11.0)	387
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	735
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1626
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1349
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	665
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	13.0 (4.00-18.0)	692
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 51. 4-Hydroxychrysene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2748
<b>Age group</b>							
6-11 years	01-02	*	< LOD	< LOD	< LOD	9.55 (7.24-12.4)	387
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	735
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1626
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1349
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	665
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	9.00 (7.49-12.2)	692
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 52. 6-Hydroxychrysene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	<b>4.50</b> (<LOD-5.30)	<b>6.00</b> (5.30-6.80)	2279
	01-02	*	< LOD	<b>7.00</b> (<LOD-13.0)	<b>43.0</b> (32.0-55.0)	<b>77.0</b> (57.0-101)	2736
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	<b>5.00</b> (<LOD-5.90)	<b>6.10</b> (5.70-7.60)	298
	01-02	*	< LOD	<b>10.0</b> (<LOD-20.0)	<b>32.0</b> (25.0-52.0)	<b>68.0</b> (34.0-115)	386
12-19 years	99-00	*	< LOD	< LOD	<b>5.70</b> (4.30-7.50)	<b>7.70</b> (5.00-11.2)	689
	01-02	*	< LOD	<b>10.0</b> (6.00-16.0)	<b>46.0</b> (29.0-59.0)	<b>79.0</b> (59.0-105)	728
20 years and older	99-00	*	< LOD	< LOD	<b>4.40</b> (<LOD-5.10)	<b>5.80</b> (4.90-6.60)	1292
	01-02	*	< LOD	<b>7.00</b> (<LOD-13.0)	<b>44.0</b> (32.0-60.0)	<b>77.0</b> (57.0-103)	1622
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>4.80</b> (<LOD-5.70)	<b>6.40</b> (5.40-7.70)	1091
	01-02	*	< LOD	<b>13.0</b> (7.00-18.0)	<b>55.0</b> (41.0-67.0)	<b>101</b> (67.0-123)	1341
Females	99-00	*	< LOD	< LOD	<b>4.20</b> (<LOD-5.10)	<b>5.80</b> (4.50-7.30)	1188
	01-02	*	< LOD	< LOD	<b>33.0</b> (22.0-46.0)	<b>59.0</b> (44.0-78.0)	1395
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>4.70</b> (3.70-5.10)	<b>6.00</b> (4.90-8.10)	749
	01-02	*	< LOD	<b>16.0</b> (7.00-20.0)	<b>48.0</b> (38.0-63.0)	<b>84.0</b> (63.0-117)	664
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>4.90</b> (<LOD-6.60)	<b>6.80</b> (4.70-9.50)	515
	01-02	*	< LOD	<b>9.00</b> (<LOD-14.0)	<b>61.0</b> (40.0-88.0)	<b>112</b> (77.0-134)	683
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>4.50</b> (<LOD-5.50)	<b>5.90</b> (5.50-6.60)	827
	01-02	*	< LOD	<b>9.00</b> (<LOD-15.0)	<b>42.0</b> (29.0-58.0)	<b>73.0</b> (52.0-107)	1206

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 53. 6-Hydroxychrysene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	<b>8.05</b> (7.06-9.15)	<b>12.6</b> (10.4-13.3)	2279
	01-02	*	< LOD	<b>9.26</b> (6.36-13.8)	<b>36.9</b> (28.0-46.0)	<b>61.5</b> (47.7-76.4)	2736
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	<b>7.74</b> (5.11-13.1)	<b>11.0</b> (8.09-24.5)	298
	01-02	*	< LOD	<b>12.2</b> (5.00-18.9)	<b>39.4</b> (24.5-62.7)	<b>80.6</b> (40.0-115)	386
12-19 years	99-00	*	< LOD	< LOD	<b>6.32</b> (4.61-9.35)	<b>9.23</b> (5.83-11.7)	689
	01-02	*	< LOD	<b>9.05</b> (6.49-12.7)	<b>36.0</b> (21.1-46.9)	<b>62.7</b> (44.3-97.6)	728
20 years and older	99-00	*	< LOD	< LOD	<b>8.18</b> (7.07-9.60)	<b>13.3</b> (11.4-14.1)	1292
	01-02	*	< LOD	<b>8.65</b> (5.19-14.2)	<b>36.4</b> (26.7-46.2)	<b>60.7</b> (46.0-76.0)	1622
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>6.67</b> (5.22-8.51)	<b>9.23</b> (8.28-11.7)	1091
	01-02	*	< LOD	<b>12.0</b> (8.24-15.5)	<b>41.5</b> (30.4-56.1)	<b>64.4</b> (52.2-97.2)	1341
Females	99-00	*	< LOD	< LOD	<b>9.88</b> (8.00-11.4)	<b>14.1</b> (12.6-17.1)	1188
	01-02	*	< LOD	< LOD	<b>32.5</b> (22.6-44.6)	<b>50.8</b> (42.6-68.8)	1395
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>8.05</b> (5.45-11.4)	<b>13.3</b> (7.74-24.2)	749
	01-02	*	< LOD	<b>14.8</b> (8.29-20.8)	<b>48.5</b> (33.6-63.4)	<b>75.0</b> (50.3-123)	664
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>4.62</b> (3.81-6.00)	<b>7.50</b> (5.71-7.93)	515
	01-02	*	< LOD	<b>7.04</b> (3.89-11.6)	<b>41.6</b> (29.9-55.5)	<b>68.8</b> (46.0-113)	683
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>8.57</b> (7.75-10.4)	<b>13.1</b> (11.4-15.5)	827
	01-02	*	< LOD	<b>9.42</b> (6.09-14.7)	<b>38.2</b> (26.5-47.7)	<b>62.4</b> (45.5-85.4)	1206

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

## 3-Hydroxyfluoranthene

*Metabolite of Fluoranthene, CAS No. 206-44-0*

Data for 3-hydroxyfluoranthene are not available for the current survey period 2001-2002. The table shown here reports data from 1999-2000 only.

### Comparing Adjusted Geometric Means

For the 1999-2000 subsample, geometric mean levels of urinary fluorene metabolites in the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, creatinine, and log serum cotinine (data not shown). There were no differences between the demographic groups in adjusted geometric mean levels of urinary 3-hydroxyfluoranthene.

**Table 54. 3-Hydroxyfluoranthene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>13.4</b> (9.43-19.0)	<b>17.5</b> (7.90-25.9)	<b>32.3</b> (27.4-40.2)	<b>58.6</b> (49.4-73.0)	<b>98.8</b> (78.9-147)	2236
<b>Age group</b>							
6-11 years	99-00	<b>12.6</b> (8.82-17.9)	<b>15.8</b> (3.90-24.7)	<b>37.6</b> (24.7-45.1)	<b>65.7</b> (44.6-146)	<b>138</b> (66.3-216)	308
12-19 years	99-00	<b>15.0</b> (9.47-23.9)	<b>20.3</b> (5.10-31.8)	<b>38.7</b> (29.6-48.8)	<b>60.6</b> (47.6-91.4)	<b>98.9</b> (75.4-162)	675
20 years and older	99-00	<b>13.2</b> (9.39-18.6)	<b>17.3</b> (8.20-24.5)	<b>31.1</b> (26.8-38.5)	<b>58.2</b> (48.9-74.0)	<b>90.7</b> (71.7-151)	1253
<b>Gender</b>							
Males	99-00	<b>13.5</b> (9.55-19.0)	<b>17.4</b> (8.80-25.1)	<b>32.6</b> (27.1-42.1)	<b>58.2</b> (47.6-74.0)	<b>98.8</b> (64.7-190)	1074
Females	99-00	<b>13.3</b> (9.26-19.1)	<b>17.5</b> (6.80-26.1)	<b>31.8</b> (26.9-39.1)	<b>58.7</b> (48.9-77.2)	<b>88.4</b> (68.4-146)	1162
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>14.0</b> (8.96-21.9)	<b>17.1</b> (6.90-26.8)	<b>30.4</b> (22.7-44.4)	<b>52.1</b> (42.9-73.8)	<b>96.6</b> (60.8-312)	715
Non-Hispanic blacks	99-00	<b>13.9</b> (8.32-23.2)	<b>17.7</b> (<LOD-29.3)	<b>38.2</b> (25.0-57.6)	<b>89.3</b> (56.8-174)	<b>185</b> (95.5-291)	527
Non-Hispanic whites	99-00	<b>13.2</b> (8.64-20.2)	<b>17.3</b> (6.50-28.1)	<b>32.0</b> (25.8-41.6)	<b>56.7</b> (43.6-74.0)	<b>87.3</b> (64.7-127)	803

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

**Table 55. 3-Hydroxyfluoranthene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>12.3</b> (8.39-18.2)	<b>14.7</b> (7.90-24.9)	<b>36.3</b> (25.0-47.8)	<b>67.9</b> (54.4-84.7)	<b>102</b> (86.0-127)	2236
<b>Age group</b>							
6-11 years	99-00	<b>12.8</b> (8.49-19.4)	<b>13.7</b> (5.32-27.2)	<b>44.3</b> (21.3-66.5)	<b>77.0</b> (54.7-115)	<b>131</b> (67.3-254)	308
12-19 years	99-00	<b>10.1</b> (5.86-17.4)	<b>13.4</b> (4.90-24.1)	<b>29.1</b> (19.0-44.3)	<b>54.9</b> (39.2-84.6)	<b>92.1</b> (66.6-134)	675
20 years and older	99-00	<b>12.7</b> (8.76-18.4)	<b>14.8</b> (8.03-25.7)	<b>36.5</b> (25.6-46.8)	<b>68.9</b> (54.4-85.0)	<b>102</b> (82.9-128)	1253
<b>Gender</b>							
Males	99-00	<b>10.7</b> (7.16-15.9)	<b>12.1</b> (6.41-20.7)	<b>32.9</b> (20.7-45.3)	<b>62.5</b> (44.3-82.4)	<b>91.3</b> (72.6-122)	1074
Females	99-00	<b>14.2</b> (9.70-20.7)	<b>17.5</b> (9.10-28.0)	<b>39.6</b> (28.9-49.9)	<b>75.5</b> (61.3-89.1)	<b>107</b> (90.5-172)	1162
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>12.7</b> (7.69-21.1)	<b>13.8</b> (6.76-23.0)	<b>30.7</b> (20.8-48.2)	<b>64.1</b> (48.2-97.4)	<b>107</b> (67.7-312)	715
Non-Hispanic blacks	99-00	<b>9.14</b> (5.44-15.4)	<b>10.4</b> (2.98-21.3)	<b>30.2</b> (19.8-42.6)	<b>72.6</b> (47.6-116)	<b>133</b> (84.2-216)	527
Non-Hispanic whites	99-00	<b>13.1</b> (8.31-20.7)	<b>16.0</b> (6.45-29.7)	<b>36.9</b> (25.0-52.1)	<b>68.8</b> (51.2-86.0)	<b>90.6</b> (77.0-127)	803

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

## 2-Hydroxyfluorene, 3-Hydroxyfluorene, and 9-Hydroxyfluorene

*Metabolites of Fluorene, CAS No. 86-73-7*

### Interpreting Levels of Urinary Fluorene Metabolites Reported in the Tables

Urinary levels of 2-hydroxyfluorene, 3-hydroxyfluorene, 9-hydroxyfluorene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Levels of 2-hydroxyfluorene have been shown to be higher in smokers than non-smokers (Toriba et al., 2003).

### Comparing Adjusted Geometric Means

Geometric mean levels of urinary fluorene metabolites for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, creatinine, and log serum cotinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of 2- and 3-fluorene were higher for the group aged 6-11

years than either of the groups aged 12-19 years or 20 years and older.

For adjusted geometric mean levels of 9-fluorene in NHANES 2001-2002, the group aged 12-19 years had lower levels than either of the groups aged 6-11 years or 20 years and older.

It is unknown whether these differences associated with age represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

**Table 56. 2-Hydroxyfluorene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>441</b> (287-678)	<b>422</b> (237-826)	<b>1350</b> (895-2290)	<b>3710</b> (2620-5250)	<b>6450</b> (4630-9470)	2315
	01-02	<b>318</b> (277-366)	<b>293</b> (252-328)	<b>619</b> (515-779)	<b>1700</b> (1330-2090)	<b>2820</b> (2340-3450)	2745
<b>Age group</b>							
6-11 years	99-00	<b>294</b> (181-477)	<b>262</b> (157-563)	<b>780</b> (447-1360)	<b>1800</b> (1140-2000)	<b>2010</b> (1810-3260)	306
	01-02	<b>246</b> (219-277)	<b>262</b> (212-298)	<b>417</b> (357-492)	<b>679</b> (530-926)	<b>979</b> (773-1180)	387
12-19 years	99-00	<b>469</b> (301-729)	<b>421</b> (243-933)	<b>1410</b> (932-2190)	<b>2810</b> (2180-4130)	<b>4980</b> (3540-6610)	694
	01-02	<b>295</b> (244-357)	<b>267</b> (237-319)	<b>548</b> (427-652)	<b>1190</b> (712-2090)	<b>2190</b> (1290-3250)	733
20 years and older	99-00	<b>461</b> (300-709)	<b>456</b> (251-857)	<b>1510</b> (973-2620)	<b>4280</b> (2750-6090)	<b>7270</b> (4720-10300)	1315
	01-02	<b>333</b> (287-385)	<b>300</b> (254-343)	<b>716</b> (546-893)	<b>1950</b> (1520-2310)	<b>3140</b> (2540-3660)	1625
<b>Gender</b>							
Males	99-00	<b>474</b> (294-765)	<b>468</b> (223-923)	<b>1450</b> (875-2460)	<b>3780</b> (2440-6350)	<b>6920</b> (4160-12500)	1106
	01-02	<b>377</b> (324-439)	<b>329</b> (287-377)	<b>773</b> (579-1010)	<b>2060</b> (1480-2690)	<b>3210</b> (2340-3930)	1346
Females	99-00	<b>412</b> (276-616)	<b>385</b> (246-755)	<b>1330</b> (866-2150)	<b>3600</b> (2700-4660)	<b>5790</b> (4350-9470)	1209
	01-02	<b>272</b> (232-317)	<b>250</b> (211-296)	<b>512</b> (425-614)	<b>1270</b> (1120-1700)	<b>2310</b> (1990-2920)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>296</b> (217-404)	<b>268</b> (164-454)	<b>807</b> (485-1290)	<b>1870</b> (1230-2530)	<b>2930</b> (1900-5400)	750
	01-02	<b>267</b> (212-337)	<b>270</b> (200-344)	<b>491</b> (368-620)	<b>951</b> (652-1190)	<b>1350</b> (1080-2130)	662
Non-Hispanic blacks	99-00	<b>646</b> (337-1240)	<b>680</b> (258-1520)	<b>2140</b> (983-4570)	<b>5790</b> (2680-11800)	<b>10800</b> (4830-19300)	534
	01-02	<b>459</b> (401-526)	<b>433</b> (377-474)	<b>1020</b> (725-1400)	<b>2200</b> (1760-3110)	<b>3480</b> (2520-4770)	692
Non-Hispanic whites	99-00	<b>418</b> (249-704)	<b>402</b> (211-860)	<b>1320</b> (825-2550)	<b>3990</b> (2590-5150)	<b>6450</b> (4600-9470)	842
	01-02	<b>310</b> (259-372)	<b>282</b> (234-332)	<b>599</b> (477-817)	<b>1710</b> (1210-2260)	<b>2920</b> (2260-3640)	1207


**Table 57. 2-Hydroxyfluorene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>408</b> (259-642)	<b>382</b> (233-713)	<b>1160</b> (756-1660)	<b>2880</b> (1960-4350)	<b>5270</b> (3540-6860)	2315
	01-02	<b>298</b> (261-340)	<b>240</b> (209-266)	<b>530</b> (432-681)	<b>1310</b> (1100-1490)	<b>1890</b> (1590-2290)	2745
<b>Age group</b>							
6-11 years	99-00	<b>307</b> (180-525)	<b>336</b> (140-724)	<b>787</b> (520-1200)	<b>1380</b> (1030-2180)	<b>1740</b> (1410-2880)	306
	01-02	<b>275</b> (238-319)	<b>256</b> (224-289)	<b>387</b> (319-508)	<b>695</b> (527-989)	<b>1040</b> (724-1470)	387
12-19 years	99-00	<b>314</b> (190-519)	<b>369</b> (153-619)	<b>785</b> (543-1300)	<b>1880</b> (1260-2550)	<b>2570</b> (2220-3360)	694
	01-02	<b>228</b> (194-268)	<b>187</b> (164-220)	<b>358</b> (278-479)	<b>852</b> (537-1100)	<b>1170</b> (885-2150)	733
20 years and older	99-00	<b>443</b> (283-692)	<b>400</b> (259-739)	<b>1260</b> (806-2080)	<b>3480</b> (2290-5200)	<b>6040</b> (3990-7970)	1315
	01-02	<b>314</b> (275-358)	<b>245</b> (213-277)	<b>597</b> (491-766)	<b>1430</b> (1270-1590)	<b>2080</b> (1700-2530)	1625
<b>Gender</b>							
Males	99-00	<b>376</b> (225-628)	<b>378</b> (195-702)	<b>1070</b> (657-1750)	<b>2440</b> (1550-4870)	<b>4870</b> (2630-6870)	1106
	01-02	<b>305</b> (263-353)	<b>248</b> (209-290)	<b>563</b> (449-717)	<b>1330</b> (1030-1590)	<b>1900</b> (1460-2460)	1346
Females	99-00	<b>441</b> (291-667)	<b>393</b> (250-741)	<b>1260</b> (841-1680)	<b>3300</b> (2200-4410)	<b>5490</b> (3580-7720)	1209
	01-02	<b>291</b> (255-332)	<b>227</b> (207-260)	<b>497</b> (399-649)	<b>1220</b> (1060-1490)	<b>1890</b> (1590-2290)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>275</b> (187-405)	<b>252</b> (155-443)	<b>597</b> (394-999)	<b>1350</b> (960-1720)	<b>2090</b> (1410-3110)	750
	01-02	<b>250</b> (206-303)	<b>221</b> (176-279)	<b>375</b> (306-501)	<b>711</b> (517-1040)	<b>1350</b> (787-2060)	662
Non-Hispanic blacks	99-00	<b>425</b> (219-823)	<b>541</b> (174-1070)	<b>1190</b> (679-2650)	<b>3090</b> (1500-7100)	<b>6040</b> (3080-8500)	534
	01-02	<b>323</b> (281-373)	<b>273</b> (220-334)	<b>660</b> (496-856)	<b>1290</b> (1050-1700)	<b>1880</b> (1590-2460)	692
Non-Hispanic whites	99-00	<b>414</b> (241-711)	<b>387</b> (215-762)	<b>1240</b> (756-1910)	<b>3110</b> (2050-4880)	<b>5620</b> (3670-7370)	842
	01-02	<b>306</b> (260-360)	<b>243</b> (208-273)	<b>546</b> (435-741)	<b>1400</b> (1140-1590)	<b>2080</b> (1530-2620)	1207

**Figure 14. 2-Hydroxyfluorene (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



**Table 58. 3-Hydroxyfluorene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>170</b> (114-254)	<b>151</b> (86.3-280)	<b>572</b> (341-956)	<b>1840</b> (1260-2530)	<b>3390</b> (2290-4680)	2312
	01-02	<b>134</b> (115-155)	<b>111</b> (96.0-125)	<b>253</b> (207-349)	<b>959</b> (666-1300)	<b>1620</b> (1390-1900)	2745
<b>Age group</b>							
6-11 years	99-00	<b>105</b> (70.3-157)	<b>92.8</b> (57.2-166)	<b>247</b> (137-439)	<b>615</b> (328-851)	<b>851</b> (647-1290)	306
	01-02	<b>106</b> (94.8-119)	<b>106</b> (90.0-124)	<b>174</b> (145-200)	<b>287</b> (235-358)	<b>377</b> (306-455)	387
12-19 years	99-00	<b>192</b> (126-293)	<b>198</b> (119-295)	<b>621</b> (358-903)	<b>1330</b> (978-1910)	<b>2110</b> (1550-2400)	692
	01-02	<b>129</b> (103-161)	<b>113</b> (97.0-137)	<b>221</b> (177-266)	<b>542</b> (325-1070)	<b>1210</b> (680-2130)	733
20 years and older	99-00	<b>178</b> (117-269)	<b>156</b> (89.1-306)	<b>639</b> (375-1160)	<b>2080</b> (1450-3350)	<b>4060</b> (2600-5020)	1314
	01-02	<b>138</b> (119-161)	<b>110</b> (94.0-128)	<b>311</b> (228-429)	<b>1130</b> (823-1400)	<b>1840</b> (1470-2080)	1625
<b>Gender</b>							
Males	99-00	<b>189</b> (119-299)	<b>167</b> (85.4-319)	<b>689</b> (341-1230)	<b>2060</b> (1320-3160)	<b>3520</b> (2090-6060)	1105
	01-02	<b>163</b> (137-194)	<b>134</b> (114-154)	<b>352</b> (242-481)	<b>1100</b> (721-1500)	<b>1810</b> (1390-2190)	1346
Females	99-00	<b>154</b> (106-224)	<b>141</b> (85.2-250)	<b>478</b> (333-742)	<b>1710</b> (986-2490)	<b>3010</b> (1900-4610)	1207
	01-02	<b>111</b> (95.0-130)	<b>93.0</b> (83.0-108)	<b>203</b> (167-248)	<b>796</b> (498-1040)	<b>1390</b> (1230-1660)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>105</b> (75.6-145)	<b>96.7</b> (53.8-167)	<b>313</b> (203-432)	<b>862</b> (493-1370)	<b>1490</b> (941-1650)	748
	01-02	<b>108</b> (87.1-134)	<b>98.0</b> (80.0-118)	<b>190</b> (144-255)	<b>476</b> (302-641)	<b>668</b> (476-1140)	662
Non-Hispanic blacks	99-00	<b>266</b> (145-489)	<b>257</b> (116-572)	<b>954</b> (441-1750)	<b>2800</b> (1320-5800)	<b>5290</b> (2390-8600)	534
	01-02	<b>203</b> (169-244)	<b>161</b> (135-188)	<b>444</b> (308-830)	<b>1420</b> (1130-1780)	<b>2350</b> (1520-3000)	692
Non-Hispanic whites	99-00	<b>161</b> (99.9-259)	<b>137</b> (72.9-298)	<b>552</b> (318-964)	<b>1910</b> (1160-2720)	<b>3590</b> (2290-4730)	842
	01-02	<b>130</b> (108-157)	<b>108</b> (93.0-127)	<b>246</b> (202-352)	<b>948</b> (621-1320)	<b>1610</b> (1320-1990)	1207


**Table 59. 3-Hydroxyfluorene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>157</b> (102-241)	<b>135</b> (79.9-234)	<b>482</b> (306-766)	<b>1510</b> (918-2540)	<b>2710</b> (1780-4060)	2312
	01-02	<b>125</b> (108-144)	<b>94.4</b> (83.3-106)	<b>219</b> (174-303)	<b>754</b> (622-873)	<b>1060</b> (909-1290)	2745
<b>Age group</b>							
6-11 years	99-00	<b>110</b> (69.8-173)	<b>111</b> (62.4-204)	<b>268</b> (175-418)	<b>504</b> (324-832)	<b>832</b> (480-1540)	306
	01-02	<b>119</b> (103-137)	<b>110</b> (96.7-121)	<b>153</b> (135-197)	<b>264</b> (206-377)	<b>382</b> (254-631)	387
12-19 years	99-00	<b>129</b> (79.4-209)	<b>140</b> (68.7-253)	<b>374</b> (228-496)	<b>799</b> (536-1120)	<b>1130</b> (917-1390)	692
	01-02	<b>99.3</b> (81.6-121)	<b>81.5</b> (74.2-92.6)	<b>144</b> (109-197)	<b>390</b> (214-700)	<b>700</b> (372-1380)	733
20 years and older	99-00	<b>170</b> (111-262)	<b>138</b> (83.9-244)	<b>613</b> (329-978)	<b>1820</b> (1130-2730)	<b>3020</b> (2140-4290)	1314
	01-02	<b>131</b> (113-151)	<b>94.0</b> (81.0-108)	<b>279</b> (195-367)	<b>853</b> (727-923)	<b>1210</b> (1010-1350)	1625
<b>Gender</b>							
Males	99-00	<b>150</b> (90.9-246)	<b>128</b> (72.9-253)	<b>496</b> (270-807)	<b>1390</b> (777-2710)	<b>2710</b> (1440-4170)	1105
	01-02	<b>132</b> (111-156)	<b>99.4</b> (87.3-116)	<b>260</b> (194-361)	<b>745</b> (560-914)	<b>1130</b> (862-1380)	1346
Females	99-00	<b>164</b> (111-243)	<b>138</b> (86.6-228)	<b>477</b> (311-792)	<b>1650</b> (1050-2400)	<b>2860</b> (2000-3790)	1207
	01-02	<b>119</b> (104-136)	<b>88.9</b> (78.6-103)	<b>179</b> (156-227)	<b>777</b> (604-888)	<b>1030</b> (923-1270)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>97.5</b> (65.6-145)	<b>89.2</b> (52.4-147)	<b>220</b> (146-338)	<b>665</b> (380-854)	<b>987</b> (709-1600)	748
	01-02	<b>101</b> (84.2-121)	<b>84.0</b> (74.8-97.2)	<b>158</b> (124-214)	<b>364</b> (227-598)	<b>598</b> (357-1230)	662
Non-Hispanic blacks	99-00	<b>175</b> (94.1-325)	<b>176</b> (74.3-364)	<b>550</b> (313-1060)	<b>1590</b> (828-2830)	<b>2710</b> (1590-3950)	534
	01-02	<b>143</b> (118-173)	<b>110</b> (90.7-133)	<b>316</b> (186-525)	<b>849</b> (622-1230)	<b>1240</b> (882-1430)	692
Non-Hispanic whites	99-00	<b>159</b> (96.6-262)	<b>138</b> (73.4-260)	<b>505</b> (314-832)	<b>1650</b> (967-2700)	<b>2920</b> (1830-4210)	842
	01-02	<b>128</b> (108-152)	<b>94.7</b> (83.4-109)	<b>223</b> (171-323)	<b>816</b> (642-914)	<b>1150</b> (910-1410)	1207

**Figure 15. 3-Hydroxyfluorene (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



**Table 60. 9-Hydroxyfluorene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>219</b> (191-251)	<b>219</b> (186-258)	<b>429</b> (363-510)	<b>779</b> (690-897)	<b>1090</b> (950-1300)	2745
<b>Age group</b>							
6-11 years	01-02	<b>169</b> (142-201)	<b>168</b> (144-202)	<b>295</b> (255-369)	<b>487</b> (415-683)	<b>720</b> (546-994)	387
12-19 years	01-02	<b>197</b> (161-242)	<b>200</b> (153-266)	<b>370</b> (319-445)	<b>666</b> (527-784)	<b>883</b> (679-1270)	733
20 years and older	01-02	<b>230</b> (199-265)	<b>231</b> (201-270)	<b>452</b> (376-568)	<b>839</b> (726-965)	<b>1150</b> (995-1360)	1625
<b>Gender</b>							
Males	01-02	<b>251</b> (217-292)	<b>249</b> (207-296)	<b>475</b> (396-578)	<b>858</b> (698-1080)	<b>1240</b> (990-1520)	1346
Females	01-02	<b>192</b> (164-225)	<b>194</b> (164-238)	<b>387</b> (328-462)	<b>701</b> (617-881)	<b>1020</b> (913-1100)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>199</b> (147-269)	<b>202</b> (155-273)	<b>347</b> (277-506)	<b>701</b> (451-1080)	<b>1080</b> (603-1690)	662
Non-Hispanic blacks	01-02	<b>327</b> (287-373)	<b>324</b> (289-348)	<b>609</b> (538-708)	<b>1060</b> (884-1430)	<b>1570</b> (1130-2350)	692
Non-Hispanic whites	01-02	<b>213</b> (182-250)	<b>214</b> (176-260)	<b>414</b> (347-508)	<b>772</b> (676-868)	<b>1060</b> (884-1300)	1207

**Table 61. 9-Hydroxyfluorene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>205</b> (183-229)	<b>206</b> (181-232)	<b>353</b> (312-393)	<b>585</b> (507-697)	<b>852</b> (736-1120)	2745
<b>Age group</b>							
6-11 years	01-02	<b>189</b> (156-228)	<b>197</b> (162-238)	<b>330</b> (285-372)	<b>542</b> (426-660)	<b>740</b> (568-1010)	387
12-19 years	01-02	<b>152</b> (130-179)	<b>145</b> (120-183)	<b>256</b> (212-313)	<b>432</b> (348-584)	<b>642</b> (497-970)	733
20 years and older	01-02	<b>217</b> (194-243)	<b>219</b> (189-245)	<b>373</b> (331-412)	<b>608</b> (525-736)	<b>933</b> (747-1250)	1625
<b>Gender</b>							
Males	01-02	<b>203</b> (180-230)	<b>198</b> (173-227)	<b>348</b> (300-408)	<b>607</b> (526-722)	<b>843</b> (745-1070)	1346
Females	01-02	<b>206</b> (182-234)	<b>213</b> (183-245)	<b>361</b> (306-395)	<b>541</b> (488-697)	<b>894</b> (702-1160)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>186</b> (143-243)	<b>182</b> (142-250)	<b>302</b> (233-416)	<b>515</b> (375-724)	<b>724</b> (515-1380)	662
Non-Hispanic blacks	01-02	<b>231</b> (201-265)	<b>224</b> (199-240)	<b>359</b> (324-388)	<b>605</b> (453-929)	<b>1190</b> (674-1680)	692
Non-Hispanic whites	01-02	<b>211</b> (186-239)	<b>211</b> (178-245)	<b>367</b> (324-411)	<b>605</b> (521-719)	<b>896</b> (747-1160)	1207

# 1-Hydroxyphenanthrene, 2-Hydroxyphenanthrene, 3-Hydroxyphenanthrene, 4-Hydroxyphenanthrene, and 9-Hydroxyphenanthrene

*Metabolites of Phenanthrene, CAS No. 85-01-8*

## Interpreting Levels of Urinary Phenanthrene Metabolites Reported in the Tables

Urinary levels of 1-hydroxyphenanthrene, 2-hydroxyphenanthrene, 3-hydroxyphenanthrene, 4-hydroxyphenanthrene, and 9-hydroxyphenanthrene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Residents of homes with PAH contaminated parquet flooring had higher mean urinary 1-, 2-, 3- and 4-hydroxy-phenanthrene levels than were found in this NHANES 1999-2002 subsample (Heudorf and Angerer, 2001a). Workers manufacturing fireproof stone had urinary levels of 1-, 2-, 3- and 4-hydroxy-phenanthrene levels that were about ten times higher than the levels that were found in this NHANES 1999-2002 subsample (Gundel et al., 2000).

Tobacco smoking increased levels of 2-, 3- and 4-hydroxyphenanthrene levels (Heudorf and Angerer, 2001b).

## Comparing Adjusted Geometric Means

Geometric means levels of urinary phenanthrene metabolites for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary 1-hydroxyphenanthrene were higher in females than males, higher in non-Hispanic whites than non-Hispanic blacks, and higher in the group aged 6-11 years than either of the groups aged 12-19 years or 20 years and older.

**Table 62. 1-Hydroxyphenanthrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>154</b> (115-206)	<b>160</b> (105-236)	<b>367</b> (280-483)	<b>698</b> (609-836)	<b>1070</b> (851-1390)	2246
	01-02	<b>140</b> (125-158)	<b>140</b> (128-152)	<b>266</b> (229-312)	<b>476</b> (426-539)	<b>684</b> (581-763)	2741
<b>Age group</b>							
6-11 years	99-00	<b>121</b> (85.4-172)	<b>102</b> (74.2-204)	<b>257</b> (184-389)	<b>513</b> (360-666)	<b>666</b> (535-1080)	294
	01-02	<b>119</b> (104-137)	<b>121</b> (98.0-142)	<b>228</b> (182-249)	<b>357</b> (265-501)	<b>493</b> (367-661)	387
12-19 years	99-00	<b>167</b> (128-218)	<b>175</b> (137-229)	<b>353</b> (266-443)	<b>688</b> (580-865)	<b>1080</b> (721-1560)	680
	01-02	<b>133</b> (110-162)	<b>130</b> (109-152)	<b>238</b> (198-303)	<b>429</b> (376-546)	<b>579</b> (439-820)	733
20 years and older	99-00	<b>157</b> (116-212)	<b>163</b> (105-247)	<b>400</b> (295-523)	<b>739</b> (623-899)	<b>1100</b> (859-1530)	1272
	01-02	<b>145</b> (127-164)	<b>145</b> (132-163)	<b>273</b> (237-326)	<b>498</b> (440-565)	<b>712</b> (582-789)	1621
<b>Gender</b>							
Males	99-00	<b>153</b> (112-209)	<b>147</b> (99.8-236)	<b>351</b> (262-498)	<b>680</b> (588-836)	<b>1020</b> (735-1590)	1072
	01-02	<b>150</b> (133-169)	<b>145</b> (132-164)	<b>284</b> (235-348)	<b>499</b> (424-593)	<b>713</b> (575-845)	1344
Females	99-00	<b>156</b> (118-205)	<b>172</b> (119-236)	<b>372</b> (290-480)	<b>753</b> (610-946)	<b>1100</b> (855-1530)	1174
	01-02	<b>132</b> (115-152)	<b>136</b> (120-151)	<b>254</b> (221-297)	<b>462</b> (390-520)	<b>654</b> (538-769)	1397
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>113</b> (94.9-134)	<b>113</b> (98.9-137)	<b>230</b> (180-314)	<b>447</b> (328-557)	<b>618</b> (459-745)	727
	01-02	<b>117</b> (90.8-152)	<b>115</b> (88.0-147)	<b>214</b> (157-294)	<b>364</b> (254-583)	<b>514</b> (342-847)	664
Non-Hispanic blacks	99-00	<b>162</b> (100-262)	<b>170</b> (82.7-303)	<b>441</b> (252-680)	<b>821</b> (574-1300)	<b>1210</b> (790-2290)	516
	01-02	<b>150</b> (127-179)	<b>145</b> (126-170)	<b>287</b> (243-327)	<b>493</b> (423-629)	<b>713</b> (568-975)	690
Non-Hispanic whites	99-00	<b>154</b> (109-218)	<b>156</b> (102-248)	<b>378</b> (267-533)	<b>704</b> (604-891)	<b>1060</b> (867-1450)	815
	01-02	<b>144</b> (125-166)	<b>143</b> (130-160)	<b>276</b> (241-330)	<b>489</b> (436-552)	<b>649</b> (550-793)	1204

For adjusted geometric mean levels of urinary 2-hydroxyphenanthrene in the NHANES 2001-2002, there were no demographic differences observed.

For adjusted geometric mean levels of urinary 3-hydroxyphenanthrene, in NHANES 2001-2002, higher levels were observed in the group aged 6-11 years than either of the groups age 12-19 years or 20 years and older. Non-Hispanic whites had higher levels than Mexican Americans.

For adjusted geometric mean levels of urinary 4-hydroxyphenanthrene, in NHANES 2001-2002, no demographic group differences were observed.

For adjusted geometric mean levels of urinary 9-hydroxyphenanthrene, in NHANES 2001-2002, non-Hispanic whites had higher levels than either non-Hispanic blacks or Mexican Americans. Also, Mexican Americans had higher levels than non-Hispanic blacks.

It is unknown whether these differences associated with age, gender or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.


**Table 63. 1-Hydroxyphenanthrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>142</b> (103-195)	<b>143</b> (102-204)	<b>299</b> (240-379)	<b>571</b> (450-693)	<b>907</b> (652-1270)	2246
	01-02	<b>132</b> (118-147)	<b>125</b> (113-141)	<b>210</b> (191-231)	<b>344</b> (310-385)	<b>464</b> (404-539)	2741
<b>Age group</b>							
6-11 years	99-00	<b>127</b> (86.4-187)	<b>135</b> (85.8-206)	<b>265</b> (185-372)	<b>457</b> (372-577)	<b>622</b> (503-913)	294
	01-02	<b>133</b> (116-153)	<b>125</b> (110-147)	<b>188</b> (165-225)	<b>344</b> (245-437)	<b>452</b> (364-598)	387
12-19 years	99-00	<b>112</b> (79.9-156)	<b>121</b> (93.5-154)	<b>207</b> (164-283)	<b>406</b> (293-632)	<b>661</b> (421-972)	680
	01-02	<b>103</b> (87.9-121)	<b>97.2</b> (81.4-117)	<b>158</b> (131-192)	<b>237</b> (198-322)	<b>354</b> (235-531)	733
20 years and older	99-00	<b>150</b> (109-207)	<b>150</b> (104-220)	<b>321</b> (254-397)	<b>603</b> (462-828)	<b>973</b> (671-1530)	1272
	01-02	<b>137</b> (122-153)	<b>131</b> (117-145)	<b>223</b> (200-243)	<b>351</b> (319-395)	<b>476</b> (421-541)	1621
<b>Gender</b>							
Males	99-00	<b>120</b> (85.0-170)	<b>124</b> (81.4-187)	<b>260</b> (195-328)	<b>479</b> (362-641)	<b>692</b> (497-1090)	1072
	01-02	<b>122</b> (108-137)	<b>116</b> (104-131)	<b>194</b> (173-218)	<b>314</b> (262-395)	<b>450</b> (348-642)	1344
Females	99-00	<b>166</b> (122-225)	<b>166</b> (120-219)	<b>351</b> (276-418)	<b>631</b> (474-969)	<b>1120</b> (643-2180)	1174
	01-02	<b>142</b> (125-160)	<b>136</b> (118-156)	<b>226</b> (199-256)	<b>353</b> (323-399)	<b>473</b> (421-541)	1397
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>104</b> (81.4-133)	<b>104</b> (78.8-141)	<b>192</b> (154-234)	<b>327</b> (241-456)	<b>474</b> (372-672)	727
	01-02	<b>110</b> (88.6-136)	<b>101</b> (85.5-131)	<b>162</b> (138-203)	<b>275</b> (187-452)	<b>396</b> (268-755)	664
Non-Hispanic blacks	99-00	<b>107</b> (65.5-174)	<b>109</b> (56.6-209)	<b>269</b> (173-395)	<b>548</b> (358-847)	<b>887</b> (534-1410)	516
	01-02	<b>106</b> (88.7-127)	<b>102</b> (92.4-111)	<b>172</b> (141-203)	<b>272</b> (224-356)	<b>384</b> (308-598)	690
Non-Hispanic whites	99-00	<b>151</b> (104-220)	<b>153</b> (99.9-236)	<b>323</b> (249-395)	<b>580</b> (468-820)	<b>1010</b> (643-1510)	815
	01-02	<b>142</b> (126-161)	<b>137</b> (119-153)	<b>226</b> (206-247)	<b>363</b> (321-406)	<b>476</b> (411-552)	1204

**Figure 16. 1-Hydroxyphenanthrene (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



**Table 64. 2-Hydroxyphenanthrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>98.3</b> (76.6-126)	<b>107</b> (79.7-141)	<b>240</b> (194-335)	<b>545</b> (448-689)	<b>828</b> (714-937)	2179
	01-02	<b>54.0</b> (46.0-63.5)	<b>57.0</b> (49.0-68.0)	<b>117</b> (102-140)	<b>240</b> (200-271)	<b>332</b> (299-377)	2742
<b>Age group</b>							
6-11 years	99-00	<b>79.6</b> (57.3-111)	<b>74.1</b> (45.8-113)	<b>189</b> (113-289)	<b>401</b> (283-585)	<b>698</b> (383-1140)	291
	01-02	<b>40.5</b> (34.3-47.7)	<b>45.0</b> (37.0-57.0)	<b>87.0</b> (71.0-101)	<b>170</b> (133-207)	<b>257</b> (195-320)	387
12-19 years	99-00	<b>109</b> (90.0-132)	<b>112</b> (92.6-139)	<b>233</b> (183-296)	<b>529</b> (427-615)	<b>767</b> (570-1250)	650
	01-02	<b>49.5</b> (37.3-65.7)	<b>51.0</b> (41.0-68.0)	<b>107</b> (90.0-122)	<b>210</b> (145-270)	<b>281</b> (214-524)	733
20 years and older	99-00	<b>99.3</b> (76.4-129)	<b>108</b> (81.2-148)	<b>253</b> (203-345)	<b>571</b> (454-721)	<b>864</b> (721-945)	1238
	01-02	<b>56.8</b> (48.1-66.9)	<b>60.0</b> (51.0-73.0)	<b>126</b> (104-152)	<b>249</b> (207-292)	<b>342</b> (308-398)	1622
<b>Gender</b>							
Males	99-00	<b>107</b> (81.9-140)	<b>109</b> (82.2-158)	<b>263</b> (199-382)	<b>592</b> (448-778)	<b>928</b> (702-1340)	1048
	01-02	<b>62.1</b> (53.3-72.5)	<b>67.0</b> (58.0-80.0)	<b>135</b> (109-161)	<b>274</b> (245-303)	<b>359</b> (329-414)	1345
Females	99-00	<b>90.6</b> (70.7-116)	<b>105</b> (72.7-132)	<b>226</b> (183-307)	<b>514</b> (402-632)	<b>797</b> (579-915)	1131
	01-02	<b>47.4</b> (39.1-57.5)	<b>50.0</b> (40.0-59.0)	<b>105</b> (88.0-128)	<b>200</b> (171-240)	<b>292</b> (236-357)	1397
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>86.0</b> (69.6-106)	<b>92.3</b> (68.9-124)	<b>217</b> (163-285)	<b>432</b> (325-482)	<b>583</b> (433-913)	698
	01-02	<b>46.8</b> (32.7-66.8)	<b>51.0</b> (35.0-72.0)	<b>95.0</b> (72.0-137)	<b>191</b> (122-332)	<b>303</b> (187-652)	665
Non-Hispanic blacks	99-00	<b>131</b> (84.6-202)	<b>141</b> (69.6-250)	<b>370</b> (214-562)	<b>698</b> (476-1080)	<b>1080</b> (782-2310)	509
	01-02	<b>71.1</b> (58.0-87.1)	<b>74.0</b> (66.0-90.0)	<b>152</b> (123-182)	<b>260</b> (217-311)	<b>374</b> (284-560)	690
Non-Hispanic whites	99-00	<b>91.7</b> (67.2-125)	<b>103</b> (70.6-139)	<b>231</b> (177-339)	<b>514</b> (409-712)	<b>810</b> (680-906)	792
	01-02	<b>53.1</b> (43.6-64.6)	<b>57.0</b> (47.0-66.0)	<b>116</b> (98.0-144)	<b>242</b> (199-286)	<b>333</b> (303-385)	1204


**Table 65. 2-Hydroxyphenanthrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>90.3</b> (69.3-118)	<b>89.8</b> (67.8-119)	<b>188</b> (147-255)	<b>368</b> (310-439)	<b>521</b> (426-748)	2179
	01-02	<b>50.6</b> (43.3-59.2)	<b>52.5</b> (46.4-59.6)	<b>91.4</b> (78.7-108)	<b>164</b> (138-200)	<b>231</b> (206-275)	2742
<b>Age group</b>							
6-11 years	99-00	<b>83.8</b> (59.6-118)	<b>74.4</b> (58.8-98.3)	<b>173</b> (98.3-289)	<b>350</b> (275-402)	<b>413</b> (350-702)	291
	01-02	<b>45.3</b> (38.8-52.8)	<b>49.7</b> (39.8-57.8)	<b>85.9</b> (69.6-100)	<b>144</b> (105-217)	<b>234</b> (138-397)	387
12-19 years	99-00	<b>74.0</b> (57.7-94.8)	<b>75.0</b> (58.8-91.4)	<b>133</b> (105-196)	<b>295</b> (214-377)	<b>441</b> (319-611)	650
	01-02	<b>38.4</b> (29.6-49.7)	<b>38.5</b> (30.6-48.7)	<b>64.9</b> (52.4-84.0)	<b>116</b> (86.7-167)	<b>173</b> (128-305)	733
20 years and older	99-00	<b>94.3</b> (71.8-124)	<b>94.9</b> (68.0-131)	<b>197</b> (157-263)	<b>392</b> (310-486)	<b>573</b> (466-810)	1238
	01-02	<b>53.7</b> (46.2-62.4)	<b>55.6</b> (49.4-62.0)	<b>94.2</b> (84.1-112)	<b>173</b> (145-201)	<b>241</b> (209-287)	1622
<b>Gender</b>							
Males	99-00	<b>85.2</b> (64.7-112)	<b>80.6</b> (63.0-110)	<b>175</b> (135-231)	<b>375</b> (293-438)	<b>544</b> (413-810)	1048
	01-02	<b>50.4</b> (43.3-58.5)	<b>52.5</b> (47.2-59.2)	<b>91.4</b> (78.6-103)	<b>176</b> (140-208)	<b>245</b> (206-349)	1345
Females	99-00	<b>95.5</b> (72.5-126)	<b>97.1</b> (71.5-133)	<b>207</b> (163-262)	<b>367</b> (310-448)	<b>536</b> (393-816)	1131
	01-02	<b>50.9</b> (42.7-60.7)	<b>52.4</b> (45.5-61.0)	<b>91.6</b> (75.0-115)	<b>158</b> (133-183)	<b>213</b> (200-245)	1397
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>78.8</b> (62.0-100)	<b>77.3</b> (61.9-101)	<b>155</b> (113-202)	<b>310</b> (222-370)	<b>382</b> (303-618)	698
	01-02	<b>43.7</b> (31.9-59.8)	<b>43.9</b> (34.3-58.8)	<b>80.5</b> (59.8-115)	<b>146</b> (103-245)	<b>242</b> (144-394)	665
Non-Hispanic blacks	99-00	<b>86.9</b> (55.8-135)	<b>93.3</b> (48.8-159)	<b>207</b> (131-318)	<b>408</b> (291-664)	<b>664</b> (470-993)	509
	01-02	<b>50.2</b> (40.5-62.2)	<b>49.6</b> (44.3-56.0)	<b>87.6</b> (72.5-103)	<b>173</b> (127-224)	<b>251</b> (178-459)	690
Non-Hispanic whites	99-00	<b>89.4</b> (64.9-123)	<b>87.8</b> (65.8-122)	<b>188</b> (141-261)	<b>366</b> (300-439)	<b>536</b> (411-810)	792
	01-02	<b>52.5</b> (43.8-62.9)	<b>54.7</b> (47.7-61.9)	<b>92.5</b> (80.5-113)	<b>170</b> (140-204)	<b>231</b> (202-293)	1204

**Figure 17. 2-Hydroxyphenanthrene (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



**Table 66. 3-Hydroxyphenanthrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>127</b> (106-152)	<b>138</b> (113-165)	<b>256</b> (225-297)	<b>464</b> (399-547)	<b>657</b> (594-721)	2299
	01-02	<b>105</b> (92.5-118)	<b>105</b> (90.0-118)	<b>200</b> (178-225)	<b>400</b> (336-480)	<b>649</b> (542-747)	2741
<b>Age group</b>							
6-11 years	99-00	<b>136</b> (102-181)	<b>140</b> (102-197)	<b>247</b> (185-334)	<b>383</b> (280-632)	<b>622</b> (336-794)	302
	01-02	<b>105</b> (91.1-122)	<b>108</b> (81.0-136)	<b>193</b> (160-231)	<b>298</b> (245-346)	<b>412</b> (319-545)	387
12-19 years	99-00	<b>147</b> (126-173)	<b>163</b> (137-196)	<b>281</b> (240-322)	<b>417</b> (363-536)	<b>611</b> (457-725)	700
	01-02	<b>104</b> (87.3-125)	<b>106</b> (90.0-122)	<b>201</b> (165-231)	<b>329</b> (255-444)	<b>447</b> (331-631)	733
20 years and older	99-00	<b>122</b> (102-146)	<b>133</b> (108-155)	<b>254</b> (223-295)	<b>477</b> (410-554)	<b>671</b> (594-760)	1297
	01-02	<b>105</b> (91.7-119)	<b>105</b> (89.0-118)	<b>200</b> (178-228)	<b>433</b> (366-515)	<b>683</b> (597-806)	1621
<b>Gender</b>							
Males	99-00	<b>141</b> (114-174)	<b>149</b> (119-185)	<b>287</b> (225-357)	<b>495</b> (409-626)	<b>658</b> (552-802)	1100
	01-02	<b>122</b> (107-138)	<b>117</b> (105-131)	<b>224</b> (187-277)	<b>474</b> (372-597)	<b>734</b> (597-1010)	1344
Females	99-00	<b>114</b> (96.2-135)	<b>130</b> (102-152)	<b>242</b> (215-270)	<b>399</b> (346-506)	<b>624</b> (554-718)	1199
	01-02	<b>90.8</b> (77.7-106)	<b>92.0</b> (80.0-106)	<b>184</b> (155-207)	<b>328</b> (287-386)	<b>518</b> (429-649)	1397
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>113</b> (103-123)	<b>120</b> (99.7-139)	<b>231</b> (193-244)	<b>353</b> (296-438)	<b>495</b> (369-635)	763
	01-02	<b>83.5</b> (64.1-109)	<b>83.0</b> (63.0-111)	<b>144</b> (116-193)	<b>259</b> (189-421)	<b>454</b> (253-1140)	664
Non-Hispanic blacks	99-00	<b>174</b> (124-245)	<b>182</b> (116-292)	<b>390</b> (289-470)	<b>671</b> (477-1060)	<b>1110</b> (775-2750)	522
	01-02	<b>145</b> (122-172)	<b>135</b> (120-163)	<b>281</b> (228-346)	<b>507</b> (407-684)	<b>957</b> (609-1410)	690
Non-Hispanic whites	99-00	<b>120</b> (95.3-151)	<b>135</b> (107-167)	<b>248</b> (217-292)	<b>448</b> (356-554)	<b>632</b> (515-721)	821
	01-02	<b>104</b> (90.8-120)	<b>105</b> (91.0-119)	<b>199</b> (177-224)	<b>401</b> (331-495)	<b>649</b> (518-747)	1204


**Table 67. 3-Hydroxyphenanthrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>116</b> (94.5-143)	<b>121</b> (101-144)	<b>198</b> (171-235)	<b>365</b> (312-400)	<b>480</b> (402-574)	2299
	01-02	<b>98.0</b> (87.4-110)	<b>86.5</b> (78.8-97.1)	<b>158</b> (142-174)	<b>299</b> (252-342)	<b>428</b> (360-621)	2741
<b>Age group</b>							
6-11 years	99-00	<b>143</b> (106-192)	<b>155</b> (114-197)	<b>226</b> (183-331)	<b>416</b> (326-436)	<b>440</b> (418-499)	302
	01-02	<b>118</b> (103-135)	<b>114</b> (94.9-131)	<b>173</b> (150-201)	<b>289</b> (238-368)	<b>408</b> (308-544)	387
12-19 years	99-00	<b>99.3</b> (78.5-126)	<b>112</b> (92.9-124)	<b>173</b> (134-213)	<b>261</b> (213-317)	<b>317</b> (273-402)	700
	01-02	<b>81.1</b> (70.1-93.8)	<b>78.0</b> (66.7-89.4)	<b>116</b> (96.5-144)	<b>205</b> (153-275)	<b>275</b> (198-511)	733
20 years and older	99-00	<b>116</b> (94.9-143)	<b>118</b> (99.2-140)	<b>201</b> (167-241)	<b>374</b> (316-444)	<b>502</b> (410-675)	1297
	01-02	<b>98.9</b> (88.3-111)	<b>85.2</b> (78.3-96.6)	<b>164</b> (147-183)	<b>320</b> (273-356)	<b>488</b> (379-774)	1621
<b>Gender</b>							
Males	99-00	<b>111</b> (86.9-143)	<b>122</b> (97.6-143)	<b>189</b> (157-240)	<b>355</b> (240-466)	<b>470</b> (387-633)	1100
	01-02	<b>98.6</b> (87.7-111)	<b>87.1</b> (79.5-98.2)	<b>159</b> (138-188)	<b>310</b> (245-368)	<b>505</b> (356-761)	1344
Females	99-00	<b>121</b> (99.8-147)	<b>120</b> (101-150)	<b>214</b> (168-265)	<b>369</b> (326-401)	<b>487</b> (400-675)	1199
	01-02	<b>97.5</b> (84.9-112)	<b>86.3</b> (76.7-100)	<b>157</b> (139-178)	<b>292</b> (245-333)	<b>410</b> (352-583)	1397
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>105</b> (93.2-118)	<b>107</b> (96.6-118)	<b>161</b> (147-174)	<b>244</b> (209-302)	<b>368</b> (279-425)	763
	01-02	<b>78.2</b> (62.4-98.0)	<b>70.5</b> (56.2-87.4)	<b>130</b> (92.9-171)	<b>224</b> (173-321)	<b>333</b> (224-656)	664
Non-Hispanic blacks	99-00	<b>115</b> (80.8-163)	<b>120</b> (90.4-167)	<b>213</b> (162-300)	<b>410</b> (300-549)	<b>652</b> (482-850)	522
	01-02	<b>102</b> (85.8-122)	<b>91.8</b> (79.8-108)	<b>160</b> (133-202)	<b>296</b> (234-475)	<b>589</b> (347-1260)	690
Non-Hispanic whites	99-00	<b>117</b> (91.4-151)	<b>124</b> (99.2-150)	<b>203</b> (173-253)	<b>373</b> (292-442)	<b>480</b> (389-671)	821
	01-02	<b>103</b> (91.5-117)	<b>89.4</b> (80.2-102)	<b>167</b> (148-193)	<b>324</b> (272-368)	<b>447</b> (365-738)	1204

**Figure 18. 3-Hydroxyphenanthrene (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



**Table 68. 4-Hydroxyphenanthrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>41.9</b> (31.3-56.0)	<b>67.0</b> (46.0-92.0)	<b>141</b> (119-170)	<b>225</b> (196-254)	<b>280</b> (250-339)	2741
<b>Age group</b>							
6-11 years	01-02	<b>34.5</b> (24.3-48.9)	<b>51.0</b> (30.0-77.0)	<b>118</b> (87.0-155)	<b>201</b> (155-256)	<b>250</b> (184-284)	387
12-19 years	01-02	<b>38.8</b> (28.9-52.1)	<b>66.0</b> (38.0-85.0)	<b>131</b> (112-156)	<b>223</b> (188-261)	<b>306</b> (257-358)	733
20 years and older	01-02	<b>43.4</b> (32.0-58.9)	<b>70.0</b> (46.0-96.0)	<b>146</b> (124-173)	<b>228</b> (196-264)	<b>292</b> (249-346)	1621
<b>Gender</b>							
Males	01-02	<b>45.3</b> (33.6-61.0)	<b>73.0</b> (46.0-99.0)	<b>142</b> (117-176)	<b>226</b> (192-250)	<b>287</b> (247-346)	1344
Females	01-02	<b>38.9</b> (28.8-52.5)	<b>64.0</b> (43.0-88.0)	<b>141</b> (118-165)	<b>222</b> (190-265)	<b>278</b> (249-350)	1397
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>42.8</b> (23.7-77.4)	<b>72.0</b> (25.0-120)	<b>144</b> (92.0-215)	<b>227</b> (183-268)	<b>289</b> (243-398)	664
Non-Hispanic blacks	01-02	<b>48.6</b> (33.8-69.9)	<b>78.0</b> (51.0-113)	<b>159</b> (129-186)	<b>233</b> (194-276)	<b>277</b> (240-335)	690
Non-Hispanic whites	01-02	<b>41.1</b> (29.6-57.0)	<b>66.0</b> (41.0-96.0)	<b>140</b> (116-171)	<b>225</b> (186-266)	<b>287</b> (247-356)	1204

**Table 69. 4-Hydroxyphenanthrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>39.2</b> (29.6-52.0)	<b>56.5</b> (39.3-76.3)	<b>121</b> (97.3-147)	<b>236</b> (196-273)	<b>347</b> (293-411)	2741
<b>Age group</b>							
6-11 years	01-02	<b>38.5</b> (26.4-56.2)	<b>56.7</b> (25.5-91.0)	<b>123</b> (92.6-168)	<b>239</b> (169-278)	<b>314</b> (243-371)	387
12-19 years	01-02	<b>30.1</b> (22.5-40.4)	<b>47.8</b> (29.1-61.4)	<b>89.6</b> (73.9-112)	<b>165</b> (132-194)	<b>236</b> (164-540)	733
20 years and older	01-02	<b>41.0</b> (30.7-54.9)	<b>58.8</b> (41.1-79.5)	<b>127</b> (105-154)	<b>245</b> (200-292)	<b>371</b> (300-447)	1621
<b>Gender</b>							
Males	01-02	<b>36.7</b> (27.6-48.8)	<b>54.5</b> (34.4-71.6)	<b>109</b> (88.0-130)	<b>189</b> (161-224)	<b>282</b> (252-307)	1344
Females	01-02	<b>41.8</b> (31.0-56.2)	<b>60.4</b> (42.4-80.4)	<b>135</b> (106-170)	<b>268</b> (227-332)	<b>418</b> (346-488)	1397
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>40.1</b> (22.8-70.4)	<b>60.7</b> (26.2-100)	<b>134</b> (97.5-173)	<b>236</b> (176-314)	<b>323</b> (242-408)	664
Non-Hispanic blacks	01-02	<b>34.3</b> (24.7-47.7)	<b>56.8</b> (36.8-71.4)	<b>98.8</b> (84.1-123)	<b>157</b> (138-176)	<b>230</b> (193-256)	690
Non-Hispanic whites	01-02	<b>40.6</b> (29.8-55.4)	<b>58.1</b> (37.8-81.4)	<b>126</b> (100-157)	<b>252</b> (198-297)	<b>387</b> (293-470)	1204

**Table 70. 9-Hydroxyphenanthrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>33.9</b> (29.7-38.6)	<b>41.0</b> (36.0-46.0)	<b>87.0</b> (75.0-103)	<b>205</b> (169-254)	<b>343</b> (291-396)	2741
<b>Age group</b>							
6-11 years	01-02	<b>24.7</b> (21.0-29.1)	<b>32.0</b> (28.0-39.0)	<b>59.0</b> (50.0-68.0)	<b>95.0</b> (70.0-125)	<b>124</b> (90.0-225)	387
12-19 years	01-02	<b>30.2</b> (25.1-36.4)	<b>34.0</b> (31.0-40.0)	<b>70.0</b> (60.0-86.0)	<b>151</b> (101-204)	<b>250</b> (161-312)	733
20 years and older	01-02	<b>35.9</b> (30.9-41.6)	<b>44.0</b> (38.0-49.0)	<b>100</b> (81.0-117)	<b>244</b> (183-292)	<b>392</b> (314-476)	1621
<b>Gender</b>							
Males	01-02	<b>39.4</b> (33.8-46.0)	<b>47.0</b> (42.0-53.0)	<b>93.0</b> (76.0-123)	<b>236</b> (170-290)	<b>381</b> (269-487)	1344
Females	01-02	<b>29.4</b> (25.1-34.5)	<b>36.0</b> (32.0-42.0)	<b>78.0</b> (69.0-97.0)	<b>179</b> (151-244)	<b>337</b> (247-392)	1397
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>26.7</b> (21.2-33.7)	<b>34.0</b> (26.0-43.0)	<b>62.0</b> (49.0-78.0)	<b>132</b> (86.0-202)	<b>202</b> (124-396)	664
Non-Hispanic blacks	01-02	<b>34.7</b> (28.5-42.4)	<b>41.0</b> (36.0-47.0)	<b>104</b> (81.0-127)	<b>269</b> (170-391)	<b>399</b> (285-550)	690
Non-Hispanic whites	01-02	<b>34.6</b> (30.2-39.7)	<b>43.0</b> (37.0-48.0)	<b>91.0</b> (78.0-108)	<b>207</b> (160-269)	<b>344</b> (281-421)	1204

**Table 71. 9-Hydroxyphenanthrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>31.7</b> (28.1-35.8)	<b>36.3</b> (32.3-40.4)	<b>72.1</b> (63.2-85.9)	<b>156</b> (139-179)	<b>240</b> (213-290)	2741
<b>Age group</b>							
6-11 years	01-02	<b>27.6</b> (23.7-32.2)	<b>35.0</b> (30.3-40.2)	<b>56.4</b> (46.3-66.7)	<b>89.5</b> (72.0-101)	<b>120</b> (88.9-152)	387
12-19 years	01-02	<b>23.5</b> (19.9-27.7)	<b>26.7</b> (22.8-30.6)	<b>44.8</b> (38.5-55.9)	<b>101</b> (77.8-118)	<b>158</b> (107-270)	733
20 years and older	01-02	<b>33.9</b> (29.7-38.7)	<b>38.8</b> (34.1-42.9)	<b>80.5</b> (69.4-102)	<b>175</b> (148-212)	<b>268</b> (216-321)	1621
<b>Gender</b>							
Males	01-02	<b>31.9</b> (27.7-36.8)	<b>36.0</b> (32.0-40.4)	<b>71.0</b> (58.6-91.6)	<b>163</b> (131-187)	<b>218</b> (182-290)	1344
Females	01-02	<b>31.6</b> (27.3-36.5)	<b>36.7</b> (31.7-41.5)	<b>73.1</b> (63.6-86.6)	<b>151</b> (133-187)	<b>271</b> (216-308)	1397
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>25.0</b> (20.7-30.3)	<b>28.2</b> (24.8-31.8)	<b>52.7</b> (42.7-68.9)	<b>110</b> (74.8-160)	<b>166</b> (107-346)	664
Non-Hispanic blacks	01-02	<b>24.5</b> (20.0-30.1)	<b>29.4</b> (25.8-32.7)	<b>63.4</b> (44.2-84.9)	<b>143</b> (96.9-209)	<b>233</b> (153-313)	690
Non-Hispanic whites	01-02	<b>34.3</b> (30.6-38.4)	<b>39.1</b> (34.0-43.3)	<b>78.7</b> (65.2-96.4)	<b>167</b> (144-199)	<b>268</b> (216-313)	1204

# 1-Hydroxypyrene

*Metabolite of Pyrene, CAS No. 129-00-0*

## Interpreting Levels of Urinary 1-Hydroxypyrene Reported in the Tables

Pyrene is commonly found in PAH mixtures, and its urinary metabolite has been used as an indicator of exposure to PAH chemicals. Urinary 1-hydroxypyrene levels were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. The geometric mean levels of 1-hydroxypyrene in the NHANES 2001-2002 subsample is similar to that of other general populations residing in an urban setting (Goen et al., 1995; Chuang et al., 1999, Heudorf and Angerer, 2001*b*; Roggi et al., 1997; Yang et al., 2003). Higher levels have been noted for residents of industrialized urban areas compared with rural or suburban settings (Adonis et al., 2003; Kanoh et al., 1993; Kuo et al., 2004).

Many-fold higher levels can be found in workers from certain occupations (Jacob and Seidel, 2002) including aluminum smelting (Alexandrie et al., 2000); diesel engine mechanics (Adonis et al., 2003, Kuusimaki et al., 2004); taxi, bus, and truck drivers (Chuang et al., 2003, Hansen et al., 2004; Kuusimaki et al., 2004); painters (Lee et al., 2003), boilermakers (Mukherjee et al., 2004); toll booth operators (Tsai et al., 2004); traffic police (Merlo et al., 1998) and coke oven plant workers (Lu et al., 2002; Serdar et al., 2003*a*; Siwinska et al., 2004). Tobacco smoking leads to higher levels in smokers (Chuang et al., 2003; Adonis et al., 2003, Heudorf and Angerer, 2001*b*) as well as the non-smoking children of smokers (Tsai et al., 2003). Coal stove exposure or consumption of broiled, fried or grilled meat contribute to higher levels of 1-hydroxypyrene (Siwinska et al., 1999; Scheepers et al., 2002, Yang et al., 2003).

**Table 72. 1-Hydroxypyrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>79.8</b> (66.9-95.1)	<b>78.0</b> (67.9-92.6)	<b>187</b> (164-229)	<b>434</b> (372-506)	<b>730</b> (571-926)	2312
	01-02	<b>49.6</b> (43.4-56.7)	<b>47.0</b> (42.0-56.0)	<b>103</b> (90.0-116)	<b>214</b> (184-245)	<b>349</b> (290-400)	2747
<b>Age group</b>							
6-11 years	99-00	<b>90.8</b> (71.4-115)	<b>94.1</b> (77.9-120)	<b>170</b> (136-201)	<b>300</b> (197-413)	<b>419</b> (257-757)	310
	01-02	<b>59.7</b> (52.8-67.5)	<b>59.0</b> (48.0-66.0)	<b>109</b> (86.0-150)	<b>212</b> (164-257)	<b>272</b> (224-453)	387
12-19 years	99-00	<b>105</b> (87.8-125)	<b>108</b> (83.0-130)	<b>226</b> (188-264)	<b>473</b> (336-596)	<b>642</b> (468-1170)	693
	01-02	<b>57.8</b> (47.4-70.6)	<b>60.0</b> (44.0-71.0)	<b>111</b> (89.0-148)	<b>230</b> (179-273)	<b>329</b> (267-489)	735
20 years and older	99-00	<b>74.8</b> (61.5-91.1)	<b>70.1</b> (61.5-86.1)	<b>187</b> (155-235)	<b>446</b> (379-547)	<b>795</b> (596-940)	1309
	01-02	<b>47.3</b> (41.1-54.6)	<b>45.0</b> (40.0-53.0)	<b>100</b> (88.0-115)	<b>216</b> (182-246)	<b>361</b> (290-416)	1625
<b>Gender</b>							
Males	99-00	<b>90.1</b> (73.2-111)	<b>85.2</b> (70.5-105)	<b>227</b> (178-287)	<b>496</b> (413-577)	<b>747</b> (577-1020)	1106
	01-02	<b>57.8</b> (49.8-67.1)	<b>55.0</b> (46.0-64.0)	<b>120</b> (97.0-149)	<b>246</b> (203-312)	<b>416</b> (299-528)	1348
Females	99-00	<b>71.2</b> (59.4-85.3)	<b>70.9</b> (63.1-87.3)	<b>163</b> (152-188)	<b>361</b> (300-412)	<b>669</b> (387-940)	1206
	01-02	<b>43.0</b> (36.7-50.4)	<b>43.0</b> (35.0-52.0)	<b>92.0</b> (76.0-107)	<b>178</b> (150-199)	<b>278</b> (219-349)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>74.2</b> (67.1-82.0)	<b>68.1</b> (62.7-76.8)	<b>161</b> (143-179)	<b>344</b> (284-460)	<b>545</b> (372-714)	766
	01-02	<b>51.0</b> (38.0-68.4)	<b>51.0</b> (40.0-68.0)	<b>99.0</b> (69.0-133)	<b>163</b> (125-269)	<b>269</b> (154-666)	665
Non-Hispanic blacks	99-00	<b>108</b> (83.9-140)	<b>99.7</b> (72.2-159)	<b>245</b> (202-352)	<b>586</b> (428-778)	<b>839</b> (496-1480)	528
	01-02	<b>66.2</b> (56.9-77.0)	<b>63.0</b> (49.0-82.0)	<b>134</b> (112-171)	<b>305</b> (236-386)	<b>442</b> (337-561)	692
Non-Hispanic whites	99-00	<b>73.7</b> (58.5-92.9)	<b>72.9</b> (63.3-86.1)	<b>178</b> (155-213)	<b>399</b> (333-506)	<b>747</b> (477-977)	832
	01-02	<b>46.9</b> (40.0-55.1)	<b>45.0</b> (38.0-56.0)	<b>98.0</b> (87.0-115)	<b>214</b> (179-249)	<b>343</b> (271-431)	1207

## Comparing Adjusted Geometric Means

Geometric mean levels of urinary 1-hydroxypyrene for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). In NHANES 2001-2002, children aged 6-11 years had higher adjusted geometric mean levels of 1-hydroxypyrene than the two other age groups. This age-related difference also has been found by other investigators (Heudorf and Angerer, 2001*b*; Chuang et al., 1999). In addition, the levels for children in this *Report* are similar to levels measured in other studies (van Wijnen et al., 1996; Chuang et al., 1999; Heudorf and Angerer, 2001*a*; Kanoh et al., 1993; Tsai et al., 2003). No differences were observed for race/ethnicity or gender, and several previous studies have also not found differences. It is unknown whether these differences associated with age represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.


**Table 73. 1-Hydroxypyrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>74.2</b> (61.6-89.3)	<b>73.3</b> (63.1-84.4)	<b>158</b> (139-178)	<b>362</b> (286-415)	<b>500</b> (436-607)	2312
	01-02	<b>46.4</b> (40.9-52.8)	<b>43.8</b> (37.8-50.7)	<b>80.8</b> (72.9-90.1)	<b>159</b> (137-188)	<b>243</b> (206-269)	2747
<b>Age group</b>							
6-11 years	99-00	<b>94.1</b> (75.3-118)	<b>91.2</b> (76.5-114)	<b>168</b> (126-234)	<b>333</b> (269-378)	<b>474</b> (371-571)	310
	01-02	<b>66.8</b> (57.5-77.7)	<b>60.6</b> (52.9-74.1)	<b>105</b> (83.3-137)	<b>195</b> (140-320)	<b>320</b> (209-399)	387
12-19 years	99-00	<b>71.5</b> (59.0-86.5)	<b>70.7</b> (55.6-90.0)	<b>137</b> (120-170)	<b>240</b> (189-341)	<b>413</b> (240-663)	693
	01-02	<b>44.7</b> (37.8-52.9)	<b>43.1</b> (33.3-51.7)	<b>71.4</b> (59.0-87.9)	<b>151</b> (107-195)	<b>233</b> (186-250)	735
20 years and older	99-00	<b>72.3</b> (58.8-88.8)	<b>68.8</b> (58.9-81.9)	<b>159</b> (131-188)	<b>377</b> (286-447)	<b>541</b> (433-648)	1309
	01-02	<b>44.7</b> (39.4-50.7)	<b>41.2</b> (36.7-48.4)	<b>79.5</b> (72.2-87.5)	<b>156</b> (131-185)	<b>233</b> (199-252)	1625
<b>Gender</b>							
Males	99-00	<b>72.1</b> (56.8-91.6)	<b>69.9</b> (58.9-89.7)	<b>167</b> (130-189)	<b>349</b> (265-420)	<b>525</b> (384-793)	1106
	01-02	<b>46.8</b> (40.8-53.7)	<b>46.2</b> (39.6-51.4)	<b>83.8</b> (74.1-96.4)	<b>169</b> (138-199)	<b>249</b> (207-303)	1348
Females	99-00	<b>76.1</b> (63.1-91.9)	<b>77.2</b> (59.9-89.7)	<b>148</b> (127-183)	<b>370</b> (244-450)	<b>500</b> (413-613)	1206
	01-02	<b>46.1</b> (40.0-53.1)	<b>42.5</b> (36.7-51.0)	<b>77.3</b> (68.5-89.5)	<b>152</b> (122-185)	<b>218</b> (199-247)	1399
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>68.2</b> (61.8-75.3)	<b>59.6</b> (53.8-68.1)	<b>124</b> (110-141)	<b>252</b> (204-333)	<b>462</b> (325-557)	766
	01-02	<b>47.6</b> (36.9-61.5)	<b>43.1</b> (33.3-58.7)	<b>76.6</b> (58.7-106)	<b>149</b> (95.2-265)	<b>208</b> (155-353)	665
Non-Hispanic blacks	99-00	<b>70.5</b> (55.6-89.4)	<b>68.6</b> (54.1-93.9)	<b>156</b> (121-177)	<b>346</b> (264-412)	<b>474</b> (365-691)	528
	01-02	<b>46.6</b> (40.1-54.2)	<b>43.9</b> (36.7-51.8)	<b>87.1</b> (75.0-108)	<b>157</b> (138-194)	<b>231</b> (196-269)	692
Non-Hispanic whites	99-00	<b>73.2</b> (58.1-92.2)	<b>72.3</b> (60.6-85.2)	<b>163</b> (133-184)	<b>377</b> (286-447)	<b>547</b> (447-636)	832
	01-02	<b>46.4</b> (40.1-53.6)	<b>43.5</b> (37.0-51.9)	<b>82.7</b> (73.7-91.2)	<b>163</b> (139-195)	<b>245</b> (211-288)	1207

**Figure 19. 1-Hydroxypyrene (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



## 3-Hydroxybenzo[a]pyrene

CAS No. 13345-21-6

*Metabolite of Benzo[a]pyrene, CAS No. 129-00-0*

### Interpreting Levels of Urinary 3-Hydroxybenzo[a]pyrene Reported in the Tables

Benzo[a]pyrene is considered a probable carcinogen by the NTP and U.S. EPA. 3-hydroxybenzo[a]pyrene is a metabolite of benzo[a]pyrene and urinary levels were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Similar levels of 3-hydroxybenzo[a] pyrene have been reported in a small sample of pre-school children (Wilson et al., 2003) and in workers manufacturing fireproof stone (Gundel et al., 2000).

**Table 74. 3-Hydroxybenzo[a]pyrene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	*	< LOD	<b>33.0</b> (28.0-39.0)	<b>95.0</b> (73.0-121)	<b>179</b> (137-251)	2748
<b>Age group</b>							
6-11 years	01-02	*	< LOD	<b>26.0</b> (18.0-41.0)	<b>73.0</b> (44.0-126)	<b>139</b> (79.0-273)	387
12-19 years	01-02	*	< LOD	<b>28.0</b> (20.0-37.0)	<b>77.0</b> (46.0-129)	<b>139</b> (82.0-284)	735
20 years and older	01-02	*	< LOD	<b>36.0</b> (30.0-41.0)	<b>97.0</b> (72.0-126)	<b>206</b> (135-285)	1626
<b>Gender</b>							
Males	01-02	*	< LOD	<b>34.0</b> (29.0-41.0)	<b>98.0</b> (72.0-126)	<b>167</b> (133-273)	1349
Females	01-02	*	< LOD	<b>31.0</b> (26.0-37.0)	<b>86.0</b> (67.0-117)	<b>206</b> (134-251)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	<b>13.0</b> (<LOD-16.0)	<b>41.0</b> (30.0-55.0)	<b>125</b> (80.0-199)	<b>253</b> (165-648)	665
Non-Hispanic blacks	01-02	*	<b>11.0</b> (<LOD-16.0)	<b>29.0</b> (25.0-37.0)	<b>68.0</b> (53.0-106)	<b>136</b> (76.0-240)	692
Non-Hispanic whites	01-02	*	< LOD	<b>32.0</b> (26.0-40.0)	<b>96.0</b> (69.0-126)	<b>167</b> (124-251)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 75. 3-Hydroxybenzo[a]pyrene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	*	< LOD	<b>32.3</b> (27.3-38.9)	<b>84.7</b> (69.2-120)	<b>184</b> (147-248)	2748
<b>Age group</b>							
6-11 years	01-02	*	< LOD	<b>28.8</b> (22.7-45.5)	<b>91.4</b> (59.0-171)	<b>207</b> (91.3-348)	387
12-19 years	01-02	*	< LOD	<b>24.0</b> (16.7-35.8)	<b>69.8</b> (43.4-86.7)	<b>103</b> (77.0-201)	735
20 years and older	01-02	*	< LOD	<b>34.3</b> (28.4-42.0)	<b>91.7</b> (69.0-134)	<b>186</b> (148-263)	1626
<b>Gender</b>							
Males	01-02	*	< LOD	<b>28.9</b> (23.8-37.8)	<b>72.9</b> (62.1-99.1)	<b>167</b> (110-226)	1349
Females	01-02	*	< LOD	<b>35.3</b> (29.6-43.9)	<b>99.0</b> (75.0-135)	<b>198</b> (148-285)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	<b>15.3</b> (12.9-18.3)	<b>41.6</b> (30.0-58.3)	<b>135</b> (74.9-188)	<b>225</b> (157-345)	665
Non-Hispanic blacks	01-02	*	<b>9.86</b> (8.47-11.1)	<b>21.7</b> (18.3-26.5)	<b>49.4</b> (36.2-91.1)	<b>116</b> (58.6-190)	692
Non-Hispanic whites	01-02	*	< LOD	<b>34.1</b> (27.3-41.4)	<b>85.7</b> (68.0-127)	<b>190</b> (147-263)	1208

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

# 1-Hydroxynaphthalene and 2-Hydroxynaphthalene

*Metabolite of Naphthalene, CAS No. 91-20-3*

## Interpreting Levels of Urinary 1-Hydroxynaphthalene and 2-Hydroxynaphthalene Reported in the Tables

Urinary levels of 1-hydroxynaphthalene and 2-hydroxynaphthalene were measured in a subsample of NHANES 2001-2002 participants aged 6 years and older. Similar levels have been reported in pre-school children (Wilson et al., 2003), middle school students living in major cities (Kang et al., 2002) and adults (Kim et al., 2003, Kuusimaki et al., 2004, Serdar et al., 2003b). Bus mechanics and truck drivers (Kuusimaki et al., 2004), coke oven workers (Nan et al., 2001; Serdar et al., 2003a), air force personnel exposed to jet fuel (Serdar 2003b), and tobacco smokers (Serdar et al., 2003a; Nan et al., 2001) had higher levels.

## Comparing Adjusted Geometric Means

Geometric means levels of urinary 1-hydroxynaphthalene and 2-hydroxynaphthalene for demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, log serum cotinine, and urinary creatinine (data not shown). For adjusted geometric mean levels of urinary 1-hydroxynaphthalene in NHANES 2001-2002, non-Hispanic whites had higher

levels than Mexican-Americans, while the group aged 12-19 years had lower levels than either of the groups 6-11 years or 20 years and older.

For adjusted geometric mean levels of urinary 2-hydroxynaphthalene in NHANES 2001-2002, females had higher levels than males, Mexican Americans had higher levels than either non-Hispanic whites or blacks, and the group aged 12-19 years had lower levels than the group aged 20 years and older. It is unknown whether these differences associated with age, gender or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

Note: 1-hydroxynaphthalene is sometimes called 1-naphthol and 2-hydroxynaphthalene is also referred to as 2-naphthol.

**Table 76. 1-Hydroxynaphthalene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>2050</b> (1790-2340)	<b>1720</b> (1490-2030)	<b>4760</b> (3890-5930)	<b>12500</b> (10600-15900)	<b>22300</b> (18000-26600)	2748
<b>Age group</b>							
6-11 years	01-02	<b>1430</b> (1170-1730)	<b>1190</b> (1010-1560)	<b>2740</b> (1770-3630)	<b>6670</b> (4340-11300)	<b>12400</b> (9410-16500)	387
12-19 years	01-02	<b>1750</b> (1440-2130)	<b>1380</b> (1210-1690)	<b>3560</b> (2840-4570)	<b>9270</b> (6760-17200)	<b>21400</b> (10400-28500)	735
20 years and older	01-02	<b>2190</b> (1900-2530)	<b>1890</b> (1580-2280)	<b>5280</b> (4250-6520)	<b>13600</b> (11100-18000)	<b>23300</b> (18100-28600)	1626
<b>Gender</b>							
Males	01-02	<b>2270</b> (1940-2650)	<b>1980</b> (1640-2440)	<b>5580</b> (4000-6950)	<b>12200</b> (9650-16700)	<b>21500</b> (15100-28500)	1349
Females	01-02	<b>1860</b> (1600-2160)	<b>1560</b> (1320-1760)	<b>4120</b> (3380-5030)	<b>13300</b> (11100-16300)	<b>22300</b> (19400-25500)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>1590</b> (1300-1960)	<b>1440</b> (1180-1860)	<b>3010</b> (2240-4080)	<b>6750</b> (4990-9270)	<b>11900</b> (7670-20600)	665
Non-Hispanic blacks	01-02	<b>2700</b> (2160-3370)	<b>2190</b> (1630-2930)	<b>7170</b> (4400-10900)	<b>14900</b> (11900-22100)	<b>24700</b> (17000-44100)	692
Non-Hispanic whites	01-02	<b>2030</b> (1720-2390)	<b>1740</b> (1470-2150)	<b>4680</b> (3630-5990)	<b>12300</b> (10200-16300)	<b>22300</b> (16600-27200)	1207

**Table 77. 1-Hydroxynaphthalene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>1910</b> (1700-2160)	<b>1560</b> (1370-1810)	<b>4160</b> (3550-5170)	<b>10500</b> (8470-12600)	<b>17800</b> (14500-20800)	2748
<b>Age group</b>							
6-11 years	01-02	<b>1600</b> (1320-1930)	<b>1370</b> (1040-1780)	<b>2880</b> (2140-3840)	<b>5280</b> (4450-9720)	<b>12900</b> (7960-26400)	387
12-19 years	01-02	<b>1350</b> (1140-1600)	<b>1130</b> (973-1360)	<b>2520</b> (2090-3160)	<b>6920</b> (3790-11000)	<b>11200</b> (8240-16100)	735
20 years and older	01-02	<b>2070</b> (1830-2350)	<b>1720</b> (1480-2000)	<b>4980</b> (3930-6120)	<b>11600</b> (9370-14200)	<b>18600</b> (15000-22000)	1626
<b>Gender</b>							
Males	01-02	<b>1830</b> (1580-2120)	<b>1550</b> (1300-1880)	<b>4050</b> (3380-5360)	<b>9440</b> (7550-11400)	<b>14200</b> (12200-16500)	1349
Females	01-02	<b>1990</b> (1760-2250)	<b>1620</b> (1360-1900)	<b>4190</b> (3560-5190)	<b>12400</b> (9810-15000)	<b>20500</b> (17100-26700)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>1490</b> (1240-1780)	<b>1310</b> (1070-1630)	<b>2590</b> (2140-3370)	<b>5710</b> (4280-7530)	<b>10300</b> (6120-18300)	665
Non-Hispanic blacks	01-02	<b>1900</b> (1500-2410)	<b>1640</b> (1340-1980)	<b>4400</b> (2830-6450)	<b>10100</b> (6560-15900)	<b>18900</b> (11700-32700)	692
Non-Hispanic whites	01-02	<b>2000</b> (1740-2300)	<b>1660</b> (1410-1940)	<b>4410</b> (3660-5790)	<b>10900</b> (8640-13400)	<b>17300</b> (13400-19600)	1207

**Table 78. 2-Hydroxynaphthalene**

Geometric mean and selected percentiles of urine concentrations (in ng/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>2470</b> (2110-2890)	<b>2280</b> (1920-2640)	<b>5680</b> (4580-6830)	<b>14700</b> (12800-19500)	<b>26000</b> (22500-29700)	2748
<b>Age group</b>							
6-11 years	01-02	<b>1690</b> (1560-1840)	<b>1700</b> (1400-1950)	<b>3000</b> (2580-3470)	<b>5350</b> (3890-6700)	<b>7720</b> (6300-9540)	387
12-19 years	01-02	<b>2220</b> (1700-2900)	<b>2150</b> (1740-2530)	<b>4390</b> (3150-6110)	<b>11000</b> (6990-20400)	<b>22500</b> (13900-28400)	735
20 years and older	01-02	<b>2620</b> (2220-3100)	<b>2440</b> (1940-2950)	<b>6380</b> (5110-8110)	<b>17600</b> (14000-21100)	<b>28100</b> (23300-33700)	1626
<b>Gender</b>							
Males	01-02	<b>2750</b> (2360-3210)	<b>2510</b> (2090-2970)	<b>6040</b> (4820-7810)	<b>16400</b> (11900-23000)	<b>28100</b> (20800-35600)	1349
Females	01-02	<b>2220</b> (1860-2660)	<b>2060</b> (1650-2480)	<b>5240</b> (3890-6440)	<b>13900</b> (12300-17700)	<b>25100</b> (19700-28300)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>2700</b> (2360-3080)	<b>2690</b> (2350-3260)	<b>5140</b> (4360-6150)	<b>9600</b> (8150-10600)	<b>13600</b> (10400-18700)	665
Non-Hispanic blacks	01-02	<b>3970</b> (3470-4540)	<b>3460</b> (3100-4020)	<b>9250</b> (6820-13200)	<b>22800</b> (16000-29100)	<b>33000</b> (25900-38700)	692
Non-Hispanic whites	01-02	<b>2190</b> (1760-2720)	<b>1910</b> (1610-2420)	<b>4880</b> (3710-6780)	<b>14100</b> (10700-20200)	<b>25900</b> (20700-30000)	1207

**Table 79. 2-Hydroxynaphthalene (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in ng/g of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>2310</b> (1980-2680)	<b>1940</b> (1670-2300)	<b>4730</b> (3820-5860)	<b>11500</b> (9980-13100)	<b>16700</b> (14100-19200)	2748
<b>Age group</b>							
6-11 years	01-02	<b>1890</b> (1740-2070)	<b>1830</b> (1720-1940)	<b>3110</b> (2510-3470)	<b>5040</b> (4380-5540)	<b>6490</b> (5270-12400)	387
12-19 years	01-02	<b>1720</b> (1350-2190)	<b>1510</b> (1340-1830)	<b>2750</b> (2080-4070)	<b>7060</b> (4070-10900)	<b>10900</b> (7860-17400)	735
20 years and older	01-02	<b>2480</b> (2130-2880)	<b>2080</b> (1680-2600)	<b>5630</b> (4460-6940)	<b>12400</b> (10900-13900)	<b>17700</b> (15200-20600)	1626
<b>Gender</b>							
Males	01-02	<b>2230</b> (1900-2610)	<b>1850</b> (1630-2100)	<b>4750</b> (3510-6120)	<b>11400</b> (8950-14300)	<b>15800</b> (13100-19200)	1349
Females	01-02	<b>2380</b> (2050-2770)	<b>1970</b> (1660-2560)	<b>4730</b> (3790-6000)	<b>11500</b> (10300-12800)	<b>17400</b> (13700-21500)	1399
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>2520</b> (2230-2850)	<b>2350</b> (2010-2950)	<b>4650</b> (3970-5210)	<b>7120</b> (6050-8090)	<b>12000</b> (7820-15300)	665
Non-Hispanic blacks	01-02	<b>2790</b> (2390-3270)	<b>2390</b> (2040-2770)	<b>5980</b> (4840-6980)	<b>11600</b> (9090-15300)	<b>17400</b> (12200-23400)	692
Non-Hispanic whites	01-02	<b>2160</b> (1780-2620)	<b>1740</b> (1440-2180)	<b>4340</b> (3320-6090)	<b>11900</b> (9930-14300)	<b>16900</b> (13800-20600)	1207

## Results by Chemical Group

---

### **Polychlorinated Dibenzo-p-dioxins, Polychlorinated Dibenzofurans, and Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls**



## Polychlorinated Dibenzo-*p*-dioxins, Polychlorinated Dibenzofurans, and Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls

### General Information

Polychlorinated dibenzo-*p*-dioxins and dibenzofurans are two similar classes of chlorinated aromatic chemicals that are produced as contaminants or byproducts. They have no known commercial or natural use. Dioxins are primarily produced during the incineration or burning of waste; the bleaching processes used in pulp and paper mills; and the chemical syntheses of trichlorophenoxyacetic acid, hexachlorophene, vinyl chloride, trichlorophenol, and pentachlorophenol. Synthesis and heat-related degradation of polychlorinated biphenyls (PCBs) will produce furan byproducts. As a result of man-made environmental release and contamination, most soil and water samples reveal trace amounts of polychlorinated dibenzo-*p*-dioxins and dibenzofurans when advanced analytical techniques are applied. Releases from industrial sources have decreased approximately 80% since the 1980s. Today, the largest release of these chemicals occurs as a result of the open burning of household trash and municipal trash, landfill fires, and agricultural and forest fires.

The coplanar and mono-ortho-substituted polychlorinated biphenyls belong to the class of chlorinated aromatic hydrocarbon chemicals that once were used as electrical insulating and heat-exchange fluids. Production of PCBs peaked in the early 1970s and was banned in the United States after 1979. Together with the polychlorinated dioxins and furans, these two classes of PCBs are often referred to as “dioxin-like” chemicals because they act through a similar mechanism. In the environment, these dioxin-like chemicals are persistent and usually occur as a mixture of congeners (i.e., compounds that differ by numbers and positions of chlorine atoms attached to the dibenzo-*p*-dioxin, dibenzofuran, or biphenyl structures). Structural nomenclature is available at <http://www.epa.gov/toxteam/pcb/consistent.htm>.

People in the general population are exposed primarily through ingestion of foods that are contaminated with polychlorinated dibenzo-*p*-dioxins and dibenzofurans as a result of the accumulation of these substances in the food chain including high-fat foods, such as dairy products, eggs, and animal fats, and some fish and wildlife. Breast feeding is a substantial source for infants (Beck et al., 1994). People have also been exposed as a result of industrial accidents (e.g., after an explosion in a factory in Seveso, Italy), the use of accidentally contaminated cooking oils (e.g., as occurred in Yusho in

Japan and Yucheng in Taiwan), the spraying of herbicides contaminated with 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD, as Agent Orange in Vietnam), and the burning of PCBs contaminated with polychlorinated dibenzofurans, such as in old electrical transformers. Workplace exposures are rare today, and generally recognized standards for external exposure have not been established.

Because exposure to these chemicals is from a mixture of varying congeners, the effects due to specific individual congeners are difficult to determine (Masuda et al., 1998; Masuda 2001). However, these four groups of chemicals (polychlorinated dibenzo-*p*-dioxins, polychlorinated dibenzofurans, and the coplanar and mono-ortho-substituted polychlorinated biphenyls) are considered to act through a similar mechanism to produce toxic effects. These dioxin-like effects are thought to be mediated through an interaction with the aryl hydrocarbon receptor (AhR), particularly the induction of gene expression for cytochromes P450, CYP1A1 and CYP1A2. Dioxins and furans require four lateral chlorine atoms on the dibenzo-*p*-dioxin or dibenzofuran backbone to bind this receptor. The rank order of interaction with the AhR receptor by degree and position of chlorination is similar for both the dioxin and furan series, with greater effect exhibited with four or five chlorine atoms and with substitution at all four lateral positions. The coplanar polychlorinated biphenyls (unsubstituted at ortho positions) and the mono-ortho-substituted polychlorinated biphenyls (which contain a chlorine atom at one of the ortho positions) can achieve a planar configuration and also interact with the AhR receptor.

The variation in the effect on AhR among the dioxin-like chemicals is 10,000-fold, with TCDD and 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin being the most potent. To compare potency, each of these congeners has been assigned a potency value relative to TCDD (toxic equivalency factor [TEF]). When a TEF is multiplied by the concentration of the congener, a toxic equivalency (TEQ) value is obtained. Thus, the dioxin-like toxicity contributed by each of the polychlorinated dibenzo-*p*-dioxins, dibenzofurans, and coplanar PCBs can then be compared. The sum of all congener TEQs in a specimen (total TEQ) can be used to compare dioxin-like activity among specimens. Many co-planar PCBs have lesser potency, but their concentrations are often much higher than concentrations of TCDD (Kang et al., 1997; Patterson et al., 1994), so their relative contribution to the total TEQ is potentially sizable.

Health effects of exposure to dioxins and furans in people have been observed as a result of industrial or accidental exposures involving large quantities of these chemicals. Chloracne, biochemical liver test abnormalities, elevated blood lipids, fetal injury, and porphyria cutanea tarda have been reported in many of the studies. In some of these exposures, endocrine, reproductive, and immunologic effects have also been suggested although with varying consistency (Baccarelli et al., 2002; Fierens et al., 2003; Kogevinas, 2001; Halperin et al., 1998; Michalek et al., 1999; Jung et al., 1998; Matsuura et al., 2001; Schnorr et al., 2001; Institute of Medicine, 2003). Congenital anomalies and intrauterine growth retardation were observed in offspring of Yucheng mothers exposed to cooking oil contaminated with electrical oil containing PCBs and dibenzofurans. Background levels of PCBs, and possibly dioxins, have been associated with impaired neurological development in newborns and children (Koopman-

Esseboom et al., 1997; Jacobsen and Jacobsen, 1996; Longnecker et al., 2003). A possible dioxin-induced neuropathy may occur in highly exposed adults (Michalek et al., 2001). Many organochlorine-type chemicals, including the dioxins, furans, and PCBs, are also considered to interact with estrogen receptors. Although human studies have yielded inconsistent findings for associations between dioxin exposure and disorders such as endometriosis (Eskenazi et al., 2002; Fierens et al., 2003; Johnson et al., 2001), animal studies have suggested a relationship (Rier and Foster, 2003). The mono-ortho-substituted PCBs (see Table 81) may also interact with estrogen-receptors in addition to their dioxin-like effects, and have been demonstrated to elevate liver enzymes in experimental animals (Parkinson et al., 1983). Carcinogenic, genetic, reproductive, and developmental effects have been observed in many animal studies although species differ dramatically in sensitivity to these

**Table 80. Polychlorinated Dibenzo-*p*-dioxins, Polychlorinated Dibenzofurans, and Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls**

<b>Polychlorinated dibenzo-<i>p</i>-dioxins</b>	<b>CAS number</b>
1,2,3,4,6,7,8,9-Octachlorodibenzo- <i>p</i> -dioxin (OCDD)	3268-87-9
1,2,3,4,6,7,8-Heptachlorodibenzo- <i>p</i> -dioxin (HpCDD)	35822-46-9
1,2,3,4,7,8-Hexachlorodibenzo- <i>p</i> -dioxin (HxCDD)	39227-28-6
1,2,3,6,7,8-Hexachlorodibenzo- <i>p</i> -dioxin (HxCDD)	57653-85-7
1,2,3,7,8,9-Hexachlorodibenzo- <i>p</i> -dioxin (HxCDD)	19408-74-3
1,2,3,7,8-Pentachlorodibenzo- <i>p</i> -dioxin (PeCDD)	40321-76-4
2,3,7,8-Tetrachlorodibenzo- <i>p</i> -dioxin (TCDD)	1746-01-6
<b>Polychlorinated dibenzofurans</b>	<b>CAS number</b>
1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF)	39001-02-0
1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF)	67562-39-4
1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF)	55673-89-7
1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF)	70648-26-9
1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF)	57117-44-9
1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF)	72918-21-9
1,2,3,7,8-Pentachlorodibenzofuran (PeCDF)	57117-41-6
2,3,4,6,7,8-Hexachlorodibenzofuran (HxCDF)	60851-34-5
2,3,4,7,8-Pentachlorodibenzofuran (PeCDF)	57117-31-4
2,3,7,8-Tetrachlorodibenzofuran (TCDF)	51207-31-9
<b>Coplanar polychlorinated biphenyls (IUPAC number)</b>	<b>CAS number</b>
3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169)	32774-16-6
3,3',4,4',5-Pentachlorobiphenyl (PCB 126)	57465-28-8
3,4,4',5-Tetrachlorobiphenyl (PCB 81)	70362-50-4
<b>Mono-ortho-substituted polychlorinated biphenyls (IUPAC number)</b>	<b>CAS number</b>
2,4,4'-Trichlorobiphenyl (PCB 28)	7012-37-5
2,3',4,4'-Tetrachlorobiphenyl (PCB 66)	32598-10-0
2,4,4',5-Tetrachlorobiphenyl (PCB 74)	32690-93-0
2,3,3',4,4'-Pentachlorobiphenyl (PCB 105)	32598-14-4
2,3',4,4',5-Pentachlorobiphenyl (PCB 118)	31508-00-6
2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156)	38380-08-4
2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157)	69782-90-7
2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167)	52663-72-6
2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189)	39635-31-9

chemicals. The Institute of Medicine (2003) has determined that human epidemiologic evidence is sufficient for causally linking exposure from herbicides contaminated with TCDD to an increased risk for non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, and soft tissue sarcoma. Generally, the increased risk for these cancers occurs in association with large exposures encountered in contaminated occupational settings or massive unintentional releases. Because of its exceptional potency and because it is the most studied dioxin or furan, TCDD is separately classified by the IARC as a known human carcinogen (Group 1) and by NTP as a known human carcinogen. Other polychlorinated dibenzo-*p*-dioxins and dibenzofurans have not been studied sufficiently for IARC to determine their carcinogenicity. Information about environmental levels and health effects is available online from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>. The U.S. EPA provides updated exposure and health assessments online at <http://www.epa.gov/ncea/pdfs/dioxin>.

#### **Interpreting Levels of Lipid-Adjusted Serum Polychlorinated Dibenzo-*p*-dioxins, Polychlorinated Dibenzofurans, Coplanar Polychlorinated Biphenyls, and Mono-ortho-substituted Polychlorinated Biphenyls Reported in the Tables**

Lipid-adjusted serum measurements and whole weight-based measurements of polychlorinated dibenzo-*p*-dioxins, dibenzofurans, and coplanar PCBs were measured in a subsample of NHANES 2001-2002 participants aged 20 years and older. Participants were selected within the specified age range to be a representative sample of the U.S. population. (Note: The NHANES 1999-2000 subsample included people aged 12-19 years and people aged 20 years and older. The NHANES 2001-2002 subsample does not include the 12-19 year-old age group). The generally low values reported here support the observation that human serum levels of polychlorinated dibenzo-*p*-dioxins, dibenzofurans, and PCBs have decreased by more than 80% since the 1980s (Aylward and Hays, 2002; Lorber, 2002).

Only the following polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar and mono-ortho-substituted polychlorinated biphenyls (IUPAC nomenclature) had demonstrable 90<sup>th</sup> percentile levels in the NHANES 2001-2002 subsample, and those in bold letters had sufficient data for calculating geometric means:

- **1,2,3,4,6,7,8,9-octachlorodibenzo-*p*-dioxin**
- **1,2,3,4,6,7,8-heptachlorodibenzo-*p*-dioxin**
- 1,2,3,4,7,8-hexachlorodibenzo-*p*-dioxin

- **1,2,3,6,7,8-hexachlorodibenzo-*p*-dioxin\***
- 1,2,3,7,8,9-hexachlorodibenzo-*p*-dioxin
- 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin\*
- **1,2,3,4,6,7,8-heptachlorodibenzofuran**
- 1,2,3,4,7,8-hexachlorodibenzofuran
- 1,2,3,6,7,8-hexachlorodibenzofuran
- 2,3,4,7,8-pentachlorodibenzofuran\*
- **coplanar polychlorinated biphenyls 126\* and 169**
- mono-ortho substituted PCBs 74, 118\* and 156\*

About 80%-90% of the total TEQ can be estimated from six of the congeners (indicated by asterisks) listed above, plus an estimate of the TCDD level. Though the mono-ortho-substituted PCBs are less potent (i.e., lower TEFs), their contribution to the total TEQ is substantial since they are present in much higher concentrations than are the coplanar PCBs, dioxins, and furans. In keeping with results from reports from Germany (Papke et al., 1998), New Zealand (Bates et al., 2004b) and elsewhere, the NHANES 1999-2000 and 2001-2002 data show that the highly chlorinated and laterally substituted congeners are frequently detected. The presence of many of these congeners in human sera is probably due to their greater solubility in body fat and slower elimination (Geyer et al., 2002), but can also be due to their greater presence in the food chain. For example, people consuming fish from the Great Lakes had mean concentrations of dioxins and furans that are several times background values in the population (Falk et al., 1999; Anderson et al., 1998; Hanrahan et al., 1999).

Of the dioxins and furans, octachlorodibenzo-*p*-dioxin typically is present in the highest concentration but contributes little to the TEQ, with the other commonly detected dioxin and furan congeners being more than eight-fold lower in concentration. Similar levels of octachlorodibenzo-*p*-dioxin are seen in a representative pooled sampling of New Zealanders aged 15 years and older who were studied during 1997-1998. The weighted mean octachlorodibenzo-*p*-dioxin level in the New Zealand study was 361 picograms per gram (pg/g) lipid (Bates et al., 2004b) compared with the NHANES 2001-2002 median level of 349 pg/g lipid for non-Hispanic whites aged 20 years and older. On the other hand, 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin concentrations in this *Report* are about 60-fold lower than octachlorodibenzo-*p*-dioxin levels (at the comparable percentiles), but because of a 10,000-fold greater TEF (equal to that of TCDD), the contribution of 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin to the TEQ is about 160 times greater than the octachlorodibenzo-*p*-dioxin. In 1996, a small convenience sample of German residents aged 18-71 years showed that levels of 1,2,3,7,8-pentachlorodibenzo-*p*-dioxin at the 95<sup>th</sup> percentile were

9.9 pg/g lipid (Papke et al., 1998). Levels at the 95<sup>th</sup> percentile in the NHANES 2001-2002 subsample reported here were 15.8 pg/g.

The three major hexachlorodibenzo-*p*-dioxins are assigned equal TEF values, but the 1,2,3,6,7,8-hexachlorodibenzo-*p*-dioxin often demonstrates multifold higher concentrations than the other two hexachlorodibenzo-*p*-dioxins, about six-fold higher in the NHANES 2001-2002 subsample. The geometric mean levels of 1,2,3,6,7,8-hexachlorodibenzo-*p*-dioxin in the 2001-2002 subsample are slightly higher than levels in either the German or New Zealand study mentioned above (Papke et al., 1998; Bates et al., 2004*b*). A small convenience sample of Japanese men and women aged 20-76 years studied during 1996-1997 also showed lower median levels of 17 pg/g and 18 pg/g lipid, respectively, than levels in the NHANES 2001-2002 subsample (Arisawa et al., 2003).

For TCDD levels in the NHANES 2001-2002 subsample, only the 95<sup>th</sup> percentiles in women and non-Hispanic blacks could be characterized, which were 6.4 and 7.4, picograms/gram (pg/g) of lipid, respectively (detection limit of 5.8 pg/g of lipid). The remainder of the U.S. population is likely to be below these levels of this hallmark dioxin. In 1996, the 95<sup>th</sup> percentile for lipid-adjusted serum TCDD levels in 139 Germans aged 18-71 years was 4.3 pg/g of lipid, with that percentile comprising mainly older individuals (Papke, 1998). The TCDD levels in this *Report* are much lower than those for chemical-production workers even when they were examined 15 years after workplace exposure had ceased (median serum TCDD concentration = 68 pg/g of lipid) (Calvert et al., 1996). TCDD levels of chemical-plant workers exposed to high concentrations have ranged as high as 2,000 pg/g lipid (World Health Organization/IARC, 1997).

In the NHANES 2001-2002 subsample, the geometric mean levels of coplanar PCBs 126 and 169 for participants aged 20 years and older were similar or slightly lower than those reported from a representative pooled sample of New Zealanders in 1996-1997 (Bates et al., 2004*b*) and of a smaller sample of non-occupationally exposed men and women aged 20-76 years in Japan in 1999 (Arisawa et al., 2003). Of the mono-ortho-chlorine-substituted PCB congeners, the most frequently detected in general population studies are PCBs 118 and 156. Of these, PCB 118 levels were higher than PCB 156 in the NHANES 1999-2000 and 2001-2002 subsamples although PCB 156 contributes more to the TEQ because its TEF is five-fold greater than the TEF of PCB 118. Compared with levels in a convenience sample of the

U.S. population in 1988 (Patterson et al., 1994), levels of PCB 118 are at least five-fold lower in the NHANES 1999-2002 subsamples. The PCB 156 levels in the NHANES data for 1999-2002 are slightly lower than those reported for a Canadian population study in 1994 (Longnecker et al., 2000). Levels of PCB 156 and PCB 118 were slightly higher in a Swedish study of 150 men than in the NHANES 1999-2002 subsample possibly due to higher fish intake in the Swedish population (Glynn et al., 2000). However, in fish-consuming Japanese men and women studied during 1996-1997, PCB 118 levels were similar to levels in the NHANES 2001-2002 subsample at the comparable 75<sup>th</sup> percentiles (Arisawa et al., 2003).

As was the case for TCDD, levels of other polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar and mono-ortho-substituted biphenyls in this *Report* are below levels associated with occupational or unintentional exposures that produce health effects. There are no firmly established relationships between serum lipid-based concentrations (mainly considering TCDD) and effects in people. Studies of industrial and accidental exposures suggest that concentrations of at least 800 pg/g of lipid might be necessary to induce chloracne, a specific effect, although levels in the thousands of pg/g of lipid do not always produce this effect (Mocarelli et al., 1991). The studies showing clinical effects in people after large unintentional exposures have demonstrated concentrations ranging from several hundred to the tens of thousands of pg/g of lipid (Masuda 2001; Masuda et al., 1998; Mocarelli et al., 1991).

### Comparing Adjusted Geometric Means

For comparison of demographic groups in the NHANES 2001-2002 subsample, geometric means of whole weight-based serum measurements were adjusted for age, gender, race/ethnicity, log serum cotinine, and lipid level (data not shown). In NHANES 2001-2002, females had higher adjusted geometric mean levels than males for 1,2,3,4,6,7,8-heptachlorodibenzo-*p*-dioxin, and 3,3,4,4,5-pentachlorobiphenyl (PCB 126). However, males had higher levels than females for 3,3,4,4,5,5-hexachlorobiphenyl (PCB 169). In the previously mentioned study of Japanese adults, women demonstrated higher levels than men for the octachlorodibenzo-*p*-dioxin, 1,2,3,4,6,7,8-heptachlorodibenzo-*p*-dioxin and 1,2,3,7,8,9-hexachlorodibenzo-*p*-dioxin, but men had higher levels for PCBs 169, 156, and 189 (Arisawa et al., 2003). In NHANES 2001-2002, Mexican Americans had lower adjusted geometric mean levels than non-Hispanic blacks

and whites for 1,2,3,4,6,7,8-heptachlorodibenzofuran, 1,2,3,6,7,8-hexachlorodibenzo-*p*-dioxin, and 3,3,4,4,5,5-hexachlorobiphenyl (PCB 126). Also, non-Hispanic whites had lower levels than non-Hispanic blacks for 1,2,3,4,6,7,8-heptachlorodibenzofuran.

Differences in levels of specific polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar and mono-ortho-substituted polychlorinated biphenyls are due in part to exposure but also result from differences in absorption, tissue distribution, metabolism, and elimination. Half-lives for all the dioxins and furans vary from 3 years to 19 years, with the half-life of TCDD estimated at around 7 years (Geyer et al., 2002). Current levels may be influenced by both past (stored in body fat) and recent exposures. Several studies have shown that levels of dioxins and furans in serum or fat increase with the age of the individual (Falk et al., 1999; Kang et al., 1997; Luotamo et al., 1991; Patterson et al., 1986). Most of the dioxins, furans and PCBs measured in the previously mentioned New Zealand representative sample showed an increasing trend with age (Bates et al., 2004b). In part, this age trend was noticeable at the higher percentiles for the more highly chlorinated congeners in the NHANES 1999-2000 subsample which included both the groups aged 12-19 years and 20 and older.

Finding a measurable amount of one or more of the polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar or mono-ortho-substituted biphenyls in serum does not mean that the level of one or more of these causes an adverse health effect. Whether the concentrations reported here are a cause for health concern is not yet known; more research is needed. These levels provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of polychlorinated dibenzo-*p*-dioxins, dibenzofurans, coplanar or mono-ortho-substituted biphenyls than levels found in the general population. These data will also help scientists plan and conduct research on exposure and health effects.

Notes: 1) As seen in other recent population studies, pooling of approximately 50 or more specimens is sometimes required to have adequate amounts of specimen to properly estimate a TEQ of dioxin-like compounds in the general population. Because of limited availability of serum volumes and the low levels detected in the NHANES 1999-2002 population, TEQ values are not estimated from this analysis of individual samples. Future plans include an analysis of pooled specimens to improve the LOD for these compounds and allow calculation of TEQ values. 2) PCB analyses by GC-high resolution mass spectrometry are usually specific for the

stated PCB congener. However, in some cases, multiple congeners of the same molecular weight could potentially contribute to the analytical result for a stated congener. Such potentially contributing congeners are not present in significant proportions in the environment or in the body and are unlikely to affect the stated results. Known situations would include: PCBs 158, 160, 163, and 164 contributing to the result for PCB 138; PCB 132 contributing to the result for PCB 153; PCB 190 contributing to the result for PCB 170; and PCB 203 contributing to the result for PCB 196.

**Table 81. 1,2,3,4,6,7,8,9-Octachlorodibenzo-*p*-dioxin (OCDD) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	<b>445</b> (389-496)	<b>704</b> (624-802)	<b>948</b> (822-1080)	1254
	01-02	<b>346</b> (<LOD-394)	<b>333</b> (<LOD-399)	<b>571</b> (498-668)	<b>939</b> (780-1090)	<b>1260</b> (997-1610)	1171
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	<b>421</b> (363-517)	667
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	<b>445</b> (389-496)	<b>704</b> (624-802)	<b>948</b> (822-1080)	1254
	01-02	<b>346</b> (<LOD-394)	<b>333</b> (<LOD-399)	<b>571</b> (498-668)	<b>939</b> (780-1090)	<b>1260</b> (997-1610)	1171
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	<b>331</b> (<LOD-378)	<b>541</b> (453-639)	<b>710</b> (572-873)	575
	01-02	*	< LOD	<b>438</b> (346-579)	<b>745</b> (593-968)	<b>1030</b> (837-1240)	517
Females	99-00	*	< LOD	<b>525</b> (475-608)	<b>846</b> (689-982)	<b>1050</b> (948-1290)	679
	01-02	<b>410</b> (356-472)	<b>405</b> (333-498)	<b>643</b> (574-731)	<b>1020</b> (858-1360)	<b>1450</b> (1060-1780)	654
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	<b>471</b> (374-572)	<b>703</b> (608-916)	<b>940</b> (746-1190)	333
	01-02	*	< LOD	<b>432</b> (394-545)	<b>754</b> (578-1220)	<b>1150</b> (696-1640)	250
Non-Hispanic blacks	99-00	*	< LOD	<b>493</b> (405-566)	<b>820</b> (727-1070)	<b>1170</b> (820-1680)	226
	01-02	<b>421</b> (352-503)	<b>420</b> (339-509)	<b>669</b> (537-907)	<b>1110</b> (956-1520)	<b>1640</b> (1130-1900)	210
Non-Hispanic whites	99-00	*	< LOD	<b>427</b> (369-484)	<b>671</b> (581-800)	<b>913</b> (731-1080)	578
	01-02	<b>349</b> (<LOD-409)	<b>333</b> (<LOD-421)	<b>574</b> (493-670)	<b>945</b> (764-1170)	<b>1290</b> (971-1650)	632

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 82. 1,2,3,4,6,7,8,9-Octachlorodibenzo-*p*-dioxin (OCDD) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	<b>2800</b> (2480-3110)	<b>4570</b> (4100-5020)	<b>6200</b> (5340-7300)	1254
	01-02	<b>2230</b> (1970-2540)	<b>2170</b> (1870-2550)	<b>3860</b> (3180-4520)	<b>6460</b> (5140-8290)	<b>9110</b> (6940-11400)	1171
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	<b>1910</b> (1600-2340)	667
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	<b>2800</b> (2480-3110)	<b>4570</b> (4100-5020)	<b>6200</b> (5340-7300)	1254
	01-02	<b>2230</b> (1970-2540)	<b>2170</b> (1870-2550)	<b>3860</b> (3180-4520)	<b>6460</b> (5140-8290)	<b>9110</b> (6940-11400)	1171
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	<b>2210</b> (1860-2480)	<b>3270</b> (2880-3900)	<b>4620</b> (3630-6870)	575
	01-02	*	< LOD	<b>3100</b> (2410-4070)	<b>5270</b> (4070-7140)	<b>7410</b> (6020-9760)	517
Females	99-00	*	< LOD	<b>3370</b> (2990-3830)	<b>5270</b> (4780-6050)	<b>7070</b> (6150-9280)	679
	01-02	<b>2590</b> (2250-2980)	<b>2620</b> (2160-3000)	<b>4340</b> (3880-4860)	<b>6990</b> (5870-9040)	<b>9460</b> (7070-12300)	654
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	<b>2880</b> (2400-3390)	<b>4450</b> (3870-6010)	<b>6690</b> (5340-7990)	333
	01-02	*	< LOD	<b>3410</b> (2760-3860)	<b>5810</b> (4250-7670)	<b>8050</b> (5760-11800)	250
Non-Hispanic blacks	99-00	*	< LOD	<b>2780</b> (2480-3660)	<b>5080</b> (4310-6550)	<b>7550</b> (4900-11600)	226
	01-02	<b>2480</b> (2050-3000)	<b>2460</b> (2060-2970)	<b>4170</b> (3160-5560)	<b>7140</b> (5470-9920)	<b>9460</b> (7990-12000)	210
Non-Hispanic whites	99-00	*	< LOD	<b>2800</b> (2400-3150)	<b>4270</b> (3790-4980)	<b>5960</b> (4930-7390)	578
	01-02	<b>2270</b> (1930-2660)	<b>2200</b> (1840-2770)	<b>3860</b> (3090-4720)	<b>6460</b> (4890-8860)	<b>9120</b> (6630-12300)	632

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 83. 1,2,3,4,6,7,8-Heptachlorodibenzo-*p*-dioxin (HpCDD) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	<b>61.9</b> (57.1-66.7)	<b>92.0</b> (81.2-101)	<b>119</b> (102-139)	1237
	01-02	<b>39.0</b> (33.7-45.0)	<b>40.2</b> (34.9-46.7)	<b>68.7</b> (56.7-82.2)	<b>115</b> (88.2-138)	<b>147</b> (126-177)	1220
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	<b>63.6</b> (<LOD-75.6)	657
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	<b>61.9</b> (57.1-66.7)	<b>92.0</b> (81.2-101)	<b>119</b> (102-139)	1237
	01-02	<b>39.0</b> (33.7-45.0)	<b>40.2</b> (34.9-46.7)	<b>68.7</b> (56.7-82.2)	<b>115</b> (88.2-138)	<b>147</b> (126-177)	1220
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	<b>56.2</b> (<LOD-63.6)	<b>75.5</b> (69.9-85.2)	<b>95.0</b> (84.0-103)	572
	01-02	<b>36.6</b> (31.7-42.3)	<b>38.7</b> (33.3-42.6)	<b>61.6</b> (49.7-75.0)	<b>101</b> (75.6-131)	<b>138</b> (103-169)	553
Females	99-00	*	< LOD	<b>67.1</b> (59.7-73.6)	<b>105</b> (94.8-122)	<b>137</b> (120-169)	665
	01-02	<b>41.2</b> (34.9-48.7)	<b>43.6</b> (35.3-52.4)	<b>76.0</b> (59.5-90.1)	<b>123</b> (92.6-143)	<b>157</b> (130-191)	667
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	<b>66.8</b> (60.7-74.1)	<b>102</b> (83.6-115)	<b>135</b> (108-169)	330
	01-02	<b>39.6</b> (35.7-43.9)	<b>39.7</b> (33.6-47.4)	<b>64.0</b> (55.8-74.7)	<b>107</b> (82.4-128)	<b>148</b> (111-171)	262
Non-Hispanic blacks	99-00	*	< LOD	<b>62.2</b> (<LOD-75.1)	<b>101</b> (81.8-114)	<b>137</b> (106-187)	224
	01-02	<b>43.7</b> (35.4-54.0)	<b>42.0</b> (32.2-59.8)	<b>80.6</b> (60.9-106)	<b>134</b> (101-166)	<b>166</b> (130-230)	218
Non-Hispanic whites	99-00	*	< LOD	<b>62.2</b> (<LOD-67.1)	<b>88.7</b> (74.0-102)	<b>116</b> (97.0-134)	567
	01-02	<b>39.3</b> (33.0-46.8)	<b>40.5</b> (34.0-50.1)	<b>70.9</b> (56.3-87.5)	<b>117</b> (85.9-145)	<b>147</b> (125-186)	657

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 84. 1,2,3,4,6,7,8-Heptachlorodibenzo-*p*-dioxin (HpCDD) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	<b>385</b> (354-418)	<b>610</b> (534-677)	<b>802</b> (681-936)	1237
	01-02	<b>252</b> (219-289)	<b>265</b> (232-303)	<b>440</b> (376-529)	<b>779</b> (591-989)	<b>1030</b> (840-1290)	1220
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	<b>287</b> (239-340)	657
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	<b>385</b> (354-418)	<b>610</b> (534-677)	<b>802</b> (681-936)	1237
	01-02	<b>252</b> (219-289)	<b>265</b> (232-303)	<b>440</b> (376-529)	<b>779</b> (591-989)	<b>1030</b> (840-1290)	1220
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	<b>363</b> (310-397)	<b>501</b> (446-578)	<b>642</b> (543-716)	572
	01-02	<b>243</b> (211-279)	<b>244</b> (213-291)	<b>422</b> (349-527)	<b>765</b> (536-976)	<b>983</b> (766-1260)	553
Females	99-00	*	< LOD	<b>414</b> (354-462)	<b>707</b> (597-867)	<b>945</b> (825-1100)	665
	01-02	<b>260</b> (221-306)	<b>281</b> (236-324)	<b>464</b> (386-551)	<b>782</b> (621-997)	<b>1140</b> (849-1330)	667
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	<b>404</b> (364-472)	<b>646</b> (585-785)	<b>906</b> (677-1090)	330
	01-02	<b>254</b> (232-278)	<b>249</b> (229-286)	<b>403</b> (360-521)	<b>789</b> (643-929)	<b>988</b> (817-1240)	262
Non-Hispanic blacks	99-00	*	< LOD	<b>373</b> (297-428)	<b>592</b> (480-752)	<b>966</b> (610-1220)	224
	01-02	<b>258</b> (208-319)	<b>262</b> (180-339)	<b>469</b> (343-600)	<b>852</b> (578-1170)	<b>1160</b> (821-1660)	218
Non-Hispanic whites	99-00	*	< LOD	<b>391</b> (353-430)	<b>610</b> (511-679)	<b>758</b> (676-871)	567
	01-02	<b>255</b> (216-302)	<b>276</b> (228-328)	<b>442</b> (374-547)	<b>779</b> (551-1010)	<b>1020</b> (803-1290)	657

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 85. 1,2,3,4,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population aged 20 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	01-02	*	< LOD	< LOD	<b>10.7</b> (<LOD-13.8)	<b>14.9</b> (11.7-20.0)	1239
<b>Age group</b>							
12-19 years	01-02	†	†	†	†	†	†
20 years and older	01-02	*	< LOD	< LOD	<b>10.7</b> (<LOD-13.8)	<b>14.9</b> (11.7-20.0)	1239
<b>Gender</b> (20 years and older)							
Males	01-02	*	< LOD	< LOD	<b>10.9</b> (<LOD-14.3)	<b>14.7</b> (11.4-16.5)	566
Females	01-02	*	< LOD	< LOD	<b>10.6</b> (<LOD-14.1)	<b>14.9</b> (11.1-23.0)	673
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	<b>9.20</b> (<LOD-11.7)	263
Non-Hispanic blacks	01-02	*	< LOD	< LOD	<b>13.9</b> (<LOD-17.6)	<b>18.3</b> (13.9-23.0)	220
Non-Hispanic whites	01-02	*	< LOD	< LOD	<b>11.2</b> (<LOD-14.4)	<b>15.1</b> (12.0-20.5)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 86. 1,2,3,4,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population aged 20 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	01-02	*	< LOD	< LOD	<b>73.8</b> (54.3-90.7)	<b>105</b> (81.2-139)	1239
<b>Age group</b>							
12-19 years	01-02	†	†	†	†	†	†
20 years and older	01-02	*	< LOD	< LOD	<b>73.8</b> (54.3-90.7)	<b>105</b> (81.2-139)	1239
<b>Gender</b> (20 years and older)							
Males	01-02	*	< LOD	< LOD	<b>73.4</b> (52.6-90.7)	<b>105</b> (77.9-134)	566
Females	01-02	*	< LOD	< LOD	<b>73.8</b> (53.2-90.7)	<b>102</b> (78.0-152)	673
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	<b>70.2</b> (48.0-118)	263
Non-Hispanic blacks	01-02	*	< LOD	< LOD	<b>82.1</b> (53.3-130)	<b>125</b> (75.7-184)	220
Non-Hispanic whites	01-02	*	< LOD	< LOD	<b>77.5</b> (53.2-97.1)	<b>105</b> (78.8-143)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 87. 1,2,3,6,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	<b>36.1</b> (31.5-40.5)	<b>62.8</b> (53.6-69.1)	<b>75.6</b> (70.5-84.2)	1237
	01-02	<b>34.6</b> (29.6-40.6)	<b>39.2</b> (32.7-44.7)	<b>60.7</b> (50.3-74.2)	<b>95.2</b> (76.2-120)	<b>127</b> (99.4-153)	1234
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	<b>26.7</b> (20.2-29.6)	648
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	<b>36.1</b> (31.5-40.5)	<b>62.8</b> (53.6-69.1)	<b>75.6</b> (70.5-84.2)	1237
	01-02	<b>34.6</b> (29.6-40.6)	<b>39.2</b> (32.7-44.7)	<b>60.7</b> (50.3-74.2)	<b>95.2</b> (76.2-120)	<b>127</b> (99.4-153)	1234
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	<b>34.4</b> (27.2-40.5)	<b>59.2</b> (47.1-68.5)	<b>73.0</b> (64.4-81.9)	569
	01-02	<b>34.1</b> (28.3-41.1)	<b>38.8</b> (31.5-44.6)	<b>61.3</b> (50.0-79.5)	<b>94.7</b> (70.8-131)	<b>128</b> (88.5-181)	564
Females	99-00	*	< LOD	<b>37.9</b> (32.5-41.6)	<b>65.6</b> (55.1-70.5)	<b>82.8</b> (69.3-98.9)	668
	01-02	<b>35.1</b> (29.9-41.2)	<b>40.1</b> (32.4-46.3)	<b>59.8</b> (49.8-72.3)	<b>97.0</b> (77.1-114)	<b>126</b> (108-142)	670
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	<b>24.2</b> (<LOD-32.4)	<b>46.8</b> (38.1-56.1)	<b>59.5</b> (52.7-67.9)	332
	01-02	<b>18.3</b> (15.6-21.4)	<b>21.2</b> (19.4-25.0)	<b>31.9</b> (27.0-40.3)	<b>51.5</b> (40.3-69.9)	<b>67.9</b> (48.0-111)	260
Non-Hispanic blacks	99-00	*	< LOD	<b>35.1</b> (28.4-44.9)	<b>62.8</b> (48.0-79.2)	<b>84.9</b> (72.2-98.1)	223
	01-02	<b>38.9</b> (33.6-45.0)	<b>40.2</b> (33.5-47.3)	<b>63.2</b> (54.6-76.9)	<b>93.9</b> (78.5-132)	<b>133</b> (92.6-185)	219
Non-Hispanic whites	99-00	*	< LOD	<b>38.2</b> (34.4-42.0)	<b>64.4</b> (54.3-69.3)	<b>77.7</b> (69.9-84.9)	567
	01-02	<b>37.8</b> (31.5-45.4)	<b>42.6</b> (33.9-51.1)	<b>65.0</b> (52.3-82.2)	<b>99.6</b> (78.4-130)	<b>130</b> (103-165)	671

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 88. 1,2,3,6,7,8-Hexachlorodibenzo-*p*-dioxin (HxCDD) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	<b>232</b> (196-268)	<b>403</b> (349-458)	<b>520</b> (458-607)	1237
	01-02	<b>224</b> (192-261)	<b>246</b> (219-287)	<b>410</b> (347-498)	<b>663</b> (549-785)	<b>870</b> (696-1100)	1234
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	<b>122</b> (93.2-155)	648
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	<b>232</b> (196-268)	<b>403</b> (349-458)	<b>520</b> (458-607)	1237
	01-02	<b>224</b> (192-261)	<b>246</b> (219-287)	<b>410</b> (347-498)	<b>663</b> (549-785)	<b>870</b> (696-1100)	1234
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	<b>211</b> (170-255)	<b>380</b> (297-440)	<b>460</b> (398-571)	569
	01-02	<b>226</b> (190-270)	<b>262</b> (223-301)	<b>425</b> (347-540)	<b>677</b> (547-794)	<b>883</b> (666-1180)	564
Females	99-00	*	< LOD	<b>246</b> (196-298)	<b>424</b> (350-521)	<b>579</b> (492-672)	668
	01-02	<b>222</b> (190-260)	<b>237</b> (207-281)	<b>397</b> (338-474)	<b>643</b> (526-771)	<b>863</b> (720-1060)	670
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	<b>154</b> (102-213)	<b>307</b> (272-359)	<b>392</b> (357-445)	332
	01-02	<b>117</b> (99.4-139)	<b>128</b> (107-157)	<b>233</b> (198-270)	<b>401</b> (278-524)	<b>524</b> (384-731)	260
Non-Hispanic blacks	99-00	*	< LOD	<b>212</b> (167-275)	<b>389</b> (302-477)	<b>522</b> (399-627)	223
	01-02	<b>229</b> (199-264)	<b>226</b> (190-284)	<b>371</b> (333-477)	<b>643</b> (480-799)	<b>799</b> (596-1260)	219
Non-Hispanic whites	99-00	*	< LOD	<b>251</b> (207-293)	<b>421</b> (353-481)	<b>526</b> (472-617)	567
	01-02	<b>246</b> (206-293)	<b>272</b> (233-325)	<b>440</b> (365-552)	<b>679</b> (549-870)	<b>897</b> (718-1150)	671

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 89. 1,2,3,7,8,9-Hexachlorodibenzo-*p*-dioxin (HxCDD) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	12.4 (10.4-15.1)	16.9 (14.3-20.0)	1238
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	642
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	12.4 (10.4-15.1)	16.9 (14.3-20.0)	1238
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	565
	01-02	*	< LOD	< LOD	12.0 (<LOD-14.5)	14.8 (12.9-18.0)	567
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	12.9 (10.7-16.7)	18.3 (15.3-20.9)	671
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	328
	01-02	*	< LOD	< LOD	9.40 (<LOD-11.2)	12.1 (<LOD-20.0)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	223
	01-02	*	< LOD	< LOD	14.4 (11.2-20.0)	19.9 (14.6-23.9)	220
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	562
	01-02	*	< LOD	< LOD	12.6 (9.90-15.9)	17.2 (14.7-20.6)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 90. 1,2,3,7,8,9-Hexachlorodibenzo-*p*-dioxin (HxCDD) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	86.5 (68.8-108)	121 (99.5-146)	1238
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	642
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1228
	01-02	*	< LOD	< LOD	86.5 (68.8-108)	121 (99.5-146)	1238
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	565
	01-02	*	< LOD	< LOD	84.1 (62.7-104)	108 (90.6-142)	567
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	89.7 (67.9-121)	123 (102-150)	671
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	328
	01-02	*	< LOD	< LOD	74.7 (50.5-104)	104 (74.7-167)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	223
	01-02	*	< LOD	< LOD	92.6 (62.8-126)	123 (82.6-169)	220
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	562
	01-02	*	< LOD	< LOD	88.1 (67.9-119)	124 (96.6-152)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 91. 1,2,3,7,8-Pentachlorodibenzo-*p*-dioxin (PeCDD) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1256
	01-02	*	< LOD	< LOD	11.2 (9.30-13.3)	15.8 (13.3-19.8)	1236
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	659
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1256
	01-02	*	< LOD	< LOD	11.2 (9.30-13.3)	15.8 (13.3-19.8)	1236
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	578
	01-02	*	< LOD	< LOD	10.5 (9.10-13.3)	14.3 (11.7-19.4)	564
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	678
	01-02	*	< LOD	6.10 (<LOD-7.80)	11.6 (9.30-13.9)	16.4 (13.7-20.8)	672
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	338
	01-02	*	< LOD	< LOD	< LOD	8.70 (<LOD-12.7)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	7.70 (<LOD-9.30)	13.8 (9.60-18.4)	18.4 (14.2-24.0)	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	576
	01-02	*	< LOD	< LOD	11.6 (9.40-14.1)	16.7 (13.6-20.2)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 92. 1,2,3,7,8-Pentachlorodibenzo-*p*-dioxin (PeCDD) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1256
	01-02	*	< LOD	< LOD	77.8 (62.8-95.1)	117 (90.3-133)	1236
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	659
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1256
	01-02	*	< LOD	< LOD	77.8 (62.8-95.1)	117 (90.3-133)	1236
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	578
	01-02	*	< LOD	< LOD	76.1 (54.7-93.7)	107 (83.5-133)	564
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	678
	01-02	*	< LOD	37.8 (25.0-50.2)	80.1 (62.9-107)	121 (85.7-167)	672
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	338
	01-02	*	< LOD	< LOD	< LOD	66.0 (43.3-111)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	43.0 (27.0-53.8)	81.9 (58.2-117)	123 (81.9-169)	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	576
	01-02	*	< LOD	< LOD	80.8 (61.6-107)	119 (88.6-142)	672

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 93. 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1240
	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	658
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1240
	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	572
	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	6.40 (<LOD-9.10)	669
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	336
	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	222
	01-02	*	< LOD	< LOD	< LOD	7.40 (<LOD-10.0)	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	567
	01-02	*	< LOD	< LOD	< LOD	< LOD	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 94. 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1240
	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	658
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1240
	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	572
	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	50.7 (29.2-74.3)	669
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	336
	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	222
	01-02	*	< LOD	< LOD	< LOD	52.1 (27.4-72.0)	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	567
	01-02	*	< LOD	< LOD	< LOD	< LOD	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 95. 1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1202
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1202
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	569
	01-02	*	< LOD	< LOD	< LOD	< LOD	541
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	< LOD	< LOD	661
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	329
	01-02	*	< LOD	< LOD	< LOD	< LOD	257
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	224
	01-02	*	< LOD	< LOD	< LOD	< LOD	212
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	653

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 96. 1,2,3,4,6,7,8,9-Octachlorodibenzofuran (OCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1202
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1202
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	569
	01-02	*	< LOD	< LOD	< LOD	< LOD	541
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	*	< LOD	< LOD	< LOD	< LOD	661
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	329
	01-02	*	< LOD	< LOD	< LOD	< LOD	257
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	224
	01-02	*	< LOD	< LOD	< LOD	< LOD	212
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	568
	01-02	*	< LOD	< LOD	< LOD	< LOD	653

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 97. 1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	14.2 (<LOD-17.5)	18.4 (15.0-23.8)	1109
	01-02	9.64 (8.53-10.9)	10.3 (8.80-11.7)	14.5 (12.7-16.6)	21.3 (18.0-25.5)	27.1 (22.5-32.0)	1219
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	17.7 (16.2-20.9)	24.0 (20.9-28.1)	600
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	14.2 (<LOD-17.5)	18.4 (15.0-23.8)	1109
	01-02	9.64 (8.53-10.9)	10.3 (8.80-11.7)	14.5 (12.7-16.6)	21.3 (18.0-25.5)	27.1 (22.5-32.0)	1219
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	15.9 (<LOD-20.0)	19.9 (16.4-26.9)	508
	01-02	10.1 (8.74-11.6)	10.9 (9.00-12.5)	15.2 (12.9-17.2)	20.8 (17.2-27.8)	28.9 (22.0-34.8)	557
Females	99-00	*	< LOD	< LOD	< LOD	17.0 (14.0-25.2)	601
	01-02	9.28 (8.20-10.5)	9.30 (8.10-11.0)	14.1 (12.3-15.9)	21.0 (17.4-25.5)	26.5 (22.3-31.9)	662
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	17.3 (<LOD-23.1)	299
	01-02	7.73 (7.19-8.31)	8.20 (7.80-8.60)	11.1 (10.6-12.5)	16.5 (14.5-19.6)	20.2 (17.2-26.8)	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	22.4 (14.0-28.3)	28.2 (25.3-29.8)	202
	01-02	12.3 (10.6-14.4)	12.8 (10.9-15.2)	17.2 (15.4-21.0)	25.5 (22.4-31.2)	32.1 (25.7-37.6)	214
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	16.8 (14.2-18.5)	503
	01-02	9.50 (8.30-10.9)	10.0 (8.20-11.8)	14.4 (12.6-16.2)	20.5 (16.9-25.3)	25.5 (20.5-31.7)	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 98. 1,2,3,4,6,7,8-Heptachlorodibenzofuran (HpCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	<b>85.7</b> (74.7-97.7)	<b>108</b> (93.6-127)	1109
	01-02	<b>62.2</b> (55.4-69.9)	<b>64.4</b> (58.0-71.6)	<b>94.1</b> (82.3-110)	<b>134</b> (119-165)	<b>181</b> (147-206)	1219
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	<b>79.3</b> (69.5-84.2)	<b>99.0</b> (83.4-120)	600
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	<b>85.7</b> (74.7-97.7)	<b>108</b> (93.6-127)	1109
	01-02	<b>62.2</b> (55.4-69.9)	<b>64.4</b> (58.0-71.6)	<b>94.1</b> (82.3-110)	<b>134</b> (119-165)	<b>181</b> (147-206)	1219
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	<b>89.0</b> (74.7-111)	<b>111</b> (93.6-138)	508
	01-02	<b>66.3</b> (58.2-75.6)	<b>70.0</b> (59.8-81.8)	<b>99.3</b> (85.5-120)	<b>143</b> (120-181)	<b>181</b> (146-237)	557
Females	99-00	*	< LOD	< LOD	< LOD	<b>101</b> (85.7-149)	601
	01-02	<b>58.8</b> (52.0-66.4)	<b>60.2</b> (53.5-67.6)	<b>89.1</b> (74.7-107)	<b>130</b> (108-164)	<b>169</b> (131-225)	662
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	<b>112</b> (81.1-121)	299
	01-02	<b>49.5</b> (46.0-53.4)	<b>50.2</b> (45.7-57.2)	<b>76.5</b> (67.1-82.1)	<b>97.2</b> (90.9-124)	<b>133</b> (94.8-202)	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>124</b> (92.0-153)	<b>157</b> (114-214)	202
	01-02	<b>72.6</b> (61.9-85.2)	<b>70.5</b> (62.4-85.2)	<b>107</b> (91.5-128)	<b>146</b> (131-177)	<b>192</b> (154-259)	214
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	<b>97.8</b> (89.3-105)	503
	01-02	<b>61.8</b> (54.3-70.4)	<b>64.5</b> (57.4-72.2)	<b>94.3</b> (78.1-112)	<b>133</b> (114-166)	<b>180</b> (137-222)	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 99. 1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population aged 20 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	1224
<b>Age group</b>							
12-19 years	01-02	†	†	†	†	†	†
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1224
<b>Gender</b> (20 years and older)							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	558
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	666
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	661

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 100. 1,2,3,4,7,8,9-Heptachlorodibenzofuran (HpCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population aged 20 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	1224
<b>Age group</b>							
12-19 years	01-02	†	†	†	†	†	†
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1224
<b>Gender</b> (20 years and older)							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	558
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	666
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	661

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 101. 1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1233
	01-02	*	< LOD	<b>8.00</b> (6.90-9.30)	<b>12.1</b> (9.40-14.9)	<b>15.4</b> (12.9-18.6)	1223
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	657
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1233
	01-02	*	< LOD	<b>8.00</b> (6.90-9.30)	<b>12.1</b> (9.40-14.9)	<b>15.4</b> (12.9-18.6)	1223
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	567
	01-02	*	< LOD	<b>8.20</b> (7.10-9.70)	<b>12.6</b> (9.50-15.9)	<b>15.9</b> (12.2-20.9)	562
Females	99-00	*	< LOD	< LOD	< LOD	<b>13.0</b> (<LOD-17.1)	666
	01-02	*	< LOD	<b>7.90</b> (6.60-9.00)	<b>11.7</b> (9.40-13.8)	<b>14.1</b> (12.1-18.6)	661
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	333
	01-02	*	< LOD	< LOD	<b>7.20</b> (<LOD-8.00)	<b>8.00</b> (6.90-10.7)	261
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	<b>14.5</b> (<LOD-18.1)	221
	01-02	*	< LOD	<b>8.90</b> (7.70-10.1)	<b>13.6</b> (11.1-17.1)	<b>18.6</b> (14.6-22.6)	214
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	563
	01-02	*	< LOD	<b>8.20</b> (7.10-10.2)	<b>12.5</b> (9.90-15.5)	<b>15.9</b> (13.1-19.0)	664

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 102. 1,2,3,4,7,8-Hexachlorodibenzofuran (HxCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1233
	01-02	*	< LOD	<b>54.0</b> (46.5-63.6)	<b>82.3</b> (65.5-104)	<b>108</b> (88.0-138)	1223
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	657
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1233
	01-02	*	< LOD	<b>54.0</b> (46.5-63.6)	<b>82.3</b> (65.5-104)	<b>108</b> (88.0-138)	1223
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	567
	01-02	*	< LOD	<b>56.9</b> (48.6-71.4)	<b>90.1</b> (71.1-108)	<b>108</b> (87.4-144)	562
Females	99-00	*	< LOD	< LOD	< LOD	<b>86.1</b> (72.5-105)	666
	01-02	*	< LOD	<b>51.6</b> (43.7-59.6)	<b>76.1</b> (62.6-97.0)	<b>104</b> (80.1-139)	661
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	333
	01-02	*	< LOD	< LOD	<b>48.4</b> (42.2-56.3)	<b>65.3</b> (48.6-79.4)	261
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	<b>96.5</b> (75.9-120)	221
	01-02	*	< LOD	<b>52.7</b> (45.0-62.7)	<b>85.2</b> (63.7-108)	<b>122</b> (85.2-147)	214
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	563
	01-02	*	< LOD	<b>56.0</b> (48.5-66.1)	<b>84.2</b> (64.5-115)	<b>112</b> (88.6-142)	664

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 103. 1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	7.10 (<LOD-8.20)	10.3 (9.00-13.1)	14.0 (11.0-17.1)	1236
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	656
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	7.10 (<LOD-8.20)	10.3 (9.00-13.1)	14.0 (11.0-17.1)	1236
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	573
	01-02	*	< LOD	7.10 (<LOD-8.50)	11.3 (8.50-13.8)	14.8 (11.3-18.7)	566
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	7.00 (6.10-7.90)	9.90 (9.20-11.2)	13.1 (10.5-15.6)	670
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	332
	01-02	*	< LOD	< LOD	< LOD	6.80 (<LOD-11.1)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	7.60 (6.10-9.10)	11.9 (10.0-14.1)	15.6 (12.3-21.0)	219
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	569
	01-02	*	< LOD	7.30 (6.20-9.00)	10.7 (9.00-14.0)	14.8 (11.6-17.2)	670

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 104. 1,2,3,6,7,8-Hexachlorodibenzofuran (HxCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	<b>46.0</b> (38.6-56.5)	<b>70.2</b> (58.3-90.2)	<b>101</b> (77.6-120)	1236
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	656
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	<b>46.0</b> (38.6-56.5)	<b>70.2</b> (58.3-90.2)	<b>101</b> (77.6-120)	1236
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	573
	01-02	*	< LOD	<b>47.6</b> (38.3-60.5)	<b>72.3</b> (57.5-105)	<b>104</b> (73.5-133)	566
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	<b>45.0</b> (37.0-54.3)	<b>66.2</b> (58.3-79.1)	<b>90.2</b> (71.9-115)	670
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	332
	01-02	*	< LOD	< LOD	< LOD	<b>52.7</b> (41.2-65.9)	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	<b>44.4</b> (37.2-57.3)	<b>71.5</b> (59.8-90.9)	<b>107</b> (70.7-142)	219
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	569
	01-02	*	< LOD	<b>49.6</b> (41.9-57.9)	<b>72.8</b> (58.4-102)	<b>103</b> (82.6-121)	670

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 105. 1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1230
	01-02	*	< LOD	< LOD	< LOD	< LOD	1223
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	645
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1230
	01-02	*	< LOD	< LOD	< LOD	< LOD	1223
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	664
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	332
	01-02	*	< LOD	< LOD	< LOD	< LOD	261
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	221
	01-02	*	< LOD	< LOD	< LOD	< LOD	216
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	560
	01-02	*	< LOD	< LOD	< LOD	< LOD	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 106. 1,2,3,7,8,9-Hexachlorodibenzofuran (HxCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1230
	01-02	*	< LOD	< LOD	< LOD	< LOD	1223
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	645
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1230
	01-02	*	< LOD	< LOD	< LOD	< LOD	1223
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	559
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	664
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	332
	01-02	*	< LOD	< LOD	< LOD	< LOD	261
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	221
	01-02	*	< LOD	< LOD	< LOD	< LOD	216
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	560
	01-02	*	< LOD	< LOD	< LOD	< LOD	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 107. 1,2,3,7,8-Pentachlorodibenzofuran (PeCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1235
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1235
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	578
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	681
	01-02	*	< LOD	< LOD	< LOD	< LOD	670
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	339
	01-02	*	< LOD	< LOD	< LOD	< LOD	263
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	226
	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	576
	01-02	*	< LOD	< LOD	< LOD	< LOD	670

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 108. 1,2,3,7,8-Pentachlorodibenzofuran (PeCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1235
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	663
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1235
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	578
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	681
	01-02	*	< LOD	< LOD	< LOD	< LOD	670
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	339
	01-02	*	< LOD	< LOD	< LOD	< LOD	263
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	226
	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	576
	01-02	*	< LOD	< LOD	< LOD	< LOD	670

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 109. 2,3,4,6,7,8-Hexachlorodibenzofuran (HxCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	566
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	665
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	326
	01-02	*	< LOD	< LOD	< LOD	< LOD	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	< LOD	< LOD	< LOD	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	671

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 110. 2,3,4,6,7,8-Hexachlorodibenzofuran (HxCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	652
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	566
	01-02	*	< LOD	< LOD	< LOD	< LOD	565
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	665
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	326
	01-02	*	< LOD	< LOD	< LOD	< LOD	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	< LOD	< LOD	< LOD	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	671

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 111. 2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	<b>16.1</b> (13.9-17.2)	1239
	01-02	*	< LOD	<b>9.10</b> (7.40-11.0)	<b>14.3</b> (12.3-16.2)	<b>18.0</b> (16.1-21.1)	1230
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	656
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	<b>16.1</b> (13.9-17.2)	1239
	01-02	*	< LOD	<b>9.10</b> (7.40-11.0)	<b>14.3</b> (12.3-16.2)	<b>18.0</b> (16.1-21.1)	1230
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	<b>14.1</b> (12.9-15.7)	569
	01-02	*	< LOD	<b>9.30</b> (7.30-11.6)	<b>14.1</b> (11.6-16.7)	<b>16.7</b> (13.9-21.4)	560
Females	99-00	*	< LOD	< LOD	<b>13.7</b> (<LOD-16.1)	<b>17.1</b> (15.5-19.3)	670
	01-02	*	< LOD	<b>9.10</b> (7.50-10.7)	<b>14.3</b> (13.0-16.1)	<b>18.5</b> (16.4-21.2)	670
<b>Race/ethnicity</b> (20 years and older)							
<b>Mexican Americans</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	339
	01-02	*	< LOD	< LOD	<b>7.80</b> (6.00-9.60)	<b>9.80</b> (7.80-12.5)	264
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>12.9</b> (<LOD-15.0)	<b>16.6</b> (13.7-21.0)	220
	01-02	*	< LOD	<b>8.30</b> (6.80-9.30)	<b>13.9</b> (11.7-16.4)	<b>18.9</b> (15.1-23.0)	216
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>12.8</b> (<LOD-14.1)	<b>16.1</b> (14.1-17.5)	564
	01-02	*	<b>5.80</b> (<LOD-6.80)	<b>10.3</b> (8.10-11.9)	<b>15.5</b> (13.0-17.6)	<b>18.4</b> (16.5-22.2)	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 112. 2,3,4,7,8-Pentachlorodibenzofuran (PeCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	<b>107</b> (98.3-125)	1239
	01-02	*	< LOD	<b>60.8</b> (51.3-70.5)	<b>98.5</b> (83.4-114)	<b>134</b> (113-152)	1230
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	656
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	<b>107</b> (98.3-125)	1239
	01-02	*	< LOD	<b>60.8</b> (51.3-70.5)	<b>98.5</b> (83.4-114)	<b>134</b> (113-152)	1230
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	<b>98.2</b> (80.7-109)	569
	01-02	*	< LOD	<b>61.7</b> (49.3-76.6)	<b>98.4</b> (76.6-134)	<b>135</b> (105-160)	560
Females	99-00	*	< LOD	< LOD	<b>93.5</b> (79.1-104)	<b>115</b> (103-129)	670
	01-02	*	< LOD	<b>59.7</b> (52.0-67.6)	<b>99.6</b> (90.5-105)	<b>126</b> (107-146)	670
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	339
	01-02	*	< LOD	< LOD	<b>55.8</b> (48.7-69.7)	<b>76.3</b> (61.9-92.4)	264
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>79.4</b> (68.3-95.6)	<b>107</b> (86.9-143)	220
	01-02	*	< LOD	<b>50.0</b> (41.3-60.4)	<b>89.5</b> (72.3-107)	<b>121</b> (92.0-154)	216
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>88.8</b> (78.2-97.2)	<b>109</b> (98.2-128)	564
	01-02	*	<b>37.3</b> (30.1-44.1)	<b>65.4</b> (52.9-78.2)	<b>104</b> (90.7-118)	<b>135</b> (118-154)	665

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 113. 2,3,7,8-Tetrachlorodibenzofuran (TCDF) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	574
	01-02	*	< LOD	< LOD	< LOD	< LOD	558
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	671
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	335
	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	226
	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	667

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 114. 2,3,7,8-Tetrachlorodibenzofuran (TCDF) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	574
	01-02	*	< LOD	< LOD	< LOD	< LOD	558
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	671
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	335
	01-02	*	< LOD	< LOD	< LOD	< LOD	262
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	226
	01-02	*	< LOD	< LOD	< LOD	< LOD	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	564
	01-02	*	< LOD	< LOD	< LOD	< LOD	667

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 115. 2,4,4'-Trichlorobiphenyl (PCB 28) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1849
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	647
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1202
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	886
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	963
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	618
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	392
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	687

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 116. 2,4,4'-Trichlorobiphenyl (PCB 28) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2000.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1849
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	647
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1202
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	886
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	963
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	618
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	392
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	687

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 117. 2,3',4,4'-Tetrachlorobiphenyl (PCB 66) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1931
	01-02	*	< LOD	< LOD	< LOD	< LOD	2250
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	671
	01-02	*	< LOD	< LOD	< LOD	< LOD	724
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1526
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1047
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1012
	01-02	*	< LOD	< LOD	< LOD	< LOD	1203
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	548
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	414
	01-02	*	< LOD	< LOD	< LOD	< LOD	495
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	723
	01-02	*	< LOD	< LOD	< LOD	< LOD	1047

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 118. 2,3',4,4'-Tetrachlorobiphenyl (PCB 66) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1931
	01-02	*	< LOD	< LOD	< LOD	< LOD	2250
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	671
	01-02	*	< LOD	< LOD	< LOD	< LOD	724
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1526
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1047
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1012
	01-02	*	< LOD	< LOD	< LOD	< LOD	1203
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	548
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	414
	01-02	*	< LOD	< LOD	< LOD	< LOD	495
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	723
	01-02	*	< LOD	< LOD	< LOD	< LOD	1047

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 119. 2,4,4',5-Tetrachlorobiphenyl (PCB 74) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	<b>20.7</b> (17.8-23.4)	<b>29.0</b> (24.5-32.3)	1924
	01-02	*	< LOD	<b>13.1</b> (11.0-15.7)	<b>23.3</b> (20.1-27.4)	<b>32.6</b> (26.9-38.7)	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	671
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	<b>12.6</b> (<LOD-14.4)	<b>22.3</b> (19.5-25.6)	<b>30.0</b> (26.2-35.8)	1253
	01-02	*	< LOD	<b>14.6</b> (12.4-17.1)	<b>25.2</b> (21.4-28.9)	<b>34.8</b> (28.5-41.1)	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>15.3</b> (12.9-17.5)	<b>21.5</b> (18.3-24.4)	915
	01-02	*	< LOD	<b>10.5</b> (<LOD-12.1)	<b>20.2</b> (15.1-24.9)	<b>28.5</b> (20.8-38.2)	1075
Females	99-00	*	< LOD	<b>13.9</b> (<LOD-16.3)	<b>24.5</b> (21.9-28.5)	<b>31.6</b> (28.8-40.3)	1009
	01-02	*	< LOD	<b>15.7</b> (13.5-18.6)	<b>26.1</b> (23.1-29.3)	<b>35.9</b> (31.4-41.4)	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	<b>15.8</b> (12.8-18.2)	636
	01-02	*	< LOD	< LOD	<b>13.0</b> (<LOD-18.1)	<b>19.6</b> (16.2-23.0)	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>29.0</b> (18.6-38.4)	<b>43.5</b> (35.4-64.0)	411
	01-02	*	< LOD	<b>12.0</b> (<LOD-14.2)	<b>21.7</b> (16.4-26.9)	<b>31.5</b> (24.5-41.0)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>21.6</b> (18.9-24.0)	<b>29.0</b> (24.1-32.0)	719
	01-02	*	< LOD	<b>14.6</b> (12.2-17.3)	<b>25.7</b> (21.3-30.1)	<b>35.5</b> (29.0-42.5)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 120. 2,4,4',5-Tetrachlorobiphenyl (PCB 74) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	.139 (.120-.151)	.183 (.162-.218)	1924
	01-02	*	< LOD	.084 (.073-.099)	.150 (.134-.174)	.212 (.181-.263)	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	671
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	.084 (.072-.096)	.148 (.137-.158)	.203 (.174-.232)	1253
	01-02	*	< LOD	.094 (.081-.110)	.166 (.140-.192)	.226 (.196-.279)	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	.098 (.088-.118)	.151 (.128-.168)	915
	01-02	*	< LOD	.069 (.057-.078)	.131 (.101-.171)	.189 (.138-.241)	1075
Females	99-00	*	< LOD	.096 (.077-.109)	.158 (.143-.184)	.223 (.186-.254)	1009
	01-02	*	< LOD	.101 (.088-.112)	.168 (.149-.190)	.236 (.205-.285)	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	.111 (.083-.126)	636
	01-02	*	< LOD	< LOD	.087 (.067-.123)	.144 (.107-.157)	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	.169 (.109-.246)	.277 (.218-.418)	411
	01-02	*	< LOD	.070 (.058-.083)	.131 (.104-.166)	.192 (.152-.251)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	.145 (.126-.157)	.185 (.163-.212)	719
	01-02	*	< LOD	.096 (.078-.111)	.167 (.139-.196)	.229 (.194-.282)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 121. 3,4,4',5-Tetrachlorobiphenyl (PCB 81) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1215
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	651
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1215
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	566
	01-02	*	< LOD	< LOD	< LOD	< LOD	554
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	661
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	333
	01-02	*	< LOD	< LOD	< LOD	< LOD	259
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	< LOD	< LOD	< LOD	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	557
	01-02	*	< LOD	< LOD	< LOD	< LOD	657

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 122. 3,4,4',5-Tetrachlorobiphenyl (PCB 81) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1215
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	651
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1232
	01-02	*	< LOD	< LOD	< LOD	< LOD	1215
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	566
	01-02	*	< LOD	< LOD	< LOD	< LOD	554
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	661
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	333
	01-02	*	< LOD	< LOD	< LOD	< LOD	259
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	225
	01-02	*	< LOD	< LOD	< LOD	< LOD	218
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	557
	01-02	*	< LOD	< LOD	< LOD	< LOD	657

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 123. 2,3,3',4,4'-Pentachlorobiphenyl (PCB 105) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1915
	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	665
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1250
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	913
	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1002
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	12.8 (<LOD-18.0)	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	714
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 124. 2,3,3',4,4'-Pentachlorobiphenyl (PCB 105) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1915
	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	665
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1250
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	913
	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1002
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	.076 (.058-.112)	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	714
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 125. 2,3',4,4',5-Pentachlorobiphenyl (PCB 118) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	<b>13.1</b> (<LOD-15.1)	<b>27.0</b> (22.1-30.3)	<b>40.3</b> (32.8-47.4)	1926
	01-02	*	< LOD	<b>15.1</b> (13.0-17.5)	<b>29.0</b> (26.1-33.7)	<b>44.6</b> (39.6-48.9)	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	<b>14.7</b> (12.8-17.4)	<b>28.0</b> (24.4-33.5)	<b>43.6</b> (35.6-52.3)	1259
	01-02	*	< LOD	<b>16.9</b> (15.1-18.8)	<b>32.4</b> (28.3-37.3)	<b>46.4</b> (41.1-51.0)	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>19.6</b> (16.6-24.4)	<b>28.0</b> (24.4-38.1)	919
	01-02	*	< LOD	<b>11.9</b> (<LOD-14.6)	<b>22.0</b> (17.6-27.1)	<b>32.7</b> (25.4-47.5)	1075
Females	99-00	*	< LOD	<b>16.7</b> (13.5-19.5)	<b>32.0</b> (27.0-40.3)	<b>46.8</b> (41.0-57.0)	1007
	01-02	*	< LOD	<b>18.7</b> (16.3-20.5)	<b>35.9</b> (31.6-40.9)	<b>48.7</b> (44.5-54.3)	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>17.0</b> (14.1-18.3)	<b>23.7</b> (20.9-27.1)	636
	01-02	*	< LOD	< LOD	<b>16.8</b> (12.5-21.7)	<b>26.4</b> (19.3-33.2)	567
Non-Hispanic blacks	99-00	*	< LOD	<b>18.9</b> (12.9-21.7)	<b>38.6</b> (28.4-54.4)	<b>59.7</b> (45.7-80.8)	413
	01-02	*	< LOD	<b>15.6</b> (12.6-19.9)	<b>37.3</b> (26.1-46.4)	<b>54.9</b> (40.0-66.6)	515
Non-Hispanic whites	99-00	*	< LOD	<b>13.1</b> (<LOD-15.6)	<b>25.6</b> (20.7-32.0)	<b>40.3</b> (30.4-46.8)	720
	01-02	*	< LOD	<b>15.8</b> (13.6-18.1)	<b>31.1</b> (27.1-35.7)	<b>45.3</b> (38.7-50.1)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 126. 2,3',4,4',5-Pentachlorobiphenyl (PCB 118) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	.085 (.077-.097)	.179 (.151-.196)	.259 (.217-.322)	1926
	01-02	*	< LOD	.095 (.084-.111)	.192 (.163-.224)	.293 (.267-.322)	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	.099 (.087-.111)	.189 (.168-.220)	.281 (.230-.360)	1259
	01-02	*	< LOD	.109 (.095-.124)	.212 (.183-.245)	.310 (.282-.367)	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	.128 (.114-.142)	.188 (.159-.217)	919
	01-02	*	< LOD	.080 (.065-.095)	.139 (.116-.167)	.208 (.162-.289)	1075
Females	99-00	*	< LOD	.110 (.088-.133)	.210 (.181-.259)	.321 (.261-.408)	1007
	01-02	*	< LOD	.125 (.102-.141)	.237 (.213-.262)	.356 (.302-.384)	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	.112 (.093-.128)	.143 (.129-.183)	636
	01-02	*	< LOD	< LOD	.120 (.082-.155)	.180 (.128-.224)	567
Non-Hispanic blacks	99-00	*	< LOD	.111 (.079-.146)	.223 (.182-.322)	.399 (.259-.503)	413
	01-02	*	< LOD	.094 (.073-.121)	.213 (.165-.271)	.322 (.231-.457)	515
Non-Hispanic whites	99-00	*	< LOD	.086 (.077-.102)	.176 (.145-.199)	.250 (.202-.331)	720
	01-02	*	< LOD	.101 (.089-.119)	.205 (.172-.239)	.301 (.269-.364)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 127. 3,3',4,4',5-Pentachlorobiphenyl (PCB 126) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	<b>30.8</b> (27.2-36.3)	<b>57.1</b> (50.5-65.8)	<b>89.5</b> (66.1-110)	1238
	01-02	<b>22.7</b> (20.9-24.7)	<b>24.5</b> (22.0-26.5)	<b>40.8</b> (36.1-47.5)	<b>69.3</b> (61.6-80.8)	<b>108</b> (92.7-116)	1226
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	<b>23.8</b> (<LOD-27.5)	<b>30.6</b> (26.2-36.0)	658
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	<b>30.8</b> (27.2-36.3)	<b>57.1</b> (50.5-65.8)	<b>89.5</b> (66.1-110)	1238
	01-02	<b>22.7</b> (20.9-24.7)	<b>24.5</b> (22.0-26.5)	<b>40.8</b> (36.1-47.5)	<b>69.3</b> (61.6-80.8)	<b>108</b> (92.7-116)	1226
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	<b>27.1</b> (<LOD-30.6)	<b>44.6</b> (38.0-50.5)	<b>65.0</b> (50.5-82.8)	572
	01-02	<b>20.3</b> (18.5-22.3)	<b>23.0</b> (20.8-25.4)	<b>36.5</b> (32.8-39.4)	<b>52.6</b> (46.2-61.6)	<b>81.9</b> (61.0-101)	561
Females	99-00	*	< LOD	<b>36.6</b> (30.4-44.4)	<b>67.8</b> (55.7-83.8)	<b>99.1</b> (75.9-122)	666
	01-02	<b>25.1</b> (22.9-27.4)	<b>26.0</b> (22.8-28.8)	<b>48.6</b> (41.4-54.4)	<b>82.7</b> (71.1-96.8)	<b>116</b> (98.6-128)	665
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	<b>27.5</b> (<LOD-34.3)	<b>49.0</b> (38.7-59.9)	<b>70.0</b> (57.2-82.4)	337
	01-02	<b>17.8</b> (15.5-20.4)	<b>19.6</b> (17.8-20.9)	<b>28.4</b> (26.2-33.9)	<b>47.9</b> (39.7-54.9)	<b>69.2</b> (49.3-103)	262
Non-Hispanic blacks	99-00	*	< LOD	<b>38.4</b> (29.4-46.0)	<b>75.1</b> (50.2-136)	<b>136</b> (71.4-279)	223
	01-02	<b>22.2</b> (18.2-27.0)	<b>22.1</b> (19.4-25.3)	<b>44.3</b> (37.9-51.5)	<b>76.5</b> (59.0-111)	<b>115</b> (96.1-153)	217
Non-Hispanic whites	99-00	*	< LOD	<b>29.6</b> (24.2-35.6)	<b>53.0</b> (43.2-61.2)	<b>75.0</b> (59.1-98.6)	562
	01-02	<b>23.1</b> (20.9-25.4)	<b>24.7</b> (22.0-27.6)	<b>42.0</b> (35.4-49.6)	<b>72.3</b> (63.9-82.9)	<b>114</b> (88.3-124)	663

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 128. 3,3',4,4',5-Pentachlorobiphenyl (PCB 126) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	<b>204</b> (173-232)	<b>381</b> (319-451)	<b>591</b> (479-709)	1238
	01-02	<b>147</b> (135-160)	<b>158</b> (143-175)	<b>270</b> (249-298)	<b>482</b> (436-541)	<b>730</b> (625-840)	1226
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	<b>108</b> (94.0-126)	<b>144</b> (116-196)	658
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	<b>204</b> (173-232)	<b>381</b> (319-451)	<b>591</b> (479-709)	1238
	01-02	<b>147</b> (135-160)	<b>158</b> (143-175)	<b>270</b> (249-298)	<b>482</b> (436-541)	<b>730</b> (625-840)	1226
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	<b>173</b> (147-194)	<b>271</b> (250-319)	<b>422</b> (319-560)	572
	01-02	<b>134</b> (121-149)	<b>152</b> (130-169)	<b>249</b> (233-267)	<b>399</b> (346-467)	<b>566</b> (467-693)	561
Females	99-00	*	< LOD	<b>237</b> (182-297)	<b>470</b> (402-586)	<b>684</b> (586-804)	666
	01-02	<b>159</b> (146-172)	<b>160</b> (149-184)	<b>298</b> (270-348)	<b>548</b> (483-637)	<b>818</b> (658-958)	665
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	<b>184</b> (123-242)	<b>327</b> (271-381)	<b>512</b> (364-576)	337
	01-02	<b>114</b> (97.8-133)	<b>125</b> (106-150)	<b>214</b> (175-257)	<b>335</b> (272-460)	<b>585</b> (354-784)	262
Non-Hispanic blacks	99-00	*	< LOD	<b>236</b> (162-308)	<b>547</b> (356-779)	<b>941</b> (517-1600)	223
	01-02	<b>131</b> (106-161)	<b>128</b> (110-158)	<b>266</b> (214-304)	<b>532</b> (361-662)	<b>779</b> (585-1060)	217
Non-Hispanic whites	99-00	*	< LOD	<b>188</b> (157-237)	<b>329</b> (285-424)	<b>554</b> (424-666)	562
	01-02	<b>150</b> (136-164)	<b>160</b> (146-179)	<b>276</b> (249-301)	<b>486</b> (431-553)	<b>746</b> (600-937)	663

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 129. 2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	12.5 (<LOD-13.8)	16.5 (15.5-18.0)	1907
	01-02	*	< LOD	< LOD	14.2 (12.1-15.8)	18.2 (15.6-20.9)	2296
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	665
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	13.5 (<LOD-14.7)	17.5 (16.0-19.7)	1242
	01-02	*	< LOD	< LOD	14.9 (13.2-16.6)	19.7 (17.0-22.1)	1540
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	12.6 (<LOD-14.0)	16.0 (14.6-18.0)	912
	01-02	*	< LOD	< LOD	13.6 (11.2-16.4)	18.2 (14.3-22.1)	1069
Females	99-00	*	< LOD	< LOD	12.8 (<LOD-14.7)	16.3 (14.7-20.1)	995
	01-02	*	< LOD	< LOD	14.7 (13.2-15.5)	18.1 (16.2-21.0)	1227
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	631
	01-02	*	< LOD	< LOD	< LOD	< LOD	566
Non-Hispanic blacks	99-00	*	< LOD	< LOD	14.6 (<LOD-20.5)	21.6 (17.2-32.1)	412
	01-02	*	< LOD	< LOD	15.5 (12.6-20.0)	23.5 (16.4-29.4)	511
Non-Hispanic whites	99-00	*	< LOD	< LOD	13.6 (<LOD-15.2)	17.4 (16.0-18.9)	711
	01-02	*	< LOD	< LOD	15.0 (13.0-17.1)	19.3 (16.2-22.1)	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 130. 2,3,3',4,4',5-Hexachlorobiphenyl (PCB 156) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	<b>.085</b> (.075-.092)	<b>.109</b> (.098-.129)	1907
	01-02	*	< LOD	< LOD	<b>.094</b> (.082-.107)	<b>.126</b> (.110-.140)	2296
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	665
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	<b>.090</b> (.081-.099)	<b>.116</b> (.104-.139)	1242
	01-02	*	< LOD	< LOD	<b>.104</b> (.089-.114)	<b>.132</b> (.118-.144)	1540
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>.085</b> (.072-.098)	<b>.109</b> (.094-.130)	912
	01-02	*	< LOD	< LOD	<b>.092</b> (.078-.113)	<b>.123</b> (.105-.151)	1069
Females	99-00	*	< LOD	< LOD	<b>.085</b> (.075-.093)	<b>.108</b> (.092-.141)	995
	01-02	*	< LOD	< LOD	<b>.096</b> (.086-.104)	<b>.134</b> (.111-.140)	1227
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	631
	01-02	*	< LOD	< LOD	< LOD	< LOD	566
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>.094</b> (.071-.124)	<b>.151</b> (.113-.188)	412
	01-02	*	< LOD	< LOD	<b>.096</b> (.079-.131)	<b>.144</b> (.104-.179)	511
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>.089</b> (.081-.098)	<b>.111</b> (.101-.129)	711
	01-02	*	< LOD	< LOD	<b>.104</b> (.089-.115)	<b>.131</b> (.117-.140)	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 131. 2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1897
	01-02	*	< LOD	< LOD	< LOD	< LOD	2294
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	654
	01-02	*	< LOD	< LOD	< LOD	< LOD	755
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1539
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	901
	01-02	*	< LOD	< LOD	< LOD	< LOD	1068
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	996
	01-02	*	< LOD	< LOD	< LOD	< LOD	1226
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	622
	01-02	*	< LOD	< LOD	< LOD	< LOD	566
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	405
	01-02	*	< LOD	< LOD	< LOD	< LOD	510
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	716
	01-02	*	< LOD	< LOD	< LOD	< LOD	1055

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 132. 2,3,3',4,4',5'-Hexachlorobiphenyl (PCB 157) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1897
	01-02	*	< LOD	< LOD	< LOD	< LOD	2294
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	654
	01-02	*	< LOD	< LOD	< LOD	< LOD	755
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1243
	01-02	*	< LOD	< LOD	< LOD	< LOD	1539
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	901
	01-02	*	< LOD	< LOD	< LOD	< LOD	1068
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	996
	01-02	*	< LOD	< LOD	< LOD	< LOD	1226
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	622
	01-02	*	< LOD	< LOD	< LOD	< LOD	566
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	405
	01-02	*	< LOD	< LOD	< LOD	< LOD	510
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	716
	01-02	*	< LOD	< LOD	< LOD	< LOD	1055

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 133. 2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1908
	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	908
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1000
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	627
	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	411
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	715
	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 134. 2,3',4,4',5,5'-Hexachlorobiphenyl (PCB 167) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1908
	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	666
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1242
	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	908
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1000
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	627
	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	411
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	715
	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 135. 3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in pg/g of lipid or parts per trillion on a lipid-weight basis) for the U.S. population, National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	<b>36.4</b> (33.8-40.3)	<b>47.8</b> (42.8-51.0)	1240
	01-02	<b>17.9</b> (16.0-19.9)	<b>19.0</b> (16.8-21.9)	<b>33.1</b> (27.5-38.6)	<b>50.0</b> (43.9-55.0)	<b>60.7</b> (55.8-65.8)	1223
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	648
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	<b>36.4</b> (33.8-40.3)	<b>47.8</b> (42.8-51.0)	1240
	01-02	<b>17.9</b> (16.0-19.9)	<b>19.0</b> (16.8-21.9)	<b>33.1</b> (27.5-38.6)	<b>50.0</b> (43.9-55.0)	<b>60.7</b> (55.8-65.8)	1223
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	<b>38.1</b> (33.8-42.3)	<b>45.7</b> (40.8-52.8)	572
	01-02	<b>20.2</b> (17.8-22.8)	<b>22.0</b> (18.5-25.3)	<b>36.0</b> (29.5-43.2)	<b>53.0</b> (45.8-56.9)	<b>60.6</b> (55.7-69.0)	559
Females	99-00	*	< LOD	< LOD	<b>34.6</b> (30.9-40.6)	<b>48.3</b> (39.4-52.0)	668
	01-02	<b>16.0</b> (14.2-18.1)	<b>16.8</b> (14.7-19.2)	<b>30.1</b> (24.5-36.5)	<b>46.0</b> (40.7-51.9)	<b>60.9</b> (52.2-70.0)	664
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	<b>33.6</b> (29.5-38.1)	335
	01-02	*	< LOD	<b>15.0</b> (11.3-18.3)	<b>24.6</b> (18.3-32.3)	<b>32.3</b> (26.3-39.6)	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>41.3</b> (34.6-52.2)	<b>53.2</b> (44.3-65.6)	224
	01-02	<b>17.2</b> (15.4-19.1)	<b>18.3</b> (15.7-20.0)	<b>31.7</b> (25.8-35.4)	<b>47.3</b> (41.1-53.9)	<b>54.8</b> (48.3-64.5)	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>36.6</b> (33.5-41.8)	<b>48.1</b> (41.8-51.6)	568
	01-02	<b>19.5</b> (17.2-22.2)	<b>21.4</b> (17.4-24.7)	<b>36.0</b> (29.6-41.1)	<b>53.5</b> (47.0-58.3)	<b>64.3</b> (59.2-72.8)	662

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 136. 3,3',4,4',5,5'-Hexachlorobiphenyl (PCB 169) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in fg/g of serum or parts per quadrillion) for the U.S. population National Health and Nutrition Examination Survey (1999-2000, aged 12 years and older; 2001-2002, aged 20 years and older).

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 20 and older</b>	99-00	*	< LOD	< LOD	240 (227-261)	303 (281-339)	1240
	01-02	115 (103-129)	125 (108-146)	217 (189-253)	343 (299-374)	416 (379-490)	1223
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	648
	01-02	†	†	†	†	†	†
20 years and older	99-00	*	< LOD	< LOD	240 (227-261)	303 (281-339)	1240
	01-02	115 (103-129)	125 (108-146)	217 (189-253)	343 (299-374)	416 (379-490)	1223
<b>Gender</b> (20 years and older)							
Males	99-00	*	< LOD	< LOD	245 (223-276)	298 (274-341)	572
	01-02	133 (117-152)	151 (130-168)	244 (198-293)	363 (309-409)	446 (372-529)	559
Females	99-00	*	< LOD	< LOD	240 (214-264)	310 (273-347)	668
	01-02	102 (90.0-115)	107 (91.0-123)	194 (170-234)	318 (282-368)	391 (373-462)	664
<b>Race/ethnicity</b> (20 years and older)							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	235 (190-295)	335
	01-02	*	< LOD	97.6 (79.3-138)	184 (143-250)	262 (179-341)	260
Non-Hispanic blacks	99-00	*	< LOD	< LOD	262 (192-334)	334 (265-505)	224
	01-02	101 (91.2-113)	103 (88.0-118)	190 (147-234)	295 (261-328)	361 (309-423)	217
Non-Hispanic whites	99-00	*	< LOD	< LOD	244 (226-273)	298 (276-347)	568
	01-02	127 (112-144)	145 (124-157)	229 (195-275)	368 (317-388)	438 (388-515)	662

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

† Data not collected for this age group for these years.

**Table 137. 2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	752
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1546
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1070
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	514
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1057

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 138. 2,3,3',4,4',5,5'-Heptachlorobiphenyl (PCB 189) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	752
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1546
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1070
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1228
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	514
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1057

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.



## Results by Chemical Group

---

### Non-dioxin-like Polychlorinated Biphenyls



## Non-dioxin-like Polychlorinated Biphenyls

*(The coplanar and mono-ortho-substituted PCBs are reported and specifically discussed in the section titled “Polychlorinated Dibenzo-p-dioxins, Polychlorinated Dibenzofurans, and Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls.”)*

### General Information

Polychlorinated biphenyls (PCBs) are a class of chlorinated aromatic hydrocarbon chemicals that once were used as electrical insulating and heat-exchange fluids. Peak production occurred in the early 1970s, and production was banned in the United States after 1979. The continued concern about these chemicals is because of their release into and persistence in the environment.

Food is the main source of exposure for the general population. PCBs enter the food chain by a variety of routes, including migration into food from packaging materials, contamination of animal feeds, and accumulation in the fatty tissues of animals. PCBs are found at higher concentrations in fatty foods. Diets that contain PCB-contaminated fats (e.g., milk and dairy products; fish, including whales) will increase exposure to PCBs. The transfer of PCBs from mother to infants via breast milk is another source of exposure. Other sources for the general population include the

release of these chemicals from PCB-containing waste sites and fires involving transformers and capacitors. Additionally, the heat from fires can result in the production of polychlorinated Dibenzo furans from PCBs. In certain occupational settings workers can be exposed to PCBs, including when repairing or manufacturing transformers, capacitors, and hydraulic systems, and when remediating hazardous-waste sites. Both U.S. FDA and OSHA have developed criteria on the allowable levels of these chemicals in foods and the workplace. The U.S. EPA has also set criteria for water and for storing and removing waste that contains PCBs. The Stockholm Treaty, signed in May 2001, will put into effect the most stringent guidelines to date regarding elimination, restriction and unintentional production of PCBs and selected pesticides (Porta and Zumeta, 2002).

Exposure to these chemicals nearly always occurs from mixtures rather than from individual PCBs. The different types of PCB chemicals are known as congeners, compounds that are distinguished by the number of

**Table 139. Non-dioxin-like Polychlorinated Biphenyls (PCBs) and their classification**

Non-dioxin-like polychlorinated biphenyls (IUPAC number)	CAS number
Polychlorinated biphenyls (general class)	1336-36-3
2,2',5,5'-Tetrachlorobiphenyl (PCB 52)	35693-99-3
2,2',3,4,5'-Pentachlorobiphenyl (PCB 87)	38380-02-8
2,2',4,4',5'-Pentachlorobiphenyl (PCB 99)	38380-01-7
2,2',4,5,5'-Pentachlorobiphenyl (PCB 101)	37680-73-2
2,3,3',4',6'-Pentachlorobiphenyl (PCB 110)	38380-03-9
2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128)	38380-07-3
2,2',3,4,4',5'-Hexachlorobiphenyl (PCB 138)	35065-28-2
2,3,3',4,4',6'-Hexachlorobiphenyl (PCB 158)	74472-42-7
2,2',3,4',5,5'-Hexachlorobiphenyl (PCB 146)	51908-16-8
2,2',3,4',5',6'-Hexachlorobiphenyl (PCB 149)	38380-04-0
2,2',3,5,5',6'-Hexachlorobiphenyl (PCB 151)	52663-63-5
2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153)	35065-27-1
2,2',3,3',4,4',5'-Heptachlorobiphenyl (PCB 170)	35065-30-6
2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172)	52663-74-8
2,2',3,3',4,5',6'-Heptachlorobiphenyl (PCB 177)	52663-70-4
2,2',3,3',5,5',6'-Heptachlorobiphenyl (PCB 178)	52663-67-9
2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180)	35065-29-3
2,2',3,4,4',5',6'-Heptachlorobiphenyl (PCB 183)	52663-69-1
2,2',3,4',5,5',6'-Heptachlorobiphenyl (PCB 187)	52663-68-0
2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194)	35694-08-7
2,2',3,3',4,4',5,6'-Octachlorobiphenyl (PCB 195)	52663-78-2
2,2',3,3',4,4',5,6'-Octachlorobiphenyl (PCB 196)	42740-50-1
2,2',3,3',4,5,5',6'-Octachlorobiphenyl (PCB 199)	52663-75-9
2,2',3,4,4',5,5',6'-Octachlorobiphenyl (PCB 203)	52663-76-0
2,2',3,3',4,4',5,5',6'-Nonachlorobiphenyl (PCB 206)	40186-72-9

chlorine atoms and their location on the biphenyl structure. PCB congeners can be divided into the coplanar, the mono-ortho-substituted PCBs, and other PCBs. The significance of this designation is that the coplanar and the mono-ortho-substituted PCBs have dioxin-like toxicologic effects. The coplanar and mono-ortho-substituted PCBs are discussed in the section titled “Polychlorinated Dibenzop-dioxins, Polychlorinated Dibenzofurans, and the Coplanar and Mono-ortho-substituted Polychlorinated Biphenyls.” Table 138 gives the nomenclature for the PCBs in this section.

Human health effects that have been reported after investigations of occupational and accidental exposures to PCBs include elevations of serum hepatic enzymes, dermal changes, and inconsistent evidence for altered serum lipid levels and some types of cancer (e.g., breast, liver, biliary) (ATSDR, 2000; Negri et al., 2003; Pavuk, et al., 2003; Charles et al., 2001; Lucena et al., 2001; Charlier et al., 2003; Warner et al., 2002). Reproductive and developmental effects demonstrated in animals may also be of concern. Background levels of PCBs from transplacental transfer after environmental exposure have been reported to be associated with impaired neurological development in newborns and children (Koopman-Essenboom et al., 1997; Jacobson and Jacobson, 1996; Longnecker et al., 2003; Sala et al., 2001), though several other studies have reported that these effects do not persist into school age (Gladen and Rogan, 1991; Gray et al., 2005). PCBs are classified as probable human carcinogens by IARC and are classified by NTP as reasonably anticipated to be carcinogens. Information about external exposure (i.e., environmental levels) and health effects is available from the U.S. EPA’s IRIS Web site at <http://www.epa.gov/iris> and from ATSDR’s Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### Interpreting Levels of Lipid-Adjusted Serum Non-dioxin-like PCBs Reported in the Tables

Lipid-adjusted serum levels of PCBs were measured in a subsample of NHANES participants aged 12 years and older. Participants were randomly selected within the specified age range to be a representative sample of the U.S. population. Measurement of serum PCBs can reflect either recent or past exposure to PCBs. Some PCBs can persist in the body for years after exposure. The contribution of individual PCB congeners to the sum of PCB measurements in the body may vary by exposure source and differences in pharmacokinetics. Some of the PCBs measured may represent exposure to the breakdown of other PCBs in a person’s environment.

The most frequently detected di-ortho-chlorine-substituted PCBs in general populations are 138, 153, and 180 (Patterson et al., 1994; Heudorf et al., 2002). These congeners also were found to contribute a substantial portion of the total PCB concentration observed in pooled specimens representative of a New Zealand population (Bates et al., 2004b) and in a smaller population of Swedish men (Glynn et al., 2000). Because of its predominance, PCB 153 has been used as a marker of exposure for the other PCBs. In 1994, levels of PCBs 138, 153, and 180 in pooled, banked serum were generally three to four times lower than levels reported in 1988 (Longnecker et al., 2000; Patterson et al., 1994). The concentrations of the di-ortho-substituted PCBs are generally higher than the mono-ortho-substituted PCBs, which in turn are higher than the coplanar PCBs (Glynn et al., 2000; Longnecker et al., 2000; Patterson et al., 1994). In a convenience sample of 624 urban Germans aged 0-65 years conducted during 1998 (Heudorf et al., 2002), 95<sup>th</sup> percentile levels for PCBs 138, 153, and 180 were similar or up to two-fold higher than 95<sup>th</sup> percentile levels in this *Report*. A representative pooled sampling of New Zealanders showed slightly lower levels than those in this *Report* (Bates et al., 2004b). Heavy fish consumption is considered to contribute to about a two-fold increase in the concentration of these PCB congeners (Patterson et al., 1994).

The tri-ortho-chlorine-substituted PCBs are 177, 178, 183, and 187. The levels for PCB 187 shown in this *Report* are similar to the levels measured in a convenience sample of the general Canadian population in 1994 (Longnecker et al., 2000).

### Comparing Adjusted Geometric Means

For comparison of demographic groups in the NHANES 2001-2002 subsample, geometric means of whole weight-based serum measurements were adjusted for age, gender, race/ethnicity, serum cotinine, and lipid level (data not shown). Due to improved limits of detection in NHANES 2001-2002, PCB 138 & 158, PCB 153, and PCB 180 had sufficient detection rates to allow comparison of adjusted geometric means of the demographic groups, which were not possible in the 1999-2000 subsample. For PCB 138 & 158, no differences between the demographic groups were found. For PCB 153, males had slightly higher levels than females, and Mexican Americans had two-fold lower levels than either non-Hispanic blacks or non-Hispanic whites. For PCB 180, males had slightly higher adjusted geometric mean levels than females. It is unknown whether these differences associated with gender or race/ethnicity represent differences in exposure,

pharmacokinetics, or the relationship of dose per body weight.

Finding a measurable amount of one or more PCBs in the blood does not indicate that the levels of the PCBs cause an adverse health effect. These data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of PCBs than levels found in the general population. Whether PCBs at the levels reported here are cause for health concern is not known; more research is needed.

**Table 140. 2,2',5,5'-Tetrachlorobiphenyl (PCB 52) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1912
	01-02	*	< LOD	< LOD	< LOD	<b>16.2</b> (14.3-17.2)	1537
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	664
	01-02	*	< LOD	< LOD	<b>16.2</b> (<LOD-23.8)	<b>22.9</b> (16.9-32.3)	291
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1248
	01-02	*	< LOD	< LOD	< LOD	<b>16.0</b> (13.5-16.9)	1246
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	908
	01-02	*	< LOD	< LOD	< LOD	<b>16.0</b> (<LOD-17.5)	716
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1004
	01-02	*	< LOD	< LOD	< LOD	<b>16.5</b> (14.0-18.2)	821
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	631
	01-02	*	< LOD	< LOD	< LOD	<b>16.9</b> (<LOD-20.6)	366
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	408
	01-02	*	< LOD	< LOD	< LOD	<b>16.1</b> (<LOD-20.9)	282
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	716
	01-02	*	< LOD	< LOD	< LOD	<b>16.5</b> (14.3-17.5)	773

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 141. 2,2',5,5'-Tetrachlorobiphenyl (PCB 52) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1912
	01-02	*	< LOD	< LOD	< LOD	.089 (.081-.097)	1537
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	664
	01-02	*	< LOD	< LOD	.079 (.048-.101)	.104 (.083-.135)	291
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1248
	01-02	*	< LOD	< LOD	< LOD	.086 (.076-.092)	1246
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	908
	01-02	*	< LOD	< LOD	< LOD	.085 (.071-.104)	716
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1004
	01-02	*	< LOD	< LOD	< LOD	.088 (.083-.094)	821
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	631
	01-02	*	< LOD	< LOD	< LOD	.083 (.051-.102)	366
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	408
	01-02	*	< LOD	< LOD	< LOD	.092 (.068-.112)	282
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	716
	01-02	*	< LOD	< LOD	< LOD	.088 (.081-.099)	773

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 142. 2,2',3,4,5'-Pentachlorobiphenyl (PCB 87) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 143. 2,2',3,4,5'-Pentachlorobiphenyl (PCB 87) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 144. 2,2',4,4',5-Pentachlorobiphenyl (PCB 99) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	13.1 (<LOD-14.6)	19.1 (16.2-20.6)	1897
	01-02	*	< LOD	< LOD	17.6 (15.3-20.8)	26.3 (22.1-30.5)	2281
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	654
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	13.9 (<LOD-16.0)	19.9 (17.0-21.1)	1243
	01-02	*	< LOD	10.8 (<LOD-12.3)	19.4 (16.6-22.3)	28.8 (23.2-32.1)	1523
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	16.7 (13.8-20.5)	905
	01-02	*	< LOD	< LOD	16.7 (13.8-21.0)	24.9 (19.8-30.1)	1061
Females	99-00	*	< LOD	< LOD	13.9 (<LOD-16.2)	20.0 (17.3-23.5)	992
	01-02	*	< LOD	< LOD	18.0 (15.8-22.2)	28.5 (22.5-33.2)	1220
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	624
	01-02	*	< LOD	< LOD	< LOD	13.4 (10.7-17.4)	562
Non-Hispanic blacks	99-00	*	< LOD	< LOD	20.3 (17.0-31.1)	31.5 (22.9-57.4)	400
	01-02	*	< LOD	11.6 (10.6-13.1)	22.4 (18.8-25.8)	28.8 (23.0-37.2)	510
Non-Hispanic whites	99-00	*	< LOD	< LOD	12.5 (<LOD-14.5)	18.1 (14.3-20.8)	715
	01-02	*	< LOD	< LOD	18.5 (15.3-22.3)	28.5 (22.1-32.4)	1046

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 145. 2,2',4,4',5-Pentachlorobiphenyl (PCB 99) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	.085 (.075-.098)	.114 (.102-.145)	1897
	01-02	*	< LOD	< LOD	.117 (.100-.139)	.183 (.149-.208)	2281
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	654
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	.093 (.082-.104)	.126 (.106-.151)	1243
	01-02	*	< LOD	.070 (.063-.079)	.131 (.109-.157)	.193 (.161-.212)	1523
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	.107 (.086-.127)	905
	01-02	*	< LOD	< LOD	.107 (.090-.137)	.161 (.120-.197)	1061
Females	99-00	*	< LOD	< LOD	.098 (.078-.108)	.133 (.102-.165)	992
	01-02	*	< LOD	< LOD	.129 (.106-.157)	.200 (.159-.212)	1220
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	624
	01-02	*	< LOD	< LOD	< LOD	.100 (.068-.120)	562
Non-Hispanic blacks	99-00	*	< LOD	< LOD	.135 (.106-.175)	.213 (.151-.395)	400
	01-02	*	< LOD	.071 (.063-.084)	.129 (.106-.151)	.187 (.139-.232)	510
Non-Hispanic whites	99-00	*	< LOD	< LOD	.085 (.070-.098)	.111 (.094-.145)	715
	01-02	*	< LOD	< LOD	.124 (.098-.159)	.187 (.156-.211)	1046

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 146. 2,2',4,5,5'-Pentachlorobiphenyl (PCB 101) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1929
	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	918
	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1011
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	634
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	413
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	724
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 147. 2,2',4,5,5'-Pentachlorobiphenyl (PCB 101) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1929
	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	918
	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1011
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	634
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	413
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	724
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 148. 2,3,3',4',6-Pentachlorobiphenyl (PCB 110) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 149. 2,3,3',4',6-Pentachlorobiphenyl (PCB 110) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 150. 2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1927
	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	917
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1010
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	725
	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 151. 2,2',3,3',4,4'-Hexachlorobiphenyl (PCB 128) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1927
	01-02	*	< LOD	< LOD	< LOD	< LOD	2298
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1259
	01-02	*	< LOD	< LOD	< LOD	< LOD	1540
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	917
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1010
	01-02	*	< LOD	< LOD	< LOD	< LOD	1229
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	< LOD	< LOD	< LOD	564
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	725
	01-02	*	< LOD	< LOD	< LOD	< LOD	1056

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 152. 2,2',3,4,4',5' and 2,3,3',4,4',6-Hexachlorobiphenyl (PCB 138 & 158) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	<b>49.2</b> (42.9-55.8)	<b>70.8</b> (59.8-82.7)	1930
	01-02	<b>19.9</b> (18.0-22.0)	<b>20.0</b> (18.0-22.8)	<b>40.4</b> (35.3-44.9)	<b>70.1</b> (61.8-78.8)	<b>94.6</b> (82.5-107)	2293
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	<b>17.0</b> (13.7-20.2)	<b>23.1</b> (17.7-41.2)	748
20 years and older	99-00	*	< LOD	< LOD	<b>54.7</b> (47.4-60.8)	<b>72.8</b> (66.0-88.9)	1261
	01-02	<b>23.3</b> (21.1-25.8)	<b>23.9</b> (21.4-26.8)	<b>44.6</b> (40.4-49.2)	<b>73.8</b> (66.2-83.0)	<b>99.5</b> (88.7-109)	1545
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>47.2</b> (<LOD-55.7)	<b>68.2</b> (55.7-83.8)	918
	01-02	<b>20.1</b> (17.9-22.6)	<b>20.4</b> (17.5-23.5)	<b>39.2</b> (32.2-46.0)	<b>68.6</b> (58.1-82.5)	<b>94.5</b> (77.8-109)	1066
Females	99-00	*	< LOD	< LOD	<b>52.8</b> (44.7-61.2)	<b>72.0</b> (61.1-88.4)	1012
	01-02	<b>19.7</b> (17.8-21.7)	<b>20.2</b> (18.2-23.1)	<b>41.8</b> (37.5-45.9)	<b>69.6</b> (63.4-78.5)	<b>93.9</b> (80.2-109)	1227
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	<b>18.6</b> (13.6-23.4)	<b>33.3</b> (26.5-44.2)	<b>51.6</b> (42.3-57.6)	559
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>72.1</b> (61.7-89.4)	<b>122</b> (86.5-185)	412
	01-02	<b>22.3</b> (19.3-25.6)	<b>21.8</b> (18.4-27.1)	<b>46.5</b> (38.0-55.6)	<b>91.5</b> (70.1-112)	<b>122</b> (91.5-169)	513
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>49.3</b> (41.4-55.8)	<b>70.1</b> (55.7-85.2)	727
	01-02	<b>21.5</b> (19.2-24.0)	<b>21.9</b> (19.4-24.8)	<b>43.0</b> (37.7-48.0)	<b>70.6</b> (62.3-79.7)	<b>96.1</b> (79.1-110)	1057

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 153. 2,2',3,4,4',5' and 2,3,3',4,4',6-Hexachlorobiphenyl (PCB 138 & 158) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	.338 (.301-.369)	.457 (.385-.532)	1930
	01-02	.122 (.110-.135)	.124 (.112-.139)	.265 (.231-.292)	.457 (.405-.508)	.649 (.558-.698)	2293
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	.085 (.064-.107)	.113 (.086-.205)	748
20 years and older	99-00	*	< LOD	< LOD	.357 (.323-.385)	.489 (.399-.556)	1261
	01-02	.148 (.133-.163)	.152 (.136-.166)	.292 (.264-.323)	.505 (.453-.554)	.676 (.605-.718)	1545
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	.323 (.286-.370)	.422 (.371-.528)	918
	01-02	.125 (.112-.140)	.125 (.111-.139)	.262 (.228-.292)	.456 (.374-.542)	.627 (.509-.711)	1066
Females	99-00	*	< LOD	< LOD	.344 (.303-.373)	.485 (.385-.540)	1012
	01-02	.119 (.107-.132)	.123 (.111-.143)	.265 (.231-.294)	.457 (.418-.496)	.656 (.588-.703)	1227
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	636
	01-02	*	< LOD	.114 (.089-.151)	.233 (.173-.334)	.349 (.267-.431)	559
Non-Hispanic blacks	99-00	*	< LOD	< LOD	.473 (.362-.666)	.828 (.525-1.22)	412
	01-02	.125 (.108-.146)	.129 (.093-.157)	.286 (.231-.347)	.546 (.424-.675)	.764 (.564-1.06)	513
Non-Hispanic whites	99-00	*	< LOD	< LOD	.339 (.296-.371)	.438 (.372-.532)	727
	01-02	.133 (.119-.149)	.136 (.119-.156)	.280 (.254-.303)	.464 (.420-.527)	.647 (.548-.717)	1057

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 154. 2,2',3,4',5,5'-Hexachlorobiphenyl (PCB 146) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	13.3 (<LOD-15.2)	1923
	01-02	*	< LOD	< LOD	11.0 (<LOD-12.4)	15.3 (13.6-16.9)	2299
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	14.2 (<LOD-17.1)	1256
	01-02	*	< LOD	< LOD	11.8 (10.7-13.5)	16.5 (14.6-17.9)	1541
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	915
	01-02	*	< LOD	< LOD	11.0 (<LOD-12.9)	15.3 (12.9-17.2)	1069
Females	99-00	*	< LOD	< LOD	< LOD	13.4 (<LOD-16.3)	1008
	01-02	*	< LOD	< LOD	11.0 (<LOD-12.2)	15.2 (13.2-17.3)	1230
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	633
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	16.9 (13.4-22.9)	28.1 (20.2-42.2)	412
	01-02	*	< LOD	< LOD	16.6 (12.7-21.4)	23.8 (16.9-31.6)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	723
	01-02	*	< LOD	< LOD	10.8 (<LOD-12.0)	15.2 (12.8-16.8)	1054

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 155. 2,2',3,4',5,5'-Hexachlorobiphenyl (PCB 146) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	.082 (.074-.101)	1923
	01-02	*	< LOD	< LOD	.073 (.067-.082)	.104 (.092-.118)	2299
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	.090 (.077-.116)	1256
	01-02	*	< LOD	< LOD	.079 (.071-.087)	.112 (.100-.123)	1541
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	915
	01-02	*	< LOD	< LOD	.071 (.061-.083)	.102 (.090-.123)	1069
Females	99-00	*	< LOD	< LOD	< LOD	.085 (.074-.114)	1008
	01-02	*	< LOD	< LOD	.073 (.066-.083)	.112 (.089-.121)	1230
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	633
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	.101 (.082-.129)	.175 (.117-.274)	412
	01-02	*	< LOD	< LOD	.103 (.079-.133)	.148 (.114-.195)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	723
	01-02	*	< LOD	< LOD	.071 (.066-.081)	.100 (.087-.115)	1054

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 156. 2,2',3,4',5',6-Hexachlorobiphenyl (PCB 149) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 158. 2,2',3,4',5',6-Hexachlorobiphenyl (PCB 149) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 159. 2,2',3,5,5',6-Hexachlorobiphenyl (PCB 151) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 160. 2,2',3,5,5',6-Hexachlorobiphenyl (PCB 151) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2307
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1075
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 161. 2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	<b>77.8</b> (70.2-87.3)	<b>112</b> (91.8-130)	1926
	01-02	<b>27.2</b> (24.7-30.1)	<b>30.1</b> (26.1-34.1)	<b>57.7</b> (52.1-63.2)	<b>94.7</b> (86.5-104)	<b>126</b> (107-142)	2306
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	<b>12.4</b> (11.1-14.1)	<b>21.2</b> (17.4-26.7)	<b>30.3</b> (23.1-64.7)	757
20 years and older	99-00	*	< LOD	< LOD	<b>83.2</b> (75.9-91.8)	<b>122</b> (98.7-139)	1258
	01-02	<b>32.6</b> (29.5-36.1)	<b>35.0</b> (31.1-39.0)	<b>62.8</b> (57.6-68.0)	<b>99.5</b> (90.7-110)	<b>132</b> (116-146)	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>75.0</b> (66.7-86.2)	<b>111</b> (87.7-128)	917
	01-02	<b>28.5</b> (25.5-32.0)	<b>31.5</b> (26.7-35.2)	<b>57.7</b> (48.2-65.5)	<b>97.5</b> (82.1-110)	<b>124</b> (104-146)	1074
Females	99-00	*	< LOD	< LOD	<b>79.0</b> (70.2-92.0)	<b>118</b> (91.4-142)	1009
	01-02	<b>26.1</b> (23.6-28.8)	<b>29.0</b> (25.1-33.4)	<b>57.8</b> (51.9-62.6)	<b>94.2</b> (87.8-98.2)	<b>126</b> (105-145)	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	<b>67.5</b> (59.5-71.8)	634
	01-02	<b>12.5</b> (10.8-14.4)	<b>10.9</b> (<LOD-13.0)	<b>24.2</b> (18.2-33.9)	<b>47.4</b> (35.7-58.1)	<b>66.7</b> (55.2-72.3)	567
Non-Hispanic blacks	99-00	*	< LOD	<b>59.1</b> (<LOD-82.0)	<b>121</b> (90.3-159)	<b>176</b> (130-287)	412
	01-02	<b>30.0</b> (26.2-34.4)	<b>31.0</b> (25.8-36.4)	<b>64.5</b> (54.2-82.7)	<b>126</b> (97.1-152)	<b>170</b> (126-246)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>76.4</b> (69.3-83.9)	<b>102</b> (87.7-125)	725
	01-02	<b>29.9</b> (26.8-33.4)	<b>32.9</b> (28.7-36.8)	<b>61.2</b> (55.8-66.7)	<b>96.3</b> (86.5-109)	<b>126</b> (104-142)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 162. 2,2',4,4',5,5'-Hexachlorobiphenyl (PCB 153) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	.530 (.493-.561)	.749 (.613-.843)	1926
	01-02	.167 (.151-.185)	.186 (.166-.207)	.378 (.337-.407)	.621 (.563-.693)	.851 (.754-.954)	2306
<b>Age group</b>							
	12-19 years						
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	.064 (.054-.072)	.104 (.084-.138)	.147 (.111-.311)	757
20 years and older	99-00	*	< LOD	< LOD	.561 (.505-.605)	.786 (.670-.879)	1258
	01-02	.206 (.187-.228)	.218 (.197-.250)	.407 (.379-.446)	.667 (.595-.742)	.898 (.815-1.04)	1549
<b>Gender</b>							
	Males						
Males	99-00	*	< LOD	< LOD	.531 (.474-.562)	.691 (.576-.846)	917
	01-02	.177 (.159-.198)	.194 (.166-.214)	.380 (.333-.429)	.611 (.506-.726)	.851 (.704-1.04)	1074
Females	99-00	*	< LOD	< LOD	.530 (.480-.592)	.759 (.612-.875)	1009
	01-02	.158 (.142-.175)	.176 (.150-.205)	.375 (.335-.395)	.626 (.565-.712)	.860 (.756-.954)	1232
<b>Race/ethnicity</b>							
	Mexican Americans						
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	.468 (.384-.543)	634
	01-02	.075 (.063-.089)	.064 (.050-.078)	.153 (.118-.207)	.330 (.269-.415)	.466 (.374-.541)	567
Non-Hispanic blacks	99-00	*	< LOD	.368 (.273-.514)	.749 (.619-.894)	1.27 (.816-1.64)	412
	01-02	.169 (.146-.195)	.179 (.144-.202)	.392 (.331-.486)	.776 (.578-.954)	1.04 (.831-1.43)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	.519 (.480-.563)	.702 (.583-.846)	725
	01-02	.185 (.165-.207)	.207 (.182-.231)	.393 (.367-.425)	.637 (.563-.720)	.838 (.738-.987)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 163. 2,2',3,3',4,4',5-Heptachlorobiphenyl (PCB 170) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	<b>23.6</b> (22.0-25.4)	<b>30.9</b> (28.1-35.1)	1798
	01-02	*	< LOD	<b>17.5</b> (15.6-19.3)	<b>26.7</b> (24.9-29.0)	<b>35.0</b> (32.4-37.3)	2301
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	645
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	<b>24.9</b> (23.3-26.4)	<b>33.9</b> (29.6-37.5)	1153
	01-02	*	<b>11.1</b> (<LOD-12.0)	<b>19.1</b> (17.2-20.9)	<b>28.2</b> (26.2-30.9)	<b>36.8</b> (33.4-39.4)	1545
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>23.8</b> (22.0-26.3)	<b>32.6</b> (28.1-37.0)	863
	01-02	*	<b>10.7</b> (<LOD-11.9)	<b>18.4</b> (16.3-20.9)	<b>27.9</b> (24.7-31.9)	<b>36.1</b> (32.1-38.3)	1073
Females	99-00	*	< LOD	< LOD	<b>22.4</b> (20.7-25.4)	<b>29.7</b> (25.8-36.3)	935
	01-02	*	< LOD	<b>16.4</b> (15.0-17.9)	<b>25.9</b> (24.0-28.4)	<b>34.0</b> (30.4-38.1)	1228
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	<b>23.2</b> (20.3-26.5)	606
	01-02	*	< LOD	< LOD	<b>15.4</b> (11.1-18.6)	<b>21.1</b> (17.1-25.1)	565
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>30.9</b> (23.1-36.3)	<b>39.6</b> (33.7-59.1)	382
	01-02	*	< LOD	<b>18.7</b> (14.8-23.1)	<b>32.4</b> (25.5-43.9)	<b>44.1</b> (32.5-61.7)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>24.0</b> (22.0-25.8)	<b>31.0</b> (26.8-37.3)	658
	01-02	*	<b>10.9</b> (<LOD-11.8)	<b>18.4</b> (16.8-20.4)	<b>27.7</b> (25.4-30.2)	<b>35.0</b> (32.3-38.1)	1059

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 164. 2,2',3,3',4,4',5-Heptachlorobiphenyl (PCB 170) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	.158 (.141-.183)	.212 (.199-.225)	1798
	01-02	*	< LOD	.114 (.104-.122)	.183 (.167-.202)	.246 (.214-.271)	2301
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	645
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	.172 (.154-.192)	.221 (.204-.252)	1153
	01-02	*	.070 (.065-.077)	.122 (.114-.133)	.197 (.177-.213)	.254 (.227-.286)	1545
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	.169 (.140-.200)	.215 (.199-.254)	863
	01-02	*	.067 (.057-.074)	.119 (.107-.134)	.194 (.166-.207)	.245 (.206-.281)	1073
Females	99-00	*	< LOD	< LOD	.149 (.130-.167)	.205 (.186-.229)	935
	01-02	*	< LOD	.110 (.100-.117)	.175 (.157-.196)	.245 (.211-.281)	1228
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	.166 (.126-.187)	606
	01-02	*	< LOD	< LOD	.104 (.082-.125)	.154 (.116-.188)	565
Non-Hispanic blacks	99-00	*	< LOD	< LOD	.188 (.147-.205)	.258 (.194-.372)	382
	01-02	*	< LOD	.112 (.094-.141)	.211 (.151-.271)	.276 (.209-.394)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	.164 (.139-.197)	.214 (.197-.242)	658
	01-02	*	.067 (.058-.074)	.119 (.112-.129)	.187 (.171-.204)	.247 (.207-.274)	1059

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 165. 2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1901
	01-02	*	< LOD	< LOD	< LOD	< LOD	2199
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
	01-02	*	< LOD	< LOD	< LOD	< LOD	679
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1241
	01-02	*	< LOD	< LOD	< LOD	< LOD	1520
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	911
	01-02	*	< LOD	< LOD	< LOD	< LOD	1027
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	990
	01-02	*	< LOD	< LOD	< LOD	< LOD	1172
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	630
	01-02	*	< LOD	< LOD	< LOD	< LOD	519
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	494
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	706
	01-02	*	< LOD	< LOD	< LOD	< LOD	1027

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 166. 2,2',3,3',4,5,5'-Heptachlorobiphenyl (PCB 172) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1901
	01-02	*	< LOD	< LOD	< LOD	< LOD	2199
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	660
	01-02	*	< LOD	< LOD	< LOD	< LOD	679
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1241
	01-02	*	< LOD	< LOD	< LOD	< LOD	1520
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	911
	01-02	*	< LOD	< LOD	< LOD	< LOD	1027
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	990
	01-02	*	< LOD	< LOD	< LOD	< LOD	1172
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	630
	01-02	*	< LOD	< LOD	< LOD	< LOD	519
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	409
	01-02	*	< LOD	< LOD	< LOD	< LOD	494
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	706
	01-02	*	< LOD	< LOD	< LOD	< LOD	1027

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 167. 2,2',3,3',4,5',6'-Heptachlorobiphenyl (PCB 177) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1873
	01-02	*	< LOD	< LOD	< LOD	< LOD	2287
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	653
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1220
	01-02	*	< LOD	< LOD	< LOD	< LOD	1531
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	887
	01-02	*	< LOD	< LOD	< LOD	< LOD	1065
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	986
	01-02	*	< LOD	< LOD	< LOD	< LOD	1222
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	622
	01-02	*	< LOD	< LOD	< LOD	< LOD	562
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	399
	01-02	*	< LOD	< LOD	< LOD	10.6 (<LOD-12.3)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	698
	01-02	*	< LOD	< LOD	< LOD	< LOD	1048

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 168. 2,2',3,3',4,5',6'-Heptachlorobiphenyl (PCB 177) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1873
	01-02	*	< LOD	< LOD	< LOD	< LOD	2287
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	653
	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1220
	01-02	*	< LOD	< LOD	< LOD	< LOD	1531
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	887
	01-02	*	< LOD	< LOD	< LOD	< LOD	1065
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	986
	01-02	*	< LOD	< LOD	< LOD	< LOD	1222
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	622
	01-02	*	< LOD	< LOD	< LOD	< LOD	562
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	399
	01-02	*	< LOD	< LOD	< LOD	.064 (.042-.099)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	698
	01-02	*	< LOD	< LOD	< LOD	< LOD	1048

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 169. 2,2',3,3',5,5',6-Heptachlorobiphenyl (PCB 178) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1932
	01-02	*	< LOD	< LOD	< LOD	< LOD	2299
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1263
	01-02	*	< LOD	< LOD	< LOD	< LOD	1541
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1013
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	415
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	724
	01-02	*	< LOD	< LOD	< LOD	< LOD	1054

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 170. 2,2',3,3',5,5',6-Heptachlorobiphenyl (PCB 178) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1932
	01-02	*	< LOD	< LOD	< LOD	< LOD	2299
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	669
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1263
	01-02	*	< LOD	< LOD	< LOD	< LOD	1541
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1069
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1013
	01-02	*	< LOD	< LOD	< LOD	< LOD	1230
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	415
	01-02	*	< LOD	< LOD	< LOD	< LOD	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	724
	01-02	*	< LOD	< LOD	< LOD	< LOD	1054

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 171. 2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	<b>37.4</b> (32.7-41.8)	<b>62.0</b> (56.6-66.6)	<b>79.0</b> (72.1-89.2)	1924
	01-02	<b>19.2</b> (17.4-21.1)	<b>21.8</b> (19.0-24.6)	<b>42.2</b> (38.3-47.5)	<b>69.7</b> (63.7-75.9)	<b>87.0</b> (83.3-93.0)	2302
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	<b>12.2</b> (<LOD-14.8)	<b>21.3</b> (14.2-26.0)	755
20 years and older	99-00	*	< LOD	<b>41.0</b> (37.6-45.2)	<b>65.5</b> (60.6-69.4)	<b>83.8</b> (75.6-96.1)	1257
	01-02	<b>23.0</b> (20.8-25.5)	<b>26.4</b> (22.7-28.5)	<b>46.7</b> (41.4-51.1)	<b>74.0</b> (66.7-79.8)	<b>90.7</b> (85.0-99.5)	1547
<b>Gender</b>							
Males	99-00	*	< LOD	<b>40.5</b> (34.5-45.0)	<b>65.1</b> (58.6-71.4)	<b>83.8</b> (75.8-96.3)	919
	01-02	<b>21.1</b> (18.8-23.7)	<b>25.1</b> (21.2-30.0)	<b>46.7</b> (39.8-51.8)	<b>73.8</b> (63.2-79.8)	<b>86.9</b> (78.0-99.4)	1073
Females	99-00	*	< LOD	<b>34.4</b> (29.8-39.3)	<b>56.7</b> (52.2-62.6)	<b>74.6</b> (66.6-90.5)	1005
	01-02	<b>17.5</b> (15.9-19.3)	<b>18.3</b> (16.0-21.6)	<b>39.6</b> (34.8-43.9)	<b>64.0</b> (57.9-72.0)	<b>87.9</b> (79.1-98.1)	1229
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>41.7</b> (33.2-50.5)	<b>56.6</b> (49.7-63.8)	633
	01-02	*	< LOD	<b>18.0</b> (11.4-22.2)	<b>36.9</b> (28.2-45.7)	<b>54.2</b> (42.2-60.0)	566
Non-Hispanic blacks	99-00	*	< LOD	<b>39.1</b> (32.2-48.4)	<b>78.4</b> (64.3-93.7)	<b>117</b> (89.6-144)	414
	01-02	<b>19.5</b> (16.5-23.1)	<b>20.7</b> (16.9-23.8)	<b>48.4</b> (36.7-57.9)	<b>89.6</b> (73.7-101)	<b>116</b> (96.1-167)	514
Non-Hispanic whites	99-00	*	< LOD	<b>39.9</b> (34.5-45.3)	<b>62.0</b> (56.5-68.6)	<b>79.0</b> (71.3-91.4)	719
	01-02	<b>21.4</b> (19.1-23.9)	<b>24.8</b> (21.4-27.9)	<b>45.6</b> (40.2-51.0)	<b>72.3</b> (63.8-78.0)	<b>87.9</b> (83.8-94.3)	1059

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 172 2,2',3,4,4',5,5'-Heptachlorobiphenyl (PCB 180) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	<b>.245</b> (.224-.266)	<b>.414</b> (.373-.452)	<b>.535</b> (.493-.604)	1924
	01-02	<b>.118</b> (.106-.130)	<b>.140</b> (.120-.155)	<b>.278</b> (.253-.304)	<b>.458</b> (.401-.508)	<b>.605</b> (.541-.692)	2302
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	<b>.061</b> (.053-.075)	<b>.092</b> (.068-.135)	755
20 years and older	99-00	*	< LOD	<b>.266</b> (.244-.296)	<b>.441</b> (.407-.482)	<b>.558</b> (.503-.617)	1257
	01-02	<b>.146</b> (.131-.162)	<b>.168</b> (.150-.188)	<b>.302</b> (.275-.337)	<b>.490</b> (.429-.555)	<b>.637</b> (.572-.738)	1547
<b>Gender</b>							
Males	99-00	*	< LOD	<b>.257</b> (.224-.300)	<b>.459</b> (.365-.506)	<b>.568</b> (.501-.648)	919
	01-02	<b>.131</b> (.117-.147)	<b>.165</b> (.137-.197)	<b>.296</b> (.258-.339)	<b>.479</b> (.405-.554)	<b>.616</b> (.526-.716)	1073
Females	99-00	*	< LOD	<b>.231</b> (.195-.266)	<b>.377</b> (.344-.413)	<b>.510</b> (.430-.557)	1005
	01-02	<b>.106</b> (.096-.117)	<b>.113</b> (.100-.135)	<b>.261</b> (.228-.281)	<b>.415</b> (.375-.470)	<b>.604</b> (.519-.701)	1229
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>.275</b> (.198-.324)	<b>.390</b> (.316-.452)	633
	01-02	*	< LOD	<b>.110</b> (.079-.157)	<b>.259</b> (.198-.307)	<b>.353</b> (.279-.419)	566
Non-Hispanic blacks	99-00	*	< LOD	<b>.245</b> (.188-.298)	<b>.497</b> (.349-.656)	<b>.727</b> (.534-1.04)	414
	01-02	<b>.110</b> (.092-.131)	<b>.119</b> (.091-.142)	<b>.287</b> (.215-.345)	<b>.560</b> (.436-.651)	<b>.719</b> (.523-1.01)	514
Non-Hispanic whites	99-00	*	< LOD	<b>.263</b> (.234-.299)	<b>.430</b> (.377-.470)	<b>.537</b> (.483-.604)	719
	01-02	<b>.132</b> (.118-.148)	<b>.160</b> (.142-.180)	<b>.292</b> (.262-.327)	<b>.471</b> (.405-.532)	<b>.617</b> (.526-.730)	1059

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 173. 2,2',3,4,4',5',6-Heptachlorobiphenyl (PCB 183) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1928
	01-02	*	< LOD	< LOD	< LOD	< LOD	2306
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	< LOD	757
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1074
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1009
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	413
	01-02	*	< LOD	< LOD	< LOD	12.7 (<LOD-14.9)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	722
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 174. 2,2',3,4,4',5',6-Heptachlorobiphenyl (PCB 183) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	< LOD	< LOD	1928
	01-02	*	< LOD	< LOD	< LOD	< LOD	2306
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	668
	01-02	*	< LOD	< LOD	< LOD	< LOD	757
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1260
	01-02	*	< LOD	< LOD	< LOD	< LOD	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	< LOD	919
	01-02	*	< LOD	< LOD	< LOD	< LOD	1074
Females	99-00	*	< LOD	< LOD	< LOD	< LOD	1009
	01-02	*	< LOD	< LOD	< LOD	< LOD	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	635
	01-02	*	< LOD	< LOD	< LOD	< LOD	567
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	< LOD	413
	01-02	*	< LOD	< LOD	< LOD	.082 (.057-.105)	514
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	< LOD	722
	01-02	*	< LOD	< LOD	< LOD	< LOD	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 175. 2,2',3,4',5,5',6-Heptachlorobiphenyl (PCB 187) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	17.7 (15.6-20.0)	24.6 (22.0-27.6)	1930
	01-02	*	< LOD	12.1 (10.5-13.7)	21.7 (19.6-23.7)	27.9 (26.8-29.7)	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	19.2 (16.8-21.8)	25.9 (24.1-29.0)	1263
	01-02	*	< LOD	13.3 (12.0-15.2)	23.0 (20.9-24.7)	29.2 (27.3-32.0)	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	17.7 (15.7-19.6)	25.9 (21.6-29.0)	917
	01-02	*	< LOD	12.7 (<LOD-15.8)	22.3 (19.4-24.1)	27.7 (25.1-30.1)	1075
Females	99-00	*	< LOD	< LOD	17.7 (15.1-21.7)	24.2 (21.6-27.0)	1013
	01-02	*	< LOD	11.9 (<LOD-13.0)	21.3 (18.5-23.5)	28.5 (26.2-31.3)	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	17.3 (15.1-19.1)	636
	01-02	*	< LOD	< LOD	10.5 (<LOD-13.4)	15.7 (12.5-18.0)	567
Non-Hispanic blacks	99-00	*	< LOD	15.3 (<LOD-21.1)	31.1 (26.0-39.0)	47.1 (36.6-72.1)	412
	01-02	*	< LOD	16.3 (12.3-21.0)	30.0 (22.9-40.6)	43.5 (30.3-61.9)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	16.8 (14.9-18.6)	22.0 (19.1-25.2)	727
	01-02	*	< LOD	12.5 (10.7-14.5)	21.7 (18.9-23.7)	27.4 (25.2-29.2)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 176. 2,2',3,4',5,5',6-Heptachlorobiphenyl (PCB 187) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	99-00	*	< LOD	< LOD	.120 (.108-.134)	.166 (.143-.181)	1930
	01-02	*	< LOD	.080 (.072-.090)	.140 (.128-.159)	.198 (.177-.218)	2307
<b>Age group</b>							
12-19 years	99-00	*	< LOD	< LOD	< LOD	< LOD	667
	01-02	*	< LOD	< LOD	< LOD	< LOD	758
20 years and older	99-00	*	< LOD	< LOD	.128 (.112-.141)	.176 (.155-.191)	1263
	01-02	*	< LOD	.090 (.077-.100)	.149 (.132-.174)	.210 (.186-.231)	1549
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	.123 (.099-.139)	.178 (.141-.198)	917
	01-02	*	< LOD	.082 (.072-.098)	.144 (.130-.163)	.187 (.165-.230)	1075
Females	99-00	*	< LOD	< LOD	.116 (.106-.130)	.162 (.136-.179)	1013
	01-02	*	< LOD	.076 (.067-.086)	.134 (.119-.150)	.202 (.178-.217)	1232
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	.118 (.100-.134)	636
	01-02	*	< LOD	< LOD	.078 (.058-.098)	.104 (.091-.121)	567
Non-Hispanic blacks	99-00	*	< LOD	.090 (.070-.132)	.203 (.164-.226)	.290 (.207-.531)	412
	01-02	*	< LOD	.102 (.074-.119)	.192 (.149-.258)	.286 (.187-.382)	515
Non-Hispanic whites	99-00	*	< LOD	< LOD	.112 (.099-.127)	.147 (.134-.168)	727
	01-02	*	< LOD	.081 (.072-.092)	.136 (.123-.157)	.191 (.167-.217)	1061

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 177. 2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	<b>11.1</b> (<LOD-11.9)	<b>18.1</b> (16.5-19.5)	<b>23.7</b> (20.9-27.0)	2279
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	746
20 years and older	01-02	*	< LOD	<b>11.9</b> (11.0-13.2)	<b>18.9</b> (17.7-20.5)	<b>25.3</b> (22.7-28.0)	1533
<b>Gender</b>							
Males	01-02	*	< LOD	<b>12.2</b> (10.6-13.9)	<b>19.1</b> (17.1-21.1)	<b>25.2</b> (21.2-28.3)	1059
Females	01-02	*	< LOD	< LOD	<b>17.0</b> (14.7-18.8)	<b>21.7</b> (19.3-26.2)	1220
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	<b>13.9</b> (10.5-17.6)	561
Non-Hispanic blacks	01-02	*	< LOD	<b>12.2</b> (<LOD-15.3)	<b>22.6</b> (18.0-27.5)	<b>29.8</b> (23.7-41.1)	508
Non-Hispanic whites	01-02	*	< LOD	<b>11.9</b> (10.9-13.1)	<b>18.7</b> (17.1-20.2)	<b>24.1</b> (20.9-28.0)	1048

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 178. 2,2',3,3',4,4',5,5'-Octachlorobiphenyl (PCB 194) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	.070 (.064-.078)	.123 (.104-.139)	.162 (.146-.187)	2279
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	746
20 years and older	01-02	*	< LOD	.079 (.070-.086)	.132 (.109-.147)	.174 (.149-.197)	1533
<b>Gender</b>							
Males	01-02	*	< LOD	.078 (.069-.087)	.132 (.106-.152)	.169 (.147-.206)	1059
Females	01-02	*	< LOD	< LOD	.109 (.094-.132)	.147 (.133-.176)	1220
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	.099 (.080-.114)	561
Non-Hispanic blacks	01-02	*	< LOD	.079 (.059-.089)	.138 (.101-.175)	.195 (.138-.253)	508
Non-Hispanic whites	01-02	*	< LOD	.076 (.069-.085)	.129 (.109-.146)	.165 (.146-.193)	1048

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 179. 2,2',3,3',4,4',5,6-Octachlorobiphenyl (PCB 195) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2230
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	716
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1514
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1035
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1195
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	544
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	490
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1037

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 180. 2,2',3,3',4,4',5,6-Octachlorobiphenyl (PCB 195) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2230
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	716
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1514
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1035
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1195
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	544
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	490
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1037

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 181. 2,2',3,3',4,4',5,6' and 2,2',3,4,4',5,5',6-Octachlorobiphenyl (PCB 196 & 203) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	<b>14.1</b> (13.0-15.7)	<b>19.2</b> (17.4-20.9)	2299
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	755
20 years and older	01-02	*	< LOD	< LOD	<b>15.0</b> (13.7-16.9)	<b>19.9</b> (18.2-21.4)	1544
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	<b>14.6</b> (13.3-16.5)	<b>19.4</b> (16.3-21.2)	1071
Females	01-02	*	< LOD	< LOD	<b>13.8</b> (11.9-15.9)	<b>19.0</b> (17.0-21.3)	1228
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	<b>11.1</b> (<LOD-12.5)	565
Non-Hispanic blacks	01-02	*	< LOD	< LOD	<b>17.5</b> (14.0-21.0)	<b>22.8</b> (19.6-30.2)	513
Non-Hispanic whites	01-02	*	< LOD	< LOD	<b>14.6</b> (13.5-16.2)	<b>19.5</b> (18.1-21.3)	1058

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 182. 2,2',3,3',4,4',5,6' and 2,2',3,4,4',5,5',6-Octachlorobiphenyl (PCB 196 & 203) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	.095 (.086-.105)	.127 (.113-.140)	2299
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	755
20 years and older	01-02	*	< LOD	< LOD	.103 (.092-.111)	.133 (.114-.150)	1544
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	.100 (.086-.115)	.126 (.110-.150)	1071
Females	01-02	*	< LOD	< LOD	.092 (.078-.101)	.126 (.110-.138)	1228
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	.071 (.060-.089)	565
Non-Hispanic blacks	01-02	*	< LOD	< LOD	.108 (.086-.135)	.148 (.108-.208)	513
Non-Hispanic whites	01-02	*	< LOD	< LOD	.099 (.090-.110)	.131 (.112-.143)	1058

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 183. 2,2',3,3',4,5,5',6'-Octachlorobiphenyl (PCB 199) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	<b>17.0</b> (15.4-18.1)	<b>22.4</b> (19.9-25.9)	2292
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	01-02	*	< LOD	<b>10.5</b> (<LOD-11.8)	<b>17.8</b> (16.2-19.2)	<b>24.4</b> (20.7-27.4)	1536
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	<b>17.3</b> (15.4-18.7)	<b>21.2</b> (19.2-24.5)	1066
Females	01-02	*	< LOD	< LOD	<b>16.1</b> (14.5-17.9)	<b>22.7</b> (19.4-27.3)	1226
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	<b>12.1</b> (<LOD-14.2)	565
Non-Hispanic blacks	01-02	*	< LOD	<b>12.4</b> (<LOD-15.2)	<b>21.9</b> (17.0-28.1)	<b>30.7</b> (22.4-37.4)	513
Non-Hispanic whites	01-02	*	< LOD	< LOD	<b>17.2</b> (15.9-18.9)	<b>22.6</b> (19.8-26.3)	1051

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 184. 2,2',3,3',4,5,5',6'-Octachlorobiphenyl (PCB 199) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	.108 (.100-.126)	.151 (.135-.168)	2292
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	756
20 years and older	01-02	*	< LOD	.069 (.060-.079)	.122 (.105-.136)	.158 (.139-.184)	1536
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	.108 (.098-.133)	.150 (.133-.179)	1066
Females	01-02	*	< LOD	< LOD	.111 (.098-.125)	.151 (.132-.167)	1226
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	.087 (.066-.107)	565
Non-Hispanic blacks	01-02	*	< LOD	.069 (.054-.087)	.135 (.104-.179)	.182 (.133-.301)	513
Non-Hispanic whites	01-02	*	< LOD	< LOD	.114 (.102-.130)	.150 (.132-.170)	1051

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 185. 2,2',3,3',4,4',5,5',6-Nonachlorobiphenyl (PCB 206) (lipid adjusted)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of lipid or parts per billion on a lipid-weight basis) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2208
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	723
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1485
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1033
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1175
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	533
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	483
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1034

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 186. 2,2',3,3',4,4',5,5',6-Nonachlorobiphenyl (PCB 206) (whole weight)**

Geometric mean and selected percentiles of serum concentrations (in ng/g of serum or parts per billion) for the U.S. population aged 12 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 12 and older</b>	01-02	*	< LOD	< LOD	< LOD	< LOD	2208
<b>Age group</b>							
12-19 years	01-02	*	< LOD	< LOD	< LOD	< LOD	723
20 years and older	01-02	*	< LOD	< LOD	< LOD	< LOD	1485
<b>Gender</b>							
Males	01-02	*	< LOD	< LOD	< LOD	< LOD	1033
Females	01-02	*	< LOD	< LOD	< LOD	< LOD	1175
<b>Race/ethnicity</b>							
Mexican Americans	01-02	*	< LOD	< LOD	< LOD	< LOD	533
Non-Hispanic blacks	01-02	*	< LOD	< LOD	< LOD	< LOD	483
Non-Hispanic whites	01-02	*	< LOD	< LOD	< LOD	< LOD	1034

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.



## Results by Chemical Group

---

### Phthalates



## Phthalates

### General Information

Phthalates are industrial chemicals that can act as plasticizers, which, when added to plastic, impart flexibility and resilience. Many consumer products contain phthalates. Among these products are vinyl flooring; adhesives; detergents; lubricating oils; solvents; automotive plastics; plastic clothing, such as raincoats; and personal-care products, such as soap, shampoo, deodorants, fragrances, hair spray, nail polish; and some medical pharmaceuticals. Phthalates are widely used in flexible polyvinyl chloride plastics, such as plastic bags, garden hoses, inflatable recreational toys, blood-storage bags, intravenous medical tubing, and children's toys. Soil and water contamination can be greatest in areas of industrial use and waste disposal.

People are exposed through direct contact with products that contain phthalates. For the general population, the oral route of exposure has been considered a major route. However, both population studies (Adibi et al., 2003) and occupational studies (Dirven et al., 1993; Liss et al., 1985; Nielsen et al., 1985) have shown that personal air-sample levels of phthalate diesters correlate modestly well with concentrations of urinary metabolites, suggesting that inhalation is an important route of exposure (Otake et al., 2004). In contrast, urinary levels in children did not correlate with home-dust measurements of phthalate content (Becker et al., 2004). Generally, phthalates are metabolized and excreted quickly and do not accumulate in the body (Anderson et al., 2001). Ingested phthalate diesters are initially hydrolyzed in the intestine to their corresponding monoester, which is then absorbed. (Albro et al., 1982; Albro and Lavenhar, 1989). Absorbed monoester metabolites may be further oxidized in the body. Table

188 shows the monoester metabolites and other oxidized metabolites of phthalates measured in this *Report* and also includes their commonly used abbreviations.

Several of the phthalates produce testicular injury, liver injury, liver cancer, and teratogenicity in rodent studies, but these effects either have not been demonstrated when tested in non-human primates or people or have not been investigated. The monoester metabolites are thought to mediate toxic effects for some of the phthalates. Phthalates have weak or no estrogenic, antiestrogenic, or androgenic activity *in vitro*, although not all metabolites have been tested (Jobling et al., 1995; Coldham et al., 1997; Harris et al., 1997; Parks et al., 2000; Okubo et al., 2003) and have shown no estrogenic activity *in vivo* (Zacharewski et al., 1998; Milligan et al., 1998). However, in animal studies, several phthalates show antiandrogenic activity and exposure to high doses of di-2-ethylhexyl phthalate (DEHP), dibutyl phthalate (DBP), and benzylbutyl phthalate (BzBP) during the fetal period have produced lowered testosterone levels, testicular atrophy, and Sertoli cell abnormalities in male animals and, at higher doses, ovarian abnormalities in female animals (see reviews by the Center for the Evaluation of Risks to Human Reproduction, 2000; McKee et al., 2004; and Jarfelt et al., 2005). Such effects may also be mediated through an inhibition of testicular, adrenal, or ovarian steroidogenesis. Phthalate levels in men from an infertility clinic have been associated with several parameters of sperm analysis (Duty et al., 2003; Duty et al., 2004; Duty et al., 2005).

Differences between human and rodent studies in the timing of dosages relative to critical developmental periods and in the amounts of putative metabolites generated in animals versus humans, as well as the large

**Table 187. Phthalates and their metabolites**

Phthalate name (CAS number)	Abbreviation	Urinary metabolite (CAS number)	Abbreviation
Dimethyl phthalate (131-11-3)	DMP	Mono-methyl phthalate (4376-18-5)	MMP
Diethyl phthalate (84-66-2)	DEP	Mono-ethyl phthalate (2306-33-4)	MEP
Dibutyl phthalates (84-74-2)	DBP	Mono-n-butyl phthalate (131-70-4)	MnBP
		Mono-isobutyl phthalate	MiBP
Benzylbutyl phthalate (85-68-7)	BzBP	Mono-benzyl phthalate (2528-16-7) (some mono-n-butyl phthalate)	MBzP
Dicyclohexyl phthalate (84-61-7)	DCHP	Mono-cyclohexyl phthalate (7517-36-4)	MCHP
Di-2-ethylhexyl phthalate (117-81-7)	DEHP	Mono-2-ethylhexyl phthalate (4376-20-9)	MEHP
		Mono-(2-ethyl-5-oxohexyl) phthalate	MEOHP
		Mono-(2-ethyl-5-hydroxyhexyl) phthalate	MEHHP
Di-n-octyl phthalate (117-84-0)	DOP	Mono-n-octyl phthalate (5393-19-1)	MOP
		Mono-(3-carboxypropyl) phthalate	MCPP
Di-isononyl phthalate (28553-12-0)	DiNP	Mono-isononyl phthalate	MiNP

doses given to test animals, make it difficult to translate the effects observed in animals to health effects in people. For instance, blood levels of phthalate monoesters can be higher in rodents than in non-human primates that are given equivalent doses due to the greater absorption in rodents or possibly greater hydrolysis to the monoester metabolite (Kessler et al., 2004; Lake et al., 1977). In addition, phthalates cause peroxisomal proliferation, which may be a pathway to the development of liver cancers in animals. However, peroxisomal proliferation may be a less relevant pathway in people (Melnick, 2001).

The Center for the Evaluation of Risks to Human Reproduction of the NTP has reviewed the reproductive effects for many of the phthalates (see <http://cerhr.niehs.nih.gov/news/phthalates/monographs.html>). Information about external exposure (i.e., environmental levels) and health effects is also available for some phthalates from the U.S. EPA's IRIS Web site at <http://www.epa.gov/iris> and from ATSDR's Toxicological Profiles at <http://www.atsdr.cdc.gov/toxprofiles>.

### **Interpreting Levels of Urinary Phthalate Metabolites Reported in the Tables**

Urinary levels of phthalate metabolites were measured in a subsample of NHANES participants aged 6 years and older. Participants were randomly selected within the specified age range to be a representative sample of the U.S. population. The concentrations for the monoester phthalate metabolites in the NHANES 2001-2002 subsample appear roughly similar to concentrations to those seen in an earlier survey of U.S. residents (Blount et al., 2000), pregnant women in New York City (Adibi et al., 2003), and in men from a Boston infertility clinic (Duty et al., 2004). In a small sample of Germans aged 7-64 years, median levels of mono-2-ethylhexyl phthalate (MEHP), mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP), mono-2-ethyl-5-oxohexyl phthalate (MEOHP) and mono-benzyl phthalate (MBzP) were about two-fold higher than median levels in the NHANES 2001-2002 subsample; the median level of mono-butyl phthalate (MBP) was about six-fold higher; and the median level of mono-ethyl phthalate (MEP) was slightly lower than the median levels of these metabolites in the NHANES 1999-2002 subsamples (Koch et al., 2003).

With the exception of MEP, the NHANES 1999-2000 and 2001-2002 subsamples showed that children aged 6-11 years excreted higher concentrations of metabolites

than did older age groups, a finding that has been noted in other studies of German adults and children for DEHP metabolites (Koch et al., 2004; Becker et al., 2004). The 1999-2000 and 2001-2002 NHANES subsamples also showed other differences in concentrations of specific phthalate metabolites by age, gender, and race/ethnicity (see data on individual phthalates). It is known that there is variation from person to person in the proportions or amounts of the metabolite excreted after people received similar doses (Anderson et al., 2001) as well as variation in the same person during repetitive monitoring (Hauser et al., 2004; Hoppin et al., 2002). The proportions of each metabolite for a given phthalate may vary also by differing routes of exposure (Liss et al., 1985; Peck and Albro, 1982).

Differences among the levels of various phthalate metabolites within a person may be due to differences in either exposure or pharmacokinetics for each of those phthalates. For instance, DEHP has been one of the more widely used phthalates, yet levels of MEHP are found in lower concentrations than MEP, MBP, or MBzP. It is now known that a greater proportion of the dose is accounted by other DEHP urinary metabolites (e.g., MEOHP and MEHHP), which demonstrate higher urinary concentrations than MEHP (Barr et al., 2003; Koch et al., 2003). Likewise, the low detection rates for some of the monoester metabolites of the long alkyl chain phthalates (di-isononyl and dioctyl) may be due to lower exposure to these compounds, to less of the parent compound being metabolized to the measured monoester metabolite, or, as seen with DEHP, to further oxidation to other unmeasured metabolites.

Finding a measurable amount of one or more phthalate metabolites in urine does not mean that they cause an adverse health effect. Whether these levels of phthalate metabolites are cause for health concern is not yet known; more research is needed. These levels of phthalate metabolites in urine provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of phthalates than levels found in the general population. These data will also help scientists plan and conduct research on phthalate exposure and health effects.

## Mono-methyl Phthalate

CAS No. 4376-18-5

*Metabolite of Dimethyl Phthalate, CAS No.131-11-3*

### General Information

Dimethyl phthalate (DMP) is used to manufacture solid rocket propellant and some consumer products such as insect repellants and plastics. People exposed to DMP will excrete mono-methyl phthalate (MMP) in their urine. The amount of MMP is an indicator of how much contact with DMP has occurred. Workplace air standards for external exposure to dimethyl phthalate have been established by NIOSH and ACGIH. DMP has not been completely classified with respect to carcinogenicity by IARC and NTP.

### Comparing Adjusted Geometric Means

MMP was not measured in NHANES 1999-2000. For NHANES 2001-2002, geometric mean levels of urinary MMP for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). Adjusted geometric mean levels of urinary MMP were found to be higher in children aged 6-11 years than in either of the groups aged 12-19 years and 20 years and older and levels in the group aged 12-19 years were higher than in the group aged 20 years and older. Females had higher levels than males. It is unknown whether these differences associated with age and gender represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

**Table 188. Mono-methyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>1.15</b> (.985-1.34)	<b>1.50</b> (1.30-1.70)	<b>3.30</b> (2.80-3.70)	<b>6.00</b> (5.10-7.40)	<b>9.80</b> (8.00-12.5)	2782
<b>Age group</b>							
6-11 years	01-02	<b>1.45</b> (1.13-1.87)	<b>1.80</b> (1.40-2.60)	<b>4.00</b> (3.30-4.70)	<b>6.90</b> (6.00-8.00)	<b>11.6</b> (7.60-20.8)	393
12-19 years	01-02	<b>1.59</b> (1.28-1.96)	<b>2.10</b> (1.80-2.50)	<b>3.80</b> (3.30-4.70)	<b>8.50</b> (5.30-10.5)	<b>12.7</b> (9.60-17.8)	742
20 years and older	01-02	<b>1.06</b> (.904-1.25)	<b>1.40</b> (1.10-1.60)	<b>3.10</b> (2.40-3.50)	<b>5.60</b> (4.60-6.90)	<b>9.10</b> (7.10-11.8)	1647
<b>Gender</b>							
Males	01-02	<b>1.17</b> (.962-1.43)	<b>1.50</b> (1.20-1.80)	<b>3.30</b> (2.80-3.80)	<b>5.90</b> (4.80-7.90)	<b>9.10</b> (7.10-12.7)	1371
Females	01-02	<b>1.13</b> (.973-1.31)	<b>1.30</b> (1.10-1.60)	<b>3.30</b> (2.80-3.70)	<b>6.40</b> (4.90-7.80)	<b>10.3</b> (8.00-15.2)	1411
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>1.21</b> (1.02-1.45)	<b>1.50</b> (1.30-1.70)	<b>3.30</b> (2.70-3.90)	<b>5.50</b> (4.70-7.30)	<b>8.30</b> (6.40-15.2)	677
Non-Hispanic blacks	01-02	<b>1.64</b> (1.37-1.98)	<b>2.00</b> (1.70-2.50)	<b>4.40</b> (3.50-5.10)	<b>8.30</b> (6.20-10.1)	<b>10.8</b> (9.50-13.4)	703
Non-Hispanic whites	01-02	<b>1.08</b> (.906-1.29)	<b>1.40</b> (1.10-1.60)	<b>3.10</b> (2.50-3.60)	<b>5.60</b> (4.60-6.60)	<b>9.70</b> (7.10-14.0)	1216

**Table 189. Mono-methyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>1.08</b> (.935-1.24)	<b>1.33</b> (1.13-1.54)	<b>2.62</b> (2.36-2.95)	<b>5.00</b> (3.96-6.00)	<b>7.97</b> (6.07-10.9)	2772
<b>Age group</b>							
6-11 years	01-02	<b>1.65</b> (1.28-2.13)	<b>2.32</b> (1.72-2.86)	<b>3.93</b> (3.27-4.71)	<b>6.77</b> (5.75-9.41)	<b>12.5</b> (7.60-22.5)	392
12-19 years	01-02	<b>1.23</b> (1.01-1.48)	<b>1.51</b> (1.32-1.81)	<b>2.84</b> (2.52-3.33)	<b>5.36</b> (3.68-6.39)	<b>7.27</b> (5.64-11.4)	742
20 years and older	01-02	<b>1.00</b> (.866-1.16)	<b>1.21</b> (1.04-1.40)	<b>2.44</b> (2.14-2.65)	<b>4.49</b> (3.49-5.88)	<b>7.72</b> (5.54-11.7)	1638
<b>Gender</b>							
Males	01-02	<b>.953</b> (.792-1.15)	<b>1.17</b> (1.01-1.40)	<b>2.38</b> (2.03-2.78)	<b>4.12</b> (3.45-5.64)	<b>6.42</b> (4.94-9.32)	1367
Females	01-02	<b>1.21</b> (1.06-1.38)	<b>1.45</b> (1.24-1.82)	<b>2.86</b> (2.60-3.04)	<b>5.45</b> (4.55-7.07)	<b>10.0</b> (7.20-15.3)	1405
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>1.14</b> (.969-1.34)	<b>1.47</b> (1.29-1.63)	<b>2.48</b> (2.19-2.94)	<b>4.19</b> (3.75-5.79)	<b>7.53</b> (4.76-15.2)	674
Non-Hispanic blacks	01-02	<b>1.15</b> (.945-1.40)	<b>1.39</b> (1.28-1.67)	<b>2.69</b> (2.35-2.93)	<b>4.86</b> (4.20-5.88)	<b>8.02</b> (5.85-10.9)	702
Non-Hispanic whites	01-02	<b>1.07</b> (.913-1.25)	<b>1.30</b> (1.05-1.58)	<b>2.60</b> (2.32-2.97)	<b>5.23</b> (3.72-6.82)	<b>8.29</b> (6.08-12.6)	1211

## Mono-ethyl Phthalate

CAS No. 2306-33-4

*Metabolite of Diethyl Phthalate, CAS No. 84-66-2*

### General Information

Diethyl phthalate (DEP) is an industrial solvent used in many consumer products, particularly those containing fragrances. Products that may contain DEP include perfume, cologne, deodorant, soap, shampoo, and hand lotion. People exposed to DEP will excrete monoethyl phthalate (MEP) in their urine. Workplace air standards for external exposure to DEP have been established by ACGIH or recommended by NIOSH. It has not been completely classified with respect to its carcinogenicity by IARC and NTP.

### Interpreting Levels of Urinary Mono-ethyl Phthalate in the Tables

MEP levels in the NHANES 2001-2002 subsample appear similar to levels in a small sample of pregnant women in New York City (Adibi et al., 2003). MEP levels found in a small sample of German residents (Koch et al., 2003) are slightly lower than levels documented in this *Report*.

**Table 190. Mono-ethyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>179</b> (156-204)	<b>164</b> (136-201)	<b>450</b> (370-538)	<b>1260</b> (1010-1480)	<b>2840</b> (2150-3770)	2536
	01-02	<b>178</b> (159-199)	<b>169</b> (141-194)	<b>465</b> (415-527)	<b>1230</b> (1040-1440)	<b>2500</b> (1860-3220)	2782
<b>Age group</b>							
6-11 years	99-00	<b>91.3</b> (74.8-111)	<b>74.7</b> (62.1-93.7)	<b>197</b> (129-249)	<b>378</b> (290-730)	<b>756</b> (379-1070)	328
	01-02	<b>85.1</b> (71.2-102)	<b>71.9</b> (61.9-92.5)	<b>181</b> (142-217)	<b>444</b> (315-636)	<b>808</b> (572-1090)	393
12-19 years	99-00	<b>211</b> (160-278)	<b>193</b> (141-256)	<b>558</b> (419-818)	<b>1510</b> (1050-2150)	<b>3260</b> (1550-4420)	752
	01-02	<b>197</b> (159-243)	<b>184</b> (148-227)	<b>479</b> (387-651)	<b>1260</b> (983-1480)	<b>2060</b> (1470-3050)	742
20 years and older	99-00	<b>190</b> (164-219)	<b>180</b> (140-220)	<b>482</b> (390-590)	<b>1340</b> (1010-1660)	<b>3480</b> (2230-4640)	1456
	01-02	<b>191</b> (171-214)	<b>181</b> (152-212)	<b>498</b> (441-567)	<b>1350</b> (1060-1660)	<b>2720</b> (2160-3670)	1647
<b>Gender</b>							
Males	99-00	<b>179</b> (149-215)	<b>154</b> (119-197)	<b>523</b> (372-650)	<b>1430</b> (1020-2280)	<b>3480</b> (2130-4560)	1214
	01-02	<b>182</b> (157-211)	<b>171</b> (139-199)	<b>502</b> (419-603)	<b>1450</b> (1060-2110)	<b>3050</b> (2110-4390)	1371
Females	99-00	<b>178</b> (154-206)	<b>174</b> (138-210)	<b>425</b> (350-508)	<b>977</b> (880-1230)	<b>2230</b> (1370-3880)	1322
	01-02	<b>174</b> (153-198)	<b>167</b> (139-194)	<b>427</b> (387-498)	<b>1050</b> (879-1310)	<b>1840</b> (1490-2500)	1411
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>181</b> (157-209)	<b>174</b> (146-210)	<b>441</b> (390-541)	<b>1250</b> (851-1510)	<b>1720</b> (1460-2130)	813
	01-02	<b>226</b> (195-262)	<b>220</b> (190-264)	<b>530</b> (444-660)	<b>1490</b> (1050-2110)	<b>2590</b> (1540-4460)	677
Non-Hispanic blacks	99-00	<b>322</b> (275-377)	<b>306</b> (256-350)	<b>789</b> (635-949)	<b>1880</b> (1410-2270)	<b>3600</b> (2130-4640)	603
	01-02	<b>352</b> (324-384)	<b>357</b> (290-407)	<b>839</b> (709-1090)	<b>2160</b> (1620-2470)	<b>3540</b> (2810-5070)	703
Non-Hispanic whites	99-00	<b>152</b> (133-175)	<b>133</b> (108-157)	<b>366</b> (287-482)	<b>977</b> (798-1340)	<b>2470</b> (1590-3880)	908
	01-02	<b>158</b> (141-178)	<b>147</b> (119-177)	<b>413</b> (366-451)	<b>1020</b> (905-1230)	<b>2310</b> (1560-2720)	1216

## Comparing Adjusted Geometric Means

Geometric mean levels of urinary MEP for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). In NHANES 2001-2002, the adjusted geometric mean levels of urinary MEP were lower in the group aged 6-11 years than either of the other age groups and the group aged 12-19 was had lower levels than the group 20 years and older. This age-related trend is opposite the direction shown for other phthalates. Non-Hispanic whites had lower levels than non-Hispanic blacks or Mexican Americans. Levels in non-Hispanic blacks were not significantly higher than in Mexican Americans. It is unknown whether these differences associated with age or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.


**Table 191. Mono-ethyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>163</b> (149-178)	<b>141</b> (129-157)	<b>360</b> (307-422)	<b>898</b> (753-1180)	<b>1950</b> (1670-2310)	2536
	01-02	<b>167</b> (150-185)	<b>147</b> (133-161)	<b>388</b> (333-435)	<b>975</b> (804-1180)	<b>1860</b> (1430-2200)	2772
<b>Age group</b>							
6-11 years	99-00	<b>92.6</b> (77.9-110)	<b>79.4</b> (65.7-110)	<b>165</b> (127-208)	<b>341</b> (219-554)	<b>625</b> (400-784)	328
	01-02	<b>96.9</b> (82.4-114)	<b>81.2</b> (66.3-105)	<b>171</b> (135-224)	<b>494</b> (290-802)	<b>837</b> (512-1320)	392
12-19 years	99-00	<b>142</b> (119-169)	<b>122</b> (93.0-156)	<b>361</b> (275-495)	<b>879</b> (676-1260)	<b>1550</b> (1000-2000)	752
	01-02	<b>152</b> (126-184)	<b>140</b> (111-180)	<b>325</b> (249-409)	<b>808</b> (590-1100)	<b>1330</b> (868-1840)	742
20 years and older	99-00	<b>179</b> (161-199)	<b>154</b> (136-177)	<b>390</b> (336-452)	<b>1010</b> (803-1460)	<b>2170</b> (1790-3350)	1456
	01-02	<b>181</b> (164-200)	<b>159</b> (143-182)	<b>419</b> (363-486)	<b>1060</b> (883-1320)	<b>2080</b> (1490-2790)	1638
<b>Gender</b>							
Males	99-00	<b>141</b> (124-159)	<b>120</b> (107-134)	<b>324</b> (249-415)	<b>996</b> (693-1480)	<b>1940</b> (1460-2900)	1214
	01-02	<b>147</b> (129-168)	<b>126</b> (110-147)	<b>347</b> (279-418)	<b>1160</b> (843-1480)	<b>2080</b> (1490-3030)	1367
Females	99-00	<b>187</b> (165-211)	<b>157</b> (142-179)	<b>377</b> (307-495)	<b>821</b> (697-1170)	<b>1920</b> (1170-3410)	1322
	01-02	<b>187</b> (166-210)	<b>171</b> (148-187)	<b>410</b> (356-476)	<b>860</b> (712-1100)	<b>1430</b> (1190-2010)	1405
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>164</b> (142-190)	<b>154</b> (136-174)	<b>382</b> (314-472)	<b>814</b> (673-974)	<b>1330</b> (974-1920)	813
	01-02	<b>214</b> (183-250)	<b>199</b> (166-242)	<b>472</b> (396-572)	<b>1070</b> (862-1650)	<b>1900</b> (1330-2630)	674
Non-Hispanic blacks	99-00	<b>208</b> (183-236)	<b>196</b> (166-228)	<b>443</b> (390-505)	<b>1030</b> (762-1700)	<b>1880</b> (1230-2590)	603
	01-02	<b>247</b> (225-271)	<b>227</b> (185-270)	<b>557</b> (478-618)	<b>1230</b> (961-1480)	<b>2070</b> (1550-2800)	702
Non-Hispanic whites	99-00	<b>149</b> (135-165)	<b>128</b> (111-142)	<b>313</b> (239-387)	<b>834</b> (655-1390)	<b>1950</b> (1480-2740)	908
	01-02	<b>156</b> (141-173)	<b>136</b> (124-149)	<b>337</b> (288-402)	<b>911</b> (712-1160)	<b>1590</b> (1320-2170)	1211

**Figure 20. Mono-ethyl phthalate (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



## Mono-n-butyl Phthalate

CAS No. 131-70-4

*Metabolite of Di-n-butyl Phthalate, CAS No. 84-74-2 and Benzylbutyl Phthalate, CAS No. 85-68-7*

## Mono-isobutyl Phthalate

*Metabolite of Di-isobutyl Phthalates, CAS No. 84-74-2*

### General Information

Dibutyl phthalates (di-n-butyl, di-isobutyl) are industrial solvents or additives used in many consumer products such as nail polish, cosmetics, some printing inks, pharmaceutical coatings, and insecticides. People exposed to dibutyl phthalates will excrete mono-butyl phthalates (n-butyl, iso-butyl) in their urine. Small amounts of mono-3-carboxypropyl phthalate are also produced from di-n-butyl phthalate. In addition, exposure to benzylbutyl phthalate (BzBP) will also result in small amounts of mono-n-butyl phthalate appearing in the urine (Anderson et al., 2001).

Workplace air standards for external exposure to dibutyl phthalate have been established by NIOSH and ACGIH. Dibutyl phthalates can produce reproductive toxicity in animals (Center for the Evaluation of Risks to Human Reproduction, 2003). Dibutyl phthalates have not been completely classified with respect to carcinogenicity by IARC or NTP.

### Interpreting Levels of Urinary Mono-n-butyl and Mono-isobutyl Phthalates in the Tables

Mono-butyl phthalate (MBP) levels in the NHANES 1999-2000 subsample represented the sum of both

**Table 192. Mono-n-butyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>24.6</b> (22.1-27.4)	<b>26.0</b> (23.6-29.2)	<b>51.6</b> (44.4-59.8)	<b>98.6</b> (90.2-114)	<b>149</b> (121-169)	2541
	01-02	<b>18.9</b> (17.4-20.6)	<b>20.4</b> (19.1-21.7)	<b>40.4</b> (36.5-44.2)	<b>73.6</b> (65.3-85.4)	<b>108</b> (94.1-122)	2782
<b>Age group</b>							
6-11 years	99-00	<b>41.4</b> (35.6-48.0)	<b>40.0</b> (36.2-49.2)	<b>75.5</b> (59.1-92.8)	<b>124</b> (98.4-159)	<b>163</b> (127-279)	328
	01-02	<b>31.1</b> (26.6-36.5)	<b>32.4</b> (25.5-36.4)	<b>62.1</b> (51.3-76.9)	<b>107</b> (84.3-136)	<b>157</b> (110-290)	393
12-19 years	99-00	<b>36.0</b> (30.8-42.1)	<b>36.1</b> (30.6-44.9)	<b>67.7</b> (55.9-79.7)	<b>119</b> (90.2-159)	<b>165</b> (121-227)	752
	01-02	<b>25.1</b> (21.6-29.2)	<b>26.4</b> (22.0-32.6)	<b>52.2</b> (48.1-60.4)	<b>92.4</b> (72.3-119)	<b>147</b> (105-183)	742
20 years and older	99-00	<b>21.6</b> (19.0-24.5)	<b>23.0</b> (19.7-26.0)	<b>46.1</b> (36.6-53.5)	<b>95.0</b> (78.7-111)	<b>142</b> (117-161)	1461
	01-02	<b>17.0</b> (15.4-18.8)	<b>19.1</b> (17.1-20.4)	<b>35.1</b> (31.6-40.2)	<b>64.8</b> (57.3-79.7)	<b>95.4</b> (84.6-113)	1647
<b>Gender</b>							
Males	99-00	<b>22.0</b> (20.1-24.1)	<b>23.1</b> (20.3-26.1)	<b>43.1</b> (36.6-49.5)	<b>83.9</b> (71.3-96.2)	<b>115</b> (97.8-132)	1215
	01-02	<b>17.7</b> (16.0-19.6)	<b>19.3</b> (17.0-20.6)	<b>34.4</b> (30.3-40.6)	<b>62.1</b> (54.1-75.5)	<b>95.2</b> (75.5-117)	1371
Females	99-00	<b>27.3</b> (23.6-31.5)	<b>30.0</b> (25.9-33.3)	<b>59.5</b> (51.6-69.6)	<b>119</b> (98.3-145)	<b>167</b> (143-223)	1326
	01-02	<b>20.2</b> (18.2-22.4)	<b>21.6</b> (19.7-24.3)	<b>46.7</b> (43.1-51.1)	<b>85.0</b> (72.7-92.5)	<b>120</b> (106-136)	1411
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>23.4</b> (21.8-25.1)	<b>26.3</b> (23.9-28.1)	<b>48.1</b> (41.2-56.7)	<b>92.2</b> (78.9-101)	<b>116</b> (104-131)	814
	01-02	<b>20.1</b> (16.6-24.5)	<b>23.0</b> (17.9-26.3)	<b>41.9</b> (34.0-51.2)	<b>76.9</b> (62.9-92.5)	<b>112</b> (84.6-143)	677
Non-Hispanic blacks	99-00	<b>37.0</b> (31.9-42.9)	<b>38.7</b> (33.4-44.5)	<b>78.2</b> (58.7-91.8)	<b>117</b> (107-143)	<b>167</b> (143-197)	603
	01-02	<b>29.6</b> (26.6-33.1)	<b>31.5</b> (28.7-34.1)	<b>58.0</b> (49.3-62.5)	<b>91.7</b> (79.5-121)	<b>138</b> (110-184)	703
Non-Hispanic whites	99-00	<b>21.8</b> (19.3-24.6)	<b>23.1</b> (19.5-27.5)	<b>45.9</b> (37.5-53.3)	<b>90.2</b> (74.7-106)	<b>138</b> (111-161)	912
	01-02	<b>17.6</b> (16.0-19.3)	<b>19.1</b> (17.0-20.9)	<b>36.5</b> (32.4-42.6)	<b>69.2</b> (59.2-87.6)	<b>107</b> (89.8-123)	1216

Note: In 99-00, concentrations of mono-isobutyl phthalate and mono-n-butyl phthalate were measured together and expressed as a combined value.

For 01-02, mono-n-butyl phthalate levels were measured separately, and only mono-n-butyl phthalate levels are given in this table.

mono-isobutyl phthalate (MiBP) and mono-n-butyl phthalate (MnBP), whereas in NHANES 2001-2002 it was possible to measure the concentrations of these two phthalates separately. Levels in the 1999-2000 and 2001-2002 subsamples appear roughly similar when the sum of the MiBP and MnBP levels in 2001-2002 are compared with the 1999-2000 MBP levels.

Concentrations reported in these two subsamples are generally similar to those reported in U.S. residents (Blount et al., 2000) and in men from an infertility clinic (Duty et al., 2004). Levels reported for 1999-2002 are six-fold lower than levels reported in German residents (Koch et al., 2003) and slightly lower than levels found in a small sample of pregnant women in New York City (Adibi et al., 2003).

### Comparing Adjusted Geometric Means

Geometric mean levels of urinary monobutyl phthalates for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age,

gender, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary MnBP were higher in children aged 6-11 years than in people aged 12-19 years and 20 years and older, and the group aged 12-19 years had higher levels than the group aged 20 years and older. Levels were higher in females than in males.

In NHANES 2001-2002, adjusted geometric mean levels of urinary MiBP were higher in children aged 6-11 years than in people aged 12-19 years and 20 years. Levels were higher in females than in males. Non-Hispanic whites had lower levels than non-Hispanic blacks or Mexican Americans. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

**Table 193. Mono-n-butyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>22.4</b> (20.6-24.4)	<b>21.9</b> (19.8-24.3)	<b>38.9</b> (35.0-41.8)	<b>68.3</b> (60.3-78.3)	<b>97.5</b> (81.4-131)	2541
	01-02	<b>17.8</b> (16.7-18.9)	<b>17.4</b> (16.3-18.3)	<b>30.4</b> (28.2-32.4)	<b>52.4</b> (47.3-61.1)	<b>81.3</b> (71.0-92.5)	2772
<b>Age group</b>							
6-11 years	99-00	<b>41.9</b> (37.4-47.1)	<b>38.9</b> (34.3-49.0)	<b>65.7</b> (56.7-80.0)	<b>107</b> (71.2-179)	<b>159</b> (102-263)	328
	01-02	<b>35.5</b> (31.7-39.6)	<b>35.1</b> (29.3-38.9)	<b>55.4</b> (50.1-62.3)	<b>84.0</b> (69.0-113)	<b>146</b> (93.8-235)	392
12-19 years	99-00	<b>24.3</b> (21.2-27.8)	<b>23.6</b> (20.6-27.4)	<b>37.6</b> (31.6-43.8)	<b>62.3</b> (52.4-76.4)	<b>88.1</b> (61.4-142)	752
	01-02	<b>19.4</b> (17.3-21.7)	<b>20.3</b> (17.5-22.3)	<b>34.9</b> (30.5-37.9)	<b>53.4</b> (45.2-73.9)	<b>88.6</b> (60.3-106)	742
20 years and older	99-00	<b>20.4</b> (18.6-22.4)	<b>19.5</b> (18.1-21.4)	<b>34.9</b> (30.3-40.0)	<b>62.4</b> (53.4-72.1)	<b>91.0</b> (70.3-135)	1461
	01-02	<b>16.1</b> (15.0-17.3)	<b>15.4</b> (14.2-16.5)	<b>26.3</b> (24.2-28.6)	<b>44.3</b> (38.7-51.1)	<b>71.6</b> (61.2-85.6)	1638
<b>Gender</b>							
Males	99-00	<b>17.3</b> (16.1-18.6)	<b>17.0</b> (15.5-18.8)	<b>28.6</b> (25.8-32.1)	<b>49.1</b> (42.6-53.5)	<b>63.6</b> (57.3-71.5)	1215
	01-02	<b>14.4</b> (13.5-15.4)	<b>13.7</b> (13.0-14.9)	<b>22.9</b> (20.8-24.9)	<b>39.9</b> (35.6-44.0)	<b>60.0</b> (50.5-78.0)	1367
Females	99-00	<b>28.6</b> (25.3-32.3)	<b>28.6</b> (25.5-30.5)	<b>50.6</b> (41.9-56.3)	<b>84.3</b> (69.2-106)	<b>131</b> (93.6-155)	1326
	01-02	<b>21.7</b> (19.6-23.9)	<b>21.5</b> (19.7-23.6)	<b>35.9</b> (33.0-39.2)	<b>64.9</b> (58.9-70.2)	<b>91.5</b> (81.4-103)	1405
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>21.2</b> (19.3-23.3)	<b>20.0</b> (18.2-22.9)	<b>40.1</b> (32.6-44.3)	<b>63.6</b> (57.5-70.1)	<b>81.6</b> (73.9-100)	814
	01-02	<b>19.0</b> (16.2-22.2)	<b>19.2</b> (16.3-21.4)	<b>33.3</b> (28.3-39.6)	<b>61.0</b> (43.9-84.0)	<b>86.7</b> (60.6-128)	674
Non-Hispanic blacks	99-00	<b>23.9</b> (21.3-26.8)	<b>25.0</b> (20.7-28.0)	<b>42.2</b> (35.9-49.6)	<b>69.6</b> (61.1-83.9)	<b>94.4</b> (83.9-105)	603
	01-02	<b>20.8</b> (18.7-23.0)	<b>20.2</b> (19.2-22.8)	<b>34.5</b> (30.8-36.6)	<b>61.9</b> (50.0-73.9)	<b>85.6</b> (71.6-99.0)	702
Non-Hispanic whites	99-00	<b>21.3</b> (19.1-23.8)	<b>20.5</b> (18.6-23.2)	<b>36.4</b> (31.5-41.0)	<b>67.1</b> (56.7-78.4)	<b>97.6</b> (73.5-142)	912
	01-02	<b>17.4</b> (16.3-18.6)	<b>16.5</b> (15.3-17.8)	<b>29.0</b> (26.6-32.2)	<b>50.7</b> (45.5-59.0)	<b>81.4</b> (68.5-103)	1211

Note: In 99-00, concentrations of mono-isobutyl phthalate and mono-n-butyl phthalate were measured together and expressed as a combined value.

For 01-02, mono-n-butyl phthalate levels were measured separately, and only mono-n-butyl phthalate levels are given in this table.

**Table 194. Mono-isobutyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>2.71</b> (2.49-2.94)	<b>2.60</b> (2.40-2.90)	<b>5.70</b> (5.30-6.00)	<b>11.9</b> (11.3-12.6)	<b>17.9</b> (16.3-19.8)	2782
<b>Age group</b>							
6-11 years	01-02	<b>4.22</b> (3.28-5.43)	<b>4.40</b> (3.10-6.10)	<b>10.7</b> (7.30-13.4)	<b>18.6</b> (14.2-22.0)	<b>23.4</b> (20.4-27.8)	393
12-19 years	01-02	<b>3.48</b> (2.90-4.17)	<b>3.80</b> (2.90-4.40)	<b>7.30</b> (6.00-9.00)	<b>14.5</b> (11.7-18.6)	<b>22.2</b> (16.2-33.4)	742
20 years and older	01-02	<b>2.46</b> (2.30-2.63)	<b>2.40</b> (2.10-2.50)	<b>5.00</b> (4.70-5.30)	<b>10.4</b> (9.40-12.0)	<b>16.3</b> (13.6-18.5)	1647
<b>Gender</b>							
Males	01-02	<b>2.73</b> (2.50-2.97)	<b>2.70</b> (2.40-3.10)	<b>5.60</b> (5.00-6.10)	<b>11.6</b> (10.1-12.6)	<b>16.6</b> (13.6-20.1)	1371
Females	01-02	<b>2.68</b> (2.44-2.96)	<b>2.50</b> (2.20-2.90)	<b>5.70</b> (5.20-6.20)	<b>12.6</b> (11.0-14.7)	<b>18.7</b> (16.3-24.0)	1411
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>3.26</b> (2.72-3.91)	<b>3.40</b> (2.60-4.10)	<b>7.10</b> (6.10-9.00)	<b>12.1</b> (11.1-14.5)	<b>18.3</b> (14.1-25.6)	677
Non-Hispanic blacks	01-02	<b>4.90</b> (4.46-5.37)	<b>5.30</b> (4.50-6.00)	<b>10.6</b> (9.20-12.0)	<b>18.3</b> (15.7-18.9)	<b>25.4</b> (20.5-30.8)	703
Non-Hispanic whites	01-02	<b>2.33</b> (2.10-2.59)	<b>2.20</b> (1.90-2.60)	<b>4.90</b> (4.40-5.30)	<b>9.60</b> (8.30-11.4)	<b>15.6</b> (13.0-18.6)	1216

Note: In 99-00, concentrations of mono-isobutyl phthalate and mono-n-butyl phthalate were measured together and expressed as a combined value. For 01-02, mono-isobutyl phthalate levels were measured separately, and only mono-isobutyl phthalate levels are given in this table.

**Table 195. Mono-isobutyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>2.53</b> (2.35-2.72)	<b>2.44</b> (2.26-2.67)	<b>4.50</b> (4.12-4.83)	<b>8.02</b> (7.60-8.66)	<b>12.0</b> (10.8-13.5)	2772
<b>Age group</b>							
6-11 years	01-02	<b>4.80</b> (3.89-5.93)	<b>5.17</b> (4.13-6.32)	<b>9.17</b> (7.03-11.6)	<b>15.0</b> (11.1-24.3)	<b>24.3</b> (13.8-40.3)	392
12-19 years	01-02	<b>2.68</b> (2.29-3.15)	<b>2.83</b> (2.39-3.33)	<b>4.79</b> (4.04-5.51)	<b>7.60</b> (6.18-10.2)	<b>12.8</b> (8.76-15.6)	742
20 years and older	01-02	<b>2.31</b> (2.18-2.45)	<b>2.24</b> (2.06-2.43)	<b>3.79</b> (3.64-4.22)	<b>7.13</b> (6.88-7.63)	<b>10.6</b> (9.46-11.3)	1638
<b>Gender</b>							
Males	01-02	<b>2.21</b> (2.08-2.35)	<b>2.16</b> (1.97-2.35)	<b>3.71</b> (3.58-4.04)	<b>7.18</b> (6.44-7.95)	<b>10.9</b> (10.0-12.5)	1367
Females	01-02	<b>2.87</b> (2.59-3.17)	<b>2.83</b> (2.51-3.18)	<b>5.10</b> (4.61-5.83)	<b>8.66</b> (8.02-10.1)	<b>13.5</b> (11.1-15.0)	1405
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>3.05</b> (2.55-3.66)	<b>2.98</b> (2.50-3.79)	<b>5.73</b> (4.86-6.99)	<b>10.5</b> (8.04-13.3)	<b>16.0</b> (12.2-19.4)	674
Non-Hispanic blacks	01-02	<b>3.43</b> (3.20-3.68)	<b>3.52</b> (2.95-3.81)	<b>6.10</b> (5.03-7.04)	<b>10.5</b> (8.80-12.6)	<b>15.6</b> (12.6-19.7)	702
Non-Hispanic whites	01-02	<b>2.29</b> (2.09-2.51)	<b>2.20</b> (1.99-2.43)	<b>3.77</b> (3.50-4.34)	<b>7.13</b> (6.67-7.78)	<b>10.7</b> (9.62-12.6)	1211

Note: In 99-00, concentrations of mono-isobutyl phthalate and mono-n-butyl phthalate were measured together and expressed as a combined value. For 01-02, mono-isobutyl phthalate levels were measured separately, and only mono-isobutyl phthalate levels are given in this table.

## Mono-benzyl Phthalate

CAS No. 2528-16-7

*Metabolite of benzylbutyl phthalate, CAS No. 85-68-7*

### General Information

Benzylbutyl phthalate (BzBP) is an industrial solvent and additive used in products such as adhesives, vinyl-flooring products, sealants, car-care products, and to a lesser extent, some personal-care products. People exposed to BzBP will excrete MBzP and small amounts of mono-n-butyl phthalate in their urine. Workplace air standards for external exposures have not been established for BzBP. Like other phthalates, BzBP has low acute toxicity. It can produce reproductive toxicity in animals (Center for the Evaluation of Risks to Human Reproduction, 2000). BzBP is classified as a possible human carcinogen by U.S. EPA, but is considered not classifiable by IARC and unlisted by NTP.

### Interpreting Levels of Urinary Mono-benzyl Phthalate in the Tables

The levels of MBzP in the NHANES 2001-2002 subsample appear generally similar to levels reported previously for U.S. residents (Blount et al., 2000), in a small sample of pregnant women in New York City (Adibi et al., 2003), in men from an infertility clinic (Duty et al., 2004), and in a small sample of German residents (Koch et al., 2003).

**Table 196. Mono-benzyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>15.3</b> (13.7-17.1)	<b>17.0</b> (15.3-18.9)	<b>35.3</b> (32.6-39.6)	<b>67.1</b> (55.3-82.0)	<b>103</b> (94.6-116)	2541
	01-02	<b>15.1</b> (13.9-16.3)	<b>15.7</b> (14.8-17.4)	<b>38.0</b> (34.5-41.2)	<b>80.8</b> (71.3-88.2)	<b>122</b> (102-142)	2782
<b>Age group</b>							
6-11 years	99-00	<b>39.4</b> (32.9-47.2)	<b>40.3</b> (33.8-48.6)	<b>82.0</b> (55.8-98.1)	<b>128</b> (98.1-214)	<b>214</b> (108-399)	328
	01-02	<b>33.4</b> (29.1-38.4)	<b>37.0</b> (26.6-43.4)	<b>68.5</b> (61.6-92.8)	<b>166</b> (116-191)	<b>226</b> (183-330)	393
12-19 years	99-00	<b>25.6</b> (21.9-30.0)	<b>28.3</b> (22.2-34.8)	<b>51.1</b> (43.7-58.5)	<b>87.9</b> (67.2-115)	<b>125</b> (93.7-170)	752
	01-02	<b>23.2</b> (19.9-27.2)	<b>24.7</b> (21.2-31.0)	<b>55.5</b> (47.4-62.9)	<b>113</b> (91.8-133)	<b>169</b> (134-198)	742
20 years and older	99-00	<b>12.4</b> (10.9-14.2)	<b>13.8</b> (12.1-15.6)	<b>28.9</b> (25.2-33.1)	<b>52.0</b> (43.9-62.5)	<b>86.3</b> (54.7-119)	1461
	01-02	<b>12.7</b> (11.7-13.9)	<b>13.8</b> (12.8-14.9)	<b>31.8</b> (28.5-33.5)	<b>65.4</b> (53.8-76.3)	<b>99.7</b> (82.8-121)	1647
<b>Gender</b>							
Males	99-00	<b>16.2</b> (14.1-18.6)	<b>17.7</b> (15.0-19.9)	<b>35.4</b> (31.5-40.3)	<b>69.4</b> (59.9-87.2)	<b>108</b> (96.3-130)	1215
	01-02	<b>15.6</b> (13.6-17.9)	<b>16.0</b> (14.2-18.3)	<b>37.0</b> (33.1-43.0)	<b>78.4</b> (63.5-97.4)	<b>122</b> (88.1-178)	1371
Females	99-00	<b>14.6</b> (12.7-16.6)	<b>16.0</b> (14.2-19.2)	<b>35.8</b> (30.8-41.4)	<b>63.7</b> (53.7-82.4)	<b>103</b> (84.2-116)	1326
	01-02	<b>14.6</b> (13.1-16.3)	<b>15.4</b> (13.7-17.9)	<b>38.1</b> (32.2-42.9)	<b>81.4</b> (68.3-91.6)	<b>122</b> (102-143)	1411
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>13.9</b> (12.1-16.1)	<b>15.7</b> (13.4-16.8)	<b>33.0</b> (27.5-36.1)	<b>67.5</b> (55.5-84.0)	<b>98.3</b> (80.6-150)	814
	01-02	<b>13.2</b> (10.8-16.2)	<b>14.7</b> (10.8-18.5)	<b>29.5</b> (25.5-38.0)	<b>70.3</b> (53.0-85.4)	<b>91.6</b> (70.3-161)	677
Non-Hispanic blacks	99-00	<b>23.0</b> (20.7-25.5)	<b>23.0</b> (20.5-25.6)	<b>49.3</b> (43.4-55.6)	<b>94.0</b> (80.0-130)	<b>138</b> (106-241)	603
	01-02	<b>23.8</b> (21.0-26.9)	<b>24.2</b> (19.9-28.0)	<b>50.6</b> (41.5-62.9)	<b>101</b> (86.4-127)	<b>139</b> (127-179)	703
Non-Hispanic whites	99-00	<b>14.3</b> (12.7-16.1)	<b>16.1</b> (14.2-18.5)	<b>33.9</b> (30.6-38.4)	<b>58.7</b> (51.3-74.1)	<b>103</b> (74.1-116)	912
	01-02	<b>14.0</b> (12.7-15.4)	<b>14.6</b> (13.3-15.5)	<b>35.3</b> (32.2-39.5)	<b>76.6</b> (66.1-90.3)	<b>121</b> (93.2-155)	1216

## Comparing Adjusted Geometric Means

Geometric mean levels of urinary mono-benzyl phthalate for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary mono-benzyl phthalate were higher in children aged 6-11 years than in people aged 12-19 years and 20 years and older, and the group aged 12-19 years had higher levels than the group aged 20 years and older. Levels in females were higher than in males. Mexican Americans had lower levels than non-Hispanic whites, but were not significantly different from non-Hispanic blacks. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.


**Table 197. Mono-benzyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>14.0</b> (13.0-15.0)	<b>13.3</b> (12.8-14.3)	<b>25.1</b> (23.4-27.2)	<b>50.1</b> (41.5-58.8)	<b>77.4</b> (69.6-86.3)	2541
	01-02	<b>14.1</b> (13.2-15.1)	<b>13.5</b> (12.7-14.4)	<b>26.6</b> (24.9-29.3)	<b>55.1</b> (49.2-59.0)	<b>90.4</b> (73.6-102)	2772
<b>Age group</b>							
6-11 years	99-00	<b>40.0</b> (33.6-47.6)	<b>38.4</b> (30.2-51.3)	<b>73.2</b> (56.6-99.1)	<b>104</b> (89.4-142)	<b>142</b> (99.8-173)	328
	01-02	<b>38.1</b> (34.5-42.1)	<b>37.2</b> (33.8-42.2)	<b>67.9</b> (55.8-80.4)	<b>134</b> (116-176)	<b>195</b> (121-305)	392
12-19 years	99-00	<b>17.3</b> (15.4-19.4)	<b>17.0</b> (14.6-20.3)	<b>28.3</b> (24.3-34.8)	<b>49.7</b> (38.8-69.2)	<b>69.3</b> (49.6-81.9)	752
	01-02	<b>17.9</b> (15.7-20.5)	<b>18.1</b> (15.7-20.8)	<b>33.9</b> (29.3-38.6)	<b>67.7</b> (55.8-85.9)	<b>99.7</b> (80.7-123)	742
20 years and older	99-00	<b>11.8</b> (10.7-12.9)	<b>12.1</b> (11.1-12.9)	<b>20.1</b> (18.4-23.3)	<b>34.3</b> (30.5-40.8)	<b>57.2</b> (41.3-73.9)	1461
	01-02	<b>12.0</b> (11.2-12.9)	<b>11.8</b> (11.2-12.5)	<b>21.6</b> (19.9-23.7)	<b>42.2</b> (35.7-48.3)	<b>64.9</b> (54.5-78.3)	1638
<b>Gender</b>							
Males	99-00	<b>12.7</b> (11.8-13.6)	<b>12.3</b> (11.6-13.0)	<b>23.7</b> (21.5-26.1)	<b>44.5</b> (35.5-57.0)	<b>73.5</b> (48.5-99.8)	1215
	01-02	<b>12.7</b> (11.4-14.2)	<b>11.9</b> (10.9-13.2)	<b>24.0</b> (21.2-26.4)	<b>49.2</b> (44.3-55.9)	<b>80.3</b> (60.9-104)	1367
Females	99-00	<b>15.3</b> (13.8-16.8)	<b>14.7</b> (13.3-16.0)	<b>25.9</b> (24.1-29.3)	<b>56.4</b> (46.8-60.6)	<b>80.0</b> (60.1-117)	1326
	01-02	<b>15.7</b> (14.2-17.3)	<b>15.1</b> (13.8-16.5)	<b>29.5</b> (25.9-34.3)	<b>58.2</b> (50.2-69.4)	<b>95.8</b> (69.4-116)	1405
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>12.6</b> (11.4-14.0)	<b>11.9</b> (10.9-13.2)	<b>24.1</b> (21.5-26.5)	<b>46.5</b> (42.0-53.8)	<b>68.1</b> (56.4-93.8)	814
	01-02	<b>12.4</b> (10.7-14.4)	<b>11.9</b> (9.97-14.8)	<b>23.7</b> (19.7-29.3)	<b>46.0</b> (36.5-61.6)	<b>72.0</b> (53.5-120)	674
Non-Hispanic blacks	99-00	<b>14.8</b> (13.5-16.3)	<b>13.6</b> (12.2-15.2)	<b>26.9</b> (22.5-31.8)	<b>55.5</b> (39.5-76.0)	<b>86.8</b> (64.4-99.8)	603
	01-02	<b>16.7</b> (14.7-19.0)	<b>15.7</b> (13.7-19.3)	<b>33.4</b> (26.5-38.0)	<b>60.1</b> (53.7-69.4)	<b>101</b> (75.6-116)	702
Non-Hispanic whites	99-00	<b>14.0</b> (12.7-15.3)	<b>13.4</b> (12.8-14.8)	<b>25.2</b> (23.1-27.4)	<b>51.5</b> (38.8-64.8)	<b>77.9</b> (67.4-90.3)	912
	01-02	<b>13.9</b> (12.9-15.0)	<b>13.0</b> (12.1-14.3)	<b>25.7</b> (24.0-28.1)	<b>53.0</b> (46.5-58.5)	<b>89.2</b> (69.4-109)	1211

**Figure 21. Mono-benzyl phthalate (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



## Mono-cyclohexyl Phthalate

CAS No. 7517-36-4

*Metabolite of Dicyclohexyl Phthalate, CAS No. 84-61-7*

### General Information

Dicyclohexyl phthalate (DCHP) is Used to stabilize some rubbers, resins, and polymers, including nitrocellulose, polyvinyl acetate, and polyvinyl chloride. People exposed to DCHP will excrete mono-cyclohexyl phthalate in their urine. Workplace air standards for external exposure have not been established for DCHP. It has not been completely classified as to its carcinogenicity by IARC and NTP.

In both the NHANES 1999-2000 and 2001-2002 subsamples, mono-cyclohexyl phthalate was characterized only at the 90<sup>th</sup> and 95<sup>th</sup> percentiles.

**Table 198. Mono-cyclohexyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	1.00 (<LOD-1.60)	2541
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.400 (.400-.500)	2782
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	1.00 (<LOD-1.10)	1.70 (1.00-3.80)	328
	01-02	*	< LOD	< LOD	.300 (.300-.500)	.600 (.500-.700)	393
12-19 years	99-00	*	< LOD	< LOD	1.00 (<LOD-1.50)	1.70 (1.00-2.40)	752
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.600)	742
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1461
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.500)	1647
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	1.00 (<LOD-2.00)	1215
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.500)	1371
Females	99-00	*	< LOD	< LOD	< LOD	1.00 (<LOD-1.70)	1326
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.500)	1411
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	814
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.300-.600)	677
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	1.00 (.900-1.20)	603
	01-02	*	< LOD	< LOD	.300 (<LOD-.400)	.400 (.400-.600)	703
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	.900 (<LOD-1.30)	912
	01-02	*	< LOD	< LOD	.400 (<LOD-.400)	.500 (.400-.500)	1216

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 199. Mono-cyclohexyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	<b>3.00</b> (2.60-3.33)	2541
	01-02	*	< LOD	< LOD	<b>.588</b> (.513-.667)	<b>.854</b> (.769-.952)	2772
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	<b>1.50</b> (1.20-1.94)	<b>2.82</b> (1.54-6.44)	328
	01-02	*	< LOD	< LOD	<b>.667</b> (.513-.741)	<b>.909</b> (.690-1.17)	392
12-19 years	99-00	*	< LOD	< LOD	<b>1.22</b> (.952-1.46)	<b>1.67</b> (1.36-1.82)	752
	01-02	*	< LOD	< LOD	<b>.465</b> (.385-.659)	<b>.769</b> (.526-1.02)	742
20 years and older	99-00	*	< LOD	< LOD	< LOD	< LOD	1461
	01-02	*	< LOD	< LOD	<b>.606</b> (.513-.669)	<b>.870</b> (.755-.952)	1638
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	<b>2.14</b> (1.62-3.16)	1215
	01-02	*	< LOD	< LOD	<b>.500</b> (.417-.625)	<b>.800</b> (.667-1.00)	1367
Females	99-00	*	< LOD	< LOD	< LOD	<b>3.28</b> (2.86-3.51)	1326
	01-02	*	< LOD	< LOD	<b>.667</b> (.588-.755)	<b>.870</b> (.769-.952)	1405
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	< LOD	814
	01-02	*	< LOD	< LOD	<b>.556</b> (.476-.669)	<b>.882</b> (.690-1.04)	674
Non-Hispanic blacks	99-00	*	< LOD	< LOD	< LOD	<b>1.43</b> (1.09-1.71)	603
	01-02	*	< LOD	< LOD	<b>.408</b> (.357-.465)	<b>.588</b> (.500-.723)	702
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	<b>3.00</b> (2.60-3.53)	912
	01-02	*	< LOD	< LOD	<b>.606</b> (.492-.690)	<b>.870</b> (.690-.952)	1211

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

## Mono-2-ethylhexyl Phthalate

CAS No. 4376-20-9

## Mono-(2-ethyl-5-hydroxyhexyl) Phthalate

## Mono-(2-ethyl-5-oxohexyl) Phthalate

CAS No. 40321-98-0

*Metabolites of Di-2-ethylhexyl Phthalate, CAS No. 117-81-7*

### General Information

Di-2-ethylhexyl phthalate (DEHP) is primarily used to produce flexible plastics, mainly polyvinyl chloride, which is used for many home and garden products, toys, packaging film, and blood-product storage and intravenous delivery systems. Concentrations in plastic materials may reach 40% by weight. DEHP has been removed from or replaced in most children's toys and food packaging in the United States. Other sources of exposure include foods and foods in contact with plastic

containing DEHP.

DEHP is metabolized into various metabolites (Albro et al., 1982; Dirven et al., 1993; Kato et al., 2004; Barr et al., 2003; Koch et al., 2003). Three of these metabolites, measured for this *Report* are mono-(2-ethyl-5-hexyl) phthalate (MEHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP).

MEHP is primarily formed by the hydrolysis of DEHP in

**Table 200. Mono-2-ethylhexyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>3.43</b> (3.19-3.69)	<b>3.20</b> (2.90-3.50)	<b>7.60</b> (6.80-8.20)	<b>14.8</b> (13.5-17.4)	<b>23.8</b> (19.2-28.6)	2541
	01-02	<b>4.27</b> (3.80-4.79)	<b>4.10</b> (3.60-4.90)	<b>9.80</b> (8.40-11.6)	<b>22.8</b> (18.9-27.4)	<b>38.9</b> (31.8-50.0)	2782
<b>Age group</b>							
6-11 years	99-00	<b>5.12</b> (4.42-5.92)	<b>4.90</b> (3.30-5.80)	<b>11.1</b> (8.30-13.6)	<b>19.0</b> (13.8-36.1)	<b>34.5</b> (15.6-130)	328
	01-02	<b>4.41</b> (3.90-5.00)	<b>4.40</b> (4.10-5.30)	<b>9.20</b> (7.80-11.7)	<b>19.3</b> (14.6-25.9)	<b>29.9</b> (20.7-47.4)	393
12-19 years	99-00	<b>3.75</b> (3.24-4.35)	<b>3.70</b> (2.80-4.60)	<b>8.10</b> (6.40-9.40)	<b>15.0</b> (11.4-20.5)	<b>22.8</b> (19.1-29.2)	752
	01-02	<b>4.57</b> (3.96-5.27)	<b>4.50</b> (3.70-5.10)	<b>11.0</b> (9.50-13.5)	<b>23.0</b> (17.6-31.7)	<b>42.5</b> (25.9-57.5)	742
20 years and older	99-00	<b>3.21</b> (2.94-3.51)	<b>3.00</b> (2.70-3.30)	<b>7.20</b> (6.40-8.00)	<b>14.2</b> (12.1-16.8)	<b>22.4</b> (17.5-27.0)	1461
	01-02	<b>4.20</b> (3.63-4.86)	<b>4.10</b> (3.40-4.80)	<b>9.40</b> (8.10-11.9)	<b>23.5</b> (18.0-29.8)	<b>39.5</b> (30.3-57.1)	1647
<b>Gender</b>							
Males	99-00	<b>3.68</b> (3.31-4.10)	<b>3.40</b> (2.90-3.90)	<b>8.00</b> (7.30-8.80)	<b>16.0</b> (14.0-19.0)	<b>25.3</b> (19.5-36.7)	1215
	01-02	<b>4.31</b> (3.84-4.83)	<b>4.30</b> (3.70-5.10)	<b>9.60</b> (8.20-11.1)	<b>23.0</b> (16.9-29.8)	<b>37.9</b> (29.9-48.4)	1371
Females	99-00	<b>3.21</b> (2.91-3.54)	<b>3.00</b> (2.80-3.40)	<b>7.00</b> (5.70-8.20)	<b>13.5</b> (11.4-15.3)	<b>21.6</b> (15.6-28.5)	1326
	01-02	<b>4.23</b> (3.67-4.86)	<b>4.10</b> (3.40-4.80)	<b>9.70</b> (8.40-12.2)	<b>23.0</b> (19.4-28.4)	<b>42.5</b> (31.4-53.7)	1411
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>3.49</b> (3.16-3.85)	<b>3.50</b> (2.90-3.80)	<b>7.00</b> (5.70-8.60)	<b>13.3</b> (10.7-18.7)	<b>23.9</b> (17.4-27.3)	814
	01-02	<b>4.32</b> (3.75-4.98)	<b>4.70</b> (3.80-5.70)	<b>10.1</b> (8.30-11.0)	<b>19.4</b> (16.6-23.0)	<b>28.4</b> (24.2-39.9)	677
Non-Hispanic blacks	99-00	<b>4.82</b> (3.92-5.93)	<b>5.10</b> (4.10-5.80)	<b>9.40</b> (7.60-11.4)	<b>19.5</b> (12.9-26.5)	<b>29.2</b> (18.6-60.3)	603
	01-02	<b>6.60</b> (5.57-7.82)	<b>6.70</b> (5.40-8.10)	<b>15.4</b> (13.0-18.7)	<b>32.7</b> (26.5-41.4)	<b>52.1</b> (41.0-84.0)	703
Non-Hispanic whites	99-00	<b>3.16</b> (2.89-3.46)	<b>2.80</b> (2.50-3.10)	<b>7.30</b> (6.30-8.20)	<b>14.4</b> (12.2-17.0)	<b>22.4</b> (16.9-28.5)	912
	01-02	<b>3.85</b> (3.37-4.40)	<b>3.60</b> (3.10-4.30)	<b>8.60</b> (7.70-9.90)	<b>20.9</b> (17.3-25.9)	<b>37.9</b> (29.9-49.5)	1216

the gastrointestinal tract and then absorbed. MEOHP and MEHHP are produced by the oxidative metabolism of MEHP and are present at roughly three- to ten-fold higher concentrations than MEHP in urine (Barr et al., 2003; Koch et al., 2003).

MEHP is considered a toxic metabolite of DEHP. Liver toxicity, decreased testicular weight, and testicular atrophy have been observed in animal studies at high or chronic doses (Center for the Evaluation of Risks to Human Reproduction, 2003). DEHP has also been observed to suppress estradiol production in female rats (Lovecamp-Swan and Davis, 2003). Recently, the U.S. Food and Drug Administration (U.S. FDA) considered the amounts of DEHP or MEHP received from intravenous delivery systems or blood transfusions (MEHP is formed in situ in blood from DEHP) to be below thresholds likely to cause injury in adults. However, in lifesaving instances during which neonates would receive exchange blood transfusions, relatively higher exposures might occur (<http://www.fda.gov/cdrh/>

[ost/dehp-pvc.pdf](#); Calafat et al., 2004).

Workplace air standards for external exposure to DEHP are generally established by OSHA and ACGIH. It is classified as a probable human carcinogen by the U.S. EPA, reasonably anticipated to be a human carcinogen by NTP, but considered not classifiable by IARC.

### Interpreting Levels of Urinary Di-2-ethylhexyl Phthalate Metabolites in the Tables

The levels of MEHP in the NHANES 2001-2002 subsample appear roughly comparable to those reported previously for U.S. residents (Blount et al., 2000) and in a small sample of pregnant women in New York City (Adibi et al., 2003), and in men from an infertility clinic (Duty et al., 2004). Levels of MEHP, MEOHP, and MHHP were similar or up to two-fold higher in a sample of German residents (Koch et al., 2003) and German children (Koch et al., 2004; Becker et al., 2004).

**Table 201. Mono-2-ethylhexyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean	Selected percentiles				Sample size
		(95% conf. interval)	(95% confidence interval)				
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>3.12</b> (2.95-3.31)	<b>3.08</b> (2.82-3.27)	<b>5.88</b> (5.38-6.25)	<b>10.8</b> (9.62-12.5)	<b>18.5</b> (15.0-21.8)	2541
	01-02	<b>3.99</b> (3.57-4.46)	<b>3.89</b> (3.42-4.44)	<b>7.94</b> (7.14-9.02)	<b>18.2</b> (15.4-21.6)	<b>32.8</b> (25.2-42.9)	2772
<b>Age group</b>							
6-11 years	99-00	<b>5.19</b> (4.55-5.93)	<b>5.37</b> (4.52-5.95)	<b>9.11</b> (8.06-11.4)	<b>21.6</b> (11.5-41.9)	<b>41.9</b> (13.5-86.2)	328
	01-02	<b>5.02</b> (4.47-5.64)	<b>5.38</b> (4.51-6.21)	<b>9.82</b> (7.87-11.0)	<b>20.9</b> (13.7-28.8)	<b>31.2</b> (24.3-40.7)	392
12-19 years	99-00	<b>2.53</b> (2.14-2.99)	<b>2.31</b> (2.05-2.76)	<b>5.83</b> (4.38-6.29)	<b>9.63</b> (7.41-11.5)	<b>12.1</b> (10.5-17.3)	752
	01-02	<b>3.53</b> (3.09-4.03)	<b>3.62</b> (2.89-4.48)	<b>7.45</b> (6.51-8.67)	<b>15.2</b> (11.7-21.9)	<b>25.2</b> (17.7-32.8)	742
20 years and older	99-00	<b>3.03</b> (2.83-3.25)	<b>2.98</b> (2.73-3.23)	<b>5.55</b> (4.90-6.06)	<b>10.0</b> (8.60-12.9)	<b>17.5</b> (13.8-22.1)	1461
	01-02	<b>3.96</b> (3.48-4.50)	<b>3.81</b> (3.24-4.37)	<b>7.77</b> (6.88-9.00)	<b>18.4</b> (15.3-22.1)	<b>33.3</b> (23.1-47.9)	1638
<b>Gender</b>							
Males	99-00	<b>2.89</b> (2.60-3.22)	<b>2.76</b> (2.52-2.96)	<b>5.58</b> (4.71-6.08)	<b>10.3</b> (9.35-12.4)	<b>21.6</b> (14.1-27.7)	1215
	01-02	<b>3.49</b> (3.06-3.98)	<b>3.32</b> (2.76-3.90)	<b>7.00</b> (6.46-7.77)	<b>16.2</b> (12.9-20.9)	<b>31.2</b> (20.1-49.9)	1367
Females	99-00	<b>3.36</b> (3.11-3.63)	<b>3.33</b> (2.90-3.80)	<b>6.15</b> (5.55-6.77)	<b>11.1</b> (9.02-14.0)	<b>16.3</b> (12.4-24.6)	1326
	01-02	<b>4.53</b> (4.01-5.11)	<b>4.43</b> (3.79-5.13)	<b>9.17</b> (7.93-10.3)	<b>20.4</b> (16.6-24.8)	<b>35.1</b> (27.7-42.0)	1405
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>3.16</b> (2.72-3.68)	<b>3.15</b> (2.52-3.81)	<b>5.88</b> (4.86-7.24)	<b>11.6</b> (9.63-13.1)	<b>15.7</b> (12.6-23.1)	814
	01-02	<b>4.05</b> (3.57-4.61)	<b>4.16</b> (3.75-4.89)	<b>7.76</b> (6.47-9.60)	<b>16.4</b> (13.5-18.9)	<b>24.5</b> (19.8-28.7)	674
Non-Hispanic blacks	99-00	<b>3.11</b> (2.59-3.73)	<b>3.13</b> (2.50-3.61)	<b>5.84</b> (4.43-7.32)	<b>10.2</b> (8.05-15.6)	<b>18.4</b> (11.6-35.2)	603
	01-02	<b>4.63</b> (3.95-5.42)	<b>4.59</b> (3.97-5.02)	<b>9.89</b> (7.95-12.5)	<b>21.2</b> (16.0-33.2)	<b>39.8</b> (27.1-48.1)	702
Non-Hispanic whites	99-00	<b>3.09</b> (2.84-3.36)	<b>3.08</b> (2.73-3.47)	<b>5.87</b> (5.11-6.67)	<b>10.6</b> (8.95-13.5)	<b>20.0</b> (13.7-23.9)	912
	01-02	<b>3.80</b> (3.33-4.33)	<b>3.63</b> (3.11-4.32)	<b>7.71</b> (6.63-9.17)	<b>17.0</b> (13.8-21.8)	<b>32.8</b> (21.5-46.9)	1211


### Comparing Adjusted Geometric Means

Geometric mean levels of urinary MEHP for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown). In NHANES 2001-2002, adjusted geometric mean levels of urinary MEHP were higher in children aged 6-11 years than in people aged 12-19 years and 20 years. Females had slightly higher levels than in males. Adjusted geometric mean levels in non-Hispanic blacks were higher than levels in non-Hispanic whites.

Geometric mean levels of urinary MEOHP and MEHHP for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine. In the NHANES 2001-2002 subsample (not measured in NHANES 1999-2000), levels of MEOHP and MEHHP were found to be higher in children aged 6-11 years than in people aged 12-19 years and 20 years and older. For MEOHP, females had slightly higher levels than males. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight. Koch et al. (2004) showed that levels of MEHP, MEOHP, and MEHHP were higher in nursery school children (aged 2-6 years) than in their teachers or parents. In another study of children (Becker et al., 2004), boys showed higher levels of all three DEHP metabolites than girls, and lower concentrations of MEHHP and MEOHP were seen in children aged 13-14 years compared with younger children.

**Figure 22. Mono-2-ethylhexyl phthalate (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older. National Health and Nutrition Examination Survey, 1999-2002.



**Table 202. Mono-(2-ethyl-5-hydroxyhexyl) phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>20.0</b> (17.8-22.5)	<b>20.1</b> (17.8-22.4)	<b>43.6</b> (38.0-49.7)	<b>91.3</b> (77.0-108)	<b>192</b> (131-256)	2782
<b>Age group</b>							
6-11 years	01-02	<b>33.6</b> (29.7-37.9)	<b>32.9</b> (26.9-39.1)	<b>66.9</b> (49.7-74.0)	<b>126</b> (103-148)	<b>210</b> (137-280)	393
12-19 years	01-02	<b>24.9</b> (21.3-29.1)	<b>25.2</b> (22.9-31.3)	<b>50.6</b> (40.7-64.5)	<b>107</b> (78.5-148)	<b>202</b> (114-280)	742
20 years and older	01-02	<b>18.1</b> (15.7-20.9)	<b>17.7</b> (14.7-20.7)	<b>39.8</b> (32.5-47.8)	<b>86.2</b> (65.7-107)	<b>175</b> (110-279)	1647
<b>Gender</b>							
Males	01-02	<b>22.0</b> (19.5-24.7)	<b>21.2</b> (19.4-23.9)	<b>47.8</b> (40.9-54.3)	<b>94.2</b> (80.8-110)	<b>212</b> (130-256)	1371
Females	01-02	<b>18.3</b> (15.7-21.4)	<b>18.2</b> (14.9-22.1)	<b>39.8</b> (34.2-46.0)	<b>86.0</b> (69.4-115)	<b>170</b> (119-273)	1411
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>18.5</b> (16.2-21.1)	<b>19.0</b> (16.2-21.6)	<b>36.3</b> (31.6-44.0)	<b>79.9</b> (66.4-93.9)	<b>123</b> (100-161)	677
Non-Hispanic blacks	01-02	<b>29.8</b> (26.1-34.1)	<b>30.9</b> (27.2-34.3)	<b>61.9</b> (52.6-68.3)	<b>126</b> (108-157)	<b>276</b> (157-339)	703
Non-Hispanic whites	01-02	<b>19.1</b> (16.7-21.9)	<b>19.2</b> (16.8-21.3)	<b>41.7</b> (35.3-50.7)	<b>91.1</b> (75.6-110)	<b>212</b> (130-275)	1216

**Table 203. Mono-(2-ethyl-5-hydroxyhexyl) phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>18.8</b> (17.0-20.8)	<b>16.6</b> (14.9-18.6)	<b>32.3</b> (27.8-37.2)	<b>70.8</b> (58.4-88.3)	<b>147</b> (101-200)	2772
<b>Age group</b>							
6-11 years	01-02	<b>38.3</b> (34.3-42.6)	<b>34.2</b> (29.9-38.9)	<b>60.4</b> (51.9-76.4)	<b>107</b> (96.3-147)	<b>211</b> (122-313)	392
12-19 years	01-02	<b>19.2</b> (17.0-21.8)	<b>17.7</b> (15.6-20.0)	<b>34.9</b> (29.2-42.6)	<b>73.4</b> (58.4-80.7)	<b>102</b> (86.6-160)	742
20 years and older	01-02	<b>17.2</b> (15.2-19.4)	<b>15.0</b> (13.3-16.7)	<b>27.7</b> (23.2-34.7)	<b>63.2</b> (48.3-88.3)	<b>134</b> (84.7-207)	1638
<b>Gender</b>							
Males	01-02	<b>17.9</b> (16.2-19.7)	<b>15.4</b> (13.8-17.8)	<b>32.4</b> (28.0-37.2)	<b>73.4</b> (55.3-91.8)	<b>136</b> (97.7-224)	1367
Females	01-02	<b>19.7</b> (17.3-22.5)	<b>17.6</b> (15.4-19.5)	<b>32.3</b> (26.8-38.9)	<b>69.3</b> (57.6-93.7)	<b>160</b> (93.7-201)	1405
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>17.5</b> (15.9-19.2)	<b>15.7</b> (14.6-17.6)	<b>30.7</b> (26.1-35.7)	<b>65.3</b> (50.6-83.9)	<b>106</b> (76.3-130)	674
Non-Hispanic blacks	01-02	<b>21.0</b> (18.8-23.3)	<b>19.7</b> (17.5-21.8)	<b>38.3</b> (32.1-46.0)	<b>93.5</b> (69.2-124)	<b>161</b> (130-183)	702
Non-Hispanic whites	01-02	<b>19.0</b> (17.1-21.1)	<b>16.3</b> (14.8-18.4)	<b>32.4</b> (27.6-37.3)	<b>71.5</b> (57.8-94.3)	<b>178</b> (99.3-242)	1211

**Table 204. Mono-(2-ethyl-5-oxohexyl) phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>13.5</b> (12.0-15.0)	<b>14.0</b> (12.5-15.1)	<b>29.6</b> (25.2-34.0)	<b>59.9</b> (50.4-70.9)	<b>120</b> (87.2-156)	2782
<b>Age group</b>							
6-11 years	01-02	<b>23.3</b> (20.9-26.1)	<b>22.6</b> (18.5-28.1)	<b>46.5</b> (38.1-52.0)	<b>80.5</b> (64.7-109)	<b>142</b> (93.9-178)	393
12-19 years	01-02	<b>17.5</b> (15.1-20.3)	<b>18.5</b> (16.0-20.7)	<b>35.0</b> (27.6-42.1)	<b>69.9</b> (52.2-104)	<b>118</b> (74.0-174)	742
20 years and older	01-02	<b>12.0</b> (10.5-13.9)	<b>12.2</b> (10.4-14.1)	<b>25.9</b> (21.3-32.1)	<b>52.3</b> (41.8-68.3)	<b>115</b> (74.9-160)	1647
<b>Gender</b>							
Males	01-02	<b>14.5</b> (13.0-16.2)	<b>14.6</b> (13.0-16.1)	<b>31.6</b> (25.6-34.7)	<b>60.4</b> (52.3-71.4)	<b>129</b> (84.4-167)	1371
Females	01-02	<b>12.5</b> (10.8-14.6)	<b>13.0</b> (10.9-14.9)	<b>28.1</b> (23.7-33.5)	<b>57.5</b> (45.8-72.7)	<b>115</b> (81.8-147)	1411
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>13.1</b> (11.6-14.9)	<b>13.2</b> (11.6-15.0)	<b>25.3</b> (21.6-30.8)	<b>56.6</b> (40.6-70.3)	<b>76.5</b> (70.5-101)	677
Non-Hispanic blacks	01-02	<b>19.6</b> (17.1-22.5)	<b>20.0</b> (17.9-22.4)	<b>39.0</b> (34.8-44.2)	<b>80.5</b> (71.4-97.4)	<b>148</b> (102-228)	703
Non-Hispanic whites	01-02	<b>12.8</b> (11.2-14.6)	<b>13.1</b> (11.6-14.6)	<b>28.5</b> (23.6-34.0)	<b>58.6</b> (48.8-70.9)	<b>126</b> (83.7-172)	1216

**Table 205. Mono-(2-ethyl-5-oxohexyl) phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>12.6</b> (11.5-13.9)	<b>11.2</b> (10.2-12.3)	<b>21.3</b> (18.3-23.9)	<b>45.1</b> (37.1-58.1)	<b>87.5</b> (69.0-124)	2772
<b>Age group</b>							
6-11 years	01-02	<b>26.6</b> (24.0-29.4)	<b>22.8</b> (20.3-25.0)	<b>43.3</b> (33.6-48.2)	<b>74.4</b> (69.0-91.9)	<b>130</b> (83.0-187)	392
12-19 years	01-02	<b>13.5</b> (12.0-15.2)	<b>12.0</b> (10.8-14.3)	<b>23.4</b> (19.9-28.5)	<b>48.4</b> (39.2-54.9)	<b>70.5</b> (55.0-97.2)	742
20 years and older	01-02	<b>11.4</b> (10.2-12.8)	<b>10.1</b> (8.90-11.4)	<b>17.5</b> (15.2-21.9)	<b>39.0</b> (30.3-53.9)	<b>84.3</b> (53.1-134)	1638
<b>Gender</b>							
Males	01-02	<b>11.8</b> (10.7-13.0)	<b>10.2</b> (8.93-11.7)	<b>21.0</b> (18.5-23.0)	<b>46.1</b> (34.9-58.7)	<b>83.1</b> (69.7-104)	1367
Females	01-02	<b>13.5</b> (11.9-15.3)	<b>12.0</b> (10.8-13.7)	<b>21.5</b> (18.0-25.9)	<b>44.8</b> (36.8-61.9)	<b>92.3</b> (59.3-139)	1405
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>12.4</b> (11.4-13.5)	<b>10.8</b> (10.5-12.4)	<b>20.8</b> (18.5-24.4)	<b>46.4</b> (33.4-56.5)	<b>65.8</b> (53.1-83.1)	674
Non-Hispanic blacks	01-02	<b>13.8</b> (12.3-15.4)	<b>13.0</b> (12.0-14.1)	<b>23.9</b> (20.0-29.2)	<b>58.3</b> (45.3-77.7)	<b>101</b> (81.3-124)	702
Non-Hispanic whites	01-02	<b>12.7</b> (11.4-14.1)	<b>11.2</b> (9.91-12.3)	<b>21.0</b> (18.0-24.0)	<b>45.8</b> (36.2-66.0)	<b>96.0</b> (68.5-161)	1211

## Mono-3-carboxypropyl Phthalate

### Mono-n-octyl Phthalate

CAS No. 5393-19-1

*Metabolites of di-n-octyl phthalate, CAS No. 117-84-0*

#### General Information

Di-n-octylphthalate (DOP) is used primarily to produce flexible plastics. People exposed to DOP will excrete primarily mono-3-carboxypropyl phthalate (MCP) and smaller amounts of mono-n-octyl phthalate (MOP) in their urine. Workplace air standards for external exposure are established for DOP by OSHA. Like other phthalates, DOP has low acute toxicity. It has not been classified with respect to carcinogenicity by IARC and NTP.

#### Interpreting Levels of Urinary Mono-3-carboxypropyl and Mono-n-octyl Phthalates in the Tables

In both the NHANES 1999-2000 and 2001-2002 subsamples, MOP was only detectable at the 90<sup>th</sup> and 95<sup>th</sup> percentiles. A low detection rate was also reported in a small sample of German residents (Koch et al., 2003). MCP levels were measured only in the 2001-2002

subsample and were higher in children aged 6-11 years than in people aged 12-19 years and 20 years and older; the group aged 12-19 years had higher levels than in the group aged 20 years and older. Females had slightly higher levels than males. Additionally, levels of MCP were lower in non-Hispanic blacks than in either non-Hispanic whites or Mexican Americans. It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

**Table 206. Mono-3-carboxypropyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>2.75</b> (2.49-3.04)	<b>3.00</b> (2.80-3.30)	<b>5.70</b> (5.00-6.30)	<b>10.0</b> (8.80-11.2)	<b>14.6</b> (12.7-17.5)	2782
<b>Age group</b>							
6-11 years	01-02	<b>6.11</b> (5.46-6.84)	<b>6.60</b> (5.40-7.50)	<b>11.8</b> (10.2-13.2)	<b>20.1</b> (17.8-23.1)	<b>24.7</b> (22.2-31.6)	393
12-19 years	01-02	<b>3.71</b> (3.18-4.33)	<b>4.00</b> (3.40-4.70)	<b>7.00</b> (6.10-8.10)	<b>11.5</b> (9.50-12.7)	<b>13.9</b> (11.8-19.0)	742
20 years and older	01-02	<b>2.37</b> (2.11-2.66)	<b>2.60</b> (2.20-3.00)	<b>4.80</b> (4.20-5.30)	<b>8.10</b> (7.10-9.20)	<b>12.0</b> (10.0-14.2)	1647
<b>Gender</b>							
Males	01-02	<b>2.89</b> (2.64-3.17)	<b>3.10</b> (2.80-3.30)	<b>5.60</b> (4.90-6.70)	<b>9.80</b> (8.70-12.0)	<b>14.2</b> (12.4-18.0)	1371
Females	01-02	<b>2.62</b> (2.29-2.99)	<b>3.00</b> (2.40-3.30)	<b>5.60</b> (4.90-6.30)	<b>10.0</b> (8.30-11.2)	<b>14.7</b> (11.2-20.3)	1411
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>2.67</b> (2.26-3.16)	<b>3.00</b> (2.30-3.40)	<b>5.30</b> (4.40-5.90)	<b>9.10</b> (7.30-12.4)	<b>13.6</b> (10.4-18.7)	677
Non-Hispanic blacks	01-02	<b>3.09</b> (2.81-3.40)	<b>3.20</b> (2.90-3.50)	<b>6.30</b> (5.50-6.50)	<b>10.8</b> (9.10-13.0)	<b>14.9</b> (13.5-22.4)	703
Non-Hispanic whites	01-02	<b>2.72</b> (2.40-3.08)	<b>2.90</b> (2.50-3.30)	<b>5.70</b> (4.80-6.70)	<b>10.3</b> (8.90-11.9)	<b>15.8</b> (12.6-19.5)	1216

**Table 207. Mono-3-carboxypropyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 2001-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	01-02	<b>2.57</b> (2.34-2.82)	<b>2.45</b> (2.23-2.76)	<b>4.07</b> (3.85-4.46)	<b>7.25</b> (6.59-8.01)	<b>11.4</b> (10.1-12.6)	2772
<b>Age group</b>							
6-11 years	01-02	<b>6.96</b> (6.29-7.71)	<b>7.07</b> (5.77-7.87)	<b>11.3</b> (9.27-14.0)	<b>20.7</b> (15.5-22.3)	<b>26.4</b> (20.7-27.0)	392
12-19 years	01-02	<b>2.86</b> (2.52-3.25)	<b>2.93</b> (2.50-3.36)	<b>4.57</b> (4.03-5.23)	<b>6.69</b> (6.30-7.25)	<b>9.44</b> (8.03-10.7)	742
20 years and older	01-02	<b>2.24</b> (2.03-2.47)	<b>2.19</b> (1.99-2.39)	<b>3.49</b> (3.10-3.93)	<b>5.32</b> (4.79-6.18)	<b>7.71</b> (6.71-9.28)	1638
<b>Gender</b>							
Males	01-02	<b>2.35</b> (2.16-2.56)	<b>2.20</b> (2.01-2.42)	<b>3.76</b> (3.45-4.20)	<b>7.16</b> (6.03-7.98)	<b>11.6</b> (9.28-15.4)	1367
Females	01-02	<b>2.80</b> (2.47-3.18)	<b>2.75</b> (2.44-3.01)	<b>4.37</b> (3.97-4.86)	<b>7.65</b> (6.17-8.69)	<b>11.1</b> (8.66-15.9)	1405
<b>Race/ethnicity</b>							
Mexican Americans	01-02	<b>2.51</b> (2.20-2.87)	<b>2.36</b> (2.05-2.73)	<b>4.24</b> (3.65-5.00)	<b>7.42</b> (5.58-10.3)	<b>11.2</b> (8.18-14.5)	674
Non-Hispanic blacks	01-02	<b>2.17</b> (2.02-2.33)	<b>2.07</b> (1.88-2.28)	<b>3.64</b> (3.24-4.07)	<b>6.73</b> (5.46-7.70)	<b>10.0</b> (8.27-13.1)	702
Non-Hispanic whites	01-02	<b>2.69</b> (2.41-3.00)	<b>2.56</b> (2.23-2.92)	<b>4.16</b> (3.87-4.76)	<b>7.66</b> (6.59-8.47)	<b>11.8</b> (10.0-14.7)	1211

**Table 208. Mono-n-octyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	<b>1.60</b> (1.20-2.00)	<b>2.90</b> (2.20-3.30)	2541
	01-02	*	< LOD	< LOD	< LOD	< LOD	2782
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	<b>2.00</b> (.900-3.50)	<b>3.20</b> (1.70-4.30)	328
	01-02	*	< LOD	< LOD	< LOD	< LOD	393
12-19 years	99-00	*	< LOD	< LOD	<b>1.60</b> (.900-2.50)	<b>2.80</b> (2.00-4.20)	752
	01-02	*	< LOD	< LOD	< LOD	< LOD	742
20 years and older	99-00	*	< LOD	< LOD	<b>1.50</b> (1.10-1.90)	<b>2.90</b> (2.00-3.50)	1461
	01-02	*	< LOD	< LOD	< LOD	< LOD	1647
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>1.60</b> (1.10-2.10)	<b>2.80</b> (2.00-3.40)	1215
	01-02	*	< LOD	< LOD	< LOD	< LOD	1371
Females	99-00	*	< LOD	< LOD	<b>1.40</b> (1.10-2.00)	<b>3.10</b> (2.20-3.70)	1326
	01-02	*	< LOD	< LOD	< LOD	< LOD	1411
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>1.00</b> (<LOD-1.40)	<b>1.50</b> (1.40-2.60)	814
	01-02	*	< LOD	< LOD	< LOD	< LOD	677
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>1.80</b> (<LOD-3.00)	<b>3.00</b> (2.20-3.70)	603
	01-02	*	< LOD	< LOD	< LOD	< LOD	703
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>1.50</b> (1.20-2.10)	<b>3.00</b> (2.30-3.50)	912
	01-02	*	< LOD	< LOD	< LOD	< LOD	1216

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 209. Mono-n-octyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	<b>2.40</b> (2.07-2.61)	<b>3.51</b> (2.86-4.29)	2541
	01-02	*	< LOD	< LOD	< LOD	< LOD	2772
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	<b>2.22</b> (1.60-3.75)	<b>3.75</b> (1.97-10.3)	328
	01-02	*	< LOD	< LOD	< LOD	< LOD	392
12-19 years	99-00	*	< LOD	< LOD	<b>1.49</b> (1.29-1.71)	<b>1.82</b> (1.54-3.33)	752
	01-02	*	< LOD	< LOD	< LOD	< LOD	742
20 years and older	99-00	*	< LOD	< LOD	<b>2.56</b> (2.07-2.91)	<b>3.47</b> (2.86-4.29)	1461
	01-02	*	< LOD	< LOD	< LOD	< LOD	1638
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	<b>1.82</b> (1.54-2.05)	<b>2.52</b> (1.94-3.45)	1215
	01-02	*	< LOD	< LOD	< LOD	< LOD	1367
Females	99-00	*	< LOD	< LOD	<b>2.95</b> (2.50-3.55)	<b>4.00</b> (3.33-5.56)	1326
	01-02	*	< LOD	< LOD	< LOD	< LOD	1405
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	<b>1.82</b> (1.43-2.61)	<b>3.16</b> (2.60-4.00)	814
	01-02	*	< LOD	< LOD	< LOD	< LOD	674
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>1.36</b> (1.03-1.94)	<b>2.18</b> (1.50-3.27)	603
	01-02	*	< LOD	< LOD	< LOD	< LOD	702
Non-Hispanic whites	99-00	*	< LOD	< LOD	<b>2.60</b> (2.07-3.00)	<b>3.60</b> (3.00-4.62)	912
	01-02	*	< LOD	< LOD	< LOD	< LOD	1211

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

## Mono-isononyl Phthalate

*Metabolite of Di-isononyl Phthalate, CAS No. 28553-12-0*

### General Information

Di-isononyl phthalate (DiNP) is actually a mixture of phthalates with branched alkyl side chains of varying length (C8, C9, and C10). DiNP is primarily used to produce flexible plastics and has been used to replace di-2-ethylhexyl phthalate (DEHP) in some plastics. DiNP is now widely used in such products as children's toys, flooring, gloves, drinking straws, and garden hoses. People exposed to DiNP will excrete small amounts of mono-isononyl phthalate (MiNP) in their urine. As with DEHP, other oxidative metabolites of DiNP are probably the most abundant urinary metabolites (McKee et al., 2002). Because DiNP is a complex mixture, MiNP may not reflect total exposure to all DiNP components.

Workplace air standards for external exposure have not been established for DiNP, which although considered an animal carcinogen, has not been completely classified as to human carcinogenicity (IARC, NTP).

In both the NHANES 1999-2000 and 2001-2002 subsamples, MiNP was detectable only at the 95<sup>th</sup> percentiles.

**Table 210. Mono-isononyl phthalate**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	<b>3.50</b> (<LOD-13.8)	2541
	01-02	*	< LOD	< LOD	< LOD	< LOD	2782
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	<b>5.70</b> (<LOD-22.5)	328
	01-02	*	< LOD	< LOD	< LOD	< LOD	393
12-19 years	99-00	*	< LOD	< LOD	< LOD	<b>2.30</b> (<LOD-20.3)	752
	01-02	*	< LOD	< LOD	< LOD	< LOD	742
20 years and older	99-00	*	< LOD	< LOD	< LOD	<b>3.10</b> (<LOD-13.2)	1461
	01-02	*	< LOD	< LOD	< LOD	< LOD	1647
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	<b>4.90</b> (<LOD-18.9)	1215
	01-02	*	< LOD	< LOD	< LOD	< LOD	1371
Females	99-00	*	< LOD	< LOD	< LOD	<b>2.50</b> (<LOD-6.80)	1326
	01-02	*	< LOD	< LOD	< LOD	< LOD	1411
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	<b>1.40</b> (<LOD-2.70)	814
	01-02	*	< LOD	< LOD	< LOD	<b>1.00</b> (<LOD-1.20)	677
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>2.30</b> (<LOD-13.8)	<b>6.80</b> (<LOD-30.2)	603
	01-02	*	< LOD	< LOD	< LOD	<b>1.00</b> (<LOD-1.70)	703
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	<b>3.50</b> (<LOD-16.0)	912
	01-02	*	< LOD	< LOD	< LOD	< LOD	1216

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

**Table 211. Mono-isononyl phthalate (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	*	< LOD	< LOD	< LOD	<b>4.29</b> (2.86-7.88)	2541
	01-02	*	< LOD	< LOD	< LOD	< LOD	2772
<b>Age group</b>							
6-11 years	99-00	*	< LOD	< LOD	< LOD	<b>6.00</b> (2.77-14.2)	328
	01-02	*	< LOD	< LOD	< LOD	< LOD	392
12-19 years	99-00	*	< LOD	< LOD	< LOD	<b>1.94</b> (1.30-7.65)	752
	01-02	*	< LOD	< LOD	< LOD	< LOD	742
20 years and older	99-00	*	< LOD	< LOD	< LOD	<b>4.62</b> (3.16-7.93)	1461
	01-02	*	< LOD	< LOD	< LOD	< LOD	1638
<b>Gender</b>							
Males	99-00	*	< LOD	< LOD	< LOD	<b>4.24</b> (1.94-10.2)	1215
	01-02	*	< LOD	< LOD	< LOD	< LOD	1367
Females	99-00	*	< LOD	< LOD	< LOD	<b>4.29</b> (3.33-5.79)	1326
	01-02	*	< LOD	< LOD	< LOD	< LOD	1405
<b>Race/ethnicity</b>							
Mexican Americans	99-00	*	< LOD	< LOD	< LOD	<b>3.51</b> (2.86-5.00)	814
	01-02	*	< LOD	< LOD	< LOD	<b>2.31</b> (1.76-2.73)	674
Non-Hispanic blacks	99-00	*	< LOD	< LOD	<b>2.03</b> (.759-5.31)	<b>4.26</b> (1.43-14.3)	603
	01-02	*	< LOD	< LOD	< LOD	<b>1.62</b> (1.25-1.88)	702
Non-Hispanic whites	99-00	*	< LOD	< LOD	< LOD	<b>5.00</b> (3.00-10.0)	912
	01-02	*	< LOD	< LOD	< LOD	< LOD	1211

< LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. See Appendix A for LODs.

\* Not calculated. Proportion of results below limit of detection was too high to provide a valid result.

## Results by Chemical Group

---

### Phytoestrogens



## Phytoestrogens

### General Information

Phytoestrogens are naturally occurring chemical constituents of certain plants that may interact with estrogen receptors to produce estrogenic effects. Two major groups of phytoestrogens found in people's diets are isoflavones and lignans.

The major isoflavones include daidzein, genistein, O-desmethylangolensin, glycitein, and equol. Plant sources of isoflavones include legumes, with the largest contribution coming from soybeans and soy-based products. Soy flour and soy protein isolates are often added to processed meats, meat substitutes, breads, and protein food bars and can be a major source of isoflavones (Grace et al., 2004, Lampe et al., 1999). Formononetin and biochanin A are methylated isoflavones found in clovers and are metabolized in the body to daidzein and genistein. Daidzein is further metabolized to O-desmethylangolensin in the body and to equol by intestinal bacteria. The richest source of total isoflavones is mature red clover leaf (containing mainly biochanin A and formononetin, with lesser amounts of genistein, daidzein, and other related molecules), followed by kudzu root, and soy (richest source of the isoflavone genistein). Naringenin (precursor to genistein) and hesperetin are flavonoids found in higher amounts in citrus fruits.

Lignans include matairesinol, secoisolariciresinol, enterolactone, and enterodiol. The dietary lignans matairesinol and secoisolariciresinol are transformed by gut flora into enterolactone and enterodiol, respectively. Enterodiol may also interconvert with enterolactone. Lignans are found in flax seeds (richest source of secoisolariciresinol and matairesinol), and cereal grains. Other phytoestrogens are found in other plants. For example, the phytoestrogens resveratrol and *trans*-resveratrol are both found in grape skins and wine.

Diet is the major source of human exposure to phytoestrogens. The absorption and metabolism of phytoestrogens demonstrate large interindividual variability, which may relate to differences in both in human pharmacokinetics and metabolism by gut flora. Phytoestrogens are ingested in their natural beta-glycosidic forms, with the bioavailability of the glycosides exceeding the bioavailability of free aglycones. The beta-glycosidic forms are hydrolyzed to their aglycones in the intestine, absorbed, and then glucuronidated in the intestinal wall. The glucuronidated

**Table 212. Phytoestrogens**

Phytoestrogen	CAS number
Daidzein	486-66-8
Enterodiol	80226-00-2
Enterolactone	78473-71-9
Equol	531-95-3
Genistein	446-72-0
O-Desmethylangolensin	21255-69-6

metabolites of isoflavones predominate in blood and urine (Setchell et al., 2001, Adlercreutz et al., 1995b).

Phytoestrogens persist in plasma for about 24 hours. The isoflavones are excreted in both urine and feces. (Setchell et al., 2001). Results of studies with flax seed show that plasma and urine concentrations increased in a dose-dependent manner (Nesbitt et al., 1999). Equol excretion may depend on diet and the type of intestinal flora present (Hutchins et al., 1995a,b; Karr et al., 1997; Setchell et al., 2001; Setchell and Cassidy, 1999).

Phytoestrogens preferentially bind to estrogen-beta receptors (ER-beta). Genistein binding to ER-beta produces a conformational change similar to that produced by the drug reloxifene (a selective estrogen receptor modulator prescribed for osteoporosis) but dissimilar to the binding of estradiol. Phytoestrogens decrease (by down-regulation) the number of ER-alpha receptors on breast and uterine tissue (Nikov et al., 2001). Generally, phytoestrogens are much less potent than the endogenously produced estrogens, but phytoestrogens can be present in much greater quantities (100 to 1000 times the concentration of endogenous estrogens). Additionally, phytoestrogens bind less tightly to steroid-hormone serum-transport proteins than do endogenous estrogens (Nagel et al., 1998). Soy-based infant formula can result in plasma concentrations of isoflavones in infants that are 13,000-22,000 times higher than endogenous estrogen concentrations in infants (Setchell et al., 1997). Equol has more potent estrogen activity than its precursor, daidzein, and has been proposed to be most important in explaining the mechanism of action of isoflavones in disease prevention (Setchell et al., 2002).

Some actions of phytoestrogens are thought to occur through pathways other than interaction with estrogen receptors. These actions include inhibiting the transformation of estrone to estradiol and inhibiting enzymes important for steroid biosynthesis, as well as having antioxidant and anti-angiogenesis activity. (Adlercreutz et al., 1995a; Dixon and Ferreira, 2002).

Studies of the effects of dietary phytoestrogens or soy protein on the incidence of breast and prostate cancer vary in outcome but suggest a protective effect (Knowles et al., 2000; den Tonkelaar et al., 2001; Stattin et al., 2002; Ingram et al., 1997; Murkies et al., 2000; Howe et al., 1990; Lee et al., 1991). In such studies, many unmeasured non-phytoestrogen flavonoid chemicals, vitamins, and other nutrients that also are present in plant foods may also contribute to observed health outcomes. *In vitro* experiments have shown both anti-cancer and stimulatory effects on cell growth of target cells. Many of the different phytoestrogens have been tested for mutagenic activity *in vitro* and do not appear to be mutagenic, but studies assessing the carcinogenicity of phytoestrogens have not been conducted. Cornwell et al. (2004) have summarized the potential anti-cancer benefits of phytoestrogens.

Comparisons of Western diets with Asian diets, which include higher intakes of soy-based foods, suggest that the higher isoflavone intake in Asian diets may account for the lower incidence of menopausal symptoms such as hot flashes and osteoporosis. The ingestion of isoflavones by pre- and post-menopausal women produces varying effects on the menstrual cycle, sex-hormone protein binding, pituitary responses, and bone density, depending on dose, the type of phytoestrogen used, the hormonal state of the subjects, and the design of the studies (see, for example, Teede et al., 2001; Murkies et al., 2000; Xu et al., 2000; Hodgert et al., 2000; Safe et al., 2001; Nicholls et al., 2002; Kotsopoulos et al., 2000; Cassidy et al., 1994; Adlercreutz et al., 1995a; Kim et al., 2002; Kreijkamp-Kaspers et al., 2004).

Adverse reproductive effects have been observed in animals that graze on clover. Although the results of these studies are conflicting, results of some chronic feeding studies suggest that high doses of phytoestrogens alter the fetal hormonal environment when consumed during gestation (Cornwell et al., 2004). Results of studies of children who had been fed soy-based formula as infants and who were followed up through adolescence (Klein, 1998) and young adulthood (Strom et al., 2001) found no adverse reproductive or endocrine effects.

### Interpreting Levels of Urinary Phytoestrogens Reported in the Tables

Urinary levels of phytoestrogens were measured in a subsample of NHANES participants aged 6 years and older. Participants were selected within the specified age range to be a representative sample of the U.S.

In general, the concentrations observed in the NHANES 1999-2000 and 2000-2001 subsamples reflect a diet lower in isoflavones than lignans, consistent with consumption of a Western diet in which whole grains and cereals rather than soybean products contribute the bulk of phytoestrogens. Enterolactone levels were highest followed by daidzein, genistein, enterodiol, equol, and O-desmethylangolensin. Isoflavone levels at the higher percentiles may reflect dietary supplementation with soy products. The relationship between the dose and urinary excretion is linear for many phytoestrogens, except for equol (Karr et al., 1997; Slavin et al. 1998; Lampe et al., 1999). Because excretory half-lives are reported to be in the range of 3-10 hours (Lu et al., 1995, Setchell et al., 2001), urinary concentrations reflect recent consumption.

Levels of lignans (enterolactone, enterodiol) in the 1999-2000 and 2001-2002 subsamples appeared broadly similar to levels found in studies of postmenopausal women in the United Kingdom (Grace et al., 2004); men and women in the United States (Valentin-Blasini et al., 2003); men and women in Minnesota (Lampe et al., 1999); postmenopausal Dutch women (den Tonkelaar et al., 2001); young African-American, Latina; and Japanese women in the San Francisco Bay Area (Horn-Ross et al., 1997); Japanese men and women (Adlercreutz et al., 1991; Uehara et al., 2000a); premenopausal omnivorous women in Boston (Adlercreutz et al., 1986); and healthy postmenopausal Finnish omnivore and vegetarians (Uehara et al., 2000a,b). Vegetarian women in Boston and Helsinki (Adlercreutz et al., 1986); men and women consuming an experimental cruciferous diet (Kirkman et al., 1995); and Boston women consuming a macrobiotic diet excrete significantly higher levels of these lignans (Hutchins, 1995a).

Levels of isoflavones (daidzein, genistein, equol, and O-desmethylangolensin) in the NHANES 1999-2000 and 2001-2002 subsamples appear broadly similar to those seen in young Caucasian, African-American, Latina, and Japanese women in the San Francisco Bay Area (Horn-Ross et al., 1997); men and women in the United States (Valentin-Blasini et al., 2003, Lampe et al., 1999); Caucasian and Filipino women living in Hawaii (Maskarinec et al., 1998); postmenopausal women from Holland (den Tonkelaar et al., 2001) and the United Kingdom (Grace et al., 2004); omnivorous and vegetarian Helsinki women (Uehara et al., 2000 a,b); and premenopausal omnivorous Boston women (Hutchins, 1995 a,b).

Isoflavone levels seen in the NHANES 1999-2000 and 2001-2002 subsamples were 4 to 50 times lower than

levels observed in Japanese men and women (Adlercreutz et al., 1991; Uehara et al., 2000a); Japanese women (Arai et al., 2000); postmenopausal Chinese women (Zheng et al., 1999); Singaporean women (Seow et al., 1998, Chen et al., 1999); and Japanese women living in Hawaii (Maskarinec et al., 1998). Genistein and daidzein levels in this *Report* were two-fold higher than levels reported in people consuming a carotenoid diet but lower than levels found in people consuming a cruciferous diet, and O-desmethylangolensin levels were seven times lower (Kirkman et al., 1995). Levels of genistein, daidzein, and O-desmethylangolensin for people consuming a soy diet were 6 to 100 times higher than levels in either NHANES subsample. Supplementing an omnivorous American diet over a three month period with 60 grams of soy powder for female subjects increased isoflavone levels by more than 13-fold. (Albertazzi et al., 1999).

### Comparing Adjusted Geometric Means

Geometric means of urinary phytoestrogen levels for the demographic groups were compared after adjusting for the covariates of race/ethnicity, age, gender, and urinary creatinine (data not shown).

In NHANES 2001-2002, both urinary enterodiol and enterolactone levels were higher in the group aged 6-11 years than in the group aged 12-19 years. Levels of the lignans previously have been reported to differ by race (Horn-Ross et al., 1997), and in an NHANES III statistical analysis, to differ by income, gender, and age (Valentin-Blasini et al., 2003).

In NHANES 2001-2002, both urinary genistein and daizein levels were higher in the group aged 6-11 years than in either of the groups aged 12-19 years or 20 years and older, and females had higher levels than males. One study found that levels were higher in males for all phytoestrogens except equol (Lampe et al., 1999).

In NHANES 2001-2002, adjusted geometric mean levels of urinary equol were higher for non-Hispanic whites than for Mexican Americans or non-Hispanic blacks. Adjusted geometric mean levels of urinary equol were higher in the group aged 6-11 years than in either of the other two age groups.

In NHANES 2001-2002, adjusted geometric mean levels of urinary O-desmethylangolensin were higher in non-Hispanic whites than in Mexican Americans. The group aged 20 years and older had lower adjusted geometric mean levels of urinary O-desmethylangolensin than either of the other two age groups.

It is unknown whether these differences associated with age, gender, or race/ethnicity represent differences in exposure, pharmacokinetics, or the relationship of dose per body weight.

These urinary phytoestrogens data provide physicians with a reference range so that they can determine whether or not people have been exposed to higher levels of phytoestrogens than those levels found in the general population. These data will also help scientists plan and conduct research about the relation between exposure to phytoestrogens and health effects.

**Table 213. Daidzein**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>75.1</b> (61.9-91.1)	<b>69.7</b> (57.8-82.6)	<b>229</b> (184-298)	<b>538</b> (471-702)	<b>1310</b> (990-1540)	2553
	01-02	<b>51.7</b> (46.6-57.5)	<b>52.3</b> (48.9-57.4)	<b>192</b> (151-226)	<b>577</b> (447-725)	<b>1250</b> (863-1640)	2794
<b>Age group</b>							
6-11 years	99-00	<b>90.5</b> (75.1-109)	<b>101</b> (70.3-138)	<b>257</b> (172-430)	<b>505</b> (437-840)	<b>1130</b> (657-1740)	330
	01-02	<b>84.9</b> (71.6-101)	<b>72.7</b> (56.3-97.0)	<b>257</b> (155-385)	<b>571</b> (437-989)	<b>1030</b> (628-1470)	396
12-19 years	99-00	<b>123</b> (91.4-166)	<b>123</b> (85.6-168)	<b>325</b> (227-454)	<b>833</b> (445-1490)	<b>1460</b> (861-2410)	753
	01-02	<b>69.3</b> (52.6-91.3)	<b>70.2</b> (52.5-87.5)	<b>251</b> (185-344)	<b>769</b> (573-984)	<b>1360</b> (922-1950)	744
20 years and older	99-00	<b>67.6</b> (55.4-82.4)	<b>60.9</b> (49.3-74.1)	<b>215</b> (167-239)	<b>518</b> (459-573)	<b>1320</b> (978-1540)	1470
	01-02	<b>46.4</b> (41.4-52.0)	<b>49.1</b> (40.8-53.4)	<b>176</b> (133-216)	<b>520</b> (396-703)	<b>1210</b> (771-1900)	1654
<b>Gender</b>							
Males	99-00	<b>88.9</b> (71.4-111)	<b>80.6</b> (66.6-112)	<b>261</b> (198-355)	<b>573</b> (501-989)	<b>1540</b> (989-2080)	1220
	01-02	<b>49.8</b> (42.8-57.9)	<b>50.7</b> (46.0-55.0)	<b>189</b> (137-237)	<b>498</b> (386-694)	<b>906</b> (717-1380)	1375
Females	99-00	<b>64.1</b> (52.9-77.6)	<b>57.8</b> (45.0-73.2)	<b>199</b> (150-244)	<b>476</b> (389-722)	<b>1220</b> (566-1700)	1333
	01-02	<b>53.6</b> (48.1-59.8)	<b>55.7</b> (49.8-62.7)	<b>197</b> (148-231)	<b>642</b> (511-816)	<b>1470</b> (1170-1980)	1419
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>78.9</b> (59.8-104)	<b>66.2</b> (48.4-87.1)	<b>254</b> (170-402)	<b>800</b> (534-1020)	<b>1360</b> (968-2780)	816
	01-02	<b>39.2</b> (28.5-54.0)	<b>39.9</b> (28.8-59.9)	<b>168</b> (100-287)	<b>515</b> (388-669)	<b>896</b> (613-1480)	679
Non-Hispanic blacks	99-00	<b>91.9</b> (71.9-118)	<b>102</b> (81.6-133)	<b>286</b> (243-377)	<b>553</b> (459-824)	<b>1190</b> (640-1900)	607
	01-02	<b>66.1</b> (48.2-90.7)	<b>72.2</b> (52.8-97.3)	<b>255</b> (176-393)	<b>757</b> (448-1400)	<b>1400</b> (757-2480)	706
Non-Hispanic whites	99-00	<b>74.4</b> (61.5-89.9)	<b>66.9</b> (56.2-78.2)	<b>216</b> (157-298)	<b>512</b> (438-745)	<b>1360</b> (989-1710)	917
	01-02	<b>48.6</b> (43.8-54.0)	<b>49.5</b> (42.7-54.1)	<b>171</b> (137-204)	<b>504</b> (389-658)	<b>1140</b> (774-1620)	1222


**Table 214. Daidzein (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>68.5</b> (55.9-83.9)	<b>65.1</b> (52.8-80.8)	<b>204</b> (156-249)	<b>555</b> (471-629)	<b>944</b> (836-1150)	2553
	01-02	<b>48.6</b> (43.7-54.0)	<b>48.5</b> (43.3-56.6)	<b>166</b> (140-196)	<b>497</b> (395-614)	<b>957</b> (801-1180)	2784
<b>Age group</b>							
6-11 years	99-00	<b>92.6</b> (76.3-112)	<b>92.9</b> (71.2-114)	<b>251</b> (157-324)	<b>529</b> (363-838)	<b>1030</b> (781-2150)	330
	01-02	<b>96.6</b> (79.2-118)	<b>86.3</b> (60.8-127)	<b>275</b> (159-395)	<b>649</b> (452-733)	<b>930</b> (679-1140)	395
12-19 years	99-00	<b>83.1</b> (58.4-118)	<b>83.9</b> (53.8-126)	<b>207</b> (138-386)	<b>628</b> (295-1060)	<b>1000</b> (628-2380)	753
	01-02	<b>53.4</b> (40.8-70.0)	<b>50.9</b> (38.3-77.6)	<b>181</b> (142-248)	<b>549</b> (385-718)	<b>1030</b> (622-1360)	744
20 years and older	99-00	<b>63.8</b> (51.5-79.1)	<b>59.3</b> (48.7-75.0)	<b>194</b> (151-234)	<b>554</b> (471-624)	<b>908</b> (783-1180)	1470
	01-02	<b>43.9</b> (39.4-48.9)	<b>43.8</b> (37.4-53.3)	<b>153</b> (127-188)	<b>441</b> (348-599)	<b>939</b> (788-1220)	1645
<b>Gender</b>							
Males	99-00	<b>69.7</b> (54.7-88.8)	<b>70.2</b> (51.3-84.3)	<b>197</b> (147-276)	<b>620</b> (494-836)	<b>1050</b> (884-1290)	1220
	01-02	<b>40.5</b> (34.8-47.1)	<b>41.7</b> (34.5-47.9)	<b>140</b> (108-179)	<b>348</b> (260-553)	<b>788</b> (585-946)	1371
Females	99-00	<b>67.4</b> (54.8-82.9)	<b>61.4</b> (51.1-80.9)	<b>207</b> (152-250)	<b>495</b> (356-624)	<b>838</b> (610-1410)	1333
	01-02	<b>57.7</b> (50.8-65.5)	<b>60.1</b> (48.6-73.4)	<b>191</b> (159-228)	<b>616</b> (536-722)	<b>1180</b> (924-1430)	1413
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>72.5</b> (59.1-88.9)	<b>64.2</b> (47.1-91.1)	<b>243</b> (176-310)	<b>674</b> (468-1080)	<b>1360</b> (753-2690)	816
	01-02	<b>36.8</b> (27.7-48.9)	<b>36.9</b> (24.8-56.9)	<b>148</b> (101-225)	<b>441</b> (307-585)	<b>722</b> (578-1160)	676
Non-Hispanic blacks	99-00	<b>59.1</b> (46.5-75.1)	<b>66.9</b> (52.1-87.1)	<b>171</b> (134-207)	<b>377</b> (316-533)	<b>797</b> (562-1010)	607
	01-02	<b>46.4</b> (33.7-63.8)	<b>51.0</b> (35.5-70.8)	<b>167</b> (105-249)	<b>499</b> (263-794)	<b>939</b> (542-1530)	705
Non-Hispanic whites	99-00	<b>72.8</b> (60.3-88.0)	<b>67.5</b> (55.3-81.5)	<b>207</b> (160-249)	<b>560</b> (442-659)	<b>908</b> (742-1350)	917
	01-02	<b>48.1</b> (43.4-53.4)	<b>47.5</b> (42.4-56.1)	<b>163</b> (138-191)	<b>463</b> (375-627)	<b>957</b> (805-1220)	1217

**Figure 23. Daidzein (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



**Table 215. Enterodiol**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>26.6</b> (21.9-32.3)	<b>34.0</b> (29.4-38.7)	<b>78.7</b> (62.6-95.5)	<b>165</b> (135-215)	<b>266</b> (215-335)	2527
	01-02	<b>35.7</b> (32.5-39.3)	<b>39.4</b> (36.3-43.4)	<b>89.0</b> (80.7-96.9)	<b>180</b> (162-205)	<b>252</b> (223-295)	2794
<b>Age group</b>							
6-11 years	99-00	<b>26.5</b> (17.1-41.0)	<b>29.4</b> (21.2-44.2)	<b>77.6</b> (44.2-109)	<b>193</b> (91.1-279)	<b>276</b> (131-458)	327
	01-02	<b>33.6</b> (29.8-37.8)	<b>35.4</b> (29.4-43.7)	<b>78.1</b> (63.8-87.0)	<b>150</b> (113-171)	<b>201</b> (167-327)	396
12-19 years	99-00	<b>29.8</b> (23.8-37.2)	<b>33.9</b> (27.4-42.0)	<b>83.9</b> (59.1-101)	<b>166</b> (112-234)	<b>247</b> (182-337)	744
	01-02	<b>35.3</b> (30.5-40.9)	<b>37.7</b> (34.8-43.4)	<b>84.2</b> (72.1-96.9)	<b>162</b> (128-206)	<b>238</b> (169-343)	744
20 years and older	99-00	<b>26.1</b> (21.8-31.3)	<b>34.3</b> (29.8-38.7)	<b>78.2</b> (63.5-94.8)	<b>160</b> (132-196)	<b>261</b> (189-335)	1456
	01-02	<b>36.1</b> (31.8-41.0)	<b>40.4</b> (36.0-45.7)	<b>91.2</b> (79.3-105)	<b>190</b> (161-220)	<b>254</b> (224-311)	1654
<b>Gender</b>							
Males	99-00	<b>25.3</b> (19.5-32.7)	<b>33.0</b> (28.0-38.0)	<b>72.6</b> (54.7-94.3)	<b>149</b> (109-219)	<b>258</b> (167-280)	1206
	01-02	<b>35.2</b> (31.8-39.1)	<b>40.5</b> (36.8-44.8)	<b>90.6</b> (82.3-103)	<b>182</b> (158-198)	<b>263</b> (223-338)	1375
Females	99-00	<b>27.9</b> (23.4-33.3)	<b>36.0</b> (29.9-40.3)	<b>84.4</b> (71.8-97.9)	<b>174</b> (146-219)	<b>279</b> (219-375)	1321
	01-02	<b>36.2</b> (32.2-40.7)	<b>38.3</b> (35.3-43.4)	<b>87.0</b> (75.6-98.5)	<b>174</b> (152-212)	<b>245</b> (220-283)	1419
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>21.7</b> (19.5-24.1)	<b>28.0</b> (24.7-34.7)	<b>70.4</b> (60.8-78.8)	<b>143</b> (117-169)	<b>213</b> (169-256)	791
	01-02	<b>30.5</b> (25.7-36.3)	<b>34.0</b> (29.0-39.2)	<b>75.2</b> (58.8-89.7)	<b>159</b> (119-202)	<b>244</b> (192-298)	679
Non-Hispanic blacks	99-00	<b>25.8</b> (21.7-30.7)	<b>31.2</b> (24.4-35.9)	<b>66.0</b> (50.2-86.7)	<b>157</b> (122-193)	<b>260</b> (185-336)	608
	01-02	<b>35.0</b> (28.9-42.3)	<b>38.7</b> (33.2-49.0)	<b>83.6</b> (70.0-103)	<b>168</b> (132-186)	<b>218</b> (175-339)	706
Non-Hispanic whites	99-00	<b>29.2</b> (24.0-35.4)	<b>37.5</b> (31.3-43.8)	<b>85.8</b> (68.3-99.4)	<b>171</b> (138-228)	<b>270</b> (187-375)	915
	01-02	<b>35.6</b> (31.8-40.0)	<b>40.4</b> (36.0-44.4)	<b>89.6</b> (78.4-101)	<b>174</b> (153-198)	<b>254</b> (214-337)	1222


**Table 216. Enterodiol (creatinine corrected)**

Geometric mean and selected percentiles of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>24.2</b> (20.3-28.9)	<b>29.9</b> (25.0-34.7)	<b>70.5</b> (59.6-82.1)	<b>146</b> (124-177)	<b>240</b> (199-320)	2527
	01-02	<b>33.4</b> (30.6-36.6)	<b>37.5</b> (33.0-42.0)	<b>78.3</b> (71.8-87.0)	<b>147</b> (135-163)	<b>224</b> (193-246)	2784
<b>Age group</b>							
6-11 years	99-00	<b>27.0</b> (18.6-39.3)	<b>33.7</b> (21.8-43.7)	<b>62.7</b> (43.0-108)	<b>150</b> (81.6-290)	<b>290</b> (150-411)	327
	01-02	<b>38.1</b> (32.5-44.7)	<b>39.3</b> (30.8-53.0)	<b>78.3</b> (66.6-101)	<b>188</b> (147-244)	<b>304</b> (242-389)	395
12-19 years	99-00	<b>20.1</b> (16.7-24.2)	<b>24.1</b> (19.6-30.1)	<b>55.0</b> (42.6-71.7)	<b>99.5</b> (91.5-116)	<b>158</b> (121-177)	744
	01-02	<b>27.2</b> (23.3-31.8)	<b>28.6</b> (24.9-34.9)	<b>62.7</b> (54.9-71.0)	<b>104</b> (84.2-139)	<b>152</b> (111-225)	744
20 years and older	99-00	<b>24.7</b> (20.6-29.5)	<b>30.6</b> (26.0-34.8)	<b>72.7</b> (62.5-84.5)	<b>155</b> (129-184)	<b>240</b> (199-344)	1456
	01-02	<b>34.0</b> (30.2-38.3)	<b>39.4</b> (32.5-44.8)	<b>83.3</b> (74.0-92.5)	<b>150</b> (136-166)	<b>223</b> (188-250)	1645
<b>Gender</b>							
Males	99-00	<b>19.8</b> (15.4-25.4)	<b>25.4</b> (20.0-31.4)	<b>55.1</b> (46.4-64.2)	<b>121</b> (94.6-168)	<b>197</b> (145-282)	1206
	01-02	<b>28.7</b> (26.0-31.7)	<b>31.4</b> (27.0-36.7)	<b>71.2</b> (64.2-78.0)	<b>138</b> (117-160)	<b>212</b> (179-259)	1371
Females	99-00	<b>29.3</b> (25.0-34.4)	<b>34.9</b> (29.5-41.6)	<b>85.2</b> (74.5-92.3)	<b>164</b> (141-201)	<b>321</b> (226-370)	1321
	01-02	<b>38.6</b> (34.6-43.1)	<b>43.5</b> (39.3-48.7)	<b>88.3</b> (74.7-102)	<b>157</b> (137-172)	<b>225</b> (179-298)	1413
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>19.6</b> (17.3-22.2)	<b>23.5</b> (19.7-28.7)	<b>59.6</b> (49.8-77.7)	<b>134</b> (114-154)	<b>193</b> (154-227)	791
	01-02	<b>28.7</b> (24.5-33.6)	<b>31.0</b> (27.0-36.8)	<b>64.1</b> (55.0-77.5)	<b>130</b> (94.4-182)	<b>223</b> (143-331)	676
Non-Hispanic blacks	99-00	<b>16.6</b> (13.9-19.7)	<b>18.8</b> (14.4-22.9)	<b>47.3</b> (37.7-55.8)	<b>113</b> (85.9-145)	<b>165</b> (131-272)	608
	01-02	<b>24.5</b> (19.7-30.6)	<b>26.8</b> (22.6-33.3)	<b>57.5</b> (48.1-73.2)	<b>117</b> (92.2-141)	<b>157</b> (118-246)	705
Non-Hispanic whites	99-00	<b>28.6</b> (24.3-33.6)	<b>33.8</b> (28.9-39.3)	<b>75.8</b> (65.3-87.2)	<b>162</b> (130-197)	<b>252</b> (203-363)	915
	01-02	<b>35.1</b> (31.5-39.2)	<b>40.8</b> (33.7-46.5)	<b>82.7</b> (74.3-90.3)	<b>151</b> (136-169)	<b>224</b> (187-275)	1217

**Figure 24. Enterodiol (creatinine corrected)**

Selected percentiles with 95% confidence intervals of urine concentrations (in  $\mu\text{g/g}$  of creatinine) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.



**Table 217. Enterolactone**

Geometric mean and selected percentiles of urine concentrations (in µg/L) for the U.S. population aged 6 years and older, National Health and Nutrition Examination Survey, 1999-2002.

	Survey years	Geometric mean (95% conf. interval)	Selected percentiles (95% confidence interval)				Sample size
			50th	75th	90th	95th	
<b>Total, age 6 and older</b>	99-00	<b>239</b> (200-286)	<b>315</b> (245-381)	<b>726</b> (595-879)	<b>1970</b> (1440-2370)	<b>2790</b> (2480-3070)	2548
	01-02	<b>259</b> (233-287)	<b>348</b> (314-389)	<b>807</b> (739-873)	<b>1590</b> (1420-1820)	<b>2720</b> (1870-3430)	2794
<b>Age group</b>							
6-11 years	99-00	<b>308</b> (219-432)	<b>353</b> (243-474)	<b>721</b> (520-1320)	<b>1730</b> (973-2840)	<b>2840</b> (1700-3590)	331
	01-02	<b>288</b> (245-339)	<b>329</b> (271-412)	<b>680</b> (566-775)	<b>1380</b> (929-1620)	<b>2160</b> (1420-2550)	396
12-19 years	99-00	<b>250</b> (191-327)	<b>317</b> (242-410)	<b>670</b> (454-888)	<b>1760</b> (973-2480)	<b>2900</b> (1950-4330)	746
	01-02	<b>267</b> (231-308)	<b>321</b> (255-399)	<b>729</b> (617-856)	<b>1480</b> (1230-1800)	<b>2180</b> (1560-3310)	744
20 years and older	99-00	<b>230</b> (193-274)	<b>310</b> (242-375)	<b>728</b> (599-888)	<b>1980</b> (1490-2390)	<b>2790</b> (2510-3540)	1471
	01-02	<b>254</b> (223-289)	<b>355</b> (310-394)	<b>835</b> (760-914)	<b>1660</b> (1460-1890)	<b>2840</b> (1890-3610)	1654
<b>Gender</b>							
Males	99-00	<b>254</b> (212-304)	<b>351</b> (265-417)	<b>778</b> (579-1050)	<b>1980</b> (1580-2400)	<b>2730</b> (2430-3350)	1219
	01-02	<b>262</b> (233-295)	<b>340</b> (314-387)	<b>873</b> (769-957)	<b>1800</b> (1490-2470)	<b>3050</b> (1990-4070)	1375
Females	99-00	<b>226</b> (180-284)	<b>287</b> (236-339)	<b>684</b> (554-795)	<b>1880</b> (1200-2460)	<b>2830</b> (2100-4330)	1329
	01-02	<b>255</b> (226-288)	<b>355</b> (293-397)	<b>759</b> (680-840)	<b>1440</b> (1190-1700)	<b>2200</b> (1710-2950)	1419
<b>Race/ethnicity</b>							
Mexican Americans	99-00	<b>212</b> (169-265)	<b>281</b> (230-335)	<b>631</b> (539-732)	<b>1650</b> (950-2210)	<b>2690</b> (2380-3350)	813
	01-02	<b>275</b> (221-342)	<b>347</b> (312-395)	<b>777</b> (671-913)	<b>1520</b> (1090-1920)	<b>2280</b> (1610-2990)	679
Non-Hispanic blacks	99-00	<b>262</b> (196-349)	<b>360</b> (293-440)	<b>759</b> (629-925)	<b>1710</b> (1000-2420)	<b>2500</b> (1870-3280)	605
	01-02	<b>278</b> (226-342)	<b>417</b> (341-479)	<b>769</b> (686-853)	<b>1450</b> (1110-1710)	<b>1960</b> (1540-2420)	706
Non-Hispanic whites	99-00	<b>247</b> (196-311)	<b>317</b> (240-403)	<b>751</b> (616-955)	<b>2040</b> (1600-2450)	<b>2950</b> (2460-3880)	917
	01-02	<b>267</b> (235-303)	<b>354</b> (307-397)	<b>834</b> (750-923)	<b>1630</b> (1420-1890)	<b>2780</b> (1820-3740)	1222

























































































































































































































































































































































